

```
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTTATTAAATAAAAAATGTGTCTCCCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACTA 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 356
ACA96945
ID ACA96945 standard; cDNA; 2846 BP.
XX
AC ACA96945;
XX
XX
DT 24-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein: PRO; cytostatic; gene therapy;
KW tumour; gene; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003032123-A1.
XX
XX 13-FEB-2003.
XX
XX 25-JUN-2002; 2002US-00180555.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081196P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083455P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088722P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088740P.
XX 10-JUN-1998; 98US-0088811P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088825P.
XX 11-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088861P.
XX 11-JUN-1998; 98US-0088863P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089090P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089653P.
XX 18-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 24-JUN-1998; 98US-0090429P.
XX 24-JUN-1998; 98US-0090435P.
XX 24-JUN-1998; 98US-0090444P.
XX 24-JUN-1998; 98US-0090461P.
XX 24-JUN-1998; 98US-0090535P.
XX 24-JUN-1998; 98US-0090540P.
XX 25-JUN-1998; 98US-0090676P.
XX 25-JUN-1998; 98US-0090678P.
XX 25-JUN-1998; 98US-0090688P.
XX 25-JUN-1998; 98US-0090690P.
```

```
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090896P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-JUL-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.

PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTACACTCTTCTTCTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCCTCCCATCTCTTGACACATTTTAATAAATAAGGTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 357
ACA90941
ID ACA90941 standard; cDNA; 2846 BP.
XX AC ACA90941;
XX XX
DT 14-JUL-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW chondrocyte stimulator; chromosome mapping; gene mapping; tumour; gene;
KW ss.
XX Homo sapiens.
XX OS
XX PN
XX US2003032108-A1.
PD 13-FEB-2003.
XX XX
PF 21-JUN-2002; 2002US-00176481.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0080107P.
```

PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081043P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083555P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084633P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088221P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088867P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100358P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.

```
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTCGCTTACCACCTCTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACATG 2180
Db 2653 CCTTTTCCTTCCCACTCTCTGTACATTTTAATAAATAGGTTGGCTTCTGACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 358
ACA70723
ID ACA70723 standard; cDNA; 2846 BP.
XX AC ACA70723;
XX DT 11-AUG-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX KW tissue typing; cytostatic.
XX OS Homo sapiens.
XX PN US2003032111-A1.
XX PD 13-FEB-2003.
XX PF 20-JUN-2002; 2002US-00176493.
XX FF 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083498P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-008580P.
PR 15-MAY-1998; 98US-008582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-008759P.
PR 02-JUN-1998; 98US-008759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-008855P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 11-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
```



```
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0091633P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100913P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0101475P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.

PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCITTTGCTTTACCACTCTTTCCTTTTATCTATTATAATAAAATGTTGTCTCCACCACGTG 2180
DB 2653 CCITTTTCTCTCCCATCTCTTGTACACATTTTATAAAATAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 359
ACA95233
ID ACA95233 standard; cDNA; 2846 BP.
XX ACA95233;
AC ACA95233;
XX 11-AUG-2003 (first entry)
DT 11-AUG-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
KW Human; ss; gene; gene therapy; chondrocyte stimulator; tumour; TNF-alpha;
KW tumour necrosis factor alpha.
XX Homo sapiens.
XX OS
XX US2003032119-A1.
XX 13-FEB-2003.
XX 25-JUN-2002; 2002US-00180544.
XX 26-JUN-1998; 98US-00105413.
XX 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
```

PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US005884.
PR 30-MAR-2000; 2000WO-US005884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 22-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-341973/32.
DR P-PSDB; ABU93693.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for measuring or detecting expression of an associated gene.
XX
PS Claim 2; Fig 169; 707pp; English.
XX
CC The invention relates to three hundred and five nucleic acids encoding
CC PRO polypeptides (secreted and transmembrane). The PRO nucleic acids and
CC polypeptides are useful for the manufacture of a medicament for
CC diagnosing or treating tumor in a mammal, for measuring or detecting
CC expression of an associated gene, for stimulation of chondrocytes and for
CC stimulating the release of tumour necrosis factor alpha (TNF-alpha) from
CC human blood. The present sequence represents cDNA encoding a secreted and
CC transmembrane PRO protein. Note: The sequence data for this patent did
CC not form part of the printed specification but was obtained in electronic
CC format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docID=20030032199
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
2121 CTTTGGTTTACACTCTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180
2653 CTTTTCCTTCCCATCTCTTGACACATTTTATTAATAAATGTTGGTCTTCTGACTA 2712.

QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 360
ACD44284
ID ACD44284 standard; cDNA; 2846 BP.
XX
AC ACD44284;
XX
DT 10-SEP-2003 (first entry)
XX
DE cDNA encoding human PRO1344 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive; transgenic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2002127576-A1.
XX
PD 12-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00991073.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.

17-JUN-1998; 98US-0089532P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089539P.
17-JUN-1998; 98US-0089599P.
17-JUN-1998; 98US-0089600P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089801P.
18-JUN-1998; 98US-0089907P.
18-JUN-1998; 98US-0089908P.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
02-JUN-1999; 99WO-US012252.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US0211547.
30-NOV-1999; 99WO-US028313.
01-DEC-1999; 99WO-US028301.
01-DEC-1999; 99WO-US028634.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
06-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
02-MAR-2000; 2000WO-US005841.
10-MAR-2000; 2000WO-US006319.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
30-MAR-2000; 2000WO-US008439.
15-MAY-2000; 2000WO-US013358.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
01-DEC-2000; 2000WO-US032678.
28-FEB-2001; 2001WO-US006520.
01-JUN-2001; 2001WO-US017800.
20-JUN-2001; 2001WO-US019692.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
28-AUG-2001; 2001US-00941992.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
Zhang Z;
WPI; 2003-340824/32.
P-PSDB; ABO25955.
Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
and are therapeutically useful for enhancing immune responses.
Claim 2; Fig 158; 661pp; English.
The present invention relates to the isolation of novel human PRO
polypeptides, and the polynucleotide sequences encoding them. The PRO
polypeptides are secreted and transmembrane proteins. The PRO

polypeptides are useful for detecting other PRO polypeptides, for linking
bioactive molecules to cells expressing PRO polypeptides, for modulating
biological activities of cells expressing PRO polypeptides, and for for
identifying agonists or antagonists. The polynucleotide sequences
encoding PRO polypeptides are useful as hybridisation probes, in
chromosome and gene mapping, in the generation of antisense RNA and DNA,
or knockout animals, to construct hybridisation probes for mapping the
gene which encodes the PRO polypeptide, and for the genetic analysis of
individuals with genetic disorders, in gene therapy, for chromosome
identification, as chromosome markers, and for generating probes for PCR,
Northern analysis, Southern analysis and Western analysis. The present
sequence encodes a human PRO polypeptide of the invention. Note: The
sequence data for this patent was obtained in electronic format directly
from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGTGCTTACCACTCTTCTTTATCTATTATAAATAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTAATAAATAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 361
ACC86176
ID ACC86176 standard; cdna; 2846 BP.
XX ACC86176;
XX 28-JUL-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cdna, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003027263-A1.
XX 06-FEB-2003.
XX 18-JUN-2002; 2002US-00174572.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082699P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088266P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089633P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090446P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091101P.
PR 01-JUL-1998; 98US-0091259P.
PR 01-JUL-1998; 98US-0091344P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097352P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.

PR	02-JUN-2000;	2000WO-US015264.	
PR	22-AUG-2000;	2000US-00644848.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	18-SEP-2000;	2000US-00664610.	
PR	18-SEP-2000;	2000US-00665150.	
PR	08-NOV-2000;	2000US-00703238.	
PR	10-NOV-2000;	2000WO-US030873.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000US-00747259.	
PR	20-DEC-2000;	2000WO-US034956.	
PR	28-FEB-2001;	2001WO-US006520.	
PR	22-MAR-2001;	2001US-00816744.	
PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001US-00854280.	
PR	30-MAY-2001;	2001US-00870574.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	29-JUN-2001;	2001US-00869599.	
PR	18-JUL-2001;	2001US-00908827.	
PR	06-DEC-2001;	2001US-00006867.	
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;		
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;		
XX			
XX	WPI: 2003-447383/42.		
DR	P-PSDB; AB027239.		
DR			
XX			
PT	New isolated antibody specifically binding a PRO polypeptide, useful for		
PT	the preparation of a medicament for treating disorders with the aberrant		
PT	expression or activity of the PRO polypeptide, such as tumor conditions		
PT	and cancer.		

[illegible]

XX DT 11-AUG-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003027271-A1.
XX PD 06-FEB-2003.
XX PF 21-JUN-2002; 2002US-00176488.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 28-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089808P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090890P.
PR 25-JUN-1998; 98US-0090894P.
PR 25-JUN-1998; 98US-0090959P.
PR 25-JUN-1998; 98US-0090966P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.

```

PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTTATCTTATTAATAAATCTGCTCCACCACTG 2180
Db 2653 CTTTTCCTCCCATCTTGTGACATTTTAATAAATAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
Db 2713 CAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 364
ACD12656
ID ACD12656 standard; cDNA; 2846 BP.
XX

```

```

AC ACD12656;
XX
DT 17-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036125-A1.
XX
PD 20-FEB-2003.
XX
PF 26-JUN-2002; 2002US-00180999.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079684P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.

```

RESULT 365
ACF19886
ID ACF19886 standard; cDNA; 2846 BP.

XX ACF19886;
XX 17-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003040068-A1.
XX 27-FEB-2003.
XX 28-JUN-2002; 2002US-00184625.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 18-DEC-1997; 97US-0069870P.
PR 10-MAR-1998; 97US-0068017P.
PR 11-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 27-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 16-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.

PR	17-AUG-1998;	98US-0096766P.	ID	ABX76830 standard; cDNA; 2846 BP.
PR	17-AUG-1998;	98US-0096867P.	XX	
PR	17-AUG-1998;	98US-0096891P.	AC	ABX76830;
PR	17-AUG-1998;	98US-0096897P.	XX	
PR	18-AUG-1998;	98US-0096949P.	DT	04-APR-2003 (first entry)
PR	18-AUG-1998;	98US-0096959P.	XX	
PR	18-AUG-1998;	98US-0097022P.	DE	Human PRO polynucleotide #85.
PR	26-AUG-1998;	98US-0097952P.	XX	
PR	26-AUG-1998;	98US-0097954P.	XX	
PR	26-AUG-1998;	98US-0097955P.	KW	Human; PRO; gene; ss; tumour necrosis factor-alpha; blood; cancer;
PR	26-AUG-1998;	98US-0097971P.	KW	chondrocyte cell; tumour; adrenal tumour; lung; colon; breast; prostate;
PR	26-AUG-1998;	98US-0097974P.	KW	kidney; rectum; cervix; liver; bone disorder; cartilage disorder;
PR	26-AUG-1998;	98US-0098014P.	KW	arthritis; sports injury; genetic disorder; antiarthritic; vulnery.
PR	01-SEP-1998;	98US-009816P.	OS	Homo sapiens.
PR	01-SEP-1998;	98US-0098723P.	XX	
PR	02-SEP-1998;	98US-0098803P.	PN	US2003027280-A1.
PR	02-SEP-1998;	98US-0098821P.	XX	
PR	02-SEP-1998;	98US-0098843P.	XX	
PR	09-SEP-1998;	98US-0099602P.	PD	06-FEB-2003.
PR	10-SEP-1998;	98US-0099741P.	XX	
PR	10-SEP-1998;	98US-0099754P.	PF	20-JUN-2002; 2002US-00176993.
PR	10-SEP-1998;	98US-0099763P.	XX	
PR	15-SEP-1998;	98US-0099812P.	PR	18-SEP-1997; 97US-0059263P.
PR	16-SEP-1998;	98US-0100682P.	PR	18-SEP-1997; 97US-0059266P.
PR	16-SEP-1998;	98US-0100684P.	PR	17-OCT-1997; 97US-0062250P.
PR	17-SEP-1998;	98US-0100683P.	PR	17-OCT-1997; 97US-0063486P.
PR	17-SEP-1998;	98US-0100919P.	PR	24-OCT-1997; 97US-0063120P.
PR	17-SEP-1998;	98US-0100930P.	PR	24-OCT-1997; 97US-0063121P.
PR	18-SEP-1998;	98US-0100849P.	PR	28-OCT-1997; 97US-0063540P.
PR	18-SEP-1998;	98US-0101014P.	PR	28-OCT-1997; 97US-0063541P.
PR	18-SEP-1998;	98US-0101068P.	PR	28-OCT-1997; 97US-0063544P.
PR	23-SEP-1998;	98US-0101471P.	PR	28-OCT-1997; 97US-0063564P.
PR	23-SEP-1998;	98US-0101472P.	PR	29-OCT-1997; 97US-0063734P.
PR	23-SEP-1998;	98US-0101475P.	PR	31-OCT-1997; 97US-0063870P.
PR	23-SEP-1998;	98US-0101477P.	PR	31-OCT-1997; 97US-0064103P.
PR	24-SEP-1998;	98US-0101738P.	PR	13-NOV-1997; 97US-0065311P.
PR	24-SEP-1998;	98US-0101739P.	PR	21-NOV-1997; 97US-0066120P.
PR	24-SEP-1998;	98US-0101743P.	PR	24-NOV-1997; 97US-0066466P.
PR	24-SEP-1998;	98US-0101922P.	PR	24-NOV-1997; 97US-0066772P.
PR	25-SEP-1998;	98US-0101786P.	PR	11-DEC-1997; 97US-0069335P.
PR	25-SEP-1998;	98US-0102207P.	PR	12-DEC-1997; 97US-0069425P.
PR	29-SEP-1998;	98US-0102240P.	PR	17-DEC-1997; 97US-0069870P.
PR	29-SEP-1998;	98US-0102330P.	PR	18-DEC-1997; 97US-0068017P.
PR	29-SEP-1998;	98US-0102331P.	PR	10-MAR-1998; 98US-0077450P.
PR	30-SEP-1998;	98US-0102487P.	PR	11-MAR-1998; 98US-0077632P.
PR	30-SEP-1998;	98US-0102570P.	PR	11-MAR-1998; 98US-0077649P.
PR	30-SEP-1998;	98US-0102571P.	PR	20-MAR-1998; 98US-0078886P.
PR	01-OCT-1998;	98US-0102684P.	PR	27-MAR-1998; 98US-0078939P.
PR	01-OCT-1998;	98US-0102687P.	PR	27-MAR-1998; 98US-0079664P.
PR	01-OCT-1998;	98US-0102688P.	PR	31-MAR-1998; 98US-0080107P.
PR	01-OCT-1998;	98US-0102689P.	PR	31-MAR-1998; 98US-0080194P.
PR	01-OCT-1998;	98US-0102690P.	PR	01-APR-1998; 98US-0080327P.
PR	01-OCT-1998;	98US-0102691P.	PR	01-APR-1998; 98US-0080333P.
PR	01-OCT-1998;	98US-0102692P.	PR	08-APR-1998; 98US-0081049P.
PR	01-OCT-1998;	98US-0102693P.	PR	08-APR-1998; 98US-0081070P.
PR	01-OCT-1998;	98US-0102694P.	PR	09-APR-1998; 98US-0081195P.
PR	01-OCT-1998;	98US-0102695P.	PR	15-APR-1998; 98US-0081838P.
PR	01-OCT-1998;	98US-0102696P.	PR	15-APR-1998; 98US-0081839P.
PR	01-OCT-1998;	98US-0102697P.	PR	21-APR-1998; 98US-0082568P.
PR	01-OCT-1998;	98US-0102698P.	PR	21-APR-1998; 98US-0082569P.
PR	01-OCT-1998;	98US-0102699P.	PR	22-APR-1998; 98US-0082704P.
PR	01-OCT-1998;	98US-0102700P.	PR	22-APR-1998; 98US-0082797P.
PR	01-OCT-1998;	98US-0102701P.	PR	28-APR-1998; 98US-0083322P.
PR	01-OCT-1998;	98US-0102702P.	PR	28-APR-1998; 98US-0083495P.
PR	01-OCT-1998;	98US-0102703P.	PR	29-APR-1998; 98US-0083496P.
PR	01-OCT-1998;	98US-0102704P.	PR	29-APR-1998; 98US-0083499P.
PR	01-OCT-1998;	98US-0102705P.	PR	29-APR-1998; 98US-0083559P.
PR	01-OCT-1998;	98US-0102706P.	PR	05-MAY-1998; 98US-0084366P.
PR	01-OCT-1998;	98US-0102707P.	PR	05-MAY-1998; 98US-0084414P.
PR	01-OCT-1998;	98US-0102708P.	PR	07-MAY-1998; 98US-0084639P.
PR	01-OCT-1998;	98US-0102709P.	PR	07-MAY-1998; 98US-0084640P.
PR	01-OCT-1998;	98US-0102710P.	PR	07-MAY-1998; 98US-0084643P.
PR	01-OCT-1998;	98US-0102711P.	PR	15-MAY-1998; 98US-0085579P.
PR	01-OCT-1998;	98US-0102712P.	PR	15-MAY-1998; 98US-0085580P.
PR	01-OCT-1998;	98US-0102713P.	PR	
PR	01-OCT-1998;	98US-0102714P.	PR	
PR	01-OCT-1998;	98US-0102715P.	PR	
PR	01-OCT-1998;	98US-0102716P.	PR	
PR	01-OCT-1998;	98US-0102717P.	PR	
PR	01-OCT-1998;	98US-0102718P.	PR	
PR	01-OCT-1998;	98US-0102719P.	PR	
PR	01-OCT-1998;	98US-0102720P.	PR	
PR	01-OCT-1998;	98US-0102721P.	PR	
PR	01-OCT-1998;	98US-0102722P.	PR	
PR	01-OCT-1998;	98US-0102723P.	PR	
PR	01-OCT-1998;	98US-0102724P.	PR	
PR	01-OCT-1998;	98US-0102725P.	PR	
PR	01-OCT-1998;	98US-0102726P.	PR	
PR	01-OCT-1998;	98US-0102727P.	PR	
PR	01-OCT-1998;	98US-0102728P.	PR	
PR	01-OCT-1998;	98US-0102729P.	PR	
PR	01-OCT-1998;	98US-0102730P.	PR	
PR	01-OCT-1998;	98US-0102731P.	PR	
PR	01-OCT-1998;	98US-0102732P.	PR	
PR	01-OCT-1998;	98US-0102733P.	PR	
PR	01-OCT-1998;	98US-0102734P.	PR	
PR	01-OCT-1998;	98US-0102735P.	PR	
PR	01-OCT-1998;	98US-0102736P.	PR	
PR	01-OCT-1998;	98US-0102737P.	PR	
PR	01-OCT-1998;	98US-0102738P.	PR	
PR	01-OCT-1998;	98US-0102739P.	PR	
PR	01-OCT-1998;	98US-0102740P.	PR	
PR	01-OCT-1998;	98US-0102741P.	PR	
PR	01-OCT-1998;	98US-0102742P.	PR	
PR	01-OCT-1998;	98US-0102743P.	PR	
PR	01-OCT-1998;	98US-0102744P.	PR	
PR	01-OCT-1998;	98US-0102745P.	PR	
PR	01-OCT-1998;	98US-0102746P.	PR	
PR	01-OCT-1998;	98US-0102747P.	PR	
PR	01-OCT-1998;	98US-0102748P.	PR	
PR	01-OCT-1998;	98US-0102749P.	PR	
PR	01-OCT-1998;	98US-0102750P.	PR	
PR	01-OCT-1998;	98US-0102751P.	PR	
PR	01-OCT-1998;	98US-0102752P.	PR	
PR	01-OCT-1998;	98US-0102753P.	PR	
PR	01-OCT-1998;	98US-0102754P.	PR	
PR	01-OCT-1998;	98US-0102755P.	PR	
PR	01-OCT-1998;	98US-0102756P.	PR	
PR	01-OCT-1998;	98US-0102757P.	PR	
PR	01-OCT-1998;	98US-0102758P.	PR	
PR	01-OCT-1998;	98US-0102759P.	PR	
PR	01-OCT-1998;	98US-0102760P.	PR	
PR	01-OCT-1998;	98US-0102761P.	PR	
PR	01-OCT-1998;	98US-0102762P.	PR	
PR	01-OCT-1998;	98US-0102763P.	PR	
PR	01-OCT-1998;	98US-0102764P.	PR	
PR	01-OCT-1998;	98US-0102765P.	PR	
PR	01-OCT-1998;	98US-0102766P.	PR	
PR	01-OCT-1998;	98US-0102767P.	PR	
PR	01-OCT-1998;	98US-0102768P.	PR	
PR	01-OCT-1998;	98US-0102769P.	PR	
PR	01-OCT-1998;	98US-0102770P.	PR	
PR	01-OCT-1998;	98US-0102771P.	PR	
PR	01-OCT-1998;	98US-0102772P.	PR	
PR	01-OCT-1998;	98US-0102773P.	PR	
PR	01-OCT-1998;	98US-0102774P.	PR	
PR	01-OCT-1998;	98US-0102775P.	PR	
PR	01-OCT-1998;	98US-0102776P.	PR	
PR	01-OCT-1998;	98US-0102777P.	PR	
PR	01-OCT-1998;	98US-0102778P.	PR	
PR	01-OCT-1998;	98US-0102779P.	PR	
PR	01-OCT-1998;	98US-0102780P.	PR	
PR	01-OCT-1998;	98US-0102781P.	PR	
PR	01-OCT-1998;	98US-0102782P.	PR	
PR	01-OCT-1998;	98US-0102783P.	PR	
PR	01-OCT-1998;	98US-0102784P.	PR	
PR	01-OCT-1998;	98US-0102785P.	PR	
PR	01-OCT-1998;	98US-0102786P.	PR	
PR	01-OCT-1998;	98US-0102787P.	PR	
PR	01-OCT-1998;	98US-0102788P.	PR	
PR	01-OCT-1998;	98US-0102789P.	PR	
PR	01-OCT-1998;	98US-0102790P.	PR	
PR	01-OCT-1998;	98US-0102791P.	PR	
PR	01-OCT-1998;	98US-0102792P.	PR	
PR	01-OCT-1998;	98US-0102793P.	PR	
PR	01-OCT-1998;	98US-0102794P.	PR	
PR	01-OCT-1998;	98US-0102795P.	PR	
PR	01-OCT-1998;	98US-0102796P.	PR	
PR	01-OCT-1998;	98US-0102797P.	PR	
PR	01-OCT-1998;	98US-0102798P.	PR	
PR	01-OCT-1998;	98US-0102799P.	PR	
PR	01-OCT-1998;	98US-0102800P.	PR	
PR	01-OCT-1998;	98US-0102801P.	PR	
PR	01-OCT-1998;	98US-0102802P.	PR	
PR	01-OCT-1998;	98US-0102803P.	PR	
PR	01-OCT-1998;	98US-0102804P.	PR	
PR	01-OCT-1998;	98US-0102805P.	PR	
PR	01-OCT-1998;	98US-0102806P.	PR	
PR	01-OCT-1998;	98US-0102807P.	PR	
PR	01-OCT-1998;	98US-0102808P.	PR	
PR	01-OCT-1998;	98US-0102809P.	PR	
PR	01-OCT-1998;	98US-0102810P.	PR	
PR	01-OCT-1998;	98US-0102811P.	PR	
PR	01-OCT-1998;	98US-0102812P.	PR	
PR	01-OCT-1998;	98US-0102813P.	PR	
PR	01-OCT-1998;	98US-0102814P.	PR	
PR	01-OCT-1998;	98US-0102815P.	PR	
PR	01-OCT-1998;	98US-0102816P.	PR	
PR	01-OCT-1998;	98US-0102817P.	PR	
PR	01-OCT-1998;	98US-0102818P.	PR	
PR	01-OCT-1998;	98US-0102819P.	PR	
PR	01-OCT-1998;	98US-0102820P.	PR	
PR	01-OCT-1998;	98US-0102821P.	PR	
PR	01-OCT-1998;	98US-0102822P.	PR	
PR	01-OCT-1998;	98US-0102823P.	PR	
PR	01-OCT-1998;	98US-0102824P.	PR	
PR	01-OCT-1998;	98US-0102825P.	PR	
PR	01-OCT-1998;	98US-0102826P.	PR	
PR	01-OCT-1998;	98US-0102827P.	PR	
PR	01-OCT-1998;	98US-0102828P.	PR	
PR	01-OCT-1998;	98US-0102829P.	PR	
PR	01-OCT-1998;	98US-0102830P.	PR	
PR	01-OCT-1998;	98US-0102831P.	PR	
PR	01-OCT-1998;	98US-0102832P.	PR	
PR	01-OCT-1998;	98US-0102833P.	PR	
PR	01-OCT-1998;	98US-0102834P.	PR	
PR	01-OCT-1998;	98US-0102835P.	PR	
PR	01-OCT-1998;	98US-0102836P.	PR	
PR	01-OCT-1998;	98US-0102837P.	PR	
PR	01-OCT-1998;	98US-0102838P.	PR	
PR	01-OCT-1998;	98US-0102839P.	PR	
PR	01-OCT-1998;	98US-0102840P.	PR	
PR	01-OCT-1998;	98US-0102841P.	PR	
PR	01-OCT-1998;	98US-0102842P.	PR	
PR	01-OCT-1998;	98US-0102843P.	PR	
PR	01-OCT-1998;	98US-0102844P.	PR	
PR	01-OCT-1998;	98US-0102845P.	PR	
PR	01-OCT-1998;	98US-0102846P.	PR	
PR	01-OCT-1998;	98US-0102847P.	PR	
PR	01-OCT-1998;	98US-0102848P.	PR	
PR	01-OCT-1998;	98US-0102849P.	PR	
PR				

PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086382P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088035P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088732P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.

PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 26-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 24-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCACCTTTCTCTTTATCTTATTAATAAATGTTGCTCTCCACCACTG 2180
|||||

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA 2712
|||||

Qy 2181 NCTCCCAA 2240
|||||

Db 2713 CAAAAAATAA 2772
|||||

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 367

ACA731162
ID ACA731162 standard; cDNA; 2846 BP.
XX AC ACA731162;
XX DT 01-JUL-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; transgenic animal; knockout animal; tissue typing; tumour;
KW chondrocyte cell proliferation; gene therapy;
KW chondrocyte cell differentiation; tumour necrosis factor-alpha release;
KW gene; ss.
XX OS Homo sapiens.
XX PN US2003022300-A1.
XX XX 30-JAN-2003.
XX PF 25-JUN-2002; 2002US-00180552.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065111P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082737P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095598P.
PR 17-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.

```

PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100913P.
PR 17-SEP-1998; 98US-0100913P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATTATTAATAAAATGTGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCGAACTA 2712
Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

```

```

RESULT 368
ACA68705
ID ACA68705 standard; cDNA; 2846 BP.
XX
AC ACA68705;
XX
DT 09-JUL-2003 (revised)
DT 26-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW TNF-Agonist-Alpha; chondrocyte stimulator; tumour; adrenal tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003036136-A1.
XX
PD 20-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184636.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.

```

PR	07-MAY-1998;	98US-0084543P.	PR	17-AUG-1998;	98US-0096757P.				
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096766P.				
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.				
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-00968891P.				
PR	18-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.				
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.				
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.				
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.				
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.				
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.				
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.				
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.				
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.				
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.				
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098016P.				
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.				
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.				
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.				
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.				
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.				
PR	05-JUN-1998;	98US-0088202P.	PR	10-SEP-1998;	98US-0099741P.				
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099754P.				
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099763P.				
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099812P.				
PR	10-JUN-1998;	98US-0088722P.	PR	15-SEP-1998;	98US-0100388P.				
PR	10-JUN-1998;	98US-0088722P.	PR	16-SEP-1998;	98US-0100662P.				
PR	10-JUN-1998;	98US-0088740P.	PR	16-SEP-1998;	98US-0100664P.				
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0101751P.				
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0101751P.				
PR	10-JUN-1998;	98US-0088825P.	PR	17-SEP-1998;	98US-0100683P.				
PR	10-JUN-1998;	98US-0088826P.	PR	17-SEP-1998;	98US-0100684P.				
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100919P.				
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100930P.				
PR	11-JUN-1998;	98US-0088876P.	PR	18-SEP-1998;	98US-0100849P.				
PR	12-JUN-1998;	98US-0089090P.	PR	18-SEP-1998;	98US-0101014P.				
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0101068P.				
PR	16-JUN-1998;	98US-0089512P.	PR	23-SEP-1998;	98US-0101471P.				
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101472P.				
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101475P.				
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101477P.				
PR	17-JUN-1998;	98US-0089653P.	PR	24-SEP-1998;	98US-0101738P.				
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101739P.				
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101743P.				
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101922P.				
PR	22-JUN-1998;	98US-0090252P.	PR	25-SEP-1998;	98US-0101786P.				
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0102207P.				
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102240P.				
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102330P.				
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102331P.				
PR	24-JUN-1998;	98US-0090535P.	PR	30-SEP-1998;	98US-0102487P.				
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102570P.				
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102571P.				
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102684P.				
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102687P.				
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102965P.				
PR	25-JUN-1998;	98US-0090694P.	PR	02-OCT-1998;	98US-0102965P.				
PR	25-JUN-1998;	98US-0090695P.	PR	06-OCT-1998;	98US-0103258P.				
PR	25-JUN-1998;	98US-0090696P.							
PR	26-JUN-1998;	98US-00105413.							
PR	26-JUN-1998;	98US-0090862P.							
PR	26-JUN-1998;	98US-0090863P.							
PR	26-JUN-1998;	98US-0091010P.							
PR	01-JUL-1998;	98US-0091315P.							
PR	01-JUL-1998;	98US-0091544P.							
PR	02-JUL-1998;	98US-0091478P.							
PR	02-JUL-1998;	98US-0091486P.							
PR	02-JUL-1998;	98US-0091626P.							
PR	02-JUL-1998;	98US-0091628P.							
PR	02-JUL-1998;	98US-0091632P.							
PR	24-JUL-1998;	98US-0094006P.							
PR	04-AUG-1998;	98US-0095282P.							
PR	10-AUG-1998;	98US-0095998P.							
PR	10-AUG-1998;	98US-0096012P.							
						Query Match 3.0%; Score 66.6; DB 8; Length 2846;			
						Best Local Similarity 71.3%; Pred. No. 0.00023;			
						Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121	CCTTTGGCTTTTACCACCTCTTTCCCTTTTATCTTATATAATAAATGTTGGTCTCCACCACTG	2180	2121	CCTTTGGCTTTTACCACCTCTTTCCCTTTTATCTTATATAATAAATGTTGGTCTCCACCACTG	2180			
DB	2653	CCTTTTCTCTCCCACTCTCTGTGACACATTTTAAATAAATAAGGTTGGTCTCTGAACCTA	2712	2653	CCTTTTCTCTCCCACTCTCTGTGACACATTTTAAATAAATAAGGTTGGTCTCTGAACCTA	2712			
QY	2181	NTCCCAAA	2240	2181	NTCCCAAA	2240			
DB	2713	CAAA	2772	2713	CAAA	2772			
QY	2241	AA 2242		2241	AA 2242				
DB	2773	AA 2774		2773	AA 2774				

```
RESULT 369
ACA74549
ID ACA74549 standard; cDNA; 2846 BP.
XX AC ACA74549;
XX DT 07-JUL-2003 (first entry)
XX DE cDNA encoding human PRO polypeptide #85.
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
KW prostate; rectal; cervical; liver; cancer; cytostatic; gene therapy;
KW gene; ss.
XX OS Homo sapiens.
XX PN US2003036138-A1.
XX PD 20-FEB-2003.
XX PF 28-JUN-2002; 2002US-00184650.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080337P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0088909P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090896P.
PR 26-JUN-1998; 98US-00103413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
```

Wed Feb 16 11:37:55 2005

```
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 13-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 06-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCCTTGTTCACCACTCTTTCCTTTATCTTATTATAAATAAATGCTGCTCCACCACTG 2180
Db 2653 CCCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 370
ACA70416
ID ACA70416 standard; cDNA; 2846 BP.
XX AC ACA70416;
AC ACA70416;
XX DT 11-AUG-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
tissue typing; cytosolic.
XX OS Homo sapiens.
XX PN US2003032109-A1.
XX PD 13-FEB-2003.
XX PF 20-JUN-2002; 2002US-00176485.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 05-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
```


Db 2773 AA 2774

RESULT 371

ACD14602

ID ACD14602 standard; cDNA; 2846 BP.

XX

XX ACD14602;

AC

XX 19-AUG-2003 (first entry)

DT

XX Human PRO polynucleotide #85.

DE

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW cytototoxic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;

KW chondrocyte cell; cancer.

XX

XX Homo sapiens.

XX

XX US2003040066-A1.

FN

XX 27-FEB-2003.

XX

XX 26-JUN-2002; 2002US-00183019.

PF

XX

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063340P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 11-MAR-1998; 98US-0078866P.

PR 20-MAR-1998; 98US-0078939P.

PR 20-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080154P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085700P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 22-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088825P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088863P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089090P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090461P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090688P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090895P.

PR 25-JUN-1998; 98US-0090896P.

PR 25-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091486P.

PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091632P.

PR 24-JUL-1998; 98US-0094006P.

PR 04-AUG-1998; 98US-0095282P.

PR 10-AUG-1998; 98US-0095998P.

PR	10-AUG-1998;	98US-0096012P.	
PR	17-AUG-1998;	98US-0096757P.	
PR	17-AUG-1998;	98US-0096766P.	
PR	17-AUG-1998;	98US-0096867P.	
PR	17-AUG-1998;	98US-0096891P.	
PR	17-AUG-1998;	98US-0096897P.	
PR	18-AUG-1998;	98US-0096949P.	
PR	18-AUG-1998;	98US-0096959P.	
PR	18-AUG-1998;	98US-0097022P.	
PR	26-AUG-1998;	98US-0097952P.	
PR	26-AUG-1998;	98US-0097954P.	
PR	26-AUG-1998;	98US-0097955P.	
PR	26-AUG-1998;	98US-0097971P.	
PR	26-AUG-1998;	98US-0097974P.	
PR	26-AUG-1998;	98US-0098014P.	
PR	01-SEP-1998;	98US-0098716P.	
PR	01-SEP-1998;	98US-0098723P.	
PR	02-SEP-1998;	98US-0098803P.	
PR	02-SEP-1998;	98US-0098821P.	
PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	
PR	10-SEP-1998;	98US-0099763P.	
PR	10-SEP-1998;	98US-0099812P.	
PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98US-0101753P.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100845P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
PR	02-OCT-1998;	98US-0102965P.	
PR	06-OCT-1998;	98US-0103258P.	
PR	06-OCT-1998;	98US-0103449P.	
PR	07-OCT-1998;	98US-00168978.	

Query Match
Best Local Similarity 3.0%; Score 66.6; DB 8; Length 2846;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCCTTGGTTTACCACTCTTCTTTTATCTTATTAAATAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCCTTTCCTCCCATCTCTTGTACACATTTTAAATAAATAGGGTTGGCTTCTGAAC	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAA	2772
Qy	2241	AA	2242

Db	2773	AA	2774
RESULT 372			
ACA93715			
ID	ACA93715	standard; cDNA; 2846	BP.
XX	ACA93715;		
XX	ACA93715;		
DT	17-JUL-2003	(first entry)	
DE	Human cDNA encoding secreted/transmembrane protein PRO1344.		
XX	Human; ss; gene; PRO; secreted protein; transmembrane protein; cytosolic; vulnary; osteopathic; antiarthritic; antirheumatic; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; liver tumour; tumour necrosis factor; pericyte cell proliferation; TNF-alpha; proteoglycans release; cartilage; cancer; wound healing; cartilage defect; osteoarthritis; rheumatoid arthritis.		
OS	Homo sapiens.		
XX	US2003045684-A1.		
PN	06-MAR-2003.		
PD	02-MAY-2002; 2002US-00063553.		
XX	30-DEC-1998; 98KR-00062142.		
PR	08-MAR-1999; 99WO-US005028.		
PR	14-MAY-1999; 99US-00311832.		
PR	14-MAY-1999; 99WO-US010733.		
PR	25-AUG-1999; 99US-00380137.		
PR	25-AUG-1999; 99US-00380138.		
PR	25-AUG-1999; 99US-00380139.		
PR	25-AUG-1999; 99US-00380142.		
PR	15-SEP-1999; 99US-00397342.		
PR	15-SEP-1999; 99US-00403297.		
PR	12-NOV-1999; 99US-00423844.		
PR	30-DEC-1999; 99WO-US031274.		
PR	18-FEB-2000; 2000WO-US004341.		
PR	01-MAR-2000; 2000WO-US005601.		
PR	02-MAR-2000; 2000WO-US005841.		
PR	21-MAR-2000; 2000WO-US007532.		
PR	22-MAY-2000; 2000WO-US014042.		
PR	02-JUN-2000; 2000WO-US015264.		
PR	22-AUG-2000; 2000US-00644848.		
PR	24-AUG-2000; 2000WO-US023328.		
PR	18-SEP-2000; 2000US-00664610.		
PR	18-SEP-2000; 2000US-00665350.		
PR	08-NOV-2000; 2000US-00709238.		
PR	10-NOV-2000; 2000WO-US030873.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	20-DEC-2000; 2000US-00747259.		
PR	20-DEC-2000; 2000WO-US034956.		
PR	28-FEB-2001; 2001WO-US006520.		
PR	22-MAR-2001; 2001US-00816744.		
PR	10-MAY-2001; 2001US-00854208.		
PR	30-MAY-2001; 2001US-00854280.		
PR	01-JUN-2001; 2001WO-US017800.		
PR	05-JUN-2001; 2001US-00874503.		
PR	29-JUN-2001; 2001US-00869599.		
PR	18-JUL-2001; 2001US-00908827.		
PR	06-DEC-2001; 2001US-00006867.		
XX	(GETH) GENENTECH INC.		
PA	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;		
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;		
XX	WPI; 2003-392892/37.		
DR			

```

DR P-PSDB; ABU92494.
XX
PT New PRO994 polypeptide, useful for detecting tumors, or for stimulating
PT Tumor Necrosis Factor alpha, or pericyte proliferation, especially for
PT treating cancer, cartilage defects, osteoarthritis and rheumatoid
PT arthritis in a mammal.
XX
PS Disclosure; Fig 37; 235pp; English.
XX
CC The invention relates to a new isolated PRO994 polypeptide comprises an
CC amino acid sequence appearing as ABU92499, PRO994 lacking its associated
CC signal peptide, the extracellular domain of PRO994, the extracellular
CC domain of PRO994 (lacking it associated signal peptide) or the protein
CC encoded by the full-length coding sequence of the cDNA ATCC 203018. Also
CC included is a chimeric molecule comprising the PRO994 polypeptide fused
CC to a heterologous amino acid sequence. The PRO polypeptide is useful in
CC pharmaceuticals, diagnostics, biosensors or bioreactors. It is
CC particularly useful for detecting tumors (e.g. lung tumour, colon
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood, for stimulating the proliferation of pericyte
CC cells, or stimulating the release of proteoglycans from cartilage. The
CC polypeptide may be employed for a variety of therapeutic purposes, e.g.
CC for treating cancer, wound healing, cartilage defects, osteoarthritis,
CC rheumatoid arthritis. Also disclosed are the cDNA encoding PRO994, 83
CC other PRO polypeptides and their encoding cDNAs. The present sequence
CC encodes a PRO polypeptide of the invention
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTTCCCATCTCTGTGTACACATTTTAAATAAAATAGGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 373
ACA68274
ID ACA68274 standard; cDNA; 2846 BP.
XX
AC ACA68274;
XX
DT 25-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy;
KW chromosome mapping; gene mapping; tumor necrosis factor-alpha; blood;
KW chondrocyte differentiation stimulator;
KW chondrocyte proliferation stimulator; tumour; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032104-A1.
XX
PD 13-FEB-2003.
XX
PF 18-JUN-2002; 2002US-00174576.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.

```

```

PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 06-MAY-1998; 98US-0084366P.
PR 07-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 02-JUN-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.

```


PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 11-NOV-1997; 97US-0065311P.
PR 11-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 24-NOV-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 12-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0077886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.

```

PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match
Best Local Similarity 3.0%; Score 66.6; DB 8; Length 2846;
Matches: 87; Conservative 71.3%; Pred. No. 0.00023;
Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCACCTCTTCCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
Db 2653 CTTTTCCTTCCCATCTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 375
ACC81216
ID ACC81216 standard; cDNA; 2846 BP.
XX
AC ACC81216;
XX
DT 28-JUL-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032120-A1.
XX
PD 13-FEB-2003.
XX

```

```

PF 25-JUN-2002; 2002US-00180546.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088266P.
PR 05-JUN-1998; 98US-0088267P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.

```


PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 13-NOV-1997; 97US-0064103P.
PR 21-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083435P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097852P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.

```

PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98NO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102955P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CTTTGGTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CTTTTCCTTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db ||
2773 AA 2774

RESULT 377
ACD04458
ID ACD04458 standard; cDNA; 2846 BP.
XX AC ACD04458;
XX AC ACD04458;
XX DT 05-AUG-2003 (first entry)
XX DE
XX DT Novel human secreted and transmembrane protein PRO1344 cDNA.
XX KW Human; ss; gene therapy; chondrocyte stimulator; tissue typing; tumour;
XX KW tumour necrosis factor alpha; TNF-alpha; gene.
XX OS Homo sapiens;
XX PN US2003022296-A1.
XX PD 30-JAN-2003.
XX PF 20-JUN-2002; 2002US-00176482.
XX PF 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077643P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 05-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
```

```
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 24-JUL-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 24-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 07-OCT-1998; 98US-0103401P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATGTTGCTCCACCACGTG 2180
Db 2653 CTTTTCCTCCCATCTCTTGACACATTTTATAAATAAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 378
ACCS7899
ID ACC87899 standard; cdna; 2846 BP.
XX ACC87899;
AC ACC87899;
XX 05-AUG-2003 (first entry)
DT Human secreted polypeptide PRO1344-encoding cdna, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX OS
XX US2003027281-A1.
EN
```

```
XX PD 06-FEB-2003.
XX PF 28-JUN-2002; 2002US-00184658.
XX PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 03-DEC-1998; 98US-00202054.
PR 07-MAR-1999; 98US-00254311.
PR 08-MAR-1999; 98WO-US005028.
PR 14-MAY-1999; 98US-00311832.
PR 14-MAY-1999; 98WO-US010733.
PR 22-JUN-1999; 99US-002202054.
PR 25-AUG-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US0644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 08-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 08-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX PR (GETH ) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI
```

```
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-417252/39.
DR P-PSDB; ABR66526.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; Fig 169; 707pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR66442-ABR66746) and nucleic acids encoding them (ACC87815-ACC88119).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterized. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC87815-ACC88119 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACACCTCTTTCTCTTTATTAATAAATAATGTTGCTCCACCATG 2180
DB 2653 CTTTTCTTCCCATCTCTTGACACATTTTAATAAATAAGGGTTGGCTTCGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 379
ACFI2561
ID ACFI2561 standard; cDNA; 2846 BP.
XX
```

AC ACF12561;
XX 09-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
OS Homo sapiens.
XX
XX US2003040058-A1.
XX
XX 27-FEB-2003.
XX 24-JUN-2002; 2002US-00179516.
XX 18-SEP-1997; 97US-005263P.
PR 18-SEP-1997; 97US-005266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077643P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078933P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084633P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088032P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL; Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PU; Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NP; Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;

```

PI Zhang Z;
XX WPI; 2003-155950/15.
DR P-PSDB; ABUS8964.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX
XX Claim 2; Fig 158; 647pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX comprising a sequence without signal peptide and the nucleic acid
XX encoding them. The polypeptides can be used to raise antibodies that
XX specifically bind to the PRO polypeptide, for linking a bioactive
XX molecule to a cell expressing a PRO protein and for modulating at least
XX one biological activity of a cell. The PRO polypeptides or
XX polynucleotides are also useful as pharmaceuticals, diagnostics,
XX biosensors or bioreactors, for detecting or treating e.g. tumours in
XX mammals, e.g. humans, dogs, cats, cattle, horses, sheep, goats or
XX rabbits as targets for therapeutic intervention in certain cancers (e.g.
XX colon, lung or breast cancers) and diagnostic determination of the
XX presence of these cancers. The PRO polypeptides are also useful as
XX molecular weight markers or for chromosome identification. The PRO genes
XX are useful as hybridisation probes or for screening libraries of human
XX cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
XX therapy, particularly for replacing a defective gene. The sequences
XX presented in ABX79290-ABX79675 are the genes encoding, the primers
XX amplifying and the probes detecting the PRO polynucleotides of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCCTTGGTTTACCACCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTTCCCTTCCCATCTCTGTACACATTTTAAATAAAATGAGGTTGGCTTCTGAAC 2712
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Db ||
QY 2773 AA 2774
Db ||

RESULT 382
ACA96276
ID ACA96276 standard; cDNA; 2846 BP.
XX
XX ACA96276;
XX
XX 23-JUL-2003 (first entry)
XX
XX Human PRO polynucleotide #85.
XX
XX Human; PRO; Gene; ss; cytostatic; tumour necrosis factor-alpha; blood;
XX TNF-alpha; chondrocyte cell; tumour; cancer.
XX
XX Homo sapiens.
XX
XX US2003017540-A1.
XX
XX 23-JAN-2003.
XX
XX 18-JUN-2002; 2002US-00174581.
XX
XX 18-SEP-1997; 97US-0059263P.
XX

```

```

PR 18-SEP-1997;
PR 17-OCT-1997;
PR 21-OCT-1997;
PR 24-OCT-1997;
PR 24-OCT-1997;
PR 28-OCT-1997;
PR 28-OCT-1997;
PR 28-OCT-1997;
PR 29-OCT-1997;
PR 31-OCT-1997;
PR 31-OCT-1997;
PR 13-NOV-1997;
PR 21-NOV-1997;
PR 24-NOV-1997;
PR 24-NOV-1997;
PR 11-DEC-1997;
PR 12-DEC-1997;
PR 17-DEC-1997;
PR 18-DEC-1997;
PR 10-MAR-1998;
PR 11-MAR-1998;
PR 11-MAR-1998;
PR 20-MAR-1998;
PR 20-MAR-1998;
PR 27-MAR-1998;
PR 27-MAR-1998;
PR 31-MAR-1998;
PR 31-MAR-1998;
PR 01-APR-1998;
PR 01-APR-1998;
PR 08-APR-1998;
PR 08-APR-1998;
PR 09-APR-1998;
PR 15-APR-1998;
PR 21-APR-1998;
PR 21-APR-1998;
PR 22-APR-1998;
PR 22-APR-1998;
PR 28-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 05-MAY-1998;
PR 06-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 18-MAY-1998;
PR 22-MAY-1998;
PR 22-MAY-1998;
PR 28-MAY-1998;
PR 28-MAY-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 03-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 09-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;

```

```

97US-0059266P.
97US-0062250P.
97US-0063486P.
97US-0063120P.
97US-0063121P.
97US-0063540P.
97US-0063541P.
97US-0063544P.
97US-0063564P.
97US-0063734P.
97US-0063870P.
97US-0064103P.
97US-0065311P.
97US-0066120P.
97US-0066466P.
97US-0066772P.
97US-0069335P.
97US-0069425P.
97US-0069870P.
97US-0068017P.
98US-0077450P.
98US-0077450P.
98US-0077632P.
98US-0077649P.
98US-0078886P.
98US-0078939P.
98US-0079664P.
98US-0079786P.
98US-0080107P.
98US-0080194P.
98US-0080327P.
98US-0080333P.
98US-0081049P.
98US-0081070P.
98US-0081195P.
98US-0081838P.
98US-0082568P.
98US-0082569P.
98US-0082704P.
98US-0082797P.
98US-0083322P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083559P.
98US-0084366P.
98US-0084414P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085579P.
98US-0085580P.
98US-0085582P.
98US-0085700P.
98US-0086023P.
98US-0086392P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088029P.
98US-0088133P.
98US-0088167P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.

```


PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 23-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088723P.
PR 10-JUN-1998; 98US-0088803P.
PR 10-JUN-1998; 98US-0088821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 17-JUN-1998; 98US-0089908P.
PR 18-JUN-1998; 98US-0089952P.
PR 19-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-009105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.

```

PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103259P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0016897P.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACGACTCTTCTTTATCTATTATTAATAATGTTGCTCCCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCCTCCCATCTCTTGTACACATTTTAAATAAAGGTTTGGCTTCTGAAC 2712
Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db ||
2773 AA 2774

RESULT 384
ID ACA73776
AC ACA73776;
XX
XX 02-JUL-2003 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; ss; gene; PRO; secreted protein; transmembrane protein;
XX tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
XX differentiation; chondrocyte; adrenal tumour; lung tumour; colon
XX breast tumour; prostate tumour; rectal tumour; cervical tumour;
XX liver tumour; gene therapy; cytostatic.
XX
XX Homo sapiens.
XX
XX US2003032129-A1.
XX
XX

```

```

PD 13-FEB-2003.
XX
XX 28-JUN-2002; 2002US-00184623.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 29-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082707P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.

```


XX PD 13-FEB-2003.
XX PF 28-JUN-2002; 2002US-00184637.
XX XX
PR 18-SEP-1997; 97US-0052626P.
PR 18-SEP-1997; 97US-0052666P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078933P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 05-MAY-1998; 98US-0083559P.
PR 06-MAY-1998; 98US-0084366P.
PR 07-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.

```
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100652P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-U8019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCCTTGGTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCCTTTCCCTCCCATCTCTGTACACATTTTAATAAAATAGGTTGGCTTCTGACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 386
ACA96583
ID ACA96583 standard; cDNA; 2846 BP.
XX
AC ACA96583;
CC
DT 23-JUL-2003 (first entry)
DE Human PRO polynucleotide #85.
XX
XX Human; PRO; gene; ss; cytostatic; tumour necrosis factor-alpha; blood;
KW TNF-alpha; chondrocyte cell; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003032103-A1.
XX
PD 13-FEB-2003.

XX
PF 17-JUN-2002; 2002US-00173705.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088126P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
```

```
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTTCCCTTTTATCTTATTAATAAAATCTTGTCTCCACCCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

ACD10689
ID ACD10689 standard; cDNA; 2846 BP.
XX AC ACD10689;
XX DT 12-AUG-2003 (first entry)
XX cDNA encoding human PRO polypeptide #85.
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
XX prostate; rectal; cervical; liver; cancer; gene therapy; cytostatic;
XX gene; ss.
XX OS Homo sapiens.
XX
```

PN US20030322107-A1.
XX 13-FEB-2003.
XX 19-JUN-2002; 2002US-00175747.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063340P.
PR 28-OCT-1997; 97US-0063341P.
PR 28-OCT-1997; 97US-0063344P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0087000P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091135P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097552P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.


```
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTCTCTTTATCTATTATAAATAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAAGGTTGGCTTCGAACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 388
ACC91385
ID ACC91385 standard; cDNA; 2846 BP.
XX
AC ACC91385;
XX
DT 19-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
```

```
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003032139-A1.
XX 13-FEB-2003.
XX
PF 01-JUL-2002; 2002US-00187886.
XX
PR 18-SEP-1997; 97US-0059283P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085800P.
PR 15-MAY-1998; 98US-0085822P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
```

Novel human secreted and transmembrane protein PRO1344 cDNA.

KW knockout animal; immunohistochemical staining; gene; ss.

OS Homo sapiens.

PN US2003022187-A1.

XX 30-JAN-2003.

XX 14-NOV-2001; 2001US-009931667.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-007594P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087106P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

XX 04-JUN-1998; 98US-0088026P.

XX 04-JUN-1998; 98US-0088028P.

XX 04-JUN-1998; 98US-0088029P.

XX 04-JUN-1998; 98US-0088030P.

XX 04-JUN-1998; 98US-0088033P.

XX 04-JUN-1998; 98US-0088326P.

XX 05-JUN-1998; 98US-0088167P.

XX 05-JUN-1998; 98US-0088202P.

XX 05-JUN-1998; 98US-0088212P.

XX 05-JUN-1998; 98US-0088217P.

XX 09-JUN-1998; 98US-0088655P.

XX 10-JUN-1998; 98US-0088734P.

XX 10-JUN-1998; 98US-0088738P.

XX 10-JUN-1998; 98US-0088742P.

XX 10-JUN-1998; 98US-0088810P.

XX 10-JUN-1998; 98US-0088824P.

XX 10-JUN-1998; 98US-0088826P.

XX 11-JUN-1998; 98US-0088858P.

PR 24-JUN-1998; 98US-0090445P.

PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.

PR 24-JUN-1998; 98US-0090557P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 01-JUL-1998; 98US-0091360P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091519P.

PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091633P.

PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.

PR 07-JUL-1998; 98US-0091978P.

PR 07-JUL-1998; 98US-0091982P.

PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.

PR 20-JUL-1998; 98US-0093339P.

PR 30-JUL-1998; 98US-0094651P.

PR 04-AUG-1998; 98US-0095285P.

PR 04-AUG-1998; 98US-0095301P.

PR 04-AUG-1998; 98US-0095302P.

PR 04-AUG-1998; 98US-0095318P.

PR 04-AUG-1998; 98US-0095321P.

PR 04-AUG-1998; 98US-0095325P.

PR 10-AUG-1998; 98US-0095916P.

PR 10-AUG-1998; 98US-0095929P.

PR 11-AUG-1998; 98US-0096012P.

PR 11-AUG-1998; 98US-0096143P.

PR 12-AUG-1998; 98US-0096329P.

PR 17-AUG-1998; 98US-0096757P.

PR 17-AUG-1998; 98US-0096766P.

PR 17-AUG-1998; 98US-0096768P.

PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.

PR 17-AUG-1998; 98US-0096867P.

PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.

PR 17-AUG-1998; 98US-0096895P.

PR 17-AUG-1998; 98US-0096897P.

PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096950P.

PR 18-AUG-1998; 98US-0096959P.

PR 18-AUG-1998; 98US-0096960P.

PR 18-AUG-1998; 98US-0097022P.

PR 19-AUG-1998; 98US-0097141P.

PR 20-AUG-1998; 98US-0097218P.

PR 24-AUG-1998; 98US-0097661P.

PR 26-AUG-1998; 98US-0097952P.

PR 26-AUG-1998; 98US-0097954P.

PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.

PR 26-AUG-1998; 98US-0097974P.

PR 26-AUG-1998; 98US-0097978P.

PR 26-AUG-1998; 98US-0097979P.

PR 26-AUG-1998; 98US-0097986P.

PR 31-AUG-1998; 98US-0098014P.

PR 16-SEP-1998; 98US-0098525P.

PR 16-SEP-1998; 98US-0100634P.

PR 17-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.

PR 17-SEP-1998; 98WO-US019437.

	cell differentiation; gene therapy; gene; sb.
	Homo sapiens.
	US2003022301-A1.
	30-JAN-2003.
	25-JUN-2002; 2002US-00180557.
	18-SEP-1997; 97US-0059263P.
	18-SEP-1997; 97US-0059266P.
	17-OCT-1997; 97US-0062250P.
	21-OCT-1997; 97US-0063486P.
	24-OCT-1997; 97US-0063120P.
	24-OCT-1997; 97US-0063121P.
	28-OCT-1997; 97US-0063540P.
	28-OCT-1997; 97US-0063541P.
	28-OCT-1997; 97US-0063544P.
	28-OCT-1997; 97US-0063564P.
	29-OCT-1997; 97US-0063734P.
	31-OCT-1997; 97US-0063870P.
	31-OCT-1997; 97US-0064103P.
	13-NOV-1997; 97US-0065311P.
	21-NOV-1997; 97US-0066120P.
	24-NOV-1997; 97US-0066466P.
	24-NOV-1997; 97US-0066772P.
	11-DEC-1997; 97US-0069335P.
	12-DEC-1997; 97US-0069425P.
	17-DEC-1997; 97US-0069870P.
	18-DEC-1997; 97US-0068017P.
	10-MAR-1998; 98US-0077450P.
	11-MAR-1998; 98US-0077632P.
	11-MAR-1998; 98US-0077649P.
	20-MAR-1998; 98US-0078866P.
	20-MAR-1998; 98US-0078939P.
	27-MAR-1998; 98US-0079664P.
	27-MAR-1998; 98US-0079786P.
	31-MAR-1998; 98US-0080107P.
	31-MAR-1998; 98US-0080194P.
	01-APR-1998; 98US-0080327P.
	01-APR-1998; 98US-0080333P.
	08-APR-1998; 98US-0081049P.
	08-APR-1998; 98US-0081070P.
	09-APR-1998; 98US-0081195P.
	15-APR-1998; 98US-0081838P.
	21-APR-1998; 98US-0082568P.
	21-APR-1998; 98US-0082569P.
	22-APR-1998; 98US-0082704P.
	22-APR-1998; 98US-0082777P.
	28-APR-1998; 98US-0083322P.
	29-APR-1998; 98US-0083495P.
	29-APR-1998; 98US-0083496P.
	29-APR-1998; 98US-0083499P.
	29-APR-1998; 98US-0083559P.
	05-MAY-1998; 98US-0084366P.
	06-MAY-1998; 98US-0084414P.
	07-MAY-1998; 98US-0084639P.
	07-MAY-1998; 98US-0084640P.
	07-MAY-1998; 98US-0084643P.
	15-MAY-1998; 98US-008579P.
	15-MAY-1998; 98US-008580P.
	15-MAY-1998; 98US-0085862P.
	15-MAY-1998; 98US-0085700P.
	18-MAY-1998; 98US-0086023P.
	22-MAY-1998; 98US-0086392P.
	22-MAY-1998; 98US-0086486P.
	22-MAY-1998; 98US-0087098P.
	28-MAY-1998; 98US-0087208P.
	02-JUN-1998; 98US-0087609P.
	02-JUN-1998; 98US-0087759P.
	03-JUN-1998; 98US-0087827P.
	04-JUN-1998; 98US-0088025P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCATTGCTTTACCACTTCCTTTCCTTTATCTTATTAATAAAATGTGGTCTCCACCACGTG	2180
Dd	2653	CCATTTTCCTTCCCCTCCTCTGTGCACATTTTAATAAAGGTGGCTTCTGAACIA	2712
Qy	2181	NCTCCCAA	2240
Dd	2713	CACAAA	2772
Qy	2241	AA 2242	
Dd	2773	AA 2774	

RESULT 390
 ACD02720
 ID ACD02720 standard; cDNA; 2846 BP.
 XX AC ACD02720;
 XX AC ACD02720;
 DT DT
 XX 01-AUG-2003 (first entry)
 DE cDNA encoding human PRO polypeptide #85.
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
 KW prostate; rectal; cervical; liver; cancer; TNF-alpha;
 KW tumour necrosis factor-alpha; cell proliferation; chondrocyte;

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 392
ACC85869
ID ACC85869 standard; cDNA; 2846 BP.
XX
AC ACC85869;
XX
DT 28-JUL-2003 (first entry)
DE
DE
DE
KW Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX
XX US2003027262-A1.
XX
XX
XX 06-FEB-2003.
XX
XX
XX 17-JUN-2002; 2002US-00173700.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 09-APR-1998; 98US-0081105P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.

QY		2241 AA 2242	
Db		2773 AA 2774	
RESULT 393			
ABX81158			
ID	ABX81158	standard; DNA; 2846 BP.	
XX			
XX	AC		
XX	ABX81159;		
XX	DT	(first entry)	
XX	22-APR-2003		
DE	Human secreted or transmembrane protein related PCR primer #50.		
XX			
KW	Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;		
KW	cardiac insufficiency disorder; cancer; tumour; immune response;		
KW	adrenal cortical capillary endothelial growth; c-fos induction;		
KW	vascular endothelial growth factor inhibition; VEGF inhibition;		
KW	endothelial cell growth inhibitor; T-lymphocytes stimulation;		
KW	retinal neurons cell survival; rod photoreceptor cell survival;		
KW	retinal disorder; retinitis pigmentosa; kidney disorder;		
KW	mammalian kidney mesangial cell proliferation; Berger disease;		
KW	dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;		
KW	chondrocyte redifferentiation; sports injury; arthritis; PCR; primer; ss.		
XX			
OS	Homo sapiens.		
XX			
XX	US2003027985-A1.		
PD			
XX	06-FEB-2003.		
PF			
XX	14-NOV-2001; 2001US-00990562.		
XX			
PR	16-JUN-1997; 97US-0049787P.		
PR	17-OCT-1997; 97US-0062250P.		
PR	05-NOV-1997; 97WO-US020069.		
PR	12-NOV-1997; 97US-0065186P.		
PR	13-NOV-1997; 97US-0065311P.		
PR	24-NOV-1997; 97US-0066770P.		
PR	25-FEB-1998; 98US-0075945P.		
PR	20-MAR-1998; 98US-0078910P.		
PR	28-APR-1998; 98US-0083322P.		
PR	07-MAY-1998; 98US-0084600P.		
PR	28-MAY-1998; 98US-0087106P.		
PR	02-JUN-1998; 98US-0087607P.		
PR	02-JUN-1998; 98US-0087609P.		
PR	02-JUN-1998; 98US-0087759P.		
PR	03-JUN-1998; 98US-0087827P.		
PR	04-JUN-1998; 98US-0088021P.		
PR	04-JUN-1998; 98US-0088025P.		
PR	04-JUN-1998; 98US-0088026P.		
PR	04-JUN-1998; 98US-0088028P.		
PR	04-JUN-1998; 98US-0088029P.		
PR	04-JUN-1998; 98US-0088030P.		
PR	04-JUN-1998; 98US-0088033P.		
PR	04-JUN-1998; 98US-0088326P.		
PR	05-JUN-1998; 98US-0088167P.		
PR	05-JUN-1998; 98US-0088202P.		
PR	05-JUN-1998; 98US-0088212P.		
PR	05-JUN-1998; 98US-0088217P.		
PR	05-JUN-1998; 98US-0088555P.		
PR	09-JUN-1998; 98US-0088734P.		
PR	10-JUN-1998; 98US-0088738P.		
PR	10-JUN-1998; 98US-0088742P.		
PR	10-JUN-1998; 98US-0088810P.		
PR	10-JUN-1998; 98US-0088824P.		
PR	10-JUN-1998; 98US-0088826P.		
PR	11-JUN-1998; 98US-0088858P.		
PR	11-JUN-1998; 98US-0088861P.		
PR	11-JUN-1998; 98US-0088876P.		
PR	12-JUN-1998; 98US-0089105P.		

PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090667P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTTCTTTTATTAATAAAAATGCTGCTCCACCACTG 2180
DB 2653 CCTTTTCTTTCCCACTCTTTTACACATTTTATAAAAATAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
|||||

Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 394
ACA65357
ID ACA65357 standard; cDNA; 2846 BP.
AC ACA65357;
XX
XX
DT 18-JUN-2003 (first entry)
TX Human PRO polynucleotide #85.
DE Human; PRO; gene; ss; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; tumour; cancer; cytostatic.
KW
XX
OS Homo sapiens.
XX
XX US2003032110-A1.
XX
XX 13-FEB-2003.
XX
XX 20-JUN-2002; 2002US-00176487.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.

```
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 24-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 02-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102955P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGTCTTACCACTCTTCTTTTATCTTTATTAATAAATGCTGCTCCCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2653 CTTTTCTTCCCATCTCTGTACACATTTAATAAATGAGGTGCTCTGAAC 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 395
ACA94174
ID ACA94174 standard; cDNA; 2846 BP.
XX AC ACA94174;
XX 18-JUL-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; ss; gene; PRO; secreted protein; transmembrane protein;
KW tumour necrosis factor alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte cell; cytostatic; tumour; gene therapy.
XX Homo sapiens.
XX US2003036142-A1.
PD 20-FEB-2003.
XX 01-JUL-2002; 2002US-00187598.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062350P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 28-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
```

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0091632P.
PR	05-MAY-1998;	98US-0084366P.	PR	04-JUL-1998;	98US-0094006P.
PR	06-MAY-1998;	98US-0084414P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084639P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998;	98US-0084643P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085700P.	PR	18-AUG-1998;	98US-0096949P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0097022P.
PR	22-MAY-1998;	98US-0086463P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097954P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097971P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097974P.
PR	03-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088722P.	PR	15-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088740P.	PR	16-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088825P.	PR	17-SEP-1998;	98US-01019330.
PR	10-JUN-1998;	98US-0088826P.	PR	17-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100919P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089090P.	PR	18-SEP-1998;	98US-0100849P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089512P.	PR	23-SEP-1998;	98US-0101471P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101477P.
PR	17-JUN-1998;	98US-0089552P.	PR	24-SEP-1998;	98US-0101738P.
PR	17-JUN-1998;	98US-0089553P.	PR	24-SEP-1998;	98US-0101739P.
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101743P.
PR	19-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101786P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101922P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090535P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090535P.	PR	30-SEP-1998;	98US-0102487P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090694P.	PR	02-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090695P.	PR	06-OCT-1998;	98US-0103258P.
PR	25-JUN-1998;	98US-0090696P.	PR	06-OCT-1998;	98US-0103449P.
PR	25-JUN-1998;	98US-0090696P.	PR	07-OCT-1998;	98US-00168978.
PR	26-JUN-1998;	98US-00105413.			
PR	26-JUN-1998;	98US-0090862P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-0091359P.			
PR	01-JUL-1998;	98US-0091544P.			
PR	02-JUL-1998;	98US-0091478P.			
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091626P.			

Query Match

Best Local Similarity

Matches

87;

Conservative

0;

Mismatches

35;

Indels

0;

Gaps

0;

Score

66.6;

DB

8;

Length

2846;

Qy

2121

CCCTTGGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG

2180

Db

2653

CCCTTTCCTTCCCACTCTCTGTACACATTTTAATAAAATAAGGTTGGTCTTCTGAACATA

2712

[illegible]

```

PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTACCACTTTTCCTTTTATCTTTATTAATAAAGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCACTCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAAC 2712

```

```

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 397
ACA91420
ID ACA91420 standard; cDNA; 2846 BP.
XX ACA91420;
AC ACA91420;
DT 14-JUL-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW antisense gene therapy; TNF-alpha release; chondrocyte proliferation;
KW tumour necrosis factor-alpha release; chondrocyte proliferation;
KW chondrocyte differentiation; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; gene; ss.
XX Homo sapiens.
OS
XX US2003036154-A1.
PN
XX 20-FEB-2003.
PD
XX
PF 02-JUL-2002; 2002US-00187757.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063970P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 11-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078886P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

```


Wed Feb 16 11:37:55 2005

us-10-036-342-56.rng

```
Db      2653 CCTTTTCCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712
Qy      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy      2241 AA 2242
Db      2773 AA 2774

RESULT 398
ID ACA90634
AC ACA90634 standard; cdna; 2846 BP.
XX
AC ACA90634;
XX
XX 11-AUG-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cdna.
XX Human; ss; gene therapy; tumour necrosis factor-alpha release; TNF;
KW chondrocyte proliferation; tumour necrosis factor-alpha release; TNF;
KW tissue typing.
XX
XX Homo sapiens.
XX US2003036153-A1.
XX
XX 20-FEB-2003.
XX
XX 02-JUL-2002; 2002US-00187754.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063110P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 21-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069423P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078888P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 18-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 22-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
```


PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 24-JUL-1998; 98US-0094008P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101922P.
PR 29-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
OY 2121 CCTTGTCTTACCACCTCTTCTTTATCTATTATAAAAAATGTTGCTCTCCACCACTG 2180

Db 2653 CTTTTCTCTCCCATCTCTTGTTACACATTTTATAAAATAGGCTTGGCTTCTGAACCTA 2712
OY 2181 NCTCCCAAA 2240
Db 2713 CAA 2772
OY 2241 AA 2242
Db 2773 AA 2774
RESULT 399
ACD16181
ID ACD16181 standard; cDNA; 2846 BP.
XX ACD16181;
AC ACD16181;
XX
DT 19-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
FN US2003044931-A1.
XX
PD 06-MAR-2003.
XX
PF 28-JUN-2002; 2002US-00184656.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082757P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085792P.
PR 15-MAY-1998; 98US-0085860P.
PR 15-MAY-1998; 98US-0085862P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089553P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTGTCTTACCACTCTTCTCTTTTATCTATTATTAATAAAATGTTGCTCCCACTG 2180
Db 2653 CTTTCTCTCCCACTCTTGTACACATTTTAAATAAATAGGTTGGCTTCTGACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 400
ACD17342
ID ACD17342 standard; cDNA; 2846 BP.
XX ACD17342;
AC ACD17342;
XX
DT 26-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036150-A1.
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00187747.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-00631120P.
PR 24-OCT-1997; 97US-00631121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069333P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
```

PR	26-JUN-1998;	98US-0091010P.	OY	2121	CCTTGGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGTCTCCACCACTG	2180
PR	01-JUL-1998;	98US-0091359P.				
PR	01-JUL-1998;	98US-0091544P.	Db	2653	CCTTTCTCTCCCACTCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACATA	2712
PR	02-JUL-1998;	98US-0091478P.				
PR	02-JUL-1998;	98US-0091486P.				
PR	02-JUL-1998;	98US-0091626P.	OY	2181	NCTCCCAAA	2240
PR	02-JUL-1998;	98US-0091628P.				
PR	02-JUL-1998;	98US-0091632P.	Db	2713	CAAA	2772
PR	02-JUL-1998;	98US-0094006P.				
PR	04-AUG-1998;	98US-0095282P.	OY	2241	AA 2242	
PR	10-AUG-1998;	98US-0095988P.				
PR	10-AUG-1998;	98US-0096012P.	Db	2773	AA 2774	
PR	17-AUG-1998;	98US-0096757P.				
PR	17-AUG-1998;	98US-0096766P.				
PR	17-AUG-1998;	98US-0096867P.				
PR	17-AUG-1998;	98US-0096891P.				
PR	17-AUG-1998;	98US-0096897P.				
PR	18-AUG-1998;	98US-0096949P.				
PR	18-AUG-1998;	98US-0096959P.				
PR	18-AUG-1998;	98US-0097022P.				
PR	26-AUG-1998;	98US-0097952P.				
PR	26-AUG-1998;	98US-0097954P.				
PR	26-AUG-1998;	98US-0097955P.				
PR	26-AUG-1998;	98US-0097971P.				
PR	26-AUG-1998;	98US-0097974P.				
PR	26-AUG-1998;	98US-0098014P.				
PR	01-SEP-1998;	98US-0098716P.				
PR	01-SEP-1998;	98US-0098723P.				
PR	02-SEP-1998;	98US-0098803P.				
PR	02-SEP-1998;	98US-0098821P.				
PR	02-SEP-1998;	98US-0098843P.				
PR	09-SEP-1998;	98US-0099602P.				
PR	10-SEP-1998;	98US-0099741P.				
PR	10-SEP-1998;	98US-0099754P.				
PR	10-SEP-1998;	98US-0099763P.				
PR	10-SEP-1998;	98US-0099812P.				
PR	15-SEP-1998;	98US-0100388P.				
PR	16-SEP-1998;	98US-0100662P.				
PR	16-SEP-1998;	98US-0101751P.				
PR	16-SEP-1998;	98US-0101751P.				
PR	17-SEP-1998;	98WO-US019330.				
PR	17-SEP-1998;	98US-0100683P.				
PR	17-SEP-1998;	98US-0100684P.				
PR	17-SEP-1998;	98US-0100919P.				
PR	17-SEP-1998;	98US-0100930P.				
PR	18-SEP-1998;	98US-0100849P.				
PR	18-SEP-1998;	98US-0101014P.				
PR	18-SEP-1998;	98US-0101068P.				
PR	23-SEP-1998;	98US-0101471P.				
PR	23-SEP-1998;	98US-0101472P.				
PR	23-SEP-1998;	98US-0101475P.				
PR	23-SEP-1998;	98US-0101477P.				
PR	24-SEP-1998;	98US-0101738P.				
PR	24-SEP-1998;	98US-0101739P.				
PR	24-SEP-1998;	98US-0101743P.				
PR	24-SEP-1998;	98US-0101922P.				
PR	25-SEP-1998;	98US-0101766P.				
PR	29-SEP-1998;	98US-0102207P.				
PR	29-SEP-1998;	98US-0102330P.				
PR	29-SEP-1998;	98US-0102331P.				
PR	30-SEP-1998;	98US-0102487P.				
PR	30-SEP-1998;	98US-0102570P.				
PR	30-SEP-1998;	98US-0102571P.				
PR	01-OCT-1998;	98US-0102684P.				
PR	01-OCT-1998;	98US-0102687P.				
PR	02-OCT-1998;	98US-0102965P.				
PR	06-OCT-1998;	98US-0103258P.				
PR	06-OCT-1998;	98US-0103443P.				
Query Match 3.0%; Score 66.6; DB 8; Length 2846;						
Best Local Similarity 71.3%; Pred. No. 0.00023;						
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;						
RESULT 401						
ACC91999						
ID	ACC91999	standard; cDNA; 2846 BP.				
XX	ACC91999;					
AC	ACC91999;					
XX	19-AUG-2003	(first entry)				
DT	19-AUG-2003					
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.					
XX	Human; PRO; secreted protein; transmembrane protein;					
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;					
KW	chondrocyte; proliferation; differentiation; cartilage disorder;					
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;					
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;					
KW	liver; drug screening; transgenic animal; genetic analysis;					
KW	antiarthritic; vulnery; gene therapy; gene; ss.					
XX	Homo sapiens.					
OS	Homo sapiens.					
XX	US2003040069-A1.					
PN	27-FEB-2003.					
XX	27-FEB-2003.					
XX	28-JUN-2002; 2002US-00184626.					
PR	18-SEP-1997;	97US-0059263P.				
PR	18-SEP-1997;	97US-0059266P.				
PR	17-OCT-1997;	97US-0062250P.				
PR	21-OCT-1997;	97US-0063486P.				
PR	24-OCT-1997;	97US-0063120P.				
PR	24-OCT-1997;	97US-0063121P.				
PR	28-OCT-1997;	97US-0063540P.				
PR	28-OCT-1997;	97US-0063541P.				
PR	28-OCT-1997;	97US-0063544P.				
PR	28-OCT-1997;	97US-0063564P.				
PR	31-OCT-1997;	97US-0063870P.				
PR	31-OCT-1997;	97US-0064103P.				
PR	13-NOV-1997;	97US-0065311P.				
PR	21-NOV-1997;	97US-0066120P.				
PR	24-NOV-1997;	97US-0066466P.				
PR	11-DEC-1997;	97US-0069335P.				
PR	12-DEC-1997;	97US-0069425P.				
PR	17-DEC-1997;	97US-0069870P.				
PR	18-DEC-1997;	97US-0068017P.				
PR	10-MAR-1998;	98US-0077450P.				
PR	11-MAR-1998;	98US-0077632P.				
PR	11-MAR-1998;	98US-0077649P.				
PR	20-MAR-1998;	98US-0078866P.				
PR	20-MAR-1998;	98US-0078939P.				
PR	27-MAR-1998;	98US-0079664P.				
PR	31-MAR-1998;	98US-0079786P.				
PR	31-MAR-1998;	98US-0080107P.				
PR	31-MAR-1998;	98US-0080194P.				
PR	01-APR-1998;	98US-0080327P.				
PR	01-APR-1998;	98US-0080333P.				
PR	08-APR-1998;	98US-0081049P.				

PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083553P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090432P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102311P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
QY	2121 CCTTGGCTTTACCACTCTTCCCTTTATCTATTATAAATAATGTTGGTCTCCACCACGTG 2180
Db	2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAATAGGTTGGTCTTGAACATA 2712
QY	2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db	2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY	2241 AA 2242
Db	2773 AA 2774
RESULT 402	
ACD02316	
ID	ACD02316 standard; cDNA; 2846 BP.
XX	ACD02316;
AC	
DT	30-JUL-2003 (first entry)
XX	Novel human secreted and transmembrane protein PRO1344 cDNA.
DE	
XX	Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW	cancer; chromosome mapping; gene mapping; diagnostic; biosensor;
KW	bioreactor; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2002183493-A1.
XX	
PD	05-DEC-2002.
XX	
PF	02-MAY-2002; 2002US-00063530.
XX	
PR	30-DEC-1998; 98KR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	15-SEP-1999; 99US-00397342.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	30-DEC-1999; 99WO-US031274.
PR	18-FEB-2000; 2000WO-US004341.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	21-MAR-2000; 2000WO-US007532.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	22-AUG-2000; 2000US-00644848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-00664610.
PR	18-SEP-2000; 2000US-00665350.
PR	08-NOV-2000; 2000US-00709238.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US0006520.
PR	22-MAR-2001; 2001US-00816744.
PR	10-MAY-2001; 2001US-00854208.
PR	10-MAY-2001; 2001US-00854280.
PR	30-MAY-2001; 2001US-00870574.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001WO-US0174503.
PR	29-JUN-2001; 2001US-00869599.
PR	18-JUL-2001; 2001US-00908827.

PR

XX

PA

PI

PI

XX

DR

XX

PT

PT

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

SQ

06-DEC-2001; 2001US-00006867.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-328636/31.

P-PSDB; ABU98281.

New antibody that specifically binds to a PRO polypeptide, useful in preparing a medicament for treating a condition, e.g. cancer, responsive to the antibody, and in diagnostic and purification assays for the PRO polypeptide.

Disclosure; Fig 37; 236pp; English.

The invention describes an antibody that binds to a polypeptide having a sequence of 277 amino acids fully defined in the specification. The antibody, PRO polypeptide, or the agonist or antagonist of the polypeptide, is useful in preparing a medicament for treating a condition responsive to the PRO polypeptide, agonist or antagonist, or the antibody, such as cancer. The antibody may also be used in diagnostic assays for PRO polypeptide in specific cells, tissue or serum, and in affinity purification of the polypeptide. The nucleic acid molecule is useful in molecular biology, as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques, and in gene therapy. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or as antisense probes. The secreted proteins are useful in industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO polypeptides may also be employed as molecular weight markers for protein electrophoresis purposes. This sequence encodes a novel human secreted and transmembrane PRO polypeptide

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match

Best Local Similarity

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTGGCTTTACCACTCTTCCCTTTATCTATTATAAATAATGTTGGTCTCCACCACGTG 2180

2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAATAGGTTGGTCTTGAACATA 2712

2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240

2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772

2241 AA 2242

2773 AA 2774

RESULT 403

ACA74856

ID ACA74856 standard; cDNA; 2846 BP.

XX ACA74856;

AC ACA74856;

XX 07-JUL-2003 (first entry)

XX cDNA encoding human PRO polypeptide #85.

XX Human; PRO polypeptide; secreted protein; transmembrane protein;

KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;

KW prostate; rectal; cervical; liver; cancer; TNF-alpha;

KW tumour necrosis factor-alpha; proliferation; differentiation;

KW chondrocyte cell; bone disorder; cartilage disorder; sports injury;

KW arthritis; cytostatic; antiarthritic; osteopathic; gene therapy; gene;

XX ss.

OS Homo sapiens.
XX US2003022293-A1.
PN 30-JAN-2003.
XX 17-JUN-2002; 2002US-00173706.
PF 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078866P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086332P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 09-JUN-1998; 98US-0088217P.
PR 10-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.

PR	02-SEP-1998;	98US-0098803P.	XX	13-FEB-2003.	
PR	02-SEP-1998;	98US-0098821P.	PD		
PR	02-SEP-1998;	98US-0098843P.	XX	27-JUN-2002;	2002US-00184614.
PR	09-SEP-1998;	98US-0099602P.	PF		
PR	10-SEP-1998;	98US-0099741P.	XX		
PR	10-SEP-1998;	98US-0099754P.	XX		
PR	10-SEP-1998;	98US-0099763P.	PR	18-SEP-1997;	97US-0059263P.
PR	10-SEP-1998;	98US-0099812P.	PR	18-SEP-1997;	97US-0059266P.
PR	10-SEP-1998;	98US-0100388P.	PR	17-OCT-1997;	97US-0062250P.
PR	15-SEP-1998;	98US-0100662P.	PR	21-OCT-1997;	97US-0063486P.
PR	16-SEP-1998;	98US-0100664P.	PR	24-OCT-1997;	97US-0063120P.
PR	16-SEP-1998;	98US-0101751P.	PR	24-OCT-1997;	97US-0063121P.
PR	16-SEP-1998;	98US-0101751P.	PR	28-OCT-1997;	97US-0063540P.
PR	16-SEP-1998;	98US-0101751P.	PR	28-OCT-1997;	97US-0063541P.
PR	16-SEP-1998;	98US-0101751P.	PR	28-OCT-1997;	97US-0063544P.
PR	16-SEP-1998;	98US-0101751P.	PR	28-OCT-1997;	97US-0063564P.
PR	17-SEP-1998;	98US-0100683P.	PR	29-OCT-1997;	97US-0063734P.
PR	17-SEP-1998;	98US-0100684P.	PR	31-OCT-1997;	97US-0063870P.
PR	17-SEP-1998;	98US-0100919P.	PR	31-OCT-1997;	97US-0064103P.
PR	17-SEP-1998;	98US-0100930P.	PR	13-NOV-1997;	97US-0065311P.
PR	18-SEP-1998;	98US-0100849P.	PR	13-NOV-1997;	97US-0066120P.
PR	18-SEP-1998;	98US-0101014P.	PR	21-NOV-1997;	97US-0066466P.
PR	18-SEP-1998;	98US-0101068P.	PR	24-NOV-1997;	97US-0066772P.
PR	18-SEP-1998;	98US-0101471P.	PR	24-NOV-1997;	97US-0069335P.
PR	23-SEP-1998;	98US-0101472P.	PR	11-DEC-1997;	97US-0069425P.
PR	23-SEP-1998;	98US-0101472P.	PR	12-DEC-1997;	97US-0069870P.
PR	23-SEP-1998;	98US-0101477P.	PR	17-DEC-1997;	97US-0069870P.
PR	23-SEP-1998;	98US-0101738P.	PR	18-DEC-1997;	97US-0068017P.
PR	24-SEP-1998;	98US-0101739P.	PR	10-MAR-1998;	98US-0077450P.
PR	24-SEP-1998;	98US-0101743P.	PR	11-MAR-1998;	98US-0077632P.
PR	24-SEP-1998;	98US-0101922P.	PR	11-MAR-1998;	98US-0077649P.
PR	25-SEP-1998;	98US-0101786P.	PR	20-MAR-1998;	98US-0078886P.
PR	25-SEP-1998;	98US-0102207P.	PR	20-MAR-1998;	98US-0078939P.
PR	29-SEP-1998;	98US-0102240P.	PR	20-MAR-1998;	98US-0079664P.
PR	29-SEP-1998;	98US-0102330P.	PR	27-MAR-1998;	98US-0079786P.
PR	29-SEP-1998;	98US-0102331P.	PR	31-MAR-1998;	98US-0080107P.
PR	29-SEP-1998;	98US-0102487P.	PR	31-MAR-1998;	98US-0080194P.
PR	30-SEP-1998;	98US-0102570P.	PR	01-APR-1998;	98US-0080327P.
PR	30-SEP-1998;	98US-0102571P.	PR	01-APR-1998;	98US-0080333P.
PR	01-OCT-1998;	98US-0102684P.	PR	08-APR-1998;	98US-0081049P.
PR	01-OCT-1998;	98US-0102687P.	PR	08-APR-1998;	98US-0081070P.
PR	01-OCT-1998;	98US-0102687P.	PR	09-APR-1998;	98US-0081195P.
PR	01-OCT-1998;	98US-0102687P.	PR	15-APR-1998;	98US-0081838P.
PR	01-OCT-1998;	98US-0102687P.	PR	21-APR-1998;	98US-0082568P.
PR	01-OCT-1998;	98US-0102687P.	PR	21-APR-1998;	98US-0082569P.
PR	01-OCT-1998;	98US-0102687P.	PR	22-APR-1998;	98US-0082704P.
PR	01-OCT-1998;	98US-0102687P.	PR	22-APR-1998;	98US-0082797P.
PR	01-OCT-1998;	98US-0102687P.	PR	28-APR-1998;	98US-0083322P.
PR	01-OCT-1998;	98US-0102687P.	PR	29-APR-1998;	98US-0083495P.
PR	01-OCT-1998;	98US-0102687P.	PR	29-APR-1998;	98US-0083496P.
PR	01-OCT-1998;	98US-0102687P.	PR	29-APR-1998;	98US-0083499P.
PR	01-OCT-1998;	98US-0102687P.	PR	29-APR-1998;	98US-0083559P.
PR	01-OCT-1998;	98US-0102687P.	PR	05-MAY-1998;	98US-0084366P.
PR	01-OCT-1998;	98US-0102687P.	PR	05-MAY-1998;	98US-0084414P.
PR	01-OCT-1998;	98US-0102687P.	PR	07-MAY-1998;	98US-0084639P.
PR	01-OCT-1998;	98US-0102687P.	PR	07-MAY-1998;	98US-0084640P.
PR	01-OCT-1998;	98US-0102687P.	PR	07-MAY-1998;	98US-0084643P.
PR	01-OCT-1998;	98US-0102687P.	PR	15-MAY-1998;	98US-0085579P.
PR	01-OCT-1998;	98US-0102687P.	PR	15-MAY-1998;	98US-0085580P.
PR	01-OCT-1998;	98US-0102687P.	PR	15-MAY-1998;	98US-0085582P.
PR	01-OCT-1998;	98US-0102687P.	PR	15-MAY-1998;	98US-0085700P.
PR	01-OCT-1998;	98US-0102687P.	PR	18-MAY-1998;	98US-0086023P.
PR	01-OCT-1998;	98US-0102687P.	PR	22-MAY-1998;	98US-0086392P.
PR	01-OCT-1998;	98US-0102687P.	PR	22-MAY-1998;	98US-0086486P.
PR	01-OCT-1998;	98US-0102687P.	PR	28-MAY-1998;	98US-0087098P.
PR	01-OCT-1998;	98US-0102687P.	PR	28-MAY-1998;	98US-0087208P.
PR	01-OCT-1998;	98US-0102687P.	PR	02-JUN-1998;	98US-0087609P.
PR	01-OCT-1998;	98US-0102687P.	PR	02-JUN-1998;	98US-0087759P.
PR	01-OCT-1998;	98US-0102687P.	PR	03-JUN-1998;	98US-0087827P.
PR	01-OCT-1998;	98US-0102687P.	PR	04-JUN-1998;	98US-0088025P.
PR	01-OCT-1998;	98US-0102687P.	PR	04-JUN-1998;	98US-0088028P.
PR	01-OCT-1998;	98US-0102687P.	PR	04-JUN-1998;	98US-0088029P.
PR	01-OCT-1998;	98US-0102687P.	PR	04-JUN-1998;	98US-0088033P.
PR	01-OCT-1998;	98US-0102687P.	PR	04-JUN-1998;	98US-0088326P.
PR	01-OCT-1998;	98US-0102687P.	PR	05-JUN-1998;	98US-0088167P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCCTTGGTTTACCACTCTTCCCTTTATCTTATATATAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCCTTTCCCTCCCATCTCTGTACACATTTTATAAAATGTTGGTCTTGAACTA	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	

RESULT 404
ACA91727
ID ACA91727 standard; cDNA; 2846 BP.
AC ACA91727;
XX
XX
DT 14-JUL-2003 (first entry)
XX
XX Human PRO polynucleotide #85.
XX
XX Human; PRO; gene; ss; cytostatic; secreted polypeptide; cancer; tumour;
KW transmembrane polypeptide; adrenal; lung; colon; breast; prostate; liver;
KW rectum; cervix.
XX
XX Homo sapiens.
XX
XX OS
XX
XX US2003032128-A1.

PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095598P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096881P.
PR 17-AUG-1998; 98US-0096887P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.

PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCCACCCTG 2180
Db 2653 CCTTTCTTTCCCATCTCTGTACACATTTTAATAAAATAGGTTGGCTTCTGAACA 2712
Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 405

ACAB9307
ID ACAB9307 standard; cDNA; 2846 BP.

XX ACAB9307;
XX ACAB9307;
DT 08-JUL-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE Human; secreted and transmembrane protein; PRO; ATCC 209902;
XX gene therapy; chromosome identification; tissue typing; gene; ss.
XX Homo sapiens.
XX US2003036634-A1.
PN

PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089922P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
OY 2121 CCTTCTTACACCTCTTCTCTTTATCTATTATATAAATGTTGGTCTCCACCACTG 2180
DB 2653 CTTTTCTTCCCACTCTCTGTACACATTTTAATAAATAAGGGTGGCTTCTGAACATA 2712
OY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
OY 2241 AA 2242
DB 2773 AA 2774

RESULT 407
ACC90771
ID ACC90771 standard; cDNA; 2846 BP.
XX AC ACC90771,
XX DT 19-AUG-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003032122-A1.
XX PD 13-FEB-2003.
XX PF 25-JUN-2002; 2002US-00180549.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
```

```
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096953P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097552P.
PR 26-AUG-1998; 98US-0097554P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGCTCTCCACCACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTTTGTACACATTTTAAATAAATAGGCTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 408
ACA65781
ID ACA65781 standard; cDNA; 2846 BP.
XX
AC ACA65781;
XX
DT 19-JUN-2003 (first entry)
XX
DE cDNA encoding human PRO protein #85.
XX
KW Human; PRO; tumour; adrenal; lung; colon; breast; prostate; rectal;
KW cervical; liver; gene therapy; cytostatic; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003036139-A1.
XX
PD 20-FEB-2003.
XX
PF 27-JUN-2002; 2002US-00184651.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
```

PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082722P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 29-APR-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 18-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090354P.
PR 22-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102887P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match

3.0%; Score 66.6; DB 8; Length 2846;

	Best Local Similarity	71.3%;	Pred. No.	0.00023;	
	Matches	87;	Conservative	0;	Mismatches 35; Indels 0; Gaps 0;
Qy	2121	CCTTTGCTTTTACCACTCTTTTCCTTTATCTATTATAAAAAAGTGTGCTCCTCACACTG	2180		
Dd	2653	CCTTTTCTTCCCACATCTCTGTACACATTTTAATAAAATGAAGGTGGCTTCTGAAC TA	2712		
Qy	2181	NCTCCCAA	2240		
Dd	2713	CAA	2772		
Qy	2241	AA 2242			
Dd	2773	AA 2774			
RESULT 409					
ID	ACA68944	standard; cDNA; 2846 BP.			
XX	ACA68944;				
DT	26-JUN-2003	(first entry)			
DE	Novel human secreted and transmembrane protein PRO1344	cDNA.			
XX	Human; secreted and transmembrane protein; PRO; cytostatic;				
KW	immunotherapy; cancer; gene; ss.				
OS	Homo sapiens.				
XX	US2002183494-A1.				
PD	05-DEC-2002.				
XX	02-MAY-2002;	2002US-00063551.			
PR	30-DEC-1998;	98KR-00062142.			
PR	08-MAR-1999;	99WO-US005028.			
PR	14-MAY-1999;	99US-00311832.			
PR	14-MAY-1999;	99WO-US010733.			
PR	25-AUG-1999;	99US-00380137.			
PR	25-AUG-1999;	99US-00380138.			
PR	25-AUG-1999;	99US-00380139.			
PR	25-AUG-1999;	99US-00380142.			
PR	15-SEP-1999;	99US-00397342.			
PR	18-OCT-1999;	99US-00403297.			
PR	12-NOV-1999;	99US-00423844.			
PR	30-DEC-1999;	99WO-US0031274.			
PR	18-FEB-2000;	2000WO-US004341.			
PR	01-MAR-2000;	2000WO-US005601.			
PR	02-MAR-2000;	2000WO-US005841.			
PR	21-MAR-2000;	2000WO-US007532.			
PR	22-MAY-2000;	2000WO-US014042.			
PR	22-JUN-2000;	2000WO-US015264.			
PR	02-AUG-2000;	2000US-00644848.			
PR	24-AUG-2000;	2000WO-US023328.			
PR	18-SEP-2000;	2000US-00664610.			
PR	18-SEP-2000;	2000US-00665350.			
PR	08-NOV-2000;	2000US-00709238.			
PR	10-NOV-2000;	2000WO-US030873.			
PR	01-DEC-2000;	2000WO-US032678.			
PR	20-DEC-2000;	2000US-00747259.			
PR	28-FEB-2001;	2000WO-US034956.			
PR	28-FEB-2001;	2001WO-US006520.			
PR	22-MAR-2001;	2001US-00816744.			
PR	10-MAY-2001;	2001US-00854208.			
PR	10-MAY-2001;	2001US-00854280.			
PR	30-MAY-2001;	2001US-00870574.			
PR	01-JUN-2001;	2001WO-US017800.			
PR	05-JUN-2001;	2001US-00874503.			
PR	28-JUN-2001;	2001US-00869599.			
PR	18-JUL-2001;	2001US-00909827.			
PR	06-DEC-2001;	2001US-00006867.			
XX	(GETH) GENENTECH INC.				
PA	Raton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;				
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;				
PI	WPI; 2003-340981/32.				
DR	P-PSDB; ABU82493.				
XX	New antibody that specifically binds to a PRO polypeptide, useful in preparing a medicament for treating a condition, e.g. cancer, responsive to the antibody, and in diagnostic and purification assays for the PRO polypeptide.				
PT	Disclosure; Fig 37; 235pp; English.				
XX	The invention describes an antibody that binds to a novel human secreted CC and transmembrane PRO polypeptide. The antibody is useful in preparing a CC medicament for treating a condition e.g. cancer. The antibody may also be used in diagnostic assays for PRO polypeptide in specific cells, tissue or serum, and in affinity purification of the polypeptide. This sequence CC encodes a novel human secreted and transmembrane PRO polypeptide XX				
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;				
	Query Match	3.0%;	Score 66.6;	DB 8;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No.	0.00023;	
	Matches	87;	Conservative	0;	Mismatches 35; Indels 0; Gaps 0;
QY	2121	CCTTTGCTTTTACCACCTCTTTTCCTTTTATCTATTATAAAAAATGTTGGTCTCCACACTG	2180		
Dd	2653	CCTTTTCTTCCCACATCTCTGTACACATTTTAATAAAATAAGGTGGTCTTCTGAAC TA	2712		
QY	2181	NCTCCCAA	2240		
Dd	2713	CAA	2772		
QY	2241	AA 2242			
Dd	2773	AA 2774			
RESULT 410					
ID	ACA92974	standard; cDNA; 2846 BP.			
XX	ACA92974;				
DT	16-JUL-2003	(first entry)			
DE	Novel human secreted and transmembrane protein PRO1344	cDNA.		</	


```
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTTCTTTTATCTTTATTAATAAAAAATGTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTGTACACATTTTATAAAATAAGGTTGGCTTCTGACTA 2712

Qy 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 411
ACA94926
ID ACA94926 standard; cDNA; 2846 BP.
XX ACA94926;
AC
XX
XX
XX 22-JUL-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #85.
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
XX prostate; rectal; cervical; liver; cancer; gene therapy; gene; ss.
XX Homo sapiens.
XX
XX US2003017541-A1.
XX
XX 23-JAN-2003.
XX
XX 20-JUN-2002; 2002US-00176483.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 13-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 13-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 22-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088126P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088722P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088740P.
XX 10-JUN-1998; 98US-0088811P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088825P.
XX 11-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088861P.
```

```
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089598P.
PR 19-JUN-1998; 98US-0089598P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091344P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098820P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089598P.
PR 19-JUN-1998; 98US-0089598P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091344P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098820P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACCTG 2180
DB 2653 CCTTTCTCTCCCACTCTTCTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACCTG 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 412
ACD16488
ID ACD16488 standard; cDNA; 2846 BP.
XX
AC ACD16488;
XX
DT 19-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003017543-A1.
XX
PD 23-JAN-2003.
XX
PF 20-JUN-2002; 2002US-00176914.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
```



```

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTCCTTTACCACTCTTCTCTTTATCTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CTTTCCTTCCCACTCTCTGTGACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 413
ACD1567
ID ACD1567 standard; cDNA; 2846 BP.
XX
AC ACD1567;
XX
DT 17-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036152-A1.
XX
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00187753.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
97US-0063120P.
97US-0063121P.
97US-0063540P.
97US-0063541P.
97US-0063544P.
97US-0063564P.
97US-0063734P.
97US-0063870P.
97US-0064103P.
97US-0065311P.
97US-0066120P.
97US-0066466P.
97US-0066772P.
97US-0069335P.
97US-0069425P.
97US-0069870P.
97US-0068017P.
98US-0077450P.
98US-0077632P.
98US-0077649P.
98US-0078886P.
98US-0078939P.
98US-0079664P.
98US-0079786P.
98US-0080107P.
98US-0080194P.
98US-0080327P.
98US-0080333P.
98US-0081049P.
98US-0081070P.
98US-0081195P.
98US-0081838P.
98US-0082568P.
98US-0082569P.
98US-0082704P.
98US-0082797P.
98US-0083222P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083559P.
98US-0084366P.
98US-0084414P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085799P.
98US-0085808P.
98US-008582P.
98US-0085700P.
98US-0086023P.
98US-0086392P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088029P.
98US-0088033P.
98US-0088326P.
98US-0088167P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.
98US-0088740P.
98US-0088811P.
98US-0088824P.
24-OCT-1997;
24-OCT-1997;
28-OCT-1997;
28-OCT-1997;
28-OCT-1997;
28-OCT-1997;
29-OCT-1997;
31-OCT-1997;
31-OCT-1997;
13-NOV-1997;
21-NOV-1997;
24-NOV-1997;
24-NOV-1997;
11-DEC-1997;
12-DEC-1997;
18-DEC-1997;
10-MAR-1998;
11-MAR-1998;
11-MAR-1998;
20-MAR-1998;
20-MAR-1998;
27-MAR-1998;
27-MAR-1998;
31-MAR-1998;
31-MAR-1998;
01-APR-1998;
01-APR-1998;
08-APR-1998;
08-APR-1998;
09-APR-1998;
15-APR-1998;
21-APR-1998;
22-APR-1998;
22-APR-1998;
28-APR-1998;
29-APR-1998;
29-APR-1998;
29-APR-1998;
05-MAY-1998;
06-MAY-1998;
07-MAY-1998;
07-MAY-1998;
15-MAY-1998;
15-MAY-1998;
15-MAY-1998;
18-MAY-1998;
22-MAY-1998;
22-MAY-1998;
28-MAY-1998;
28-MAY-1998;
02-JUN-1998;
02-JUN-1998;
03-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
04-JUN-1998;
05-JUN-1998;
05-JUN-1998;
05-JUN-1998;
09-JUN-1998;
10-JUN-1998;
10-JUN-1998;
10-JUN-1998;
10-JUN-1998;

```



```

PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-417284/39.
DR P-PSDB; ABU96457.
XX
XX
PT New anti-PRO antibody, useful in diagnostic assays for PRO polypeptide or
PT for affinity purification of PRO from the recombinant cell culture or
PT natural source.
XX
XX
XX Disclosure; Fig 37; 236pp; English.
XX
XX
CC The invention relates to an antibody which binds to a PRO polypeptide.
CC The antibody is useful in diagnostic assays for the PRO polypeptide or
CC for affinity purification of PRO from a recombinant cell culture or
CC natural source. Sequences ACA98448-ACA98531 represent cDNA molecules
CC encoding human PRO polypeptides of the invention
XX
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACTCTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTTCCCATCTCTGTGACACATTTAATAAATAAGGTTGGCTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Db |||||
QY 2773 AA 2774
Db |||||

RESULT 415
ABX17058
```

```

ID ABX17058 standard; cDNA; 2846 BP.
XX
XX AC ABX17058;
XX
XX DT 04-FEB-2003 (first entry)
XX
XX DE Human PRO polynucleotide #65.
XX
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
XX OS Homo sapiens.
XX
XX FN US2002123463-A1.
XX
XX PD 05-SEP-2002.
XX
XX PF 19-NOV-2001; 2001US-00989732.
XX
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 02-JUN-1998; 98US-0087759P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
XX PR 04-JUN-1998; 98US-0088326P.
XX PR 05-JUN-1998; 98US-0088167P.
XX PR 05-JUN-1998; 98US-0088202P.
XX PR 05-JUN-1998; 98US-0088212P.
XX PR 05-JUN-1998; 98US-0088217P.
XX PR 09-JUN-1998; 98US-0088655P.
XX PR 10-JUN-1998; 98US-0088734P.
XX PR 10-JUN-1998; 98US-0088738P.
XX PR 10-JUN-1998; 98US-0088742P.
XX PR 10-JUN-1998; 98US-0088810P.
XX PR 10-JUN-1998; 98US-0088824P.
XX PR 10-JUN-1998; 98US-0088826P.
XX PR 11-JUN-1998; 98US-0088858P.
XX PR 11-JUN-1998; 98US-0088861P.
XX PR 11-JUN-1998; 98US-0088876P.
XX PR 12-JUN-1998; 98US-0089105P.
XX PR 16-JUN-1998; 98US-0089440P.
XX PR 16-JUN-1998; 98US-0089512P.
XX PR 16-JUN-1998; 98US-0089514P.
XX PR 17-JUN-1998; 98US-0089532P.
XX PR 17-JUN-1998; 98US-0089538P.
XX PR 17-JUN-1998; 98US-0089598P.
XX PR 17-JUN-1998; 98US-0089599P.
XX PR 17-JUN-1998; 98US-0089600P.
XX PR 17-JUN-1998; 98US-0089653P.
XX PR 18-JUN-1998; 98US-0089801P.
XX PR 18-JUN-1998; 98US-0089907P.
XX PR 18-JUN-1998; 98US-0089908P.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
```

PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US028634.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
XX
XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Garney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
XX Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
XX Zhang Z;

XX WPI; 2003-066810/06.
XX P-PSDB; ABU10879.

XX Novel secreted and transmembrane polypeptide for modulating biological
XX activity of cell expressing the polypeptide, identifying agonists or
XX antagonists of polypeptide, and as molecular weight markers.

XX Claim 2; Fig 158; 655pp; English.

XX The invention relates to a secreted and transmembrane polypeptide, termed
XX PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
XX useful for detecting PRO polypeptides and for linking a bioactive
XX molecule to a cell expressing the above polypeptides, where the bioactive
XX molecule is a toxin, radiolabel or an antibody. The bioactive material
XX causes the death of the cell. The polypeptide is useful for identifying
XX agonists or antagonists of the PRO polypeptide, for preparing variants of
XX PRO, as a molecular weight marker for protein electrophoresis purposes
XX and the PRO polynucleotide is useful for recombinantly expressing those
XX markers. The polynucleotide is also useful as a hybridisation probe, in
XX chromosome and gene mapping, in generation of antisense RNA and DNA, in
XX the preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, to construct hybridisation

CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polynucleotide of the
CC invention
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.08; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTATCTATTATAAAATGTTGCTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCACTCTTTGACATTTTATAAAATAGGTTGGCTTCGAACTA 2712
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
|||
Db 2773 AA 2774

RESULT 416

ABX16670

ID ABX16670 standard; cDNA; 2846 BP.

XX AC ABX16670;

XX 03-FEB-2003 (first entry)

DE Human cDNA encoding secreted/transmembrane protein #85.

XX Human; ss; gene; secreted and transmembrane protein; blood;
XX tumour necrosis factor-alpha; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour; adrenal tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; bone disorder; cartilage disorder;
XX arthritis; sports injury.

XX Homo sapiens.

XX US2002127584-A1.

XX 12-SEP-2002.

XX 15-JAN-2002; 2002US-00052586.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 17-OCT-1997; 97US-0062250P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 28-OCT-1997; 97US-0063540P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063734P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066466P.

XX 24-NOV-1997; 97US-0066772P.

XX 11-DEC-1997; 97US-0069335P.

XX 17-DEC-1997; 97US-0069425P.

XX 18-DEC-1997; 97US-0069870P.

XX 18-DEC-1997; 97US-0068017P.

XX 10-MAR-1998; 98US-0077450P.

[illegible]


```
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 02-JUN-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088035P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 09-JUN-1998; 98US-0088217P.
PR 10-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088732P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
```

```
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023; Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
Qy 2121 CCTTTGCTTTACCACCTCTTTCCCTTTTATCTTTATTAATAAAAAATGTCCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCACTCTCTTGTCACATTTTATAATAATAGGGTTGGCTTCTGACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2241 AA 2242
    ||
Db 2773 AA 2774
```

Wed Feb 16 11:37:55 2005

us-10-036-342-56.rng

RESULT 420
ACA99060
ID ACA99060 standard; cDNA; 2846 BP.
XX
AC ACA99060;
XX
DT 29-JUL-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE
XX Human; ss; tissue typing; tumour; chondrocyte stimulator; gene therapy;
KW tumour necrosis factor-alpha release; affinity purification; gene.
XX
XX Homo sapiens.
XX
XX US2003032140-A1.
XX
XX 13-FEB-2003.
XX
XX 19-JUL-2002; 2002US-00199464.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080134P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090464P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 26-JUN-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.

```
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100939P.
PR 17-SEP-1998; 98US-0100939P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102571P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
```

```
Query March 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAATAATGCTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCACTCTTGTACACATTTTAATAAATAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
Db 2713 CAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774
```

```
RESULT 421
ACC91692
ID ACC91692 standard; cDNA; 2846 BP.
XX AC ACC91692;
XX DT 19-AUG-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003040076-A1.
XX PD 27-FEB-2003.
XX 12-JUL-2002; 2002US-00194462.
XX 26-JUN-1998; 98US-00105413.
XX 16-SEP-1998; 98WO-US019330.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98WO-US021141.
XX 06-NOV-1998; 98US-00187368.
XX 01-DEC-1998; 98WO-US025108.
XX 07-DEC-1998; 98US-00202054.
XX 03-MAR-1999; 99US-00254311.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 02-JUN-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 01-SEP-1999; 99WO-US020111.
XX 15-SEP-1999; 99WO-US021090.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 02-DEC-1999; 99WO-US028301.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.
XX 15-MAR-2000; 2000WO-US006884.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 22-AUG-2000; 2000US-00644848.
XX 24-AUG-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 08-NOV-2000; 2000WO-US030952.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
```

28-FEB-2001; 2001WO-US006520.
 22-MAR-2001; 2001US-00818744.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 25-MAY-2001; 2001US-00866028.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 20-JUN-2001; 2001US-00919692.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 30-JUL-2001; 2001US-00918585.
 06-AUG-2001; 2001US-00924419.
 13-AUG-2001; 2001US-00929404.
 16-AUG-2001; 2001US-00931836.
 28-AUG-2001; 2001US-00941992.
 29-AUG-2001; 2001WO-US027099.
 04-SEP-2001; 2001US-00946374.
 15-JAN-2002; 2002US-00052586.
 (GETH) GENENTECH INC.
 Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-342069/32.
 P-PSDB; ABR70657.
 Three hundred and five nucleic acids encoding a PRO polypeptide, e.g.
 PRO1079 or PRO827, useful in molecular biology, chromosome and gene
 mapping, in gene therapy and for treating tumors.
 Claim 2; Fig 169; 706pp; English.
 The invention relates to human PRO secreted/transmembrane polypeptides
 (ABR70573-ABR70877) and nucleic acids encoding them (ACC91608-ACC91912).
 The invention also relates to sequences at least 80% identical to the PRO
 nucleic acid and polypeptide sequences of the invention, recombinant
 vectors and host cells comprising a PRO nucleic acid, a method for the
 recombinant production of a PRO polypeptide, antibodies against a PRO
 polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 acids encoding PRO polypeptides of the invention were initially
 identified via homology screening using consensus sequences based on the
 extracellular domain sequences from known secreted proteins. Human cDNA
 libraries containing sequences of interest were identified using
 oligonucleotides based on the consensus sequences, and cDNA clones were
 isolated and characterised. The PRO polypeptides are useful for
 stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 human blood and may thus be used in the treatment of conditions in which
 enhanced TNF-alpha release would be beneficial. They are also useful for
 stimulating the proliferation or differentiation of chondrocytes and as
 such may be used in the treatment of various bone and/or cartilage
 disorders such as arthritis and sports injuries. The PRO polypeptides may
 be used in a method for detecting the presence of a tumour (e.g., an
 adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 method involves comparing the level of expression of the PRO polypeptide
 in test and control samples, where a higher level of expression of PRO
 polypeptide in the test sample as compared to the control sample is
 indicative of the presence of a tumour. The PRO polypeptides are
 additionally useful for in drug screening to identify agonists and
 antagonists of PRO polypeptides. PRO nucleic acids are useful as
 hybridisation probes (for isolation of cDNA molecules), in chromosome and
 gene mapping, in the generation of antisense RNA and DNA and in gene
 therapy. The nucleic acids can also be used for mapping genes encoding
 PRO polypeptides, for genetic analysis of individuals with genetic
 disorders, and for generating either transgenic animals or knock-out
 animals which are useful in the development and screening of
 therapeutically useful compounds. Sequences ACC91608-ACC91912 represent
 cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 invention. Note: The sequence data for this patent is also available in
 electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CTTTGGCTTTACACCTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
 Db 2653 CTTTTCTCTCCCATCTCTGTACACATTTTAATAAATAGGGTTGGCTTCTGACTA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774
 RESULT 422
 ACD11103
 ID ACD11103 standard; cDNA; 2846 BP.
 XX AC ACD11103;
 XX DT 12-AUG-2003 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO1344 cDNA.
 XX KW Human; ds; gene; gene therapy; tumour necrosis factor-alpha; tumour;
 XX KW chondrocyte stimulation; tissue typing.
 XX OS Homo sapiens.
 XX US2003008352-A1.
 XX 09-JAN-2003.
 XX 18-JUN-2002; 2002US-00174590.
 XX 18-SEP-1997; 97US-0059263P.
 XX 18-SEP-1997; 97US-0059266P.
 XX 17-OCT-1997; 97US-0062250P.
 XX 21-OCT-1997; 97US-0063486P.
 XX 24-OCT-1997; 97US-0063120P.
 XX 24-OCT-1997; 97US-0063121P.
 XX 28-OCT-1997; 97US-0063540P.
 XX 28-OCT-1997; 97US-0063541P.
 XX 28-OCT-1997; 97US-0063544P.
 XX 28-OCT-1997; 97US-0063564P.
 XX 29-OCT-1997; 97US-0063734P.
 XX 31-OCT-1997; 97US-0063870P.
 XX 31-OCT-1997; 97US-0064103P.
 XX 13-NOV-1997; 97US-0065311P.
 XX 21-NOV-1997; 97US-0066120P.
 XX 24-NOV-1997; 97US-0066466P.
 XX 24-NOV-1997; 97US-0066772P.
 XX 11-DEC-1997; 97US-0069335P.
 XX 12-DEC-1997; 97US-0069425P.
 XX 17-DEC-1997; 97US-0069870P.
 XX 18-DEC-1997; 97US-0068017P.
 XX 10-MAR-1998; 98US-0077450P.
 XX 11-MAR-1998; 98US-0077632P.
 XX 11-MAR-1998; 98US-0077649P.
 XX 20-MAR-1998; 98US-0078886P.
 XX 20-MAR-1998; 98US-0078939P.
 XX 27-MAR-1998; 98US-0079664P.
 XX 27-MAR-1998; 98US-0079786P.
 XX 31-MAR-1998; 98US-0080107P.
 XX 31-MAR-1998; 98US-0080194P.
 XX 01-APR-1998; 98US-0080327P.
 XX 01-APR-1998; 98US-0080333P.
 XX 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.
 PR 09-APR-1998; 98US-0081195P.
 PR 15-APR-1998; 98US-0081838P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082568P.
 PR 22-APR-1998; 98US-0082704P.
 PR 22-APR-1998; 98US-0082797P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083495P.
 PR 29-APR-1998; 98US-0083496P.
 PR 29-APR-1998; 98US-0083499P.
 PR 29-APR-1998; 98US-0083559P.
 PR 05-MAY-1998; 98US-0084366P.
 PR 06-MAY-1998; 98US-0084414P.
 PR 07-MAY-1998; 98US-0084639P.
 PR 07-MAY-1998; 98US-0084640P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98WO-US021141.
 PR 01-DEC-1998; 98WO-US025108.
 PR 08-MAR-1999; 99WO-US005028.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021090.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028551.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 29-AUG-2001; 2001WO-US027099.
 PR 15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-341327/32.
 DR P-PSDB; ABO05008.

XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.

XX Claim 2; Fig 169; 708pp; English.

XX The invention relates to an isolated PRO polypeptide. The PRO nucleotide
 CC sequences are useful as hybridisation probes in chromosome and gene
 CC mapping, for stimulating the release of tumour necrosis factor-alpha, for
 CC stimulating proliferation or differentiation of chondrocyte cells and for
 CC detecting the presence of tumour in a mammal, or in generating antisense
 CC RNA and DNA. PRO nucleic acids are also useful in preparing PRO

CC polypeptides, in assays to identify other proteins or molecules involved
 CC in binding reaction, to generate transgenic animals or knockout animals,
 CC which in turn are useful in the development and screening of
 CC therapeutically useful reagents, for chromosome identification and tissue
 CC typing. The PRO polypeptides and nucleic acid molecules are also useful
 CC in gene therapy, and as molecular weight markers for protein
 CC electrophoresis purposes. The anti-PRO antibodies may be used in
 CC diagnostic assays for PRO, or for the affinity purification of PRO from
 CC recombinant cell culture or natural sources. The present sequence
 CC represents cDNA encoding a secreted and transmembrane PRO polypeptide
 XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTATTATTAATAAATGTGTCTCCCACTG 2180

Db 2653 CTTTTCTTCCCATCTCTTGACACATTTTATAAATAAGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 423

ACD14953

ID ACD14953 standard; cDNA; 2846 BP.

XX ACD14953;

DT 17-AUG-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

OS Homo sapiens.

XX US2003044922-A1.

PN 06-MAR-2003.

XX 24-JUN-2002; 2002US-00179514.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 29-APR-1998; 98US-0084366P.
PR 03-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087088P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088036P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091135P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097959P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.


```
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTTCTTTATCTTATTATAAATGTTGGTCTCCACCACTG 2180
    ||||| || || || || || || || || || || || || || || || || || ||
Db 2653 CCTTTTCTCCCACTCTCTGTACACATTTTATAAATAAGGCTTGGCTTCTGAAC TA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 424
ID ACA88362 standard; cDNA; 2846 BP.
AC ACA88362;
XX
XX 11-AUG-2003 (first entry)
XX Human secreted and transmembrane polypeptide PRO1344 cDNA.
XX Human; gene; ss; gene therapy; cancer; retinal disorder; wound healing;
XX kidney disorder.
XX Homo sapiens.
XX US2002197615-A1.
XX
XX 26-DEC-2002.
XX
XX 16-NOV-2001; 2001US-00991181.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97WO-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088036P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088734P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088742P.
XX 10-JUN-1998; 98US-0088810P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088858P.
XX 11-JUN-1998; 98US-0088861P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089440P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089532P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089599P.
XX 17-JUN-1998; 98US-0089600P.
XX 17-JUN-1998; 98US-0089653P.
XX 18-JUN-1998; 98US-0089801P.
XX 18-JUN-1998; 98US-0089907P.
XX 18-JUN-1998; 98US-0089908P.
XX 18-JUN-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 02-JUN-1999; 99WO-US012252.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 30-NOV-1999; 99WO-US028313.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 02-MAR-2000; 2000WO-US005004.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 30-MAR-2000; 2000WO-US008439.
XX 15-MAY-2000; 2000WO-US013358.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US022031.
XX 23-AUG-2000; 2000WO-US023522.
XX 08-NOV-2000; 2000WO-US030952.
XX 01-DEC-2000; 2000WO-US032678.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-JUN-2001; 2001WO-US017800.
XX 20-JUN-2001; 2001WO-US019692.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-JUL-2001; 2001WO-US021735.
XX 28-AUG-2001; 2001US-00941992.
XX
```

Wed Feb 16 11:37:55 2005

us-10-036-342-56.rng

```
(GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams FM, Wood WI;
PI Zhang Z;
XX WPI: 2003-370792/35.
DR P-PSDB; ABU8570.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for the preparation of a medicament for treating a
PT condition that is responsive to the PRO polypeptide. e.g., cancer.
XX
PS Claim 2; Fig 158; 647pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC for the preparation of a medicament for treating a condition that is
CC responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC molecular biology including being used as hybridisation probes, in
CC chromosome and gene mapping and in the generation of anti-sense RNA and
CC DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC cancer, retinal disorders, wound healing and kidney disorders. The
CC present sequence represents a cDNA encoding a human secreted and
CC transmembrane PRO polypeptide of the present invention. Note: The
CC sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CTTTGTGTTACCACTCTTCTCTTTATCTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTTAATAAAATGAGGTGGTCTTGAACTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 425
ACD81869
ID ACD81869 standard; cDNA; 2846 BP.
XX
AC ACD81869;
XX
XX 19-SEP-2003 (first entry)
XX
DE cDNA encoding human PRO1344 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW biosensor; bioeffector; tumour; cancer; diabetes; ALS; ulcer;
KW rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;
KW antidiabetic; antiarthritic; antirheumatic; antiulcer; gene therapy;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2003017981-A1.
XX
PD 23-JAN-2003.
XX
XX 20-NOV-2001; 2001US-00989728.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088828P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089601P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
```

```
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096889P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0144758P.
PR 28-JUL-1999; 99US-0145698P.
PR 17-AUG-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.

PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATCTTGCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2241 AA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2273 AA 2774
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 426
ACD11717
ID ACD11717 standard; cDNA; 2846 BP.
XX AC ACD11717;
XX AC ACD11717;
XX AC ACD11717;
DT 13-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
DE tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
DE tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
DE prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX US2003032118-A1.
XX 13-FEB-2003.
XX 25-JUN-2002; 2002US-00180543.
```

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

XX	18-SEP-1997;	97US-0059263P.	PR	10-JUN-1998;	98US-0088722P.
PR	18-SEP-1997;	97US-0059266P.	PR	10-JUN-1998;	98US-0088738P.
PR	17-OCT-1997;	97US-0062250P.	PR	10-JUN-1998;	98US-0088740P.
PR	21-OCT-1997;	97US-0063486P.	PR	10-JUN-1998;	98US-0088811P.
PR	24-OCT-1997;	97US-0063120P.	PR	10-JUN-1998;	98US-0088824P.
PR	24-OCT-1997;	97US-0063121P.	PR	10-JUN-1998;	98US-0088825P.
PR	28-OCT-1997;	97US-0063540P.	PR	10-JUN-1998;	98US-0088826P.
PR	28-OCT-1997;	97US-0063541P.	PR	11-JUN-1998;	98US-0088861P.
PR	28-OCT-1997;	97US-0063544P.	PR	11-JUN-1998;	98US-0088863P.
PR	28-OCT-1997;	97US-0063564P.	PR	11-JUN-1998;	98US-0088876P.
PR	29-OCT-1997;	97US-0063734P.	PR	12-JUN-1998;	98US-0089090P.
PR	31-OCT-1997;	97US-0063870P.	PR	12-JUN-1998;	98US-0089105P.
PR	31-OCT-1997;	97US-0064103P.	PR	16-JUN-1998;	98US-0089512P.
PR	13-NOV-1997;	97US-0065311P.	PR	16-JUN-1998;	98US-0089514P.
PR	21-NOV-1997;	97US-0066120P.	PR	17-JUN-1998;	98US-0089538P.
PR	24-NOV-1997;	97US-0066466P.	PR	17-JUN-1998;	98US-0089598P.
PR	24-NOV-1997;	97US-0066772P.	PR	17-JUN-1998;	98US-0089653P.
PR	11-DEC-1997;	97US-0069335P.	PR	19-JUN-1998;	98US-0089952P.
PR	12-DEC-1997;	97US-0069425P.	PR	22-JUN-1998;	98US-0089952P.
PR	17-DEC-1997;	97US-0069870P.	PR	22-JUN-1998;	98US-0090246P.
PR	18-DEC-1997;	97US-0068017P.	PR	22-JUN-1998;	98US-0090252P.
PR	10-MAR-1998;	98US-0077450P.	PR	24-JUN-1998;	98US-0090254P.
PR	11-MAR-1998;	98US-0077632P.	PR	24-JUN-1998;	98US-0090435P.
PR	20-MAR-1998;	98US-0077649P.	PR	24-JUN-1998;	98US-0090444P.
PR	20-MAR-1998;	98US-0078886P.	PR	24-JUN-1998;	98US-0090461P.
PR	20-MAR-1998;	98US-0078939P.	PR	24-JUN-1998;	98US-0090535P.
PR	27-MAR-1998;	98US-0079664P.	PR	24-JUN-1998;	98US-0090540P.
PR	27-MAR-1998;	98US-0079786P.	PR	25-JUN-1998;	98US-0090676P.
PR	31-MAR-1998;	98US-0080107P.	PR	25-JUN-1998;	98US-0090678P.
PR	31-MAR-1998;	98US-0080194P.	PR	25-JUN-1998;	98US-0090688P.
PR	01-APR-1998;	98US-0080327P.	PR	25-JUN-1998;	98US-0090690P.
PR	01-APR-1998;	98US-0080333P.	PR	25-JUN-1998;	98US-0090694P.
PR	08-APR-1998;	98US-0081049P.	PR	25-JUN-1998;	98US-0090695P.
PR	08-APR-1998;	98US-0081070P.	PR	25-JUN-1998;	98US-0090696P.
PR	09-APR-1998;	98US-0081195P.	PR	26-JUN-1998;	98US-00105413.
PR	15-APR-1998;	98US-0081838P.	PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998;	98US-0082568P.	PR	26-JUN-1998;	98US-0090863P.
PR	21-APR-1998;	98US-0082569P.	PR	26-JUN-1998;	98US-0091010P.
PR	22-APR-1998;	98US-0082704P.	PR	01-JUL-1998;	98US-0091359P.
PR	22-APR-1998;	98US-0082797P.	PR	01-JUL-1998;	98US-0091544P.
PR	28-APR-1998;	98US-0083322P.	PR	02-JUL-1998;	98US-0091478P.
PR	28-APR-1998;	98US-0083495P.	PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998;	98US-0083496P.	PR	02-JUL-1998;	98US-0091626P.
PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091628P.
PR	05-MAY-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0091632P.
PR	06-MAY-1998;	98US-0084366P.	PR	24-JUL-1998;	98US-0094006P.
PR	07-MAY-1998;	98US-0084619P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084643P.	PR	10-AUG-1998;	98US-0096012P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096891P.
PR	18-MAY-1998;	98US-0086032P.	PR	17-AUG-1998;	98US-0096897P.
PR	22-MAY-1998;	98US-0086332P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0096959P.
PR	28-MAY-1998;	98US-0087098P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097952P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097954P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097955P.
PR	03-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0097971P.
PR	04-JUN-1998;	98US-0088028P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088029P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088033P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088326P.	PR	01-SEP-1998;	98US-0098723P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098803P.
PR	05-JUN-1998;	98US-0088202P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088212P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088212P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	09-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.

PR	10-SEP-1998;	98US-00998112P.	XX	20-FEB-2003.	
PR	15-SEP-1998;	98US-0100388P.	PD		
PR	16-SEP-1998;	98US-0100662P.	XX		
PR	16-SEP-1998;	98US-0100664P.	PF	28-JUN-2002;	2002US-00184632.
PR	16-SEP-1998;	98US-0101751P.	XX		
PR	16-SEP-1998;	98WO-US019330.	PR	18-SEP-1997;	97US-0059263P.
PR	17-SEP-1998;	98US-0100683P.	PR	18-SEP-1997;	97US-0059266P.
PR	17-SEP-1998;	98US-0100684P.	PR	17-OCT-1997;	97US-0062250P.
PR	17-SEP-1998;	98US-0100919P.	PR	21-OCT-1997;	97US-0063486P.
PR	17-SEP-1998;	98US-0100930P.	PR	24-OCT-1997;	97US-0063120P.
PR	18-SEP-1998;	98US-0100849P.	PR	24-OCT-1997;	97US-0063121P.
PR	18-SEP-1998;	98US-0101014P.	PR	28-OCT-1997;	97US-0063540P.
PR	18-SEP-1998;	98US-0101068P.	PR	28-OCT-1997;	97US-0063541P.
PR	23-SEP-1998;	98US-0101471P.	PR	28-OCT-1997;	97US-0063544P.
PR	23-SEP-1998;	98US-0101472P.	PR	29-OCT-1997;	97US-0063734P.
PR	23-SEP-1998;	98US-0101475P.	PR	31-OCT-1997;	97US-0063870P.
PR	23-SEP-1998;	98US-0101477P.	PR	31-OCT-1997;	97US-0064103P.
PR	24-SEP-1998;	98US-0101738P.	PR	13-NOV-1997;	97US-0065311P.
PR	24-SEP-1998;	98US-0101739P.	PR	21-NOV-1997;	97US-0066120P.
PR	24-SEP-1998;	98US-0101743P.	PR	24-NOV-1997;	97US-0066466P.
PR	25-SEP-1998;	98US-0101922P.	PR	11-DEC-1997;	97US-0069335P.
PR	29-SEP-1998;	98US-0101786P.	PR	12-DEC-1997;	97US-0069425P.
PR	29-SEP-1998;	98US-0102207P.	PR	17-DEC-1997;	97US-0069870P.
PR	29-SEP-1998;	98US-0102240P.	PR	18-DEC-1997;	97US-0068017P.
PR	29-SEP-1998;	98US-0102330P.	PR	10-MAR-1998;	98US-0077450P.
PR	29-SEP-1998;	98US-0102331P.	PR	11-MAR-1998;	98US-0077632P.
PR	30-SEP-1998;	98US-0102487P.	PR	11-MAR-1998;	98US-0077649P.
PR	30-SEP-1998;	98US-0102570P.	PR	20-MAR-1998;	98US-0078939P.
PR	30-SEP-1998;	98US-0102571P.	PR	27-MAR-1998;	98US-0079664P.
PR	01-OCT-1998;	98US-0102684P.	PR	27-MAR-1998;	98US-0079786P.
PR	01-OCT-1998;	98US-0102687P.	PR	31-MAR-1998;	98US-0080107P.
PR	02-OCT-1998;	98US-0102965P.	PR	31-MAR-1998;	98US-0080194P.
PR	06-OCT-1998;	98US-0103258P.	PR	01-APR-1998;	98US-0080327P.
PR	06-OCT-1998;	98US-0103449P.	PR	01-APR-1998;	98US-0080333P.
PR			PR	08-APR-1998;	98US-0081049P.
PR			PR	09-APR-1998;	98US-0081195P.
PR			PR	15-APR-1998;	98US-0081838P.
PR			PR	21-APR-1998;	98US-0082569P.
PR			PR	22-APR-1998;	98US-0082704P.
PR			PR	22-APR-1998;	98US-0082797P.
PR			PR	28-APR-1998;	98US-0083322P.
PR			PR	29-APR-1998;	98US-0083495P.
PR			PR	29-APR-1998;	98US-0083496P.
PR			PR	29-APR-1998;	98US-0083499P.
PR			PR	05-MAY-1998;	98US-0084366P.
PR			PR	06-MAY-1998;	98US-0084414P.
PR			PR	07-MAY-1998;	98US-0084639P.
PR			PR	07-MAY-1998;	98US-0084640P.
PR			PR	07-MAY-1998;	98US-0084643P.
PR			PR	15-MAY-1998;	98US-0085579P.
PR			PR	15-MAY-1998;	98US-0085580P.
PR			PR	15-MAY-1998;	98US-0085582P.
PR			PR	15-MAY-1998;	98US-0085700P.
PR			PR	22-MAY-1998;	98US-0086023P.
PR			PR	22-MAY-1998;	98US-0086392P.
PR			PR	22-MAY-1998;	98US-0086486P.
PR			PR	28-MAY-1998;	98US-0087098P.
PR			PR	28-MAY-1998;	98US-0087208P.
PR			PR	02-JUN-1998;	98US-0087609P.
PR			PR	02-JUN-1998;	98US-0087759P.
PR			PR	03-JUN-1998;	98US-0087827P.
PR			PR	04-JUN-1998;	98US-0088025P.
PR			PR	04-JUN-1998;	98US-0088028P.
PR			PR	04-JUN-1998;	98US-0088029P.
PR			PR	04-JUN-1998;	98US-0088033P.
PR			PR	04-JUN-1998;	98US-0088326P.
PR			PR	05-JUN-1998;	98US-0088167P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCTTTGGTTTACCACTCTTCTTTATCTTATTAATAAATAATGTCCTCCACCACTG	2180
Db	2653	CCTTTTCCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCGAACTA	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	

RESULT 427

ACC95846

ID ACC95846 standard; cDNA; 2846 BP.

XX

AC ACC95846;

XX

DT 10-SEP-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003036135-A1.

ID AC02527 standard; cDNA; 2846 BP.
XX AC AC02527;
XX DT 05-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumor necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumor; diagnosis;
KW adrenal tumor; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnerary; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003049741-A1.
XX PD 13-MAR-2003.
XX PF 02-JUL-2002; 2002US-00188780.
XX PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 06-NOV-1998; 98WO-US021141.
PR 01-DEC-1998; 98US-00187368.
PR 07-DEC-1998; 98WO-US025108.
PR 03-MAR-1999; 98US-00202054.
PR 08-MAR-1999; 98US-00254311.
PR 14-MAY-1999; 99WO-US010733.
PR 25-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99WO-US020111.
PR 01-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 01-DEC-1999; 99US-00423844.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 23-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00918585.
PR 13-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00929404.
PR 28-AUG-2001; 2001US-00931836.
PR 29-AUG-2001; 2001US-00941992.
PR 04-SEP-2001; 2001WO-US027099.
PR 15-JAN-2002; 2001US-00946374.
XX 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Fan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-555152/52.
DR P-PSDB; ABR80901.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating tumor necrosis factor alpha or chondrocyte proliferation
PT in a mammal.
XX Claim 2; Fig 169; 701pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR80817-ABR81121) and nucleic acids encoding them (ACF02443-ACF02747).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterized. The PRO polypeptides are useful for
CC stimulating release of tumor necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF02443-ACF02747 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTAAATAAAATGTTGCTCCACCACTG 2180
|||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAAATGAAGGTTGGCTTCGAACTA 2712
|||||

QY 2181 NCTCCCAAAAAA 2240
2713 CAAAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 430
ACF02834
ID ACF02834 standard; cDNA; 2846 BP.
XX AC ACF02834;
XX AC ACF02834;
DT 05-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003049743-A1.
XX 13-MAR-2003.
XX 11-JUL-2002; 2002US-00194394.
XX 15-SEP-2000; 2000US-0232887P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-555153/52.
XX P-PSDB; ABR81206.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX particularly for treating tumors in a mammal.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR81122-ABR81426) and nucleic acids encoding them (ACF02750-ACF03054).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for

stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF02750-ACF03054 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTAAATAAAATGTTGCTCCACCACTG 2180
|||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAAATGAAGGTTGGCTTCGAACTA 2712
|||||

QY 2181 NCTCCCAAAAAA 2240
2713 CAAAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 431
ACF21421
ID ACF21421 standard; cDNA; 2846 BP.
XX AC ACF21421;
XX AC ACF21421;
DT 19-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003049769-A1.
XX 13-MAR-2003.
XX 23-JUL-2002; 2002US-00201855.
XX 10-SEP-1998; 98US-0099754P.
XX 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-555158/52.
XX P-PSDB; ABW00902.
DR Three hundred and five nucleic acids encoding PRO polypeptides which are
DR diagnostic assays.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM00818-ABM01122) and nucleic acids encoding them (ACF21337-ACF21641).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CTTTGGCTTACCACCTCTTCTTTATTAATAAATAATGCTGCTCCACCACTG 2180
Db 2653 CTTTTCTCTCCCACTCTTGTACACATTTAATAAATAAGGCTTGTGACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAA 2772
QY 2241 AA 2242
||

Db 2773 AA 2774
RESULT 432
ACF10105
ID ACF10105 standard; cDNA; 2846 BP.
XX ACF10105;
AC ACF10105;
XX 06-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003068743-A1.
XX 10-APR-2003.
XX 23-JUL-2002; 2002US-00202473.
XX 27-OCT-1998; 98US-0105807P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-576428/54.
DR P-PSDB; ABR88504.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX molecular biology, chromosome and gene mapping, in generating antisense
XX RNA and DNA, and in gene therapy.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR88420-ABR88724) and nucleic acids encoding them (ACF10021-ACF10325).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO


```
Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTATCTATTAATAAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAATAGGCTTGCTTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
DB 2773 AA 2774

RESULT 436
ACF28233
ID ACF28233 standard; cDNA; 2846 BP.
XX AC ACF28233;
XX AC ACF28233;
XX 20-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnary; gene therapy; gene; ss.
XX Homo sapiens.
XX OS
XX US2003068752-A1.
XX PN
XX 10-APR-2003.
XX PD
XX 25-JUL-2002; 2002US-00205903.
XX PF
XX 05-JUN-2000; 2000US-0209832P.
XX PR
XX 28-FEB-2001; 2001WO-US006520.
XX PR
XX 15-JAN-2002; 2002US-00052586.
XX PR
XX (GETH ) GENENTECH INC.
XX FA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX PI
XX WPI; 2003-615900/58.
XX DR
XX P-PSDB; ABM07971.
XX DR
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy for cancer, chromosome identification, tissue typing, or
XX as hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 169; 700pp; English.
XX PS
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM07887-ABM08191) and nucleic acids encoding them (ACF28149-ACF28453).
XX CC The invention also relates to sequences at least 80% identical to the PRO
XX CC nucleic acid and polypeptide sequences of the invention, recombinant
XX CC vectors and host cells comprising a PRO nucleic acid, a method for the
XX CC recombinant production of a PRO polypeptide, antibodies against a PRO
XX CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX CC acids encoding PRO polypeptides of the invention were initially
XX CC identified via homology screening using consensus sequences based on the
XX CC extracellular domain sequences from known secreted proteins. Human cDNA
XX CC libraries containing sequences of interest were identified using
XX CC oligonucleotides based on the consensus sequences, and cDNA clones were
```

```
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF28149-ACF28453 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX CC
XX SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;
Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTATCTATTAATAAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAATAGGCTTGCTTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
DB 2773 AA 2774

RESULT 437
ACD88923
ID ACD88923 standard; cDNA; 2846 BP.
XX AC ACD88923;
XX AC ACD88923;
XX 08-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX DE
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX KW
XX Homo sapiens.
XX OS
XX US2003068682-A1.
XX PN
XX 10-APR-2003.
XX PD
XX 26-JUN-2002; 2002US-00183011.
XX PF
XX 26-JUN-1998; 98US-00105413.
XX PR
XX 16-SEP-1998; 98WO-US019330.
XX PR
XX 07-OCT-1998; 98US-00168978.
XX PR
XX 07-OCT-1998; 98WO-US021141.
```


PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097032P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match Best Local Similarity 3.0%; Score 66.6; DB 9; Length 2846;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCACTCTTCTTTATCTTTATTAATAAATGTTGCTCCCACTG 2180
Dy 2653 CCTTTCTTCCCATCTCTGTACACATTTTAATAAATAGGCTTCTTGAAC 2712
Qy 2181 NCTCCCAA 2240
Dy 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Dy 2773 AA 2774

RESULT 442
ACD09154
ID ACD09154 standard; cdna; 2846 BP.
AC ACD09154;
XX
DT 09-AUG-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein.; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; arthritis.
XX Homo sapiens.
XX
XX US2003036131-A1.
XX 20-FEB-2003.
XX
XX 27-JUN-2002; 2002US-00184628.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 18-SEP-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-00633486P.
PR 24-OCT-1997; 97US-00633120P.
PR 28-OCT-1997; 97US-00633540P.
PR 28-OCT-1997; 97US-00633541P.
PR 28-OCT-1997; 97US-00633544P.
PR 28-OCT-1997; 97US-00633564P.
PR 29-OCT-1997; 97US-00633734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089598P.
PR 19-JUN-1998; 98US-008952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.

```

PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098841P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 15-SEP-1998; 98US-0098812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100913P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTATCTTATTAATAAAAGTGTGCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db ||

Qy 2773 AA 2774

RESULT 443
ACFI1947
ID ACFI1947 standard; cDNA; 2846 BP.
XX
AC ACFI1947;
XX

```

```

DT 13-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003040075-A1.
XX
PD 27-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00188775.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0082250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0086120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0088017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.

```

RESULT 444
ACF41181
ID ACF41181 standard; cDNA; 2846 BP.
XX
AC ACF41181;

XX	06-NOV-2003	(first entry)
DT		
DE		Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX		
XX		Human, PRO; secreted protein; transmembrane protein;
KW		extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW		chondrocyte; proliferation; differentiation; cartilage disorder;
KW		bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW		adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW		liver; drug screening; transgenic animal; genetic analysis;
KW		antiarthritic; vulnery; gene therapy; gene; ss.
XX		
OS		Homo sapiens.
XX		
PN		US2003054459-A1.
XX		
PD		20-MAR-2003.
XX		
PF		12-JUL-2002; 2002US-00194461.
XX		
PR		26-JUN-1998; 98US-00105413.
PR		16-SEP-1998; 98WO-US019330.
PR		07-OCT-1998; 98US-00158978.
PR		07-OCT-1998; 98WO-US021141.
PR		06-NOV-1998; 98US-00187368.
PR		01-DEC-1998; 98WO-US025108.
PR		07-DEC-1998; 98US-00202054.
PR		03-MAR-1999; 99US-00254311.
PR		08-MAR-1999; 99WO-US005028.
PR		14-MAY-1999; 99US-00311832.
PR		14-MAY-1999; 99WO-US010733.
PR		02-JUN-1999; 99WO-US012252.
PR		25-AUG-1999; 99US-00380137.
PR		25-AUG-1999; 99US-00380138.
PR		25-AUG-1999; 99US-00380139.
PR		25-AUG-1999; 99US-00380142.
PR		01-SEP-1999; 99WO-US020111.
PR		15-SEP-1999; 99WO-US021090.
PR		18-OCT-1999; 99US-00401297.
PR		12-NOV-1999; 99US-00423844.
PR		01-DEC-1999; 99WO-US028301.
PR		02-DEC-1999; 99WO-US028551.
PR		30-DEC-1999; 99WO-US031274.
PR		05-JAN-2000; 2000WO-US000219.
PR		18-FEB-2000; 2000WO-US004341.
PR		18-FEB-2000; 2000WO-US004342.
PR		22-FEB-2000; 2000WO-US004414.
PR		24-FEB-2000; 2000WO-US005004.
PR		01-MAR-2000; 2000WO-US005601.
PR		02-MAR-2000; 2000WO-US005841.
PR		15-MAR-2000; 2000WO-US006884.
PR		30-MAR-2000; 2000WO-US008439.
PR		17-MAY-2000; 2000WO-US013705.
PR		22-MAY-2000; 2000WO-US014042.
PR		30-MAY-2000; 2000WO-US014941.
PR		02-JUN-2000; 2000WO-US015264.
PR		28-JUL-2000; 2000WO-US020710.
PR		22-AUG-2000; 2000US-00644848.
PR		24-AUG-2000; 2000WO-US023328.
PR		15-SEP-2000; 2000US-0232887P.
PR		18-SEP-2000; 2000US-00664610.
PR		18-SEP-2000; 2000US-00665350.
PR		08-NOV-2000; 2000US-00709238.
PR		08-NOV-2000; 2000WO-US030952.
PR		01-DEC-2000; 2000WO-US032678.
PR		20-DEC-2000; 2000US-00747259.
PR		20-DEC-2000; 2000WO-US034956.
PR		22-FEB-2001; 2001WO-US006520.
PR		22-MAR-2001; 2001US-00816744.
PR		10-MAY-2001; 2001US-00854208.
PR		10-MAY-2001; 2001US-00854280.
PR		25-MAY-2001; 2001US-00866028.

Db	2653	CCCTTTCCCTCCCATCTCTGTGACACATTTTAAATAAATAAGGGTTGGCTTCTGACTA	2712
Qy	2181	NCTCCGAAAAA	2240
Db	2713	CAAAAAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	
RESULT	445		
ACF15795			
ID	ACF15795	standard; cDNA; 2846 BP.	
XX	ACF15795;		
XX	13-SEP-2003	(first entry)	
XX	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
XX	Human; PRO; secreted protein; transmembrane protein;		
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulnery; gene therapy; gene; ss.		
OS	Human sapiens.		
XX	US2003044930-A1.		
XX	06-MAR-2003.		
XX	28-JUN-2002; 2002US-00184644.		
XX	18-SEP-1997; 97US-0059263P.		
PR	18-SEP-1997; 97US-0059266P.		
PR	17-OCT-1997; 97US-0062250P.		
PR	21-OCT-1997; 97US-0063486P.		
PR	24-OCT-1997; 97US-0063120P.		
PR	24-OCT-1997; 97US-0063121P.		
PR	28-OCT-1997; 97US-0063540P.		
PR	28-OCT-1997; 97US-0063541P.		
PR	28-OCT-1997; 97US-0063544P.		
PR	28-OCT-1997; 97US-0063564P.		
PR	29-OCT-1997; 97US-0063734P.		
PR	31-OCT-1997; 97US-0063870P.		
PR	31-OCT-1997; 97US-0064103P.		
PR	13-NOV-1997; 97US-0065311P.		
PR	21-NOV-1997; 97US-0066120P.		
PR	24-NOV-1997; 97US-0066772P.		
PR	11-DEC-1997; 97US-0069335P.		
PR	12-DEC-1997; 97US-0069425P.		
PR	17-DEC-1997; 97US-0069870P.		
PR	18-DEC-1997; 97US-0068017P.		
PR	10-MAR-1998; 98US-0077450P.		
PR	11-MAR-1998; 98US-0077632P.		
PR	11-MAR-1998; 98US-0077649P.		
PR	20-MAR-1998; 98US-0078886P.		
PR	20-MAR-1998; 98US-0078939P.		
PR	27-MAR-1998; 98US-0079664P.		
PR	27-MAR-1998; 98US-0079786P.		
PR	31-MAR-1998; 98US-0080107P.		
PR	31-MAR-1998; 98US-0080194P.		
PR	01-APR-1998; 98US-0080327P.		
PR	01-APR-1998; 98US-0080333P.		
PR	08-APR-1998; 98US-0081049P.		
PR	08-APR-1998; 98US-0081070P.		
PR	09-APR-1998; 98US-0081195P.		

```
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098071P.
PR 01-SEP-1998; 98US-0098168P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

```
QY 2121 CCTTTGCTTACCACTCTTCTTTTATCTTATTATAAATGTTGCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTATAAATAAGGTTGCTTCTGACTA 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 446
ACF16102
ID ACF16102 standard; cDNA; 2846 BP.
XX ACF16102;
XX 13-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
  extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
  chondrocyte; proliferation; differentiation; cartilage disorder;
  bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
  adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
  liver; drug screening; transgenic animal; genetic analysis;
  antiarthritic; vulnery; gene therapy; gene; ss.
OS Homo sapiens.
XX
PN US2003040071-A1.
XX
PD 27-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184645.
XX
PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
```

30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
22-AUG-2000; 2000US-0064848.
24-AUG-2000; 2000WO-US023328.
18-SEP-2000; 2000US-00664610.
18-SEP-2000; 2000US-00665350.
08-NOV-2000; 2000US-00709238.
08-NOV-2000; 2000WO-US030952.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001WO-US006520.
22-MAR-2001; 2001US-00816744.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
25-MAY-2001; 2001US-00860028.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001WO-00874503.
20-JUN-2001; 2001WO-US019692.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
30-JUL-2001; 2001US-00918585.
06-AUG-2001; 2001US-00924419.
13-AUG-2001; 2001US-00929404.
16-AUG-2001; 2001US-00931836.
28-AUG-2001; 2001US-00941992.
29-AUG-2001; 2001WO-US027099.
04-SEP-2001; 2001US-00946374.
15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-503400/47.
P-PSDB; ABR95299.

New nucleic acid encoding a secreted and transmembrane protein, termed
PRO polypeptide, useful for the manufacture of a medicament for
diagnosing or treating a tumor or for measuring or detecting expression
of an associated gene.

Claim 2; Fig 169; 710pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides
(ABR95215-ABR95519) and nucleic acids encoding them (ACF16018-ACF16322).
The invention also relates to sequences at least 80% identical to the PRO
nucleic acid and polypeptide sequences of the invention, recombinant
vectors and host cells comprising a PRO nucleic acid, a method for the
recombinant production of a PRO polypeptide, antibodies against a PRO
polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
acids encoding PRO polypeptides of the invention were initially
identified via homology screening using consensus sequences based on the
extracellular domain sequences from known secreted proteins. Human cDNA
libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are

adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF18957 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html

CC XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACACTCTTCCTTTTTATCATTATAAAAAAGTGTGCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCITTTCTCTCCCACACTCTTGTCACATTTTAATAAAATAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAIAA 2772

QY 2241 AA 2242
||| |
Db 2773 AA 2774

RESULT 450
ACF09184
ID ACF09184 standard; cDNA; 2846 BP.
XX AC ACF09184;
XT 06-SEP-2003 (first entry)
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX US2003068705-A1.
FN
XX 10-APR-2003.
PD
XX 15-JUL-2002; 2002US-00195886.
PF
XX 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
FA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-670246/63.
DR P-PSDB; ABM26335.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM26251-ABM26555) and nucleic acids encoding them (ACF50285-ACF50589).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF50285-ACF50589 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGGTGTCCACCACTG 2180
Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATGAAGGTTGGCTTCTGAACTA 2712
Qy 2181 NCTCCCAAA 2240
Db 2713 CAAAAAATAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

ID ACH07840 standard; cDNA; 2846 BP.
XX ACH07840;
AC ACH07840;
XX 10-OCT-2003 (first entry)
DT 10-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS US2003049749-A1.
XX 13-MAR-2003.
PD 16-JUL-2002; 2002US-00196750.
XX 03-MAY-2000; 2000US-0201516P.
PR 17-MAY-2000; 2000US-0204675P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI WPI: 2003-669837/63.
XX P-PSDB; ABO48117.
DR Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX gene therapy, in chromosome and gene mapping, as chromosome markers, in
XX tissue typing, and in identifying chromosome.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this
XX patent can also be obtained in electronic format directly from USPTO at
XX seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGGTGTCCACCACTG 2180

Db 2653 CCTTTCTCCCATCTCTTGTACACATTTTAAATAAAGGTGGCTTCTGAACATA 2712
 Qy 2181 NCTCCCAA 2240
 Db 2713 CAA 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 458
 ACF13646
 ID ACF13646 standard; cDNA; 2846 BP.
 XX
 AC ACF13646;
 DT 02-OCT-2003 (first entry)
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FN US2003064462-A1.
 XX
 PD 03-APR-2003.
 XX
 PF 26-JUL-2002; 2002US-00206919.
 XX
 PR 15-SEP-2000; 2000US-0232887P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-531720/50.
 DR P-PSDB; ABR92859.
 XX
 PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; Fig 169; 699pp; English.
 XX
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABR92775-ABR93079) and nucleic acids encoding them (ACF13562-ACF13866).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage

disorders such as arthritis and sports injuries. The PRO polypeptides may
 be used in a method for detecting the presence of a tumour (e.g., an
 adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 method involves comparing the level of expression of the PRO polypeptide
 in test and control samples, where a higher level of expression of PRO
 polypeptide in the test sample as compared to the control sample is
 indicative of the presence of a tumour. The PRO polypeptides are
 additionally useful for in drug screening to identify agonists and
 antagonists of PRO polypeptides. PRO nucleic acids are useful as
 hybridisation probes (for isolation of cDNA molecules), in chromosome and
 gene mapping, in the generation of antisense RNA and DNA and in gene
 therapy. The nucleic acids can also be used for mapping genes encoding
 PRO polypeptides, for genetic analysis of individuals with genetic
 disorders, and for generating either transgenic animals or knock-out
 animals which are useful in the development and screening of
 therapeutically useful compounds. Sequences ACF13562-ACF13866 represent
 cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 537 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTTGCTTTACCACTCTTCTTTATCTATTAATAAATGTTGGTCTCCACCACTG 2180
 Db 2653 CCTTTTCTCCCATCTCTTGTACACATTTTAAATAAAGGTGGCTTCTGAACATA 2712
 Qy 2181 NCTCCCAA 2240
 Db 2713 CAA 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774
 RESULT 459
 ACD41572
 ID ACD41572 standard; cDNA; 2846 BP.
 XX
 AC ACD41572;
 DT 11-SEP-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX
 OS Homo sapiens.
 XX
 FN US2003065159-A1.
 XX
 PD 03-APR-2003.
 XX
 PF 16-JUL-2002; 2002US-00196757.
 PR 25-APR-2000; 2000US-0199550P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-531737/50.

DR P-PSDB; ABO24620.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation
PT in a mammal.
XX
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTATTATATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTTAAATAAATAGGTTGGCTTCTGAACTA 2712
Qy 2181 NCTCCCAAA 2240
Db 2713 CAAAAAATAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 460
ADA37741
ID ADA37741 standard; cDNA; 2846 BP.
XX
AC ADA37741;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein PRO1344.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX

PN US2003008297-A1.
XX
PD 09-JAN-2003.
XX
PF 15-NOV-2001; 2001US-00997653.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
PA (GETH) GENENTECH INC.
XX
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski P;
PI Grimaldi JC, Gurney AL, Klijavin IJ, Napier MA, Pan J, Paoni NP;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-531419/50.
DR P-PSDB; ADA37742.
XX
XX
PT New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT transmembrane polypeptides, useful as targets for the diagnosis and
PT treatment of cancers, such as lung and breast cancers.
XX
PS Claim 2; Fig 158; 660pp; English.
XX
XX
CC The invention relates to an isolated nucleic acid molecule comprising the
CC full-length coding sequence of the DNA ATCC Accession Numbers given in
CC the specification, or comprising a sequence with at least 80% identity
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC sequences fully defined in the specification. Also included are the PRO
CC proteins (or their extracellular domains) with or without their associated
CC extracellular domains), expression vectors, host cells, PRO chimeric
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC sample, methods of linking a bioactive molecule to a cell expressing a
CC polypeptide and methods of modulating at least one biological activity of
CC a cell expressing the polypeptide. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC flog in endothelial cells, modulating glucose or PFA uptake by adipocyte
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC or inducing pancreatic beta-cell precursor differentiation. In
CC particular, these are useful for detecting or treating tumours and
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC may also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence is a cDNA encoding a PRO protein.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATAAATAATGTTGCTCCACACTG 2180
Db 2653 CCTTTTCTTCCCATCTCTTGACATTTTAAATAAATAGGCTTGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 461
ACF31985
ID ACF31985 standard; cDNA; 2846 BP.
XX
AC ACF31985;
XX
DT 24-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003064447-A1.
XX
PD 03-APR-2003.
XX
PF 11-JUL-2002; 2002US-00194463.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
FA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski P, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-567182/53.
DR P-PSDB; ABM11631.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM11547-ABM11851) and nucleic acids encoding them (ACF31901-ACF32205).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were

```
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF31901-ACF32205 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from: USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCCTCCCATCTCTGTACACATTTTAAATAAAATAGGTTGGTCTTGAACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
Db ||
RESULT 462
ACF23263
ID ACF23263 standard; cDNA; 2846 BP.
AC ACF23263;
XX
XX 19-SEP-2003 (first entry)
DT
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
DE Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerability; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003073184-A1.
XX
XX 17-APR-2003.
XX
XX 29-JUL-2002; 2002US-00207923.
PF
XX 15-SEP-2000; 2000US-0232887P.
PR
```

```
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
PA (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-585301/55.
DR P-PSDB; ABM02732.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for measuring or detecting expression of an associated gene.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in this
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
```

RESULT 463
ACF39953
ID ACF39953 standard; cDNA; 2846 BP.
XX ACF39953;
XX 06-NOV-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003064463-A1.
XX
PD 03-APR-2003.
XX
XX 26-JUL-2002; 2002US-00206922.
XX
PR 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-596623/56.
DR P-PSDB; ABM16028.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing and in treating
PT a condition responsive to the polypeptide e.g., cancer.
XX
XX Claim 2; Fig 169; 699pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 537 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGGTTTACCACTCTTTCTTTATCTATTATTAATAAAATGTTGTCTCCACCACTG 2180
Db 2653 CCTTTTCTCTCCCATCTCTTGATACACATTTATAATAAATAGGGTTGGCTTCTGAACATA 2712
Qy 2181 NCTCCCAAA 2240
Db 2713 CAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 464
ACD45475
ID ACD45475 standard; cDNA; 2846 BP.
XX
AC ACD45475;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
XX US2003064451-A1.
XX
PD 03-APR-2003.
XX
XX 16-JUL-2002; 2002US-00196755.
XX
PR 21-MAR-2000; 2000US-0191048P.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605858/57.
DR P-PSDB; ABO27589.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.,
XX cancer.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis

factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
Qy	2121	CGTTTCGTTTACCACACTTTTCCTTTTATCTATTAATAAAATGTGTGGTCTCCACCACACTG	2180		
Db	2653	CGTTTTCCTTCCCACTCTCTGTACACATTTTAAATAAATAGCGTTGGCTTCTGAACCTA	2712		
Qy	2181	NCTCCCAAAAAAATAA	2240		
Db	2713	CAAAAAAATAA	2772		
Qy	2241	AA 2242			
Db	2773	AA 2774			

RESULT	465	
ACF53132		
ID	ACF53132 standard; cDNA; 2846 BP.	
XX		
XX	ACF53132;	
XX		
XX	AC AC	
XX		
XX	10-OCT-2003 (first entry)	
XX		
XX	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX		
XX	Human; PRO; secreted protein; transmembrane protein;	
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
KW	chondrocyte; proliferation; differentiation; cartilage disorder;	
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
KW	liver; drug screening; transgenic animal; genetic analysis;	
KW	antiarthritic; vulnery; gene therapy; gene; ss.	
XX		
XX	Homo sapiens.	
XX		
XX	US2003068721-A1.	
XX		
XX	10-APR-2003.	
XX		
XX	19-JUL-2002; 2002US-00198767.	
XX		
XX	02-JUN-1999; 99WO-US012252.	
XX	25-AUG-1999; 99US-00380137.	
XX	28-FEB-2001; 2001WO-US006520.	
XX	15-JAN-2002; 2002US-00052586.	
XX		
XX	(GETH) GENENTECH INC.	
XX		
XX		

[illegible]

QY Db QY Db QY Db RE AC ID XX

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-605918/57.
P-PSDB: RBM29080.

New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumor or for tissue typing.

Claim 2: Fig 169: 700bp: English.

Claim 2; Fig 169; 700pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM2996-ABM29300) and nucleic acids encoding them (ACF53048-ACF53352). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF53048-ACF53352 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

	Sequence	2846 BP;	768 A;	696 C;	745 G;	637 T;	0 U;	0 Other;	
Q	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;				
Q	Best Local Similarity	71.3%;	Pred. No. 0.00023;						
Q	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;				
y	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAGTTGGTCTCCACCAC	CTG	2180					
b	2653	CTTTTCTCTCCCATCTCTTGTCACATTTTATAATAAATAAGGGTTGGCTTCTGAACTA		2712					
y	2181	NCTCCCAAAAAA	AA	2240					
b	2713	CAAAAAA	AA	2772					
y	2241	AA	2242						
y	2773	AA	2774						

RESULT 466
ACF27312
ID ACF27312 standard; cDNA; 2846 BP.
XX

Db 2653 CCTTTTCCTCCCATCTCTGTACACATTTTAAATAAATAGGCTTGGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAAAAAA 2240
 Db 2713 CAAAAA 2774
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 469

ACD89844

ID ACD89844 standard; cDNA; 2846 BP.

XX AC

XX ACD89844;

XX 08-OCT-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

XX prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003068695-A1.

XX 10-APR-2003.

XX 09-JUL-2002; 2002US-00192012.

XX 15-SEP-2000; 2000US-0232887P.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-625463/59.

XX P-PSDB; ABO41366.

XX New PRO nucleic acid, useful for the manufacture of a medicament for

XX diagnosing or treating tumor or for tissue typing.

XX Claim 2; Fig 169; 700pp; English.

XX The invention discloses human nucleic acids encoding secreted and

XX transmembrane (PRO) polypeptides, with or without their associated signal

XX peptide. Also disclosed is an antibody that specifically binds to the PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor alpha (TNF-alpha) from human blood by contacting the blood with a

XX PRO polypeptide, a method for stimulating the proliferation or

XX differentiation of chondrocyte cells by contacting the cells with a PRO

XX polypeptide, a method for detecting the presence of a tumour in a mammal

XX and an oligonucleotide probe derived from any of the PRO nucleotide

XX sequences. The nucleotide sequences are useful as probes, in chromosome

XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO

XX polypeptides by recombinant techniques and in gene therapy (e.g. for

XX replacement of defective gene). The PRO polypeptides are useful as

XX molecular weight markers for protein electrophoresis purposes, for

XX chromosome identification, as chromosome markers, as therapeutic agents,

XX for stimulating the release of TNF-alpha from human blood, for

XX stimulating the proliferation or differentiation of chondrocytes and

XX detecting the presence, prevention and/or treatment of a tumour, such as

XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

XX The PRO polypeptides and nucleic acids may also be used diagnostically

XX for tissue typing. The sequence presented is a cDNA encoding one of the

XX PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. NO. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGGCTTTACCACTCTTTCCTTTTATCTTATTAATAAATAATGTTGCTTCCCACTG 2180

Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTATAATAAATAATGTTGCTTCCCACTA 2712

QY 2181 NCTCCCAAAAAA 2240

Db 2713 CAAAAA 2774

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 470

ACD84625

ID ACD84625 standard; cDNA; 2846 BP.

XX AC

XX ACD84625;

XX 22-SEP-2003 (first entry)

XX Human PRO polynucleotide #85.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

XX cytosolic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;

XX chondrocyte cell; cancer; antiarthritic; sports injury; arthritis.

XX Homo sapiens.

XX US2003068703-A1.

XX 10-APR-2003.

XX 11-JUL-2002; 2002US-00194459.

XX 05-JUN-2000; 2000US-0209832P.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-625465/59.

XX P-PSDB; ABO36181.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX in gene therapy, as diagnostic markers for the presence of a disease

XX condition, or as therapeutic targets for treating tumors, sports injuries

XX or arthritis.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal. The polynucleotides are

XX useful in molecular biology, including uses as hybridisation probes, in

XX chromosome and gene mapping, in generating antisense RNA and DNA and in

XX gene therapy. The polynucleotides may also be used in preparing PRO

PR 11-DEC-1997; 97US-00693335P.
PR 12-DEC-1997; 97US-00694252P.
PR 17-DEC-1997; 97US-00698702P.
PR 18-DEC-1997; 97US-00680172P.
PR 10-MAR-1998; 98US-00774502P.
PR 11-MAR-1998; 98US-00776332P.
PR 11-MAR-1998; 98US-00776492P.
PR 20-MAR-1998; 98US-00788862P.
PR 20-MAR-1998; 98US-00789332P.
PR 27-MAR-1998; 98US-00796642P.
PR 27-MAR-1998; 98US-00797862P.
PR 31-MAR-1998; 98US-00801072P.
PR 31-MAR-1998; 98US-00801942P.
PR 01-APR-1998; 98US-00803272P.
PR 01-APR-1998; 98US-00803332P.
PR 08-APR-1998; 98US-00810492P.
PR 08-APR-1998; 98US-00810702P.
PR 09-APR-1998; 98US-00811932P.
PR 15-APR-1998; 98US-00818382P.
PR 21-APR-1998; 98US-00825682P.
PR 21-APR-1998; 98US-00825692P.
PR 22-APR-1998; 98US-00827042P.
PR 22-APR-1998; 98US-00827972P.
PR 28-APR-1998; 98US-00833222P.
PR 29-APR-1998; 98US-00834952P.
PR 29-APR-1998; 98US-00834962P.
PR 29-APR-1998; 98US-00834992P.
PR 29-APR-1998; 98US-00835552P.
PR 05-MAY-1998; 98US-00843662P.
PR 06-MAY-1998; 98US-00844142P.
PR 07-MAY-1998; 98US-00846332P.
PR 07-MAY-1998; 98US-00846402P.
PR 07-MAY-1998; 98US-00846432P.
PR 15-MAY-1998; 98US-00855792P.
PR 15-MAY-1998; 98US-00855802P.
PR 15-MAY-1998; 98US-00855822P.
PR 18-MAY-1998; 98US-00860232P.
PR 22-MAY-1998; 98US-00863922P.
PR 22-MAY-1998; 98US-00864862P.
PR 28-MAY-1998; 98US-00870982P.
PR 28-MAY-1998; 98US-00872082P.
PR 02-JUN-1998; 98US-00876092P.
PR 02-JUN-1998; 98US-00877592P.
PR 03-JUN-1998; 98US-00878272P.
PR 04-JUN-1998; 98US-00880252P.
PR 04-JUN-1998; 98US-00880282P.
PR 04-JUN-1998; 98US-00880292P.
PR 04-JUN-1998; 98US-00880332P.
PR 04-JUN-1998; 98US-00883262P.
PR 05-JUN-1998; 98US-00881672P.
PR 05-JUN-1998; 98US-00882022P.
PR 05-JUN-1998; 98US-00882122P.
PR 05-JUN-1998; 98US-00882172P.
PR 09-JUN-1998; 98US-00886552P.
PR 10-JUN-1998; 98US-00887222P.
PR 10-JUN-1998; 98US-00887382P.
PR 10-JUN-1998; 98US-00887402P.
PR 10-JUN-1998; 98US-00888112P.
PR 10-JUN-1998; 98US-00888242P.
PR 10-JUN-1998; 98US-00888252P.
PR 10-JUN-1998; 98US-00888262P.
PR 11-JUN-1998; 98US-00888612P.
PR 11-JUN-1998; 98US-00888632P.
PR 11-JUN-1998; 98US-00888762P.
PR 12-JUN-1998; 98US-00890902P.
PR 12-JUN-1998; 98US-00891052P.
PR 16-JUN-1998; 98US-00895122P.
PR 16-JUN-1998; 98US-00895142P.
PR 17-JUN-1998; 98US-00895382P.
PR 17-JUN-1998; 98US-00895982P.
PR 17-JUN-1998; 98US-00896532P.
PR 18-JUN-1998; 98US-00899082P.
PR 19-JUN-1998; 98US-00900002P.
PR 22-JUN-1998; 98US-00902522P.
PR 22-JUN-1998; 98US-00902542P.
PR 24-JUN-1998; 98US-00904232P.
PR 24-JUN-1998; 98US-00904352P.
PR 24-JUN-1998; 98US-00904442P.
PR 24-JUN-1998; 98US-00904612P.
PR 24-JUN-1998; 98US-00905352P.
PR 24-JUN-1998; 98US-00905402P.
PR 25-JUN-1998; 98US-00906762P.
PR 25-JUN-1998; 98US-00906782P.
PR 25-JUN-1998; 98US-00906882P.
PR 25-JUN-1998; 98US-00906902P.
PR 25-JUN-1998; 98US-00906942P.
PR 25-JUN-1998; 98US-00906952P.
PR 25-JUN-1998; 98US-00906962P.
PR 26-JUN-1998; 98US-00908622P.
PR 26-JUN-1998; 98US-00908632P.
PR 26-JUN-1998; 98US-00910102P.
PR 01-JUL-1998; 98US-00913592P.
PR 01-JUL-1998; 98US-00915442P.
PR 02-JUL-1998; 98US-00914782P.
PR 02-JUL-1998; 98US-00914862P.
PR 02-JUL-1998; 98US-00916262P.
PR 02-JUL-1998; 98US-00916282P.
PR 02-JUL-1998; 98US-00916322P.
PR 04-JUL-1998; 98US-00940062P.
PR 10-AUG-1998; 98US-00952822P.
PR 10-AUG-1998; 98US-00959982P.
PR 17-AUG-1998; 98US-00967572P.
PR 17-AUG-1998; 98US-00967662P.
PR 17-AUG-1998; 98US-00968672P.
PR 17-AUG-1998; 98US-00968912P.
PR 17-AUG-1998; 98US-00968972P.
PR 18-AUG-1998; 98US-00969492P.
PR 18-AUG-1998; 98US-00969592P.
PR 18-AUG-1998; 98US-00970222P.
PR 26-AUG-1998; 98US-00979522P.
PR 26-AUG-1998; 98US-00979542P.
PR 26-AUG-1998; 98US-00979552P.
PR 26-AUG-1998; 98US-00979712P.
PR 26-AUG-1998; 98US-00979742P.
PR 01-SEP-1998; 98US-00980142P.
PR 01-SEP-1998; 98US-00987162P.
PR 02-SEP-1998; 98US-00987232P.
PR 02-SEP-1998; 98US-00988032P.
PR 02-SEP-1998; 98US-00988212P.
PR 02-SEP-1998; 98US-00988432P.
PR 09-SEP-1998; 98US-00996022P.
PR 10-SEP-1998; 98US-00997412P.
PR 10-SEP-1998; 98US-00997542P.
PR 10-SEP-1998; 98US-00997632P.
PR 10-SEP-1998; 98US-00998122P.
PR 15-SEP-1998; 98US-01003882P.
PR 16-SEP-1998; 98US-01006622P.
PR 16-SEP-1998; 98US-01006642P.
PR 16-SEP-1998; 98US-01017512P.
PR 16-SEP-1998; 98US-01019332P.
PR 17-SEP-1998; 98US-01006832P.
PR 17-SEP-1998; 98US-01006842P.
PR 17-SEP-1998; 98US-01009192P.
PR 17-SEP-1998; 98US-01009302P.
PR 18-SEP-1998; 98US-01008492P.
PR 18-SEP-1998; 98US-01010142P.
PR 18-SEP-1998; 98US-01010682P.
PR 23-SEP-1998; 98US-01014712P.
PR 23-SEP-1998; 98US-01014722P.
PR 23-SEP-1998; 98US-01014752P.
PR 23-SEP-1998; 98US-01014772P.
PR 24-SEP-1998; 98US-01017382P.

```
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTATCTATTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCACTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGACTA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 473
ACF76770
ID ACF76770 standard; cDNA; 2846 BP.
XX
AC ACF76770;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003104548-A1.
XX
PD 05-JUN-2003.
XX
PF 17-JUL-2002; 2002US-00197706.
XX
PR 31-OCT-1997; 97US-0063870P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PR (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Deanoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-658685/62.
XX P-PSDB; ABM76106.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
```

```
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM76022-ABM76326) and nucleic acids encoding them (ACF76686-ACF76990).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF76686-ACF76990 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTATCTATTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCACTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGACTA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 474
ACF49755
ID ACF49755 standard; cDNA; 2846 BP.
XX
AC ACF49755;
XX
DT 04-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
```

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

PN US2003104542-A1.

XX 05-JUN-2003.

XX 28-JUN-2002; 2002US-00184624.

PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086032P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088035P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089553P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0091633P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.

PR	28-MAY-1998,	98US-00870988,
PR	28-MAY-1998,	98US-0087208P,
PR	02-JUN-1998,	98US-0087609P,
PR	02-JUN-1998,	98US-0087759P,
PR	03-JUN-1998,	98US-0087827P,
PR	04-JUN-1998,	98US-0088025P,
PR	04-JUN-1998,	98US-0088028P,
PR	04-JUN-1998,	98US-0088029P,
PR	04-JUN-1998,	98US-0088033P,
PR	04-JUN-1998,	98US-0088326P,
PR	05-JUN-1998,	98US-0088167P,
PR	05-JUN-1998,	98US-0088202P,
PR	05-JUN-1998,	98US-0088212P,
PR	05-JUN-1998,	98US-0088217P,
PR	05-JUN-1998,	98US-0088555P,
PR	10-JUN-1998,	98US-0088722P,
PR	10-JUN-1998,	98US-0088738P,
PR	10-JUN-1998,	98US-0088740P,
PR	10-JUN-1998,	98US-0088811P,
PR	10-JUN-1998,	98US-0088824P,
PR	10-JUN-1998,	98US-0088825P,
PR	10-JUN-1998,	98US-0088826P,
PR	11-JUN-1998,	98US-0088861P,
PR	11-JUN-1998,	98US-0088863P,
PR	11-JUN-1998,	98US-0088876P,
PR	12-JUN-1998,	98US-0089090P,
PR	12-JUN-1998,	98US-0089105P,
PR	16-JUN-1998,	98US-0089512P,
PR	16-JUN-1998,	98US-0089514P,
PR	17-JUN-1998,	98US-0089538P,
PR	17-JUN-1998,	98US-0089598P,
PR	17-JUN-1998,	98US-0089653P,
PR	18-JUN-1998,	98US-0089908P,
PR	19-JUN-1998,	98US-0089952P,
PR	22-JUN-1998,	98US-0090246P,
PR	22-JUN-1998,	98US-0090252P,
PR	22-JUN-1998,	98US-0090254P,
PR	24-JUN-1998,	98US-0090435P,
PR	24-JUN-1998,	98US-0090444P,
PR	24-JUN-1998,	98US-0090461P,
PR	24-JUN-1998,	98US-0090535P,
PR	24-JUN-1998,	98US-0090540P,
PR	25-JUN-1998,	98US-0090676P,
PR	25-JUN-1998,	98US-0090678P,
PR	25-JUN-1998,	98US-0090688P,
PR	25-JUN-1998,	98US-0090690P,
PR	25-JUN-1998,	98US-0090694P,
PR	25-JUN-1998,	98US-0090695P,
PR	25-JUN-1998,	98US-0090696P,
PR	26-JUN-1998,	98US-00910513,
PR	01-JUL-1998,	98US-0091544P,
PR	02-JUL-1998,	98US-0091478P,
PR	02-JUL-1998,	98US-0091486P,
PR	02-JUL-1998,	98US-0091626P,
PR	02-JUL-1998,	98US-0091628P,
PR	02-JUL-1998,	98US-0091632P,
PR	24-AUG-1998,	98US-0094006P,
PR	04-AUG-1998,	98US-0095282P,
PR	10-AUG-1998,	98US-0095998P,
PR	10-AUG-1998,	98US-0096012P,
PR	17-AUG-1998,	98US-0096757P,
PR	17-AUG-1998,	98US-0096766P,
PR	17-AUG-1998,	98US-0096867P,
PR	17-AUG-1998,	98US-0096891P,
PR	17-AUG-1998,	98US-0096897P,
PR	18-AUG-1998,	98US-0096949P,
PR	18-AUG-1998,	98US-0096959P,
PR	18-AUG-1998,	98US-0097022P,

PR	26-AUG-1998,	98US-00979521P,
PR	26-AUG-1998,	98US-0097954P,
PR	26-AUG-1998,	98US-0097955P,
PR	26-AUG-1998,	98US-00979571P,
PR	26-AUG-1998,	98US-0097974P,
PR	26-AUG-1998,	98US-0098014P,
PR	01-SEP-1998,	98US-0098716P,
PR	01-SEP-1998,	98US-0098723P,
PR	02-SEP-1998,	98US-0098803P,
PR	02-SEP-1998,	98US-0098821P,
PR	02-SEP-1998,	98US-0098843P,
PR	09-SEP-1998,	98US-0098943P,
PR	10-SEP-1998,	98US-0099741P,
PR	10-SEP-1998,	98US-0099754P,
PR	10-SEP-1998,	98US-0099763P,
PR	15-SEP-1998,	98US-0099812P,
PR	15-SEP-1998,	98US-0100388P,
PR	16-SEP-1998,	98US-0100662P,
PR	16-SEP-1998,	98US-0100664P,
PR	16-SEP-1998,	98US-0101751P,
PR	16-SEP-1998,	98WO-US019330,
PR	17-SEP-1998,	98US-0100683P,
PR	17-SEP-1998,	98US-0100684P,
PR	17-SEP-1998,	98US-0100919P,
PR	17-SEP-1998,	98US-0100930P,
PR	18-SEP-1998,	98US-0100849P,
PR	18-SEP-1998,	98US-0101014P,
PR	23-SEP-1998,	98US-0101068P,
PR	23-SEP-1998,	98US-0101471P,
PR	23-SEP-1998,	98US-0101475P,
PR	23-SEP-1998,	98US-0101472P,
PR	24-SEP-1998,	98US-0101477P,
PR	24-SEP-1998,	98US-0101738P,
PR	24-SEP-1998,	98US-0101739P,
PR	24-SEP-1998,	98US-0101743P,
PR	25-SEP-1998,	98US-0101922P,
PR	29-SEP-1998,	98US-0101786P,
PR	29-SEP-1998,	98US-0102027P,
PR	29-SEP-1998,	98US-0102240P,
PR	29-SEP-1998,	98US-0102330P,
PR	29-SEP-1998,	98US-0102331P,
PR	30-SEP-1998,	98US-0102487P,
PR	30-SEP-1998,	98US-0102570P,
PR	30-SEP-1998,	98US-0102571P,
PR	01-OCT-1998,	98US-0102687P,
PR	01-OCT-1998,	98US-0102684P,

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0

Qy	2121	CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTATAAANAATGTGGTCTCCACCAGTG	2180
Db	2653	CCTTTTCCTCCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC TA	2712
Qy	2181	NCTCCCAAA	2240
Db	2713	CAA	2772
Qy	2241	AA	2242
Db	2773	AA	2774

RESULT	476
ADA21427	
ID	ADA21427 standard; cDNA; 2846 BP.
XX	
AC	ADA21427;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Human cDNA encoding secreted/transmembrane protein 1427.

XX ss; gene; human; tumour; cancer; colorectal cancer; gene therapy;
KW chondrocyte differentiation; VEGF inhibition;
KW vascular endothelial growth factor; Alzheimer's disease;
KW Parkinson's disease; atherosclerosis; cystic fibrosis;
KW multiple sclerosis; ovarian cancer; tissue typing.
XX
OS Homo sapiens.
XX
XX US2003054404-A1.
XX 20-MAR-2003.
XX
XX 15-NOV-2001; 2001US-00997601.
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 13-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088367P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 10-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088851P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 02-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.


```

PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146232P.
PR 17-AUG-1999; 99US-0149366P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020201.
PR 23-AUG-2000; 2000WO-US023522.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACTCTTCTTTATCTTTATTAATAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGTCTTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 477
ACD09461
ID ACD09461 standard; cDNA; 2846 BP.
XX
AC ACD09461;
XX
DT 09-AUG-2003 (first entry)
XX

```

```

DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; Gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; arthritis.
XX Homo sapiens.
XX OS
XX US2003036127-A1.
XX 20-FEB-2003.
XX
XX 27-JUN-2002; 2002US-00184612.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.

```


XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNP-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX XX
XX PN US2003040061-A1.
XX PD 27-FEB-2003.
XX XX
XX PF 25-JUN-2002; 2002US-00180540.
XX XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077642P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.

```
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTTACCACCTCTTTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAATAGGGTGGTCTTCTGACTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 479
ACH03594
ID ACH03594 standard; cDNA; 2846 BP.
XX
AC ACH03594;
XX
```

```
DT 26-SEP-2003 (first entry)
XX Human secreted/transmembrane polypeptide PRO 1344 cDNA.
DE Human; ss; tumour; cancer; tissue typing; gene.
KW Human; ss; tumour; cancer; tissue typing; gene.
OS Homo sapiens.
XX US2003018172-A1.
PD 23-JAN-2003.
XX 01-MAY-2002; 2002US-00063513.
XX 06-DEC-2001; 2001US-00006867.
XX (GETH ) GENENTECH INC.
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-479475/45.
DR P-PSDB; ABO44257.
XX Isolated antibody specifically binding a PRO polypeptide, useful for the
PT diagnosis and treatment of disorders with the aberrant expression or
PT activity of the PRO polypeptide, such as tumor conditions and cancer.
XX Disclosure; Fig 37; 409pp; English.
PS The invention relates to an antibody that binds to a fully defined PRO
XX polypeptide. The antibody is useful for the diagnosis, prevention and/or
CC treatment of disorders associated with the aberrant expression or
CC activity of the PRO polypeptide, such as tumour conditions and cancer.
CC They can also be used to generate transgenic or knockout animals useful
CC in the development and screening of therapeutically useful reagents. The
CC PRO polypeptides and encoding nucleic acids can be used as molecular
CC weight markers for protein electrophoresis, chromosome identification and
CC tissue typing. The antibodies may be used in various diagnostic,
CC competitive binding and/or immunoprecipitation assays. The present
CC sequence represents cDNA encoding a human secreted and transmembrane PRO
XX polypeptide
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTTACCACCTCTTTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAATAGGGTGGTCTTCTGACTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 480
ACF12254
ID ACF12254 standard; cDNA; 2846 BP.
XX
AC ACF12254;
XX
XX 13-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
XX
```

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

PN US2003036130-A1.

XX 20-FEB-2003.

XX 29-JUN-2002; 2002US-00184622.

PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069435P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084619P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.

```
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098016P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100583P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 25-SEP-1998; 98US-0102330P.
PR 25-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102664P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGTTTACCACCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAAATAAAATGAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 481
ACC94762
ID ACC94762 standard; cDNA; 2846 BP.
XX
AC ACC94762;
XX
DT 29-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
```

```
Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
Homo sapiens.
US2003054468-A1.
20-MAR-2003.
19-JUL-2002; 2002US-00199462.
26-JUN-1998; 98US-00105413.
16-SEP-1998; 98WO-US019330.
07-OCT-1998; 98US-00168978.
07-OCT-1998; 98WO-US021141.
06-NOV-1998; 98US-00187368.
01-DEC-1998; 98WO-US025108.
07-DEC-1998; 98US-00202054.
03-MAR-1999; 99US-00254311.
08-MAR-1999; 99WO-US005028.
14-MAY-1999; 99US-00311832.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
25-AUG-1999; 99US-00380137.
25-AUG-1999; 99US-00380138.
25-AUG-1999; 99US-00380139.
25-AUG-1999; 99US-00380142.
01-SEP-1999; 99WO-US020111.
15-SEP-1999; 99WO-US021090.
18-OCT-1999; 99US-00403297.
12-NOV-1999; 99US-00423844.
01-DEC-1999; 99WO-US028301.
02-DEC-1999; 99WO-US028551.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006884.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
22-AUG-2000; 2000US-00644848.
24-AUG-2000; 2000WO-US023328.
18-SEP-2000; 2000US-00664610.
18-SEP-2000; 2000US-00665350.
08-NOV-2000; 2000US-00709238.
08-NOV-2000; 2000WO-US030952.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001WO-US006520.
22-MAR-2001; 2001US-00816744.
10-MAY-2001; 2001US-00854208.
25-MAY-2001; 2001US-00866028.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
20-JUN-2001; 2001WO-US019692.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
```

```

PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-479874/45.
XX P-PSDB; ABR73707.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
XX colon, breast, prostate, rectal, cervical or liver tumors.
XX
XX Claim 2; Fig 169; 701pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR73623-ABR73927) and nucleic acids encoding them (ACC94678-ACC94982).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic
XX disorders, and for generating either transgenic animals or knock-out
XX animals which are useful in the development and screening of
XX therapeutically useful compounds. Sequences ACC94678-ACC94982 represent
XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 G; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. NO. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTGGCTTACCACTCTTCTTATCTTATTAATAAATGTTGCTTCCACACTG 2180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX DB 2653 CTTTCTCTCCCATCTCTTGTACACATTTTAAATAAATAGGGTTTGGCTTCTGAAC 2712
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

```

```

Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
XX
XX RESULT 482
XX ACD22481
XX ID ACD22481 standard; cDNA; 2846 BP.
XX AC ACD22481;
XX DT 25-AUG-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX PN US2003054470-A1.
XX PD 20-MAR-2003.
XX PR 22-JUL-2002; 2002US-00201328.
XX PR 24-JUN-1998; 98US-0090535P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-479875/45.
XX P-PSDB; ABO16959.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
XX colon, breast, prostate, rectal, cervical or liver tumors.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this

```

PR	20-MAR-1998,	98US-00789399,
PR	27-MAR-1998,	98US-00796649,
PR	27-MAR-1998,	98US-00797869,
PR	31-MAR-1998,	98US-00801079,
PR	31-MAR-1998,	98US-00801949,
PR	01-APR-1998,	98US-00803279,
PR	01-APR-1998,	98US-00803339,
PR	08-APR-1998,	98US-00810449,
PR	08-APR-1998,	98US-00810709,
PR	09-APR-1998,	98US-00811959,
PR	15-APR-1998,	98US-00818389,
PR	21-APR-1998,	98US-00825689,
PR	21-APR-1998,	98US-00825699,
PR	22-APR-1998,	98US-00827049,
PR	22-APR-1998,	98US-00827979,
PR	28-APR-1998,	98US-00833229,
PR	28-APR-1998,	98US-00833259,
PR	28-APR-1998,	98US-00834959,
PR	29-APR-1998,	98US-00834969,
PR	29-APR-1998,	98US-00834999,
PR	29-APR-1998,	98US-00835599,
PR	05-MAY-1998,	98US-00843669,
PR	06-MAY-1998,	98US-00844149,
PR	07-MAY-1998,	98US-00846339,
PR	07-MAY-1998,	98US-00846409,
PR	15-MAY-1998,	98US-00855799,
PR	15-MAY-1998,	98US-00855809,
PR	15-MAY-1998,	98US-00855829,
PR	15-MAY-1998,	98US-00857009,
PR	18-MAY-1998,	98US-00860239,
PR	22-MAY-1998,	98US-00863929,
PR	22-MAY-1998,	98US-00864869,
PR	28-MAY-1998,	98US-00870989,
PR	28-MAY-1998,	98US-00872089,
PR	02-JUN-1998,	98US-00876099,
PR	02-JUN-1998,	98US-00877599,
PR	03-JUN-1998,	98US-00878279,
PR	04-JUN-1998,	98US-00880259,
PR	04-JUN-1998,	98US-00880289,
PR	04-JUN-1998,	98US-00880829,
PR	04-JUN-1998,	98US-00880339,
PR	04-JUN-1998,	98US-00883269,
PR	05-JUN-1998,	98US-00881679,
PR	05-JUN-1998,	98US-00882029,
PR	05-JUN-1998,	98US-00882129,
PR	05-JUN-1998,	98US-00882179,
PR	09-JUN-1998,	98US-00886559,
PR	10-JUN-1998,	98US-00887229,
PR	10-JUN-1998,	98US-00887389,
PR	10-JUN-1998,	98US-00887409,
PR	10-JUN-1998,	98US-00888119,
PR	10-JUN-1998,	98US-00888249,
PR	10-JUN-1998,	98US-00888259,
PR	10-JUN-1998,	98US-00888269,
PR	11-JUN-1998,	98US-00888619,
PR	11-JUN-1998,	98US-00888639,
PR	11-JUN-1998,	98US-00888769,
PR	12-JUN-1998,	98US-00890909,
PR	12-JUN-1998,	98US-00891059,
PR	16-JUN-1998,	98US-00895129,
PR	16-JUN-1998,	98US-00895149,
PR	17-JUN-1998,	98US-00895389,
PR	17-JUN-1998,	98US-00895989,
PR	17-JUN-1998,	98US-00896539,
PR	18-JUN-1998,	98US-00899089,
PR	19-JUN-1998,	98US-00899529,
PR	22-JUN-1998,	98US-00902469,
PR	22-JUN-1998,	98US-00902529,
PR	23-JUN-1998,	98US-00902549,
PR	24-JUN-1998,	98US-00904299,
PR	24-JUN-1998,	98US-00904359,
PR	24-JUN-1998,	98US-00904449,
PR	24-JUN-1998,	98US-00904619,
PR	24-JUN-1998,	98US-00905359,

PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 13-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102077P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.

PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTACCACTCTTCCCTTTATCTATTATAAAATGTTGGTCTCCCACTG 2180
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAAGGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2240
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 484

ACC97276

ID ACC97276 standard; cDNA; 2846 BP.

XX AC ACC97276;

DT 19-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003044929-A1.

XX 06-MAR-2003.

XX 28-JUN-2002; 2002US-00184643.

XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 03-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088302P.
PR 05-JUN-1998; 98US-0088312P.
PR 05-JUN-1998; 98US-0088317P.
PR 09-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 25-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.

```

PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCCCATCTCTTGACACATTTTAAATAAAGGCTTGGCTTCTGAACATA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 485
ACC92306
ID ACC92306 standard; cDNA; 2846 BP.
AC ACC92306;
AC ACC92306;
DT 19-AUG-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX
XX US2003059880-A1.
XX
XX 27-MAR-2003.
XX
XX 16-JUL-2002; 2002US-00196758.
XX
XX 29-MAR-2000; 2000US-0193032P.
XX
XX 28-FEB-2001; 2001WO-US006520.
XX
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Deanoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-521911/49.
XX P-PSDB; ABR71267.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX gene therapy, or for preparing a medicament for treating a condition that
XX is responsive to the PRO polypeptide or anti-PRO antibody.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR71183-ABR71487) and nucleic acids encoding them (ACC92222-ACC92526).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the

```

```

CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC92526 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCCCATCTCTTGACACATTTTAAATAAAGGCTTGGCTTCTGAACATA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 486
ACFI3953
ID ACFI3953 standard; cDNA; 2846 BP.
XX
XX ACFI3953;
XX
XX 02-OCT-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX

```

PN US2003064465-A1.
 XX 03-APR-2003.
 XX 25-JUL-2002; 2002US-00206928.
 XX 26-OCT-1998; 98US-0105694P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 28-FEB-2000; 2000WO-US0004342.
 PR 28-FEB-2001; 2001WO-US0006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX P-PSDB; ABR93164.
 DR WPI; 2003-531721/50.
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
 PT gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABR93080-ABR93384) and nucleic acids encoding them (ACF13869-ACF14173).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human CDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF13869-ACF14173 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGTCTTACCACCTCTTCTCTTATCTATTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTCTCCCATCTCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACCTA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774
 RESULT 487
 ID ACF14260 standard; cDNA; 2846 BP.
 XX ACF14260;
 AC ACF14260;
 XX 07-OCT-2003 (first entry)
 DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 DE Human; PRO; secreted protein; transmembrane protein;
 XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX Homo sapiens.
 OS US2003054478-A1.
 PN 20-MAR-2003.
 PD 23-JUL-2002; 2002US-00202472.
 PF 11-JUN-1998; 98US-0088861P.
 PR 02-JUN-1999; 99WO-US022252.
 PR 25-AUG-1999; 99US-00380137.
 PR 28-FEB-2001; 2001WO-US0006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-540611/51.
 DR P-PSDB; ABR93469.
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody.
 XX Claim 2; Fig 169; 700pp; English.
 PS The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABR93385-ABR93689) and nucleic acids encoding them (ACF14176-ACF14480).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human CDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which


```
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095331P.
PR 04-AUG-1998; 98US-0095332P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 22-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US0113296P.
PR 08-MAR-1999; 99WO-US000106.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACACATCTTCTCTTTATCTATTATTAATAATGTTGGTCTCCACCACG 2180
Db 2653 CCTTTTCCTCCCATCTCTCTGTACACATTTAAATAAATAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 489
ID ACF09491 standard; cDNA; 2846 BP.
XX ACF09491;
XX ACF09491;
DT 06-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
OS Homo sapiens.
XX US2003068718-A1.
PN 10-APR-2003.
PD 18-JUL-2002; 2002US-00198761.
PF 31-MAR-1998; 98US-0080107P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
```


The present invention relates to the isolation of novel human PRO polypeptides, and the polynucleotide sequences encoding them. The PRO polypeptides are secreted and transmembrane proteins. The PRO polypeptide and polynucleotide sequences are useful for detecting the presence of tumours in a mammal, stimulating proliferation or differentiation of chondrocyte cells, and stimulating the release of tumour necrosis factor- α from human blood. The PRO polynucleotide sequences are useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes. Anti-PRO antibodies may be used in diagnostic assays for PRO polypeptides, or for the affinity purification of PRO polypeptides from recombinant cell culture or natural sources. AC067578-ACD67882 represent cDNA sequences encoding the human PRO polypeptides of the invention. Note: The sequence data for this patent was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/psipatIDentry.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0

Qy	2121	CTTTGCTTTACCACTCTTTCTTTTAACTTTAATAATAAAATGTTGGTCTCCACCAC	CTG	2180
Db	2653	CTTTTCCTTCCCACTCTCTGTACACATTTTAATAAATAGGGTTGGCTCTGAACTA	CTG	2712

[illegible]

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 493

ACF25470
ID ACF25470 standard; cDNA; 2846 BP.

AC ACF25470:

DT 22-SEP-2003 (first entry)

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antithrombotic; vulnervary; gene therapy; gene; ss.

OS Homo sapiens.

XX
PN
US2003068727-A1.

10-APR-2003.

19-JUL-2002; 2002US-00199457.

AA
PR 18-SEP-1998; 98US-0101068P.

PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WC-US0006320.
PR 15-JAN-2002; 2002US-00052586.

AA (GETH) GENENTECH INC.

PI Baker KP. Chen J. De

PI PAN J, SMITH V, WALD

XX WFI; 2003-615887/58.
DR P-PSDB; ABM04926.
XX
XX New secreted and transmembrane PRO nucleic acids, useful for the
PT manufacture of a medicament for diagnosing or treating tumors or for
PT tissue typing.
PT
XX
XX Claim 2; Fig 169; 703pp; English.
PS

The invention relates to human PRO secreted/transmembrane polypeptides (AFM0482-ARM05146) and nucleic acids encoding them (ACF23386-ACF23590). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human CDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF23386-ACF23590 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP: 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other; XX

Query Match	3.0%	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches	87; Conservative	0; Mismatches	35; Indels	0

Qy	2121	2653	2712	2180
Qy	CTTTGGTTTACCACTCTTTCCGTTTATCTTATTATATAAAATGTTGGTCTCCACCACTG			
Dp		CTTTTCCTTCCCACTCTCTTGACACATTTTAATAAAATGAAGGTTGGTCTCTGAACCTA		

[illegible]

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 494

ACF29154

ID ACF29154 standard; cDNA; 2846 BP.
XX

AC ACF29154;

XX 20-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003068772-A1.
XX 10-APR-2003.
XX 29-JUL-2002; 2002US-00208022.
XX 21-MAR-2000; 2000US-0190828P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615909/58.
XX P-PSDB; ABM0886.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX particularly for treating e.g. lung or breast tumors, or arthritis in a
XX mammal.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM08802-ABM09106) and nucleic acids encoding them (ACF29070-ACF29374).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic
XX disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF29070-ACF29374 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTACCACTCTTCTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACCTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTAATAAATAAGGGTTCCTGAACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 495
ACD84932
ID ACD84932 standard; cDNA; 2846 BP.
XX
AC ACD84932;
DT 05-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
XX US2003068714-A1.
XX
XX 10-APR-2003.
XX
XX 17-JUL-2002; 2002US-00197698.
XX
XX 27-OCT-1998; 98US-0105882P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-625466/59.
XX P-PSDB; ABO36486.
XX
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
XX manufacture of a medicament for diagnosing or treating tumors or for
XX tissue typing.
XX
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a


```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTCTTATTAATAAATGTTGTCACCACTG 2180
Db 2653 CTTTTCTCTCCCACTCTTGTACACATTTTAATAAATAGGCTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 499
ACF32292
ID ACF32292 standard; cDNA; 2846 BP.
XX
AC ACF32292;
XX
DT 24-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW anarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003104555-A1.
XX
PD 05-JUN-2003.
XX
PF 25-JUL-2002; 2002US-00205905.
XX
PR 01-OCT-1998; 98US-0102687P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 12-FEB-2001; 2001WO-US004342.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-645118/61.
DR P-PSDB; ABM11936.
XX
Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT particularly for treating e.g. lung or breast tumors.
PS Claim 2; Fig 169; 700pp; English.
XX
The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM11852-ABM12156) and nucleic acids encoding them (ACF32208-ACF32512).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially

```

```

CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF32208-ACF32512 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

```

```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTCTTATTAATAAATGTTGTCACCACTG 2180
Db 2653 CTTTTCTCTCCCACTCTTGTACACATTTTAATAAATAGGCTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

```

```

RESULT 500
ACH11952
ID ACH11952 standard; cDNA; 2846 BP.
XX
AC ACH11952;
XX
DT 13-OCT-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #85.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW molecular biology; hybridisation probe; chromosome mapping; gene mapping;
KW cytosolic; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003049768-A1.
XX
PD 13-MAR-2003.
XX
PF 22-JUL-2002; 2002US-00201770.
XX
PR 02-SEP-1998; 98US-0098803P.

```


PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082588P.
PR 21-APR-1998; 98US-0082589P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089539P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090451P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.

PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTATTAAATAAATGTTGCTCTCCACCACTG 2180
D5 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGCTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
D5 2713 CAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2772
QY 2241 AA 2242
D5 2773 AA 2774

RESULT 504
ADBI7282
ID ADBI7282 standard; cDNA; 2846 BP.
XX AC ADBI7282;
XX DT 20-NOV-2003 (first entry)
XX DE Human cDNA clone (SeqID 37) encoding the transmembrane PRO protein.
XX KW ss; gene; PRO; transmembrane; immunoconjugate; cytotoxic; gene therapy;
XX KW cytostatic; cancer; human.
XX OS Homo sapiens.
XX PN US2003050465-A1.
XX PD 13-MAR-2003.
XX PF 26-AUG-2002; 2002US-00227693.
XX PR 10-AUG-1998; 98US-0096012P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 06-DEC-2001; 2001US-00006867.
XX PA (GETH) GENENTECH INC.
XX PI Eaton DL, Filvaroff E, Gerritsen MB, Goddard A, Godowski PU;
XX PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX XX WPI; 2003-521821/49.
XX DR P-PSDB; ADBI7283.
XX XX
XX FT New PRO nucleic acid, useful for manufacturing a medicament for
XX FT diagnosing or treating tumor or for tissue typing.
XX PS Claim 2; Fig 37; 406pp; English.
XX XX
XX CC This invention relates to a novel isolated and secreted PRO polypeptide.
XX CC PRO is a transmembrane protein involved in the formation, differentiation
XX CC and maintenance of multicellular organisms, and more particularly the
XX CC proliferation, differentiation and migration of individual cells. The
XX CC invention describes screening compounds to identify PRO polypeptide
XX CC agonists and antagonists, anti-PRO antibodies, and immunoconjugates
XX CC comprising an antibody conjugated to a cytotoxic agent. Specifically, the
XX CC heterologous protein of the chimeric polypeptide is an epitope tag or an
XX CC Fc region of an immunoglobulin. Through the use of gene therapy, the PRO

CC polypeptide is useful for preparing cytostatic compositions for
CC diagnosing or treating cancer. The polypeptide is also useful as a
CC molecular weight marker for protein electrophoresis purposes. This
CC polynucleotide sequence is a native cDNA clone that encodes human PRO
XX polypeptide, found in the cDNA library of the invention.
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTATTAAATAAATGTTGCTCTCCACCACTG 2180
D5 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGCTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
D5 2713 CAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2772
QY 2241 AA 2242
D5 2773 AA 2774
RESULT 505
ADAI7758
ID ADAI7758 standard; cDNA; 2846 BP.
XX AC ADAI7758;
XX DT 20-NOV-2003 (first entry)
XX DE cDNA encoding human PRO1344 polypeptide.
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
XX KW transgenic; tumour; cytostatic; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003054987-A1.
XX PD 20-MAR-2003.
XX PF 14-NOV-2001; 2001US-00990443.
XX PR 16-JUN-1997; 97US-0049787P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 05-NOV-1997; 97WO-US020069.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 24-NOV-1997; 97US-0066770P.
XX PR 25-FEB-1998; 98US-0075945P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 02-JUN-1998; 98US-0087607P.
XX PR 02-JUN-1998; 98US-0087609P.
XX PR 02-JUN-1998; 98US-0087759P.
XX PR 03-JUN-1998; 98US-0087827P.
XX PR 04-JUN-1998; 98US-0088021P.
XX PR 04-JUN-1998; 98US-0088025P.
XX PR 04-JUN-1998; 98US-0088026P.
XX PR 04-JUN-1998; 98US-0088028P.
XX PR 04-JUN-1998; 98US-0088029P.
XX PR 04-JUN-1998; 98US-0088030P.
XX PR 04-JUN-1998; 98US-0088033P.
XX PR 04-JUN-1998; 98US-0088326P.
XX PR 05-JUN-1998; 98US-0088167P.
XX PR 05-JUN-1998; 98US-0088202P.
XX PR 05-JUN-1998; 98US-0088212P.
XX PR 05-JUN-1998; 98US-0088217P.


```

PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 506
ACF18123
ID ACF18123 standard; cDNA; 2846 BP.
XX ACF18123;
AC ACF18123;
XX
DT 17-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
US2003054481-A1.
XX
PD 20-MAR-2003.
XX
XX
PF 24-JUL-2002; 2002US-00205511.
XX
PR 24-JUN-1998; 98US-0090540P.
PR 02-JUN-1999; 99WO-US012252.
PR 26-JUL-1999; 99US-0145698P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540612/51.
XX
PT P-PSDB; ABR97191.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX

```

PS Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides (ABR97107-ABR97411) and nucleic acids encoding them (ACF18039-ACF18343).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF18039-ACF18343 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180

DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAAAAATAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 507

ACF08570

ID ACF08570 standard; cDNA; 2846 BP.

XX ACF08570;

DT 06-SEP-2003 (first entry)

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;

bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
Homo sapiens.
US2003049778-A1.
13-MAR-2003.
24-JUL-2002; 2002US-00205504.
28-OCT-1998; 98US-0106178P.
01-SEP-1999; 99WO-US020111.
18-OCT-1999; 99US-00403297.
18-FEB-2000; 2000WO-US004342.
28-FEB-2001; 2001WO-US006520.
15-JAN-2002; 2002US-00052586.
(GETH) GENENTECH INC.
Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-567066/53.
P-PSDB; ABR86979.
Three hundred and five nucleic acids encoding PRO polypeptides, useful
for the manufacture of a medicament for diagnosing or treating tumor or
for tissue typing.
Claim 2; Fig 169; 700pp; English.
The invention relates to human PRO secreted/transmembrane polypeptides
(ABR8695-ABR87199) and nucleic acids encoding them (ACF08486-ACF08790).
The invention also relates to sequences at least 80% identical to the PRO
nucleic acid and polypeptide sequences of the invention, recombinant
vectors and host cells comprising a PRO nucleic acid, a method for the
recombinant production of a PRO polypeptide, antibodies against a PRO
polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
acids encoding PRO polypeptides of the invention were initially
identified via homology screening using consensus sequences based on the
extracellular domain sequences from known secreted proteins. Human cDNA
libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF08486-ACF08790 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
OY 2121 CTTTTGCTTTACCACTCTTTCTCTTTATCTATTATATAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CTTTTCTCTCCCATCTCTCTGTACACATTTAAATAAATAAGGTTGGCTTCTGAACATA 2712
OY 2181 NCTCCCAAA 2240
Db 2713 CAA 2772
OY 2241 AA 2242
Db 2773 AA 2774
RESULT 508
ACF31371
ID ACF31371 standard; cDNA; 2846 BP.
XX AC ACF31371;
XX AC ACF31371;
DT 24-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003049782-A1.
PD 13-MAR-2003.
XX 26-JUL-2002; 2002US-00205900.
XX 03-MAR-2000; 2000US-0187202P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-576294/54.
DR P-PSDB; ABM11021.
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM10937-ABM11241) and nucleic acids encoding them (ACF31287-ACF31591).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using

oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF31287-ACF31591 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTATAAATAATGGTGTCTCCACCACTG 2180
Db 2653 CTTTTCTCCCATCTCTTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 509

ACF52211
ID ACF52211 standard; cDNA; 2846 BP.

XX ACF52211;

DT 07-OCT-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritis; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003054476-A1.

XX 20-MAR-2003.

XX 23-JUL-2002; 2002US-00202409.

PR 11-JUN-1998; 98US-0088876P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Deanyers L, Goddard A, Godowski EJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-596539/56.
DR P-PSDB; ABM28165.

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM28081-ABM28385) and nucleic acids encoding them (ACF52127-ACF52431).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF52127-ACF52431 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTATAAATAATGGTGTCTCCACCACTG 2180
Db 2653 CTTTTCTCCCATCTCTTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772

```
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 510
ACD50080
ID ACD50080 standard; cDNA; 2846 BP.
XX
AC ACD50080;
XX
XX 05-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX
XX US2003068733-A1.
XX
XX 10-APR-2003.
XX
XX 22-JUL-2002; 2002US-00201321.
XX
XX 03-NOV-1998; 98US-0106902P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-605922/57.
XX P-PSDB; ABO32164.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
XX PRO827, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this
XX patent can also be obtained in electronic format directly from USPTO at
XX seqdata.uspto.gov/sequence.html
XX
```

```
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTTACCACCTCTTTTCTTTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCCTTTTCCCATCTCTTGACACATTTTAATAAAATAGGGTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 511
ACF38783
ID ACF38783 standard; cDNA; 2846 BP.
XX
XX ACF38783;
XX
XX 08-OCT-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003068692-A1.
XX
XX 10-APR-2003.
XX
XX 09-JUL-2002; 2002US-00192006.
XX
XX 05-JUN-2000; 2000US-0209832P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615872/58.
XX P-PSDB; ABM15291.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM14902-ABM15206) and nucleic acids encoding them (ACF38392-ACF38696)...
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
```

CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF38696 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTGCTCCACCACTG 2180
Db 2653 CTTTTCTTCCCATCTTGTACACATTTTAAATAAATAGGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 512
ACF26698
ID ACF26698 standard; cDNA; 2846 BP.

ACF26698;

22-SEP-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnary; gene therapy; gene; ss.

Homo sapiens.

US2003068709-A1.

10-APR-2003.

16-JUL-2002; 2002US-00196753.

PR 29-MAR-2000; 2000US-0193053P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-615880/58.
DR P-PSDB; ABM06446.

New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumor or for tissue typing.

Claim 2; Fig 169; 703pp; English.

CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM06362-ABM06666) and nucleic acids encoding them (ACF26614-ACF26918).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF26614-ACF26918 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTATCTATTATTAATAAATGTGCTCCACCACTG 2180
Db 2653 CTTTTCTTCCCATCTTGTACACATTTTAAATAAATAGGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 513
ACF24798
ID ACF24798 standard; cDNA; 2846 BP.
XX
AC ACF24798;
XX
DT 01-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068716-A1.
XX
XX 10-APR-2003.
XX
PF 17-JUL-2002; 2002US-00197711.
XX
PR 21-OCT-1997; 97US-0063486P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615883/58.
DR P-PSDB; ABM04257.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM04173-ABM04477) and nucleic acids encoding them (ACF24714-ACF25018).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF24714-ACF25018 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTGCTCCACCACGTG 2180
DB 2653 CCTTTTCTCTCCCATCTCTTGACACATTTTAAATAAATAAGGGTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB 2713 CAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 514
ACF46378
ID ACF46378 standard; cDNA; 2846 BP.
XX
AC ACF46378;
XX
DT 09-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068740-A1.
XX
PD 10-APR-2003.
XX
PF 22-JUL-2002; 2002US-00201771.
XX
PR 26-AUG-1998; 98US-0097955P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615892/58.
DR P-PSDB; ABM22370.
XX
XX New isolated nucleic acid encoding a secreted and transmembrane PRO

PT polypeptide e.g. PRO1079 or PRO827, useful in molecular biology,
PT chromosome and gene mapping, in generating antisense RNA and DNA, and in
PT gene therapy for cancers.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM22286-ABM22590) and nucleic acids encoding them (ACF46294-ACF46599).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF46294-ACF46599 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCITTTGTTTACCACTCTTCTTTTATCTTATTAATAAAATTTGCTTCCACACTG 2180
Db 2653 CTTTTCTTCCCATCTCTTGTCACATTTTATAAATTAAGGTGTTCTTGAACCTA 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 515
ACF27926
ID ACF27926 standard; cDNA; 2846 BP.
XX
AC ACF27926;
XX
DT 20-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003068751-A1.
XX 10-APR-2003.
XX 26-JUL-2002; 2002US-00205901.
XX 05-JUN-2000; 2000US-0209832P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-615895/58.
XX P-PSDB; ABM07666.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM07583-ABM07886) and nucleic acids encoding them (ACF27842-ACF28146).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF27842-ACF28146 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
CC

```
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTACCACTCTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTTCCTTTCCCACTCTCTGTACACATTTTATAAAATAAGGGTTGGCTTCTGAAC 2712
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2241 AA 2242
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2773 AA 2774

RESULT 516
ACD89230
ID ACD89230 standard; cDNA; 2846 BP.
XX AC ACD89230;
XX DT 09-OCT-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX PN US2003068684-A1.
XX PD 10-APR-2003.
XX PF 28-JUN-2002; 2002US-00184634.
XX PR 26-JUN-1998; 98US-00105413.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 07-OCT-1998; 98US-00168978.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 06-NOV-1998; 98US-00187368.
XX PR 01-DEC-1998; 98WO-US025108.
XX PR 07-DEC-1998; 98US-00202054.
XX PR 03-MAR-1999; 99US-00254311.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 14-MAY-1999; 99US-00311832.
XX PR 02-JUN-1999; 99WO-US010733.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 25-AUG-1999; 99US-00380142.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 12-NOV-1999; 99US-00423844.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 22-FEB-2000; 2000WO-US004342.
XX PR 24-FEB-2000; 2000WO-US004414.
XX PR 01-MAR-2000; 2000WO-US005004.
XX PR 02-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005841.
```

```
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 23-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Fan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-625460/59.
XX P-PSDB; ABO40756.
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT manufacture of a medicament for diagnosing or treating tumors or for
PT tissue typing.
XX Claim 2; Fig 169; 706pp; English.
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
```

```

CC seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
    Query Match      3.0%; Score 66.6; DB 9; Length 2846;
    Best Local Similarity 71.3%; Pred. No. 0.00023;
    Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTCTTCCTTTATCTATTATTAATAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACIA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 517
ACF63802
ID ACF63802 standard; cDNA; 2846 BP.
XX
AC ACF63802;
DT 10-OCT-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003073179-A1.
XX
PD 17-APR-2003.
XX
PF 19-JUL-2002; 2002US-00199302.
XX
PR 24-JUN-1998; 98US-0090461P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
FA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-657646/62.
XX
P-PSDB; ABM35403.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT useful for diagnosing or treating tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially

```

```

CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
    Query Match      3.0%; Score 66.6; DB 9; Length 2846;
    Best Local Similarity 71.3%; Pred. No. 0.00023;
    Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTCTTCCTTTATCTATTATTAATAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACIA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 518
ACF60442
ID ACF60442 standard; cDNA; 2846 BP.
XX
AC ACF60442;
DT 10-OCT-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087374-A1.
XX
PD 08-MAY-2003.

```

XX 21-JUN-2002; 2002US-00176979.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063564P.
PR 28-OCT-1997; 97US-0063724P.
PR 29-OCT-1997; 97US-0063724P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088336P.
PR 05-JUN-1998; 98US-0088357P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.

	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
Qy	2121	CCYTTGGTTTTACACACCTCTTCCYTTTATCTTATATAATAAATGTTGGTCTCCACCAC	CTG	2180	
Db	2653	CCYTTTTCCTTCCCATCTCTGTGACACATTTTATAAATAAAGGGTTGGCTTCTGAAC	TA	2712	
Qy	2181	NCTCCCAA		2240	
Db	2713	CAA		2772	
Qy	2241	AA	2242		
Db	2773	AA	2774		

RESULT 520	
ACH0989	
ID	ACH0989 standard; cDNA; 2846 BP.
XX	
XX	
XX	ACH0989;
XX	
XX	10-OCT-2003 (first entry)
XX	
XX	Human secreted/transmembrane protein (PRO) cDNA #85.
XX	
XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX	
XX	Homio sapiens.
OS	
XX	
XX	
PN	US2003049777-A1.
XX	
XX	
PD	13-MAR-2003.
XX	
XX	
PF	24-JUL-2002; 2002US-0020939.

PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089658P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090689P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096953P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCACTCTTCTTTATCTTATTAATAAATGTTGCTCCCACTG 2180
|||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGGTTGCTTCTGAAC 2712
|||||
Qy 2181 NCTCCCAAA 2240
|||||
Db 2713 CAATAAA 2772
|||||
Qy 2241 AA 2242
||
Db 2773 AA 2774

RESULT 522
ACD10382.
ID ACD10382 standard; cDNA; 2846 BP.
XX
AC ACD10382;
XX
DT 12-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
OS Homo sapiens.
XX
XX
XX US2003036164-A1.
XX
XX 20-FEB-2003.
XX
XX 15-JUL-2002; 2002US-00195897.
XX
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059263P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 28-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090576P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.


```

PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

```

```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGCTCCCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGTCACATTTTAATAAATAGGCTTGCTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2241 AA 2242
    ||
Db 2773 AA 2774

```

```

RESULT 523
ACD12024
ID ACD12024 standard; cDNA; 2846 BP.
XX ACD12024;
XX ACD12024;
XX 12-AUG-2003 (first entry)
DT
XX

```

```

DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; ss; gene; secreted protein; transmembrane protein; tumour;
KW cytosolic; tumour necrosis factor alpha; TNF-alpha; blood;
KW chondrocyte cell proliferation; chondrocyte cell differentiation.
XX Homo sapiens.
XX OS
XX US2003040074-A1.
XX 27-FEB-2003.
XX 02-JUL-2002; 2002US-00188774.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079684P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0080499P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086352P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.

```

PR 02-JUN-1998;	98US-0087609P.	PR 26-AUG-1998;	98US-0097955P.
PR 03-JUN-1998;	98US-0087759P.	PR 26-AUG-1998;	98US-0097971P.
PR 03-JUN-1998;	98US-0087827P.	PR 26-AUG-1998;	98US-0097974P.
PR 04-JUN-1998;	98US-0088025P.	PR 26-AUG-1998;	98US-0098014P.
PR 04-JUN-1998;	98US-0088028P.	PR 01-SEP-1998;	98US-0098716P.
PR 04-JUN-1998;	98US-0088029P.	PR 01-SEP-1998;	98US-0098723P.
PR 04-JUN-1998;	98US-0088033P.	PR 02-SEP-1998;	98US-0098803P.
PR 04-JUN-1998;	98US-0088326P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088167P.	PR 02-SEP-1998;	98US-0098843P.
PR 05-JUN-1998;	98US-0088202P.	PR 09-SEP-1998;	98US-0099602P.
PR 05-JUN-1998;	98US-0088212P.	PR 10-SEP-1998;	98US-0099741P.
PR 05-JUN-1998;	98US-0088217P.	PR 10-SEP-1998;	98US-0099754P.
PR 05-JUN-1998;	98US-0088555P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088722P.	PR 10-SEP-1998;	98US-0099812P.
PR 10-JUN-1998;	98US-0088738P.	PR 15-SEP-1998;	98US-0100388P.
PR 10-JUN-1998;	98US-0088740P.	PR 16-SEP-1998;	98US-0100662P.
PR 10-JUN-1998;	98US-0088811P.	PR 16-SEP-1998;	98US-0100664P.
PR 10-JUN-1998;	98US-0088824P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088825P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088826P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-1998;	98US-0100919P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-SEP-1998;	98US-0100930P.
PR 12-JUN-1998;	98US-0089090P.	PR 18-SEP-1998;	98US-0100849P.
PR 12-JUN-1998;	98US-0089105P.	PR 18-SEP-1998;	98US-0101014P.
PR 16-JUN-1998;	98US-0089512P.	PR 18-SEP-1998;	98US-0101068P.
PR 16-JUN-1998;	98US-0089514P.	PR 23-SEP-1998;	98US-0101471P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101472P.
PR 17-JUN-1998;	98US-0089588P.	PR 23-SEP-1998;	98US-0101475P.
PR 17-JUN-1998;	98US-0089653P.	PR 23-SEP-1998;	98US-0101477P.
PR 18-JUN-1998;	98US-0089908P.	PR 24-SEP-1998;	98US-0101738P.
PR 19-JUN-1998;	98US-0089952P.	PR 24-SEP-1998;	98US-0101739P.
PR 22-JUN-1998;	98US-0090246P.	PR 24-SEP-1998;	98US-0101743P.
PR 22-JUN-1998;	98US-0090252P.	PR 24-SEP-1998;	98US-0101922P.
PR 22-JUN-1998;	98US-0090254P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090429P.	PR 29-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090435P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090444P.	PR 29-SEP-1998;	98US-0102330P.
PR 24-JUN-1998;	98US-0090461P.	PR 29-SEP-1998;	98US-0102331P.
PR 24-JUN-1998;	98US-0090535P.	PR 30-SEP-1998;	98US-0102487P.
PR 24-JUN-1998;	98US-0090540P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090676P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090678P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090688P.	PR 01-OCT-1998;	98US-0102687P.
PR 25-JUN-1998;	98US-0090690P.	PR 02-OCT-1998;	98US-0102965P.
PR 25-JUN-1998;	98US-0090694P.	PR 06-OCT-1998;	98US-0103258P.
PR 25-JUN-1998;	98US-0090695P.	PR 06-OCT-1998;	98US-0103449P.
PR 25-JUN-1998;	98US-0090696P.	PR 07-OCT-1998;	98US-00168978.
PR 26-JUN-1998;	98US-00105413.		
PR 26-JUN-1998;	98US-0090862P.		
PR 26-JUN-1998;	98US-0090863P.		
PR 26-JUN-1998;	98US-0091010P.		
PR 01-JUL-1998;	98US-0091359P.		
PR 01-JUL-1998;	98US-0091544P.		
PR 02-JUL-1998;	98US-0091478P.		
PR 02-JUL-1998;	98US-0091486P.		
PR 02-JUL-1998;	98US-0091626P.		
PR 02-JUL-1998;	98US-0091628P.		
PR 02-JUL-1998;	98US-0091632P.		
PR 24-JUL-1998;	98US-0094006P.		
PR 04-AUG-1998;	98US-0095282P.		
PR 10-AUG-1998;	98US-0095998P.		
PR 10-AUG-1998;	98US-0096012P.		
PR 17-AUG-1998;	98US-0096757P.		
PR 17-AUG-1998;	98US-0096867P.		
PR 17-AUG-1998;	98US-0096891P.		
PR 17-AUG-1998;	98US-0096897P.		
PR 18-AUG-1998;	98US-0096949P.		
PR 18-AUG-1998;	98US-0096959P.		
PR 18-AUG-1998;	98US-0097022P.		
PR 26-AUG-1998;	98US-0097952P.		
PR 26-AUG-1998;	98US-0097954P.		
<hr/>			
Query Match 3.0%; Score 66.6; DB 9; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY 2121 CCTTTGCTTTTACACATCTTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180			
Db 2653 CCTTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGGTTGGTCTTGAACCTA 2712			
QY 2181 NCTCCCAAA 2240			
Db 2713 CAA 2772			
QY 2241 AA 2242			
Db 2773 AA 2774			
RESULT 524			
ACF42409			
ID ACF42409 standard; cDNA; 2846 BP.			
XX ACF42409;			
AC ACF42409;			
XX 06-NOV-2003 (first entry)			

XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX KW Human; PRO; secreted protein; transmembrane protein;

XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

XX KW chondrocyte; proliferation; differentiation; cartilage disorder;

XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

XX KW liver; drug screening; transgenic animal; genetic analysis;

XX KW antiarthritic; vulnery; gene therapy; gene; ss.

XX OS Homo sapiens.

XX PN US2003054480-A1.

XX XX 20-MAR-2003.

XX XX 24-JUL-2002; 2002US-00205507.

XX XX 22-MAY-1998; 98US-0086392P.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 25-AUG-1999; 98US-00380138.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 15-JAN-2002; 2002US-00052586.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX FI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX XX WPI; 2003-503632/47.

XX DR P-PSDB; ABM18468.

XX XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX PT in gene therapy, or for preparing a medicament for treating a condition

XX PT that is responsive to the PRO polypeptide or anti-PRO antibody.

XX XX Claim 2; Fig 169; 699pp; English.

XX XX The invention relates to human PRO secreted/transmembrane polypeptides

XX CC and nucleic acids encoding them, the invention also provides recombinant

XX CC vectors and host cells comprising a PRO nucleic acid, a method for the

XX CC recombinant production of a PRO polypeptide, antibodies against a PRO

XX CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

XX CC acids encoding PRO polypeptides of the invention were initially

XX CC identified via homology screening using consensus sequences based on the

XX CC extracellular domain sequences from known secreted proteins. Human cDNA

XX CC libraries containing sequences of interest were identified using

XX CC oligonucleotides based on the consensus sequences, and cDNA clones were

XX CC isolated and characterised. The PRO polypeptides are useful for

XX CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

XX CC human blood and may thus be used in the treatment of conditions in which

XX CC enhanced TNF-alpha release would be beneficial. They are also useful for

XX CC stimulating the proliferation or differentiation of chondrocytes and as

XX CC such may be used in the treatment of various bone and/or cartilage

XX CC disorders such as arthritis and sports injuries. The PRO polypeptides may

XX CC be used in a method for detecting the presence of a tumour (e.g., an

XX CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

XX CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

XX CC method involves comparing the level of expression of the PRO polypeptide

XX CC in test and control samples, where a higher level of expression of PRO

XX CC polypeptide in the test sample as compared to the control sample is

XX CC indicative of the presence of a tumour. The PRO polypeptides are

XX CC additionally useful for in drug screening to identify agonists and

XX CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

XX CC hybridisation probes (for isolation of cDNA molecules), in chromosome and

XX CC gene mapping, in the generation of antisense RNA and DNA and in gene

XX CC therapy. The nucleic acids can also be used for mapping genes encoding

XX CC PRO polypeptides, for genetic analysis of individuals with genetic

XX CC disorders, and for generating either transgenic animals or knock-out

XX CC animals which are useful in the development and screening of

XX CC therapeutically useful compounds. The present sequence appears in the

CC exemplification of the specification. Note: The sequence data for this

CC patent is also available in electronic format from USPTO at

CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Oy 2121 CCTTGGCTTTACCACTCTTCTTTTATCTATTATAAATAATGTTGCTCCCACTG 2180

Db 2653 CCTTTCTTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAAC 2712

Oy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Oy 2241 AA 2242

Db 2773 AA 2774

RESULT 525

ADA27866

ID ADA27866 standard; cDNA; 2846 BP.

XX AC ADA27866;

XX XX 20-NOV-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein PRO1344.

XX KW PRO; secreted protein; transmembrane protein;

XX KW hypertrophy of neonatal heart; angiogenesis;

XX KW vascular endothelial growth factor; VEGF-stimulated proliferation;

XX KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

XX KW rod photoreceptor cell; c-fos induction; adipocyte cell;

XX KW chondrocyte differentiation;

XX KW pancreatic beta-cell precursor differentiation;

XX KW cardiac insufficiency disorder; wound; cancerous tumour;

XX KW retinal disorders; loss of sight; retinitis pigmentosa; kidney disorder;

XX KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;

XX KW cartilage disorder; sports injury; arthritis; cancer; human; ss; gene.

XX OS Homo sapiens.

XX XX US2003054359-A1.

XX PN 20-MAR-2003.

XX PD 14-NOV-2001; 2001US-00990726.

XX PF 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

XX PR 04-JUN-1998; 98US-0088028P.

XX PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088367P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089947P.
PR 17-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 19-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 23-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091364P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091526P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094451P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.

PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US021141.
PR 22-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.

```

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTCTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGCTTGCTTCTGAACTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 526
ACF18430
ID ACF18430 standard; cDNA; 2846 BP.
AC ACF18430;
AC ACF18430;
DT 17-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX
XX US2003059885-A1.
XX
XX 27-MAR-2003.
XX
XX 25-JUL-2002; 2002US-00205893.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Deanoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-540682/51.
XX P-PSDB; ABR97496.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR97412-ABR97716) and nucleic acids encoding them (ACF18346-ACF18650).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the

```

```

CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF18346-ACF18650 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTCTTCTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGCTTGCTTCTGAACTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 527
ACF02220
ID ACF02220 standard; cDNA; 2846 BP.
XX
XX ACF02220;
XX
XX 05-SEP-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX

```


CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACP21644-ACP21948 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGGTTTACCACTCTTCTCTTTTATTTATTAATAAAATGTGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCGAACTA 2712

Qy 2181 NCTCCCAAAAAA AA 2240

Db 2713 CAAAAA AA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 529

ACF10412 ID ACF10412 standard; cDNA; 2846 BP.

XX AC ACF10412;

XX DT 06-SEP-2003 (first entry)

XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.

XX OS Homo sapiens.

XX PN US2003073169-A1.

XX PD 17-APR-2003.

XX PF 17-JUN-2002; 2002US-00173693.

XX PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059265P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083455P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 05-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085700P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 22-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088825P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088863P.

Wed Feb 16 11:37:55 2005

```

PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 16-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090335P.
PR 24-JUN-1998; 98US-0090340P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 28-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.

PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTAGACACTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACG 2180
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTTCCTCCCATCTCTTGACACATTTTAAATAAATAAGGGTGGCTTCTGAACATA 2712
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 530
ACF33864
ID ACF33864 standard; cDNA; 2846 BP.
XX ACF33864;
AC ACF33864;
XX
DT 24-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003064457-A1.
XX
PD 03-APR-2003.
XX
PF 18-JUL-2002; 2002US-00199309.
XX
PR 15-MAY-1998; 98US-0085582P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
```


XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-596621/56.
DR P-PSDB; ABM13461.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX Claim 2; Fig 169; 699pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACCACTCTTCTCTTTTATTTAATAAATCTGTGCTCCACCACTG 2180
|||||
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTAATAAATAGGGTGTCTTGAACCTA 2712
|||||
QY 2181 NCTCCCAA 2240
|||||
DB 2713 CAA 2772
|||||
QY 2241 AA 2242
|||
DB 2773 AA 2774
|||||
RESULT 531
ACF44826
ID ACF44826 standard; cDNA; 2846 BP.
XX

AC ACF44826;
XX 09-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX US2003068711-A1.
XX 10-APR-2003.
XX 17-JUL-2002; 2002US-00197692.
XX 28-OCT-1997; 97US-0063541P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615881/58.
DR P-PSDB; ABM20845.
XX New secreted and transmembrane PRO nucleic acids, useful for the
PT manufacture of a medicament for diagnosing or treating tumor or for
PT tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM20761-ABM21065) and nucleic acids encoding them (ACF44742-ACF45046).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding

PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACP44742-ACF45046 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTGCTTTACCACTCTTCTTTTATTTATTAATAAAATGTTGGTCTCCACACTG 2180
2653 CCTTTCTCTCCCACTCTGTACACATTTTAATAAATAGGGTTCCTCTGACTA 2712
2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
2241 AA 2242
2773 AA 2774

RESULT 532
ACD90458
ID ACD90458 standard; cDNA; 2846 BP.
AC ACD90458;
XX
XX
XX 09-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX US2003049745-A1.
XX 13-MAR-2003.
XX 11-JUL-2002; 2002US-00194485.
XX 15-SEP-2000; 2000US-0232887P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhng Z;
XX WPI; 2003-625417/59.
XX P-PSDB; ABO41976.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
XX PRO827, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 169; 699pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a

PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and for stimulating the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTGCTTTACCACTCTTCTTTTATTTATTAATAAAATGTTGGTCTCCACACTG 2180
2653 CCTTTCTCTCCCACTCTGTACACATTTTAATAAATAGGGTTCCTCTGACTA 2712
2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
2241 AA 2242
2773 AA 2774

RESULT 533
ACD91071
ID ACD91071 standard; cDNA; 2846 BP.
AC ACD91071;
XX
XX 09-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX US2003049751-A1.
XX 13-MAR-2003.
XX 17-JUL-2002; 2002US-00197700.
XX 18-SEP-1997; 97US-0059266P.
XX 16-SEP-1998; 98WO-US019330.
XX 25-AUG-1999; 99US-00380139.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-625419/59.
 DR P-PSDB; ABO42586.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
 PT in tissue typing, and in identifying chromosome.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 CC
 CC The invention discloses human nucleic acids encoding secreted and
 CC transmembrane (PRO) polypeptides, with or without their associated signal
 CC peptide. Also disclosed is an antibody that specifically binds to the PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
 CC PRO polypeptide, a method for stimulating the proliferation or
 CC differentiation of chondrocyte cells by contacting the cells with a PRO
 CC polypeptide, a method for detecting the presence of a tumour in a mammal
 CC and an oligonucleotide probe derived from any of the PRO nucleotide
 CC sequences. The nucleotide sequences are useful as probes, in chromosome
 CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 CC polypeptides by recombinant techniques and in gene therapy (e.g. for
 CC replacement of defective gene). The PRO polypeptides are useful as
 CC molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence, prevention and/or treatment of a tumour, such as
 CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
 CC The PRO polypeptides and nucleic acids may also be used diagnostically
 CC for tissue typing. The sequence presented is a cDNA encoding one of the
 CC PRO polypeptides of the invention. Note: The sequence data for this
 CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTAATAAAATGTTGCTCCACCACTG 2180
 DB 2653 CTTTTCCTCCCACTCTTGTACACATTTTAATAAAATAGGCTTGCTTCTGAAC 2712
 QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 534
 ID ACF30382
 AC ACF30382 standard; cDNA; 2846 BP.
 XX ACF30382;
 XX
 DT 20-SEP-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX

PN US2003067478-A1.
 XX
 PD 10-APR-2003.
 XX
 PF 16-JUL-2002; 2002US-00196754.
 XX
 PR 21-MAR-2000; 2000US-0190828P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-625450/59.
 DR P-PSDB; ABM10106.
 XX
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 PT for stimulating the release of tumor necrosis factor alpha from human
 PT blood and for stimulating the proliferation or differentiation of
 PT chondrocyte cells.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 CC
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM10022-ABM10326) and nucleic acids encoding them (ACF30298-ACF30602).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterized. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF30298-ACF30602 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTAATAAAATGTTGCTCCACCACTG 2180
 DB 2653 CTTTTCCTCCCACTCTTGTACACATTTTAATAAAATAGGCTTGCTTCTGAAC 2712
 QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
 DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 534
 ID ACF30382
 AC ACF30382 standard; cDNA; 2846 BP.
 XX ACF30382;
 XX
 DT 20-SEP-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX

QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 535
ACD87081
ID ACD87081 standard; cDNA; 2846 BP.
AC AC
AC ACD87081;
DT 06-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS US2003068773-A1.
XX 10-APR-2003.
XX 29-JUL-2002; 2002US-00208023.
XX 15-SEP-2000; 2000US-0232887P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-625479/59.
XX P-PSDB; ABO38621.
XX Novel isolated PRO polypeptides e.g. PRO1079, PRO827 and PRO791, useful
XX for stimulating the release of TNF alpha from human blood and for
XX stimulating the proliferation or differentiation of chondrocyte cells.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation or
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX The PRO polypeptides and nucleic acids may also be used diagnostically
XX for tissue typing. The sequence presented is a cDNA encoding one of the
XX PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTTATCTTATTAATAAATGTTGCTTCACCACTG 2180
Db 2653 CCTTTTCTCTCCCATCTCTCTGTACACATTTTAAATAAATAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 536
ACF60135
ID ACF60135 standard; cDNA; 2846 BP.
XX AC ACF60135;
XX 06-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS US2003073185-A1.
XX 17-APR-2003.
XX 29-JUL-2002; 2002US-00207924.
XX 18-APR-2000; 2000US-0198585P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-657649/62.
XX P-PSDB; ABM32861.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX useful diagnosing or treating tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX and nucleic acids encoding them, the invention also provides recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. The present sequence appears in the
 CC exemplification of the specification. Note: The sequence data for this
 CC patent is also available in electronic format from USPTO at
 CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCTTTTATCTATTATAAAAAATGTGCTCCACCACTG 2180

Db 2653 CTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCGAACTA 2712

Qy 2181 NCTCCCAAAAAA AA 2240

Db 2713 CAAAAA AA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 537

ACF46685

ID ACF46685 standard; cDNA; 2846 BP.

XX AC ACF46685;

XX DT 06-OCT-2003 (first entry)

XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

XX OS Homo sapiens.

XX KW US2003087373-A1.

XX PN 08-MAY-2003.

XX PD

XX

PF 20-JUN-2002; 2002US-00176491.
 XX 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059286P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 28-OCT-1997; 97US-0063540P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 11-DEC-1997; 97US-0066772P.
 PR 12-DEC-1997; 97US-0069335P.
 PR 17-DEC-1997; 97US-0069425P.
 PR 18-DEC-1997; 97US-0069870P.
 PR 10-MAR-1998; 97US-007450P.
 PR 11-MAR-1998; 98US-0077632P.
 PR 11-MAR-1998; 98US-0077649P.
 PR 20-MAR-1998; 98US-0078886P.
 PR 20-MAR-1998; 98US-0078939P.
 PR 27-MAR-1998; 98US-0079664P.
 PR 27-MAR-1998; 98US-0079786P.
 PR 31-MAR-1998; 98US-0080107P.
 PR 31-MAR-1998; 98US-0080194P.
 PR 01-APR-1998; 98US-0080327P.
 PR 01-APR-1998; 98US-0080333P.
 PR 08-APR-1998; 98US-0081049P.
 PR 08-APR-1998; 98US-0081070P.
 PR 09-APR-1998; 98US-0081195P.
 PR 15-APR-1998; 98US-0081838P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082599P.
 PR 22-APR-1998; 98US-0082704P.
 PR 22-APR-1998; 98US-0082797P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083495P.
 PR 29-APR-1998; 98US-0083496P.
 PR 29-APR-1998; 98US-0083499P.
 PR 29-APR-1998; 98US-0083559P.
 PR 05-MAY-1998; 98US-0084366P.
 PR 06-MAY-1998; 98US-0084414P.
 PR 07-MAY-1998; 98US-0084639P.
 PR 07-MAY-1998; 98US-0084640P.
 PR 15-MAY-1998; 98US-0085579P.
 PR 15-MAY-1998; 98US-0085580P.
 PR 15-MAY-1998; 98US-0085582P.
 PR 15-MAY-1998; 98US-0085700P.
 PR 18-MAY-1998; 98US-0086023P.
 PR 22-MAY-1998; 98US-0086392P.
 PR 22-MAY-1998; 98US-0086486P.
 PR 28-MAY-1998; 98US-0087098P.
 PR 28-MAY-1998; 98US-0087208P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.

[illegible]

XX 24-JUN-2002; 2002US-00179520.
PF 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0052266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088836P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.

PR	10-SEP-1998;	98US-0099754P.	XX	18-SEP-1997;	97US-0059263P.
PR	10-SEP-1998;	98US-0099763P.	PR	18-SEP-1997;	97US-0059266P.
PR	10-SEP-1998;	98US-0099812P.	PR	17-OCT-1997;	97US-0062250P.
PR	15-SEP-1998;	98US-0100388P.	PR	21-OCT-1997;	97US-0063486P.
PR	16-SEP-1998;	98US-0100662P.	PR	24-OCT-1997;	97US-0063120P.
PR	16-SEP-1998;	98US-0100664P.	PR	24-OCT-1997;	97US-0063121P.
PR	16-SEP-1998;	98US-0101751P.	PR	28-OCT-1997;	97US-0063540P.
PR	16-SEP-1998;	98WO-US019330.	PR	28-OCT-1997;	97US-0063541P.
PR	17-SEP-1998;	98US-0100683P.	PR	28-OCT-1997;	97US-0063544P.
PR	17-SEP-1998;	98US-0100684P.	PR	28-OCT-1997;	97US-0063564P.
PR	17-SEP-1998;	98US-0100919P.	PR	29-OCT-1997;	97US-0063734P.
PR	17-SEP-1998;	98US-0100930P.	PR	29-OCT-1997;	97US-0063870P.
PR	18-SEP-1998;	98US-0100849P.	PR	31-OCT-1997;	97US-0064103P.
PR	18-SEP-1998;	98US-0101014P.	PR	31-OCT-1997;	97US-0065311P.
PR	18-SEP-1998;	98US-0101068P.	PR	13-NOV-1997;	97US-0066120P.
PR	23-SEP-1998;	98US-0101471P.	PR	24-NOV-1997;	97US-0066466P.
PR	23-SEP-1998;	98US-0101472P.	PR	24-NOV-1997;	97US-0066772P.
PR	23-SEP-1998;	98US-0101475P.	PR	12-DEC-1997;	97US-0069335P.
PR	23-SEP-1998;	98US-0101477P.	PR	17-DEC-1997;	97US-0069870P.
PR	24-SEP-1998;	98US-0101738P.	PR	18-DEC-1997;	97US-0068017P.
PR	24-SEP-1998;	98US-0101739P.	PR	11-MAR-1998;	98US-0077450P.
PR	24-SEP-1998;	98US-0101743P.	PR	11-MAR-1998;	98US-0077632P.
PR	25-SEP-1998;	98US-0101786P.	PR	20-MAR-1998;	98US-0078866P.
PR	25-SEP-1998;	98US-0102207P.	PR	20-MAR-1998;	98US-0078939P.
PR	29-SEP-1998;	98US-0102240P.	PR	27-MAR-1998;	98US-0079664P.
PR	29-SEP-1998;	98US-0102330P.	PR	27-MAR-1998;	98US-0079786P.
PR	29-SEP-1998;	98US-0102331P.	PR	31-MAR-1998;	98US-0080107P.
PR	30-SEP-1998;	98US-0102487P.	PR	01-APR-1998;	98US-0080194P.
PR	30-SEP-1998;	98US-0102570P.	PR	01-APR-1998;	98US-0080327P.
PR	30-SEP-1998;	98US-0102571P.	PR	08-APR-1998;	98US-0080333P.
PR	01-OCT-1998;	98US-0102684P.	PR	08-APR-1998;	98US-0081049P.
PR	01-OCT-1998;	98US-0102687P.	PR	08-APR-1998;	98US-0081070P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;					98US-0081195P.
Best Local Similarity 71.3%; Pred. No. 0.00023;					98US-0081838P.
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;					98US-0082568P.
Qy	2121	CGTTTGCTTTACCACTCTTCCCTTTTCTTTATTAATAAAATGTTGGTCTCCACACTG	2180	21-APR-1998;	98US-0082569P.
Db	2653	CGTTTCTCTCCCATCTCTGTACACATTTTAATAAAATGTTGGTCTCTGAACCTA	2712	22-APR-1998;	98US-0082704P.
Qy	2181	NCTCCCAA	2240	22-APR-1998;	98US-0083222P.
Db	2713	CAAA	2772	23-APR-1998;	98US-0083495P.
Qy	2241	AA 2242		23-APR-1998;	98US-0083496P.
Db	2773	AA 2774		23-APR-1998;	98US-0083499P.
RESULT 539					98US-0083559P.
ADA79713					98US-0084366P.
ID	ADA79713 standard; cDNA; 2846 BP.				98US-0084414P.
XX					98US-0084639P.
AC	ADA79713;				98US-0084640P.
XX					98US-0085579P.
DT	20-NOV-2003 (first entry)				98US-0085580P.
XX					98US-0085582P.
DE	Human secreted/transmembrane protein (PRO) cDNA #85.				98US-0085700P.
XX					98US-0086023P.
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;				98US-0086486P.
KW	tumour necrosis factor alpha; chondrocyte cell; gene therapy;				98US-0087098P.
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;				98US-0087208P.
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.				98US-0087609P.
XX	Homo sapiens.				98US-0088029P.
XX					98US-0088033P.
XX	US2003073173-A1.				98US-0088326P.
PD	17-APR-2003.				98US-0088167P.
XX					98US-0088202P.
XX					98US-0088212P.
PF	21-JUN-2002; 2002US-00176986.				98US-0088217P.
					98US-0088555P.

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

XX	20-MAR-2003.		
PD			
XX	01-JUL-2002; 2002US-00187887.		
PF			
XX	18-SEP-1997;	97US-0059263P.	
PR	18-SEP-1997;	97US-0059266P.	
PR	17-OCT-1997;	97US-0062250P.	
PR	17-OCT-1997;	97US-0063486P.	
PR	24-OCT-1997;	97US-0063120P.	
PR	24-OCT-1997;	97US-0063121P.	
PR	28-OCT-1997;	97US-0063540P.	
PR	28-OCT-1997;	97US-0063541P.	
PR	28-OCT-1997;	97US-0063544P.	
PR	28-OCT-1997;	97US-0063564P.	
PR	29-OCT-1997;	97US-0063734P.	
PR	31-OCT-1997;	97US-0063870P.	
PR	31-OCT-1997;	97US-0064103P.	
PR	13-NOV-1997;	97US-0065311P.	
PR	21-NOV-1997;	97US-0066120P.	
PR	21-NOV-1997;	97US-0066466P.	
PR	24-NOV-1997;	97US-0066772P.	
PR	11-DEC-1997;	97US-0069335P.	
PR	12-DEC-1997;	97US-0069425P.	
PR	17-DEC-1997;	97US-0069870P.	
PR	18-DEC-1997;	97US-0068017P.	
PR	10-MAR-1998;	98US-0077450P.	
PR	11-MAR-1998;	98US-0077632P.	
PR	11-MAR-1998;	98US-0077649P.	
PR	20-MAR-1998;	98US-0078886P.	
PR	20-MAR-1998;	98US-0078939P.	
PR	27-MAR-1998;	98US-0079664P.	
PR	27-MAR-1998;	98US-0079786P.	
PR	31-MAR-1998;	98US-0080107P.	
PR	31-MAR-1998;	98US-0080194P.	
PR	01-APR-1998;	98US-0080327P.	
PR	01-APR-1998;	98US-0080333P.	
PR	08-APR-1998;	98US-0081049P.	
PR	08-APR-1998;	98US-0081070P.	
PR	09-APR-1998;	98US-0081195P.	
PR	15-APR-1998;	98US-0081838P.	
PR	21-APR-1998;	98US-0082568P.	
PR	21-APR-1998;	98US-0082599P.	
PR	22-APR-1998;	98US-0082704P.	
PR	22-APR-1998;	98US-0082797P.	
PR	28-APR-1998;	98US-0083322P.	
PR	29-APR-1998;	98US-0083495P.	
PR	29-APR-1998;	98US-0083496P.	
PR	29-APR-1998;	98US-0083499P.	
PR	29-APR-1998;	98US-0083559P.	
PR	05-MAY-1998;	98US-0084366P.	
PR	06-MAY-1998;	98US-0084414P.	
PR	07-MAY-1998;	98US-0084639P.	
PR	07-MAY-1998;	98US-0084640P.	
PR	07-MAY-1998;	98US-0084643P.	
PR	15-MAY-1998;	98US-0085579P.	
PR	15-MAY-1998;	98US-0085580P.	
PR	15-MAY-1998;	98US-0085582P.	
PR	15-MAY-1998;	98US-0085700P.	
PR	18-MAY-1998;	98US-0086023P.	
PR	22-MAY-1998;	98US-0086392P.	
PR	22-MAY-1998;	98US-0086486P.	
PR	28-MAY-1998;	98US-0087098P.	
PR	28-MAY-1998;	98US-0087208P.	
PR	02-JUN-1998;	98US-0087609P.	
PR	02-JUN-1998;	98US-0087759P.	
PR	03-JUN-1998;	98US-0088027P.	
PR	04-JUN-1998;	98US-0088028P.	
PR	04-JUN-1998;	98US-0088029P.	
PR	04-JUN-1998;	98US-0088033P.	
PR	04-JUN-1998;	98US-0088326P.	
PR	05-JUN-1998;	98US-0088167P.	
PR	05-JUN-1998;		98US-0088202P.
PR	05-JUN-1998;		98US-0088216P.
PR	05-JUN-1998;		98US-0088217P.
PR	05-JUN-1998;		98US-0088255P.
PR	05-JUN-1998;		98US-0088722P.
PR	10-JUN-1998;		98US-0088738P.
PR	10-JUN-1998;		98US-0088740P.
PR	10-JUN-1998;		98US-0088811P.
PR	10-JUN-1998;		98US-0088824P.
PR	10-JUN-1998;		98US-0088825P.
PR	10-JUN-1998;		98US-0088826P.
PR	11-JUN-1998;		98US-0088861P.
PR	11-JUN-1998;		98US-0088863P.
PR	11-JUN-1998;		98US-0088876P.
PR	12-JUN-1998;		98US-0089090P.
PR	12-JUN-1998;		98US-0089105P.
PR	16-JUN-1998;		98US-0089512P.
PR	17-JUN-1998;		98US-0089514P.
PR	17-JUN-1998;		98US-0089538P.
PR	17-JUN-1998;		98US-0089598P.
PR	17-JUN-1998;		98US-0089653P.
PR	18-JUN-1998;		98US-0089908P.
PR	19-JUN-1998;		98US-0089952P.
PR	22-JUN-1998;		98US-0090246P.
PR	22-JUN-1998;		98US-0090252P.
PR	22-JUN-1998;		98US-0090254P.
PR	24-JUN-1998;		98US-0090429P.
PR	24-JUN-1998;		98US-0090435P.
PR	24-JUN-1998;		98US-0090444P.
PR	24-JUN-1998;		98US-0090461P.
PR	24-JUN-1998;		98US-0090535P.
PR	24-JUN-1998;		98US-0090540P.
PR	25-JUN-1998;		98US-0090676P.
PR	25-JUN-1998;		98US-0090678P.
PR	25-JUN-1998;		98US-0090688P.
PR	25-JUN-1998;		98US-0090690P.
PR	25-JUN-1998;		98US-0090694P.
PR	25-JUN-1998;		98US-0090695P.
PR	25-JUN-1998;		98US-0090696P.
PR	26-JUN-1998;		98US-00105413.
PR	26-JUN-1998;		98US-0090862P.
PR	26-JUN-1998;		98US-0090863P.
PR	26-JUN-1998;		98US-0091010P.
PR	01-JUL-1998;		98US-0091359P.
PR	01-JUL-1998;		98US-0091544P.
PR	02-JUL-1998;		98US-0091478P.
PR	02-JUL-1998;		98US-0091486P.
PR	02-JUL-1998;		98US-0091626P.
PR	02-JUL-1998;		98US-0091628P.
PR	02-JUL-1998;		98US-0091632P.
PR	24-JUL-1998;		98US-0094006P.
PR	24-JUL-1998;		98US-0095282P.
PR	10-AUG-1998;		98US-0095998P.
PR	10-AUG-1998;		98US-0096012P.
PR	17-AUG-1998;		98US-0096757P.
PR	17-AUG-1998;		98US-0096766P.
PR	17-AUG-1998;		98US-0096867P.
PR	17-AUG-1998;		98US-0096891P.
PR	17-AUG-1998;		98US-0096897P.
PR	18-AUG-1998;		98US-0096949P.
PR	18-AUG-1998;		98US-0096959P.
PR	18-AUG-1998;		98US-0097022P.
PR	26-AUG-1998;		98US-0097952P.
PR	26-AUG-1998;		98US-0097954P.
PR	26-AUG-1998;		98US-0097955P.
PR	26-AUG-1998;		98US-0097971P.
PR	26-AUG-1998;		98US-0097974P.
PR	26-AUG-1998;		98US-0098014P.
PR	01-SEP-1998;		98US-0098716P.
PR	01-SEP-1998;		98US-0098723P.
PR	02-SEP-1998;		98US-0098803P.
PR	02-SEP-1998;		98US-0098821P.
PR	02-SEP-1998;		98US-0098843P.

```

PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTAATAAATGTTGTCCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 541
ID ACP22956
AC ACP22956 standard; cDNA; 2846 BP.
XX AC ACP22956;
XX AC ACP22956;
XX 19-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnary; gene therapy; gene; ss.
XX OS Homo sapiens.
XX

```

```

PN US2003059886-A1.
XX 27-MAR-2003.
XX 25-JUL-2002; 2002US-00205897.
XX 05-JUN-2000; 2000US-0209832P.
XX 28-FEB-2001; 2001WO-0006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-555484/52.
XX P-PSDB; ABM02427.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM02343-ABM02647) and nucleic acids encoding them (ACF22872-ACF23176).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human CDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic
XX disorders, and for generating either transgenic animals or knock-out
XX animals which are useful in the development and screening of
XX therapeutically useful compounds. Sequences ACF22872-ACF23176 represent
XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 596 C; 745 G; 537 T; 0 U; 0 Other;

```

```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTTTATCTATTAATAAATGTTGTCCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712

```

		2181	NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2244
Qy				
Dd		2713	CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2772
Qy		2241	AA 2242	
Dd		2773	AA 2774	
RESULT 542				
ACF07956				
ID	ACF07956 standard; cDNA; 2846 BP.			
XX	ACF07956;			
AC				
DT	06-SEP-2003 (first entry)			
XX				
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.			
XX				
KW	Human; PRO; secreted protein; transmembrane protein;			
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alphai;			
KW	chondrocyte proliferation; differentiation; cartilage disorder;			
KW	bone disorder; arthritis; sports injury; cancer; diagnosis;			
KW	adrenal tumour; lung; colon; breast; prostate; cervix;			
KW	liver; drug screening; transgenic animal; genetic analysis;			
KW	antiarthritic; vulneryary; gene therapy; gene; ss.			
OS	Homo sapiens.			
XX				
FN	US2003049758-AI.			
XX				
PD	13-MAR-2003.			
XX				
PF	19-JUL-2002; 2002US-00199305.			
XX				
PR	10-JUN-1998; 98US-0088722P.			
PR	02-JUN-1999; 99WO-USO1225Z.			
PR	25-AUG-1999; 99US-00380137.			
PR	28-FEB-2001; 2001WO-USO06520.			
PR	15-JAN-2002; 2002US-00052586.			
XX	(GETH) GENENTECH INC.			
PA	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;			
PI	Pan J, Smith V, Watanbe CK, Wood WI, Zhang Z;			
XX				
DR	WPI : 2003-567064/53.			
DR	P-PSDB; ABR86369.			
XX				
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful			
PT	for diagnosing, preventing and/or treating tumors, such as adrenal, lung,			
PT	colon, breast, prostate, rectal, cervical or liver tumors.			
XX				
BS	Claim 2; Fig 169; 700pp; English.			
XX				
CC	The invention relates to human PRO secreted/transmembrane polypeptides			
CC	((ABR86285-ABR86599) and nucleic acids encoding them (ACF07872-ACF08176)).			
CC	The invention also relates to sequences at least 80% identical to the PRO			
CC	nucleic acid and polypeptide sequences of the invention, recombinant			
CC	vectors and host cells comprising a PRO nucleic acid, a method for the			
CC	recombinant production of a PRO polypeptide, antibodies against a PRO			
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic			
CC	acids encoding PRO polypeptides of the invention were initially			
CC	identified via homology screening using consensus sequences based on the			
CC	extracellular domain sequences from known secreted proteins. Human cdna			
CC	libraries containing sequences of interest were identified using			
CC	oligonucleotides based on the consensus sequences, and cdna clones were			
CC	isolated and characterised. The PRO polypeptides are useful for			
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from			
CC	human blood and may thus be used in the treatment of conditions in which			
CC	enhanced TNF-alpha release would be beneficial. They are also useful for			
CC	stimulating the proliferation or differentiation of chondocytes and as			
CC	such may be used in the treatment of various bone and/or cartilage			

xx The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM29608-ABM29910) and nucleic acids encoding them (ACF53662-ACF53966).
CC The invention also relates to sequences at least 80% identical to the PRO
CC The invention also relates to sequences at least 80% identical to the PRO

CC	animals which are useful in the development and screening of
CC	therapeutically useful compounds. Sequences ACF47829-ACF48133 represent
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;	
Best Local Similarity 71.3%; Pred. No. 0.00023;	
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
Qy	2121 CCTTTGTTTACCACCTCTTCCTTTTATCATTATAAAAAAATGGTGCTCCACCACTG 2180
Dd	2553 CCITTTCTTCCCCTCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712
Qy	2181 NCTCCCCAAA 2240
Dd	2713 CAIAAA 2772
Qy	2241 AA 2242
Dd	2773 AA 2774
RESULT 548	
ACF47299	
ID	ACF47299 standard; cDNA; 2846 BP.
XX	
AC	ACF47299;
XX	
DT	08-OCT-2003 (first entry)
XX	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX	
KW	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
XX	antiarthritic; vulnary; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
FN	US2003068753-A1.
XX	
PD	10-APR-2003.
XX	
PF	26-JUL-2002; 2002US-00206909.
XX	
PR	05-JUN-2000; 2000US-0209832P.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-605927/57.
DR	P-PSDB; ABM23285.
XX	
PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PT	PRO827, useful in molecular biology, chromosome and gene mapping, in
PT	generating antisense RNA and DNA, and in gene therapy.
XX	
PS	Claim 2; Fig 169; 70opp; English.
XX	
CC	The invention relates to human PRO secreted/transmembrane polypeptides
CC	(ABM23201-ABM233505) and nucleic acids encoding them (ACF47215-ACF47519).
CC	The invention also relates to sequences at least 80% identical to the PRO
CC	nucleic acid and polypeptide sequences of the invention, recombinant

CC	vectors and host cells comprising a PRO nucleic acid, a method for the
CC	recombinant production of a PRO polypeptide, antibodies against a PRO
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC	acids encoding PRO polypeptides of the invention were initially
CC	identified via homology screening using consensus sequences based on the
CC	extracellular domain sequences from known secreted proteins. Human cDNA
CC	libraries containing sequences of interest were identified using
CC	oligonucleotides based on the consensus sequences, and cDNA clones were
CC	isolated and characterised. The PRO polypeptides are useful for
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC	human blood and may thus be used in the treatment of conditions in which
CC	enhanced TNF-alpha release would be beneficial. They are also useful for
CC	stimulating the proliferation or differentiation of chondrocytes and as
CC	such may be used in the treatment of various bone and/or cartilage
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may
CC	be used in a method for detecting the presence of a tumour (e.g., an
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC	method involves comparing the level of expression of the PRO polypeptide
CC	in test and control samples, where a higher level of expression of PRO
CC	polypeptide in the test sample as compared to the control sample is
CC	indicative of the presence of a tumour. The PRO polypeptides are
CC	additionally useful for in drug screening to identify agonists and
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC	gene mapping, in the generation of antisense RNA and DNA and in gene
CC	therapy. The nucleic acids can also be used for mapping genes encoding
CC	PRO polypeptides, for genetic analysis of individuals with genetic
CC	disorders, and for generating either transgenic animals or knock-out
CC	animals which are useful in the development and screening of
CC	therapeutically useful compounds. Sequences ACF47215-ACF47519 represent
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
	Query Match 3.0%; Score 66.6; DB 9; Length 2846;
	Best Local Similarity 71.3%; Pred. No. 0.00023;
	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy	2121 CCTTGGCTTTACACACTCTTCCTTTATCATTTATAATAAAGTTGGTCTCCACCACTG 2180
Db	2653 CCITTTCTCTCCCATCTCTGTGACATTTTAATAAAATGAAGGTTGGCTTGAACTA 2712
Qy	2181 NCTCCCAA 2240
Db	2713 CAIAA 2772
Qy	2241 AA 2242
Db	2773 AA 2774
RESULT 549	
ACF46071	
ID	ACF46071 standard; cDNA; 2846 BP.
XX	
AC	ACF46071;
XX	
DT	09-OCT-2003 (first entry)
XX	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
KW	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnary; gene therapy; gene; ss.
OS	Homo sapiens.

XX US2003068742-A1.
 XX 10-APR-2003.
 XX 23-JUL-2002; 2002US-00202410.
 XX 17-SEP-1998; 98US-0100919P.
 XX 01-SEP-1999; 99WO-US020111.
 XX 18-OCT-1999; 99US-00403297.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-615894/58.
 XX P-PSDB; ABM22065.
 XX New isolated nucleic acid encoding a secreted and transmembrane PRO
 XX polypeptide e.g. PRO1079 or PRO827, useful in molecular biology,
 XX chromosome and gene mapping, in generating antisense RNA and DNA, and in
 XX gene therapy for cancer.
 XX Claim 2; Fig 169; 700pp; English.
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 XX (ABM21981-ABM22285) and nucleic acids encoding them (ACF45987-ACF46291).
 XX The invention also relates to sequences at least 80% identical to the PRO
 XX nucleic acid and polypeptide sequences of the invention, recombinant
 XX vectors and host cells comprising a PRO nucleic acid, a method for the
 XX recombinant production of a PRO polypeptide, antibodies against a PRO
 XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 XX acids encoding PRO polypeptides of the invention were initially
 XX identified via homology screening using consensus sequences based on the
 XX extracellular domain sequences from known secreted proteins. Human cDNA
 XX libraries containing sequences of interest were identified using
 XX oligonucleotides based on the consensus sequences, and cDNA clones were
 XX isolated and characterised. The PRO polypeptides are useful for
 XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 XX human blood and may thus be used in the treatment of conditions in which
 XX enhanced TNF-alpha release would be beneficial. They are also useful for
 XX stimulating the proliferation or differentiation of chondrocytes and as
 XX such may be used in the treatment of various bone and/or cartilage
 XX disorders such as arthritis and sports injuries. The PRO polypeptides may
 XX be used in a method for detecting the presence of a tumour (e.g., an
 XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 XX method involves comparing the level of expression of the PRO polypeptide
 XX in test and control samples, where a higher level of expression of PRO
 XX polypeptide in the test sample as compared to the control sample is
 XX indicative of the presence of a tumour. The PRO polypeptides are
 XX additionally useful for in drug screening to identify agonists and
 XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
 XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
 XX gene mapping, in the generation of antisense RNA and DNA and in gene
 XX therapy. The nucleic acids can also be used for mapping genes encoding
 XX PRO polypeptides, for genetic analysis of individuals with genetic
 XX disorders, and for generating either transgenic animals or knock-out
 XX animals which are useful in the development and screening of
 XX therapeutically useful compounds. Sequences ACF46292-ACF46293 represent
 XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 XX invention. Note: The sequence data for this patent is also available in
 XX electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 XX Best Local Similarity 71.3%; Pred. No. 0.00023;
 XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

2121 CCTTTGCTTTACCACTCTCTTTTATCTTTATTAATAAAAAATGTTGCTCCCACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2653 CCTTTCTCTCCCATCTCTTTGTACACATTTTATAAAATAAGGTTGGCTTCTGAAC 2712
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2181 NCTCCCAAAAAA ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2713 CAAAAA ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| 2772
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2241 AA 2242
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 2773 AA 2774

RESULT 550
 ACD86160
 ID ACD86160 standard; cDNA; 2846 BP.
 XX AC ACD86160;
 XX DT 06-OCT-2003 (first entry)
 XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 XX KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 XX KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 XX KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX OS Homo sapiens.
 XX US2003068756-A1.
 XX 10-APR-2003.
 XX 26-JUL-2002; 2002US-00206912.
 XX 15-SEP-2000; 2000US-0232887P.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-625475/59.
 XX P-PSDB; ABO37706.
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
 XX PRO827, useful in molecular biology, chromosome and gene mapping, in
 XX generating antisense RNA and DNA, and in gene therapy.
 XX Claim 2; Fig 169; 700pp; English.
 XX The invention discloses human nucleic acids encoding secreted and
 XX transmembrane (PRO) polypeptides, with or without their associated signal
 XX peptide. Also disclosed is an antibody that specifically binds to the PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
 XX PRO polypeptide, a method for stimulating the proliferation or
 XX differentiation of chondrocyte cells by contacting the cells with a PRO
 XX polypeptide, a method for detecting the presence of a tumour in a mammal
 XX and an oligonucleotide probe derived from any of the PRO nucleotide
 XX sequences. The nucleotide sequences are useful as probes, in chromosome
 XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 XX polypeptides by recombinant techniques and in gene therapy (e.g. for
 XX replacement of defective gene). The PRO polypeptides are useful as
 XX molecular weight markers for protein electrophoresis purposes, for
 XX chromosome identification, as chromosome markers, as therapeutic agents,
 XX for stimulating the release of TNF-alpha from human blood, for
 XX stimulating the proliferation or differentiation of chondrocytes and
 XX detecting the presence, prevention and/or treatment of a tumour, such as
 XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 20-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 21-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 22-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095988P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101522P.
PR 25-SEP-1998; 98US-0101786P.

```

PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTTGTACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB || ||
2773 AA 2774

RESULT 553
ACF64818
ID ACF64818 standard; cDNA; 2846 BP.
XX
AC ACF64818;
XX
14-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; sex.
XX
OS Homo sapiens.
XX
XX US2003068737-A1.
XX
PD 10-APR-2003.
XX
XX 22-JUL-2002; 2002US-00201533.
XX
XX 18-JUN-1998; 98US-0089908P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-657573/62.
XX P-PSDB; ABM66419.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
XX useful as therapeutic targets for treating tumors, sports injuries or
XX arthritis.
XX
XX Claim 2; Fig 169; 700pp; English.

```

```

XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human CDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCACTCTTGTACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB || ||
2773 AA 2774

RESULT 554
ACF76463
ID ACF76463 standard; cDNA; 2846 BP.
XX
AC ACF76463;
XX
XX 06-NOV-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX

```

Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
QY	2121	CGTTTCGCTTTACACACTCTTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG	2180						
Db	2653	CGTTTTCCTTCCCATCTCTTGTCACACATTTTAATTAATAAAGGGTTGGCTTCTGAACCTA	2712						
QY	2181	NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2240						
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2772						
QY	2241	AA 2242							
Db	2773	AA 2774							
RESULT	555								
ACF61363									
ID	ACF61363	standard; cDNA; 2846 BP.							
XX	AC								
AC	ACF61363;								
XX	DT								
XX	10-OCT-2003	(first entry)							
XX									
XX		Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.							
XX									
KW		Human; PRO; secreted protein; transmembrane protein;							
KW		extracellular domain; tumour necrosis factor-alpha; TNF-alpha;							
KW		chondrocyte; proliferation; differentiation; cartilage disorder;							
KW		bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;							
KW		adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;							
KW		liver; drug screening; transgenic animal; genetic analysis;							
KW		antiarthritic; vulnery; gene therapy; gene; ss.							
XX	OS								
XX		Homo sapiens.							
XX									
XX	US2003096359-A1.								
PD	22-MAY-2003.								
XX									
PF	26-JUL-2002; 2002US-00205910.								
XX									
XX	15-SEP-2000; 2000US-0232887P.								
PR	28-FEB-2001; 2001WO-US006520.								
PR	15-JAN-2002; 2002US-00052586.								
XX									
PA	(GETH) GENENTECH INC.								
XX									
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;								
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;								
PI									
XX	WPI; 2003-670132/63.								
DR	P-PSDB; ABM34081.								
XX									
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful								
PT	for the manufacture of a medicament for diagnosing or treating tumor or								
PT	for tissue typing.								
XX									
PS	Claim 2; Fig 169; 705pp; English.								
XX									
CC	The invention relates to human PRO secreted/transmembrane polypeptides								
CC	(ABM33997-ABM34301) and nucleic acids encoding them (ACF61279-ACF61583).								
CC	The invention also relates to sequences at least 80% identical to the PRO								
CC	nucleic acid and polypeptide sequences of the invention, recombinant								
CC	vectors and host cells comprising a PRO nucleic acid, a method for the								
CC	recombinant production of a PRO polypeptide, antibodies against a PRO								
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic								
CC	acids encoding PRO polypeptides of the invention were initially								
CC	identified via homology screening using consensus sequences based on the								
CC	extracellular domain sequences from known secreted proteins. Human cDNA								
CC	libraries containing sequences of interest were identified using								
CC	oligonucleotides based on the consensus sequences, and cDNA clones were								
CC	isolated and characterised. The PRO polypeptides are useful for								
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from								

antiarthritic; vulnery; gene therapy; gene; ss.

Homo sapiens.

US2003104547-A1.

05-JUN-2003.

17-JUL-2002; 2002US-00197701.

28-OCT-1997; 97US-0063564P.

16-SEP-1998; 98WO-US019330.

25-AUG-1999; 99US-00380139.

28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-658684/62.

P-PSDB; ABM75801.

Three hundred and five nucleic acids encoding PRO polypeptides, useful for diagnosing, preventing and/or treating tumors, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.

Claim 2; Fig 169; 700pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM75171-ABM76021) and nucleic acids encoding them (ACF76379-ACF76683). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF76379-ACF76683 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF61279-ACF61583 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CTTTGGCTTTACCACTCTTCTTTATCTATTAAATAAATGTTGCTCCACCACTG 2180
Db 2653 CTTTCTCTCCCACTCTTGTACACATTTTATAAATAGGTTGGCTCTGACTA 2712
Qy 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 556
ACF61670
ID ACP61670 standard; cDNA; 2846 BP.
XX
AC ACP61670;
XX
DT 13-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX

XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX

OS Homo sapiens.

XX US2003100061-A1.

XX 29-MAY-2003.

XX 24-JUN-2002; 2002US-00179526.

XX 26-JUN-1998; 98US-00105413.

PR 16-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98US-00168978.

PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US0110733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-0064848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030352.
PR 01-DEC-2000; 2000WO-US032878.
PR 20-DEC-2000; 2000US-0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.

Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-670164/63.
P-PSDB; ABM34386.

Three hundred and five nucleic acids encoding PRO polypeptides, useful
for the manufacture of a medicament for diagnosing or treating tumor or

PT	for tissue typing.	
XX	Claim 2; Fig 169; 701pp; English.	
PS		
XX	The invention relates to human PRO secreted/transmembrane polypeptides	
CC	(ABM34302-ABM34606) and nucleic acids encoding them (ACF61586-ACF61890).	
CC	The invention also relates to sequences at least 80% identical to the PRO	
CC	nucleic acid and polypeptide sequences of the invention, recombinant	
CC	vectors and host cells comprising a PRO nucleic acid, a method for the	
CC	recombinant production of a PRO polypeptide, antibodies against a PRO	
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic	
CC	acids encoding PRO polypeptides of the invention were initially	
CC	identified via homology screening using consensus sequences based on the	
CC	extracellular domain sequences from known secreted proteins. Human CDNA	
CC	libraries containing sequences of interest were identified using	
CC	oligonucleotides based on the consensus sequences, and CDNA clones were	
CC	isolated and characterised. The PRO polypeptides are useful for	
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from	
CC	human blood and may thus be used in the treatment of conditions in which	
CC	enhanced TNF-alpha release would be beneficial. They are also useful for	
CC	stimulating the proliferation or differentiation of chondrocytes and as	
CC	such may be used in the treatment of various bone and/or cartilage	
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may	
CC	be used in a method for detecting the presence of a tumour (e.g., an	
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate	
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This	
CC	method involves comparing the level of expression of the PRO polypeptide	
CC	in test and control samples, where a higher level of expression of PRO	
CC	polypeptide in the test sample as compared to the control sample is	
CC	indicative of the presence of a tumour. The PRO polypeptides are	
CC	additionally useful for in drug screening to identify agonists and	
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as	
CC	hybridisation probes (for isolation of CDNA molecules), in chromosome and	
CC	gene mapping, in the generation of antisense RNA and DNA and in gene	
CC	therapy. The nucleic acids can also be used for mapping genes encoding	
CC	PRO polypeptides, for genetic analysis of individuals with genetic	
CC	disorders, and for generating either transgenic animals or knock-out	
CC	animals which are useful in the development and screening of	
CC	therapeutically useful compounds. Sequences ACF61586-ACF61890 represent	
CC	CDNAs encoding the human PRO secreted/transmembrane polypeptides of the	
CC	invention. Note: The sequence data for this patent is also available in	
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html	
XX	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	
SQ		
Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATAAATGTTGGTCTCCACCACTG	2180
Db	2653 CCTTTTCTTCCCATCTCTTGACACATTTTATAATAAATGTTGGTCTCTGAACCTA	2712
QY	2181 NCTCCCAA	2240
Db	2713 CAAAAAATAA	2772
QY	2241 AA 2242	
Db	2773 AA 2774	
RESULT 557		
ACD30701		
ID	ACD30701 standard; cDNA; 2846 BP.	
XX		
AC	ACD30701;	
XX		
DT	30-AUG-2003 (first entry)	
XX		
DE	Human secreted/transmembrane protein (PRO) cDNA #85.	
XX		
XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	

KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003032125-A1.	
XX		
PD	13-FEB-2003.	
XX		
PF	26-JUN-2002; 2002US-00181000.	
XX		
PR	18-SEP-1997; 97US-0059263P.	
PR	18-SEP-1997; 97US-0059266P.	
PR	17-OCT-1997; 97US-0062250P.	
PR	21-OCT-1997; 97US-0063486P.	
PR	24-OCT-1997; 97US-0063120P.	
PR	24-OCT-1997; 97US-0063121P.	
PR	28-OCT-1997; 97US-0063540P.	
PR	28-OCT-1997; 97US-0063541P.	
PR	28-OCT-1997; 97US-0063544P.	
PR	28-OCT-1997; 97US-0063564P.	
PR	29-OCT-1997; 97US-0063734P.	
PR	31-OCT-1997; 97US-0063870P.	
PR	31-OCT-1997; 97US-0064103P.	
PR	13-NOV-1997; 97US-0065311P.	
PR	21-NOV-1997; 97US-0065311P.	
PR	24-NOV-1997; 97US-0066466P.	
PR	24-NOV-1997; 97US-0066772P.	
PR	11-DEC-1997; 97US-0069335P.	
PR	12-DEC-1997; 97US-0069425P.	
PR	17-DEC-1997; 97US-0069870P.	
PR	18-DEC-1997; 97US-0068017P.	
PR	10-MAR-1998; 97US-0077450P.	
PR	11-MAR-1998; 98US-0077632P.	
PR	11-MAR-1998; 98US-0077649P.	
PR	20-MAR-1998; 98US-0078886P.	
PR	20-MAR-1998; 98US-0078939P.	
PR	27-MAR-1998; 98US-0079664P.	
PR	27-MAR-1998; 98US-0079786P.	
PR	31-MAR-1998; 98US-0080107P.	
PR	31-MAR-1998; 98US-0080194P.	
PR	01-APR-1998; 98US-0080327P.	
PR	01-APR-1998; 98US-0080333P.	
PR	08-APR-1998; 98US-0081049P.	
PR	08-APR-1998; 98US-0081070P.	
PR	09-APR-1998; 98US-0081195P.	
PR	15-APR-1998; 98US-0081838P.	
PR	21-APR-1998; 98US-0082568P.	
PR	21-APR-1998; 98US-0082569P.	
PR	22-APR-1998; 98US-0082704P.	
PR	22-APR-1998; 98US-0082797P.	
PR	28-APR-1998; 98US-0083322P.	
PR	29-APR-1998; 98US-0083495P.	
PR	29-APR-1998; 98US-0083496P.	
PR	29-APR-1998; 98US-0083499P.	
PR	29-APR-1998; 98US-0083559P.	
PR	05-MAY-1998; 98US-0084366P.	
PR	06-MAY-1998; 98US-0084414P.	
PR	07-MAY-1998; 98US-0084639P.	
PR	07-MAY-1998; 98US-0084640P.	
PR	07-MAY-1998; 98US-0084643P.	
PR	15-MAY-1998; 98US-0085579P.	
PR	15-MAY-1998; 98US-0085580P.	
PR	15-MAY-1998; 98US-0085582P.	
PR	15-MAY-1998; 98US-0085700P.	
PR	18-MAY-1998; 98US-0086023P.	
PR	22-MAY-1998; 98US-0086392P.	
PR	22-MAY-1998; 98US-0086486P.	
PR	28-MAY-1998; 98US-0087098P.	
PR	28-MAY-1998; 98US-0087208P.	
PR	02-JUN-1998; 98US-0087609P.	
PR	02-JUN-1998; 98US-0087759P.	

PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0080252P.
PR 04-JUN-1998; 98US-0080282P.
PR 04-JUN-1998; 98US-0080292P.
PR 04-JUN-1998; 98US-0080332P.
PR 04-JUN-1998; 98US-0080326P.
PR 05-JUN-1998; 98US-0080167P.
PR 05-JUN-1998; 98US-0080202P.
PR 05-JUN-1998; 98US-0080212P.
PR 05-JUN-1998; 98US-0080217P.
PR 09-JUN-1998; 98US-0080552P.
PR 10-JUN-1998; 98US-0080722P.
PR 10-JUN-1998; 98US-0080738P.
PR 10-JUN-1998; 98US-0080740P.
PR 10-JUN-1998; 98US-0080811P.
PR 10-JUN-1998; 98US-0080824P.
PR 10-JUN-1998; 98US-0080825P.
PR 10-JUN-1998; 98US-0080826P.
PR 11-JUN-1998; 98US-0080863P.
PR 11-JUN-1998; 98US-0080863P.
PR 11-JUN-1998; 98US-0080876P.
PR 12-JUN-1998; 98US-0080909P.
PR 12-JUN-1998; 98US-0080910P.
PR 16-JUN-1998; 98US-00809512P.
PR 16-JUN-1998; 98US-00809514P.
PR 17-JUN-1998; 98US-00809538P.
PR 17-JUN-1998; 98US-00809598P.
PR 17-JUN-1998; 98US-00809653P.
PR 18-JUN-1998; 98US-00809908P.
PR 19-JUN-1998; 98US-00809952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.

PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTCTTCTTTTATCTTTATTAATAAAAAATGTTGCTCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 558

ACD31622

ID ACD31622 standard; cDNA; 2846 BP.

XX ACD31622;

XX ACD31622;

DT 09-SEP-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.

XX

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.
OS
PN US2003054454-A1.
XX
PD 20-MAR-2003.
XX
PF 26-JUN-2002; 2002US-00183002.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 01-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.

PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 23-JUN-2001; 2001WO-US021066.
PR 03-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-540607/51.
DR P-PSDB; ABR96581.
DR
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 701pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR96497-ABR96801) and nucleic acids encoding them (ACFI7425-ACFI7729).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human CDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterized. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACFI7425-ACFI7729 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CTTTTCCTTTACACACTCTTTTCCTTTATCTTATTAATAAATGTTGGTCTCCACACTG 2180
DB 2653 CTTTTCCTTTCCCATCTCTGTACACATTTTAAATAAATAAGGGTTGCTTCTGAACATA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAAAAAATAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 563
ADA94446
ID ADA94446 standard; cDNA; 2846 BP.
XX
AC ADA94446;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein PRO1344.
XX
XX PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003059832-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997349.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.

CC	libraries containing sequences of interest were identified using																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

XX 29-SEP-1998; 98US-0102330P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI WPI; 2003-585112/55.
 DR P-PSDB; ABR99741.
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody.
 XX Claim 2; Fig 169; 700pp; English.
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC and nucleic acids encoding them, the invention also provides recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. The present sequence appears in the
 CC exemplification of the specification. Note: The sequence data for this
 CC patent is also available in electronic format from USPTO at
 CC seqdata.uspto.gov/sequence.html
 XX
 XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 SQ
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCATTGCTTTACCACTCTTCTTTTATCTATTAAATAAATGTTGGTCTCCACACTG 2180
 |||||
 DB 2653 CCATTTCCTTCCCATCTCTTGTCACATTTTATAATAAAGGTTGGTCTTGAAC 2712
 |||||
 QY 2181 NCTCCCAA 2240
 |||||
 DB 2713 CAAAAAATAA 2772
 |||||
 QY 2241 AA 2242

Db 2773 AA 2774
 |||
 RESULT 566
 ACF20807
 ID ACF20807 standard; cDNA; 2846 BP.
 XX
 XX ACF20807;
 AC
 DT 18-SEP-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003073172-A1.
 XX
 PD 17-APR-2003.
 XX
 PF 19-JUN-2002; 2002US-00175750.
 XX
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 28-OCT-1997; 97US-0063540P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 11-DEC-1997; 97US-0069335P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 17-DEC-1997; 97US-0069870P.
 PR 18-DEC-1997; 97US-0068017P.
 PR 10-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077632P.
 PR 11-MAR-1998; 98US-0077649P.
 PR 20-MAR-1998; 98US-0078886P.
 PR 20-MAR-1998; 98US-0078939P.
 PR 27-MAR-1998; 98US-0079664P.
 PR 27-MAR-1998; 98US-0079786P.
 PR 31-MAR-1998; 98US-0080107P.
 PR 31-MAR-1998; 98US-0080194P.
 PR 01-APR-1998; 98US-0080327P.
 PR 01-APR-1998; 98US-0080333P.
 PR 08-APR-1998; 98US-0081049P.
 PR 08-APR-1998; 98US-0081070P.
 PR 09-APR-1998; 98US-0081195P.
 PR 15-APR-1998; 98US-0081838P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082569P.
 PR 22-APR-1998; 98US-0082704P.
 PR 22-APR-1998; 98US-0082797P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083495P.
 PR 29-APR-1998; 98US-0083496P.

[illegible]

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTAAATAAATGTTGCTCCCACTG 2180
 DB 2653 CTTTTCCTCCCACTCTTGTGACACATTTTAATAAATAAGGCTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240
 DB 2713 CAAAAAATAA 2772

QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 569
 ACF47606
 ID ACF47606 standard; cDNA; 2846 BP.
 XX AC ACF47606;
 XX DT 08-OCT-2003 (first entry)
 XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX OS Homo sapiens.
 XX PN US2003068736-A1.
 XX PD 10-APR-2003.
 XX PF 22-JUL-2002; 2002US-00201532.
 XX PR 26-OCT-1998; 98US-0105693P.
 XX PR 01-SEP-1999; 99MO-US020111.
 XX PR 18-OCT-1999; 99US-00403297.
 XX PR 28-FEB-2001; 2001WO-US006520.
 XX PR 15-JAN-2002; 2002US-00052586.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-605924/57.
 XX P-PSDB; ABM23590.
 XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
 PT PRO827, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX PS Claim 2; Fig 169; 700pp; English.
 XX CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM23506-ABM23810) and nucleic acids encoding them (ACF47522-ACF47826).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF47522-ACF47826 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTAAATAAATGTTGCTCCCACTG 2180

DB 2653 CTTTTCCTCCCACTCTTGTGACACATTTTAATAAATAAGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAAAAATAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 570

ACF53439

ID ACF53439 standard; cDNA; 2846 BP.

XX AC ACF53439;

XX DT 10-OCT-2003 (first entry)

XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX KW Human; PRO; secreted protein; transmembrane protein;

XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

XX chondrocyte; proliferation; differentiation; cartilage disorder;

XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

XX liver; drug screening; transgenic animal; genetic analysis;

XX antiarthritic; vulnery; gene therapy; gene; ss.

XX OS Homo sapiens.

XX PN US2003068679-A1.

XX PD 10-APR-2003.

XX

PF 18-JUN-2002; 2002US-00174571.
XX
PR 05-MAY-1998; 98US-0084366P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PR (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI WPI; 2003-615868/58.
DR P-PSDB; ABM29385.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
PT
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM29301-ABM29605) and nucleic acids encoding them (ACF53355-ACF53659).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterized. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF53355-ACF53659 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGGTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGTGGTCTCCACCACTG 2180
DB 2553 CCTTTCTCTCCCATCTCTGTACATTTTATAATAAAGGTTGGTCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774
RESULT 571
ACD86774
ID ACD86774 standard; cDNA; 2846 BP.
XX
AC ACD86774;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068767-A1.
XX
PD 10-APR-2003.
XX
PF 29-JUL-2002; 2002US-00207918.
XX
PR 14-MAR-2000; 2000US-0189328P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625478/59.
DR P-PSDB; ABO38316.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful for
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATGTTGCTCCCACTG 2180
 DB 2653 CTTTTCTCTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
 QY 2181 NCTCCCAAA 2240
 DB 2713 CAA 2772

QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 572
 ACH05022
 ID ACH05022 standard; cDNA; 2846 BP.
 XX
 AC ACH05022;
 DT 02-OCT-2003 (first entry)
 DE
 XX
 KW cDNA encoding human PRO polypeptide #85.
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW molecular biology; hybridisation probe; chromosome mapping; gene mapping;
 KW tumour; cytostatic; gene; ss.
 OS Homo sapiens.
 XX
 FN US2003073182-A1.
 XX
 PD 17-APR-2003.
 XX
 PF 25-JUL-2002; 2002US-00205891.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-644799/61.
 DR P-PSDB; ABO45616.
 XX
 PT New nucleic acid, useful for the manufacture of a medicament for
 PT diagnosing or treating tumor or for measuring or detecting expression of
 PT an associated gene.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polynucleotide sequences are useful in molecular biology as hybridisation
 CC probes, in chromosome and gene mapping, in generating antisense RNA and
 CC DNA, and in gene therapy. The PRO polypeptides and polynucleotides are
 CC useful in preparing a medicament for diagnosing or treating tumours.
 CC ACH04938-ACH05242 represent cDNA sequences encoding the human PRO
 CC polypeptides of the invention. Note: The sequence data for this patent
 CC was obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdbEntry.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 P-PSDB; ABO45616.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATGTTGCTCCCACTG 2180
 DB 2653 CTTTTCTCTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
 QY 2181 NCTCCCAAA 2240
 DB 2713 CAA 2772

QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 573
 ACF44519
 ID ACF44519 standard; cDNA; 2846 BP.
 XX
 AC ACF44519;
 DT 03-OCT-2003 (first entry)
 DE
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FN US2003104557-A1.
 XX
 PD 05-JUN-2003.
 XX
 PF 29-JUL-2002; 2002US-00208025.
 XX
 PR 23-MAR-1999; 99US-0125775P.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-670252/63.
 DR P-PSDB; ABM20540.
 XX
 PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
 PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
 PT colon, breast, prostate, rectal, cervical or liver tumors.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM20456-ABM20760) and nucleic acids encoding them (ACF44435-ACF44739).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003027276-A1.

XX 06-FEB-2003.

XX 20-JUN-2002; 2002US-00176921.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 17-OCT-1997; 97US-0062250P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 28-OCT-1997; 97US-0063540P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063734P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066120P.

XX 24-NOV-1997; 97US-0066466P.

XX 24-NOV-1997; 97US-0066772P.

XX 11-DEC-1997; 97US-0069335P.

XX 12-DEC-1997; 97US-0069425P.

XX 17-DEC-1997; 97US-0069870P.

XX 18-DEC-1997; 97US-0069801P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077649P.

XX 20-MAR-1998; 98US-0078886P.

XX 20-MAR-1998; 98US-0078939P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079786P.

XX 31-MAR-1998; 98US-0081077P.

XX 31-MAR-1998; 98US-0080194P.

XX 01-APR-1998; 98US-0080327P.

XX 01-APR-1998; 98US-0080333P.

XX 08-APR-1998; 98US-0081049P.

XX 08-APR-1998; 98US-0081070P.

XX 09-APR-1998; 98US-0081195P.

XX 15-APR-1998; 98US-0081838P.

XX 21-APR-1998; 98US-0082568P.

XX 21-APR-1998; 98US-0082569P.

XX 22-APR-1998; 98US-0082704P.

XX 22-APR-1998; 98US-0082797P.

XX 28-APR-1998; 98US-0083322P.

XX 29-APR-1998; 98US-0083495P.

XX 29-APR-1998; 98US-0083496P.

XX 29-APR-1998; 98US-0083499P.

XX 29-APR-1998; 98US-0083559P.

XX 05-MAY-1998; 98US-0084366P.

XX 06-MAY-1998; 98US-0084414P.

XX 07-MAY-1998; 98US-0084639P.

XX 07-MAY-1998; 98US-0084640P.

XX 07-MAY-1998; 98US-0084643P.

XX 15-MAY-1998; 98US-0085579P.

XX 15-MAY-1998; 98US-0085580P.

XX 15-MAY-1998; 98US-0085582P.

XX 15-MAY-1998; 98US-0085700P.

XX 18-MAY-1998; 98US-0086023P.

XX 22-MAY-1998; 98US-0086392P.

XX 22-MAY-1998; 98US-0086486P.

XX 28-MAY-1998; 98US-0087098P.

XX 28-MAY-1998; 98US-0087208P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088825P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088863P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089090P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090461P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090688P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.

PR 26-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091486P.

PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091632P.

PR 04-AUG-1998; 98US-0095282P.

PR 10-AUG-1998; 98US-0095998P.

PR 10-AUG-1998; 98US-0096012P.

PR 17-AUG-1998; 98US-0096757P.

PR 17-AUG-1998; 98US-0096766P.

PR 17-AUG-1998; 98US-0096867P.

PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096897P.

PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096959P.

PR 18-AUG-1998; 98US-0097022P.

PR 26-AUG-1998; 98US-0097952P.

PR 26-AUG-1998; 98US-0097954P.

PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.

PR 26-AUG-1998; 98US-0097974P.

PR 26-AUG-1998; 98US-0098014P.

```
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 25-SEP-1998; 98US-0102330P.
PR 25-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCACTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db ||
2773 AA 2774

RESULT 576
ACD24521
ID ACD24521 standard; cDNA; 2846 BP.
XX
XX ACD24521;
XX
XX 29-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW
```

```
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS
PN US2003044920-A1.
XX
PD 06-MAR-2003.
XX
XX 24-JUN-2002; 2002US-00179506.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 05-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
```

```
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088031P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088828P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091625P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.

PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No: 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACATTTTAATAAAATAGGGTTGGCTTCTGAAC 2712

Qy 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 577
ACD39724
ID ACD39724 standard; cDNA; 2846 BP.
XX
AC ACD39724;
XX
DT 04-SEP-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #85.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
```

KW chromosome mapping; gene mapping; biosensor; bioreactor; tumour;
KW tumour necrosis factor-alpha; TNF-alpha; proliferation; differentiation;
KW chondrocyte cell; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003027265-A1.
XX 06-FEB-2003.
XX 18-JUN-2002; 2002US-00174582.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 28-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 03-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.

KW	Human; PRO polypeptide; secreted protein; transmembrane protein; chromosome mapping; gene mapping; biosensor; bioreactor; tumour; lung; colon; breast; prostate; rectal; cervical; liver; cancer; cytostatic; gene therapy; gene; ss.
XX	Homo sapiens.
FN	US2003054461-A1.
XX	20-MAR-2003.
XX	16-JUL-2002; 2002US-00196751.
PR	11-APR-2000; 2000US-0195975P.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	(GETH) GENENTECH INC.
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI	WI: 2003-503629/47.
XX	P-PSDB; ABO23012.
DR	Three hundred and five nucleic acids encoding PRO polypeptides, useful for diagnosing, preventing and/or treating tumors, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
DR	Claim 2; Fig 169; 699pp; English.
XX	The present invention relates to the isolation of novel human PRO polypeptides, and the polynucleotide sequences encoding them. The PRO polypeptides are secreted and transmembrane proteins. The PRO polynucleotide sequences are useful in molecular biology as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy. The PRO polypeptides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors for the detection of tumours in adrenal, lung, colon, breast, prostate, rectal, cervical or liver cancers. ACD19947-ACD40251 represent cDNA sequences encoding the human PRO polypeptides of the invention. Note: The sequence data for this patent was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/psipsdIDEntry.html
CC	at seqdata.uspto.gov/psipsdIDEntry.html
XX	SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match	3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity	71.3%; Pred. No. 0.00023;
Matches	87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY	2121 CCTTTCCTTTACCACCTCTTTTCCTTTATCTATTATAAAATGTTGGTCTCCACACTG 2180
Db	2653 CCITTTTCCTTCCCACCTCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGACTA 2712
QY	2181 NCTCCCAA 2240
Db	2713 CAAAIAA 2772
QY	2241 AA 2242
Db	2773 AA 2774
RESULT 578	
ACD40031	ACD40031 standard; cDNA; 2846 BP.
XX	XX AC ACD40031;
XX	XX AC ACD40031;
DT	04-SEP-2003 (first entry)
DE	cDNA encoding human PRO polypeptide #85.
XX	XX

KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX Homo sapiens.
 XX US2003064446-A1.
 XX 03-APR-2003.
 XX 11-JUL-2002; 2002US-00194460.
 XX 15-SEP-2000; 2000US-0232887P.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-531719/50.
 XX P-PSDB; ABR92554.
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
 XX colon, breast, prostate, rectal, cervical or liver tumors.
 XX Claim 2; Fig 169; 699pp; English.
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 XX (ABR92470-ABR92774) and nucleic acids encoding them (ACF13255-ACF13559).
 XX The invention also relates to sequences at least 80% identical to the PRO
 XX nucleic acid and polypeptide sequences of the invention, recombinant
 XX vectors and host cells comprising a PRO nucleic acid, a method for the
 XX recombinant production of a PRO polypeptide, antibodies against a PRO
 XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 XX acids encoding PRO polypeptides of the invention were initially
 XX identified via homology screening using consensus sequences based on the
 XX extracellular domain sequences from known secreted proteins. Human cDNA
 XX libraries containing sequences of interest were identified using
 XX oligonucleotides based on the consensus sequences, and cDNA clones were
 XX isolated and characterised. The PRO polypeptides are useful for
 XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 XX human blood and may thus be used in the treatment of conditions in which
 XX enhanced TNF-alpha release would be beneficial. They are also useful for
 XX stimulating the proliferation or differentiation of chondrocytes and as
 XX such may be used in the treatment of various bone and/or cartilage
 XX disorders such as arthritis and sports injuries. The PRO polypeptides may
 XX be used in a method for detecting the presence of a tumour (e.g., an
 XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 XX method involves comparing the level of expression of the PRO polypeptide
 XX in test and control samples, where a higher level of expression of PRO
 XX polypeptide in the test sample as compared to the control sample is
 XX indicative of the presence of a tumour. The PRO polypeptides are
 XX additionally useful for in drug screening to identify agonists and
 XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
 XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
 XX gene mapping, in the generation of antisense RNA and DNA and in gene
 XX therapy. The nucleic acids can also be used for mapping genes encoding
 XX PRO polypeptides, for genetic analysis of individuals with genetic
 XX disorders, and for generating either transgenic animals or knock-out
 XX animals which are useful in the development and screening of
 XX therapeutically useful compounds. Sequences ACF13255-ACF1359 represent
 XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 XX invention. Note: The sequence data for this patent is also available in
 XX electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CTTTGGCTTTACACCTCTTCTCTTTATCTTATTAATAAATGTTGGTCTCCACCACATG 2180
 DB 2653 CTTTTCCTCCCATCTCTGTACACATTTAATAAATAAGGTTGGCTTCTGACACTA 2712
 QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
 DB 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 580
 ACF03141
 ID ACF03141 standard; cDNA; 2846 BP.
 XX AC ACF03141;
 XX 05-SEP-2003 (first entry)
 XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 OS Homo sapiens.
 XX US2003049744-A1.
 XX 13-MAR-2003.
 XX 11-JUL-2002; 2002US-00194425.
 XX 05-JUN-2000; 2000US-0209832P.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-555154/52.
 XX P-PSDB; ABR81511.
 XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 XX for stimulating tumor necrosis factor alpha or chondrocyte proliferation,
 XX particularly for treating tumors in a mammal.
 XX Claim 2; Fig 169; 700pp; English.
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 XX (ABR81427-ABR81731) and nucleic acids encoding them (ACF03057-ACF03361).
 XX The invention also relates to sequences at least 80% identical to the PRO
 XX nucleic acid and polypeptide sequences of the invention, recombinant
 XX vectors and host cells comprising a PRO nucleic acid, a method for the
 XX recombinant production of a PRO polypeptide, antibodies against a PRO
 XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 XX acids encoding PRO polypeptides of the invention were initially
 XX identified via homology screening using consensus sequences based on the
 XX extracellular domain sequences from known secreted proteins. Human cDNA

RESULT 582
ACF11333
ID ACF11333 standard; cDNA; 2846 BP.
XX AC ACF11333;
XX AC ACF11333;
XX DT 09-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003073171-A1.
XX PD 17-APR-2003.
XX PF 19-JUN-2002; 2002US-Q0175741.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 28-OCT-1997; 97US-0063540P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066120P.
XX PR 24-NOV-1997; 97US-0066466P.
XX PR 24-NOV-1997; 97US-0066772P.
XX PR 11-DEC-1997; 97US-0069335P.
XX PR 12-DEC-1997; 97US-0069425P.
XX PR 17-DEC-1997; 97US-0069870P.
XX PR 18-DEC-1997; 97US-0068017P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 27-MAR-1998; 98US-0078939P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 31-MAR-1998; 98US-0080107P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
XX PR 09-APR-1998; 98US-0081195P.
XX PR 15-APR-1998; 98US-0081838P.
XX PR 21-APR-1998; 98US-0082568P.
XX PR 21-APR-1998; 98US-0082569P.
XX PR 22-APR-1998; 98US-0082704P.
XX PR 22-APR-1998; 98US-0082797P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 29-APR-1998; 98US-0083495P.
XX PR 29-APR-1998; 98US-0083436P.
XX PR 29-APR-1998; 98US-0083496P.
XX PR 29-APR-1998; 98US-0083497P.
XX PR 05-MAY-1998; 98US-0083559P.
XX PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.

PR	05-MAY-1998;	98US-0084366P.	PR	24-JUL-1998;	98US-0094006P.
PR	06-MAY-1998;	98US-0084414P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084439P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998;	98US-0084643P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	26-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	03-JUN-1998;	98US-0088027P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	05-JUN-1998;	98US-0088255P.	PR	10-SEP-1998;	98US-0099763P.
PR	05-JUN-1998;	98US-0088555P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088722P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088740P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088825P.	PR	17-SEP-1998;	98US-0100683P.
PR	10-JUN-1998;	98US-0088826P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100919P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100930P.
PR	11-JUN-1998;	98US-0088876P.	PR	18-SEP-1998;	98US-0100849P.
PR	12-JUN-1998;	98US-0089090P.	PR	18-SEP-1998;	98US-0101014P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0101068P.
PR	12-JUN-1998;	98US-0089512P.	PR	23-SEP-1998;	98US-0101471P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101472P.
PR	16-JUN-1998;	98US-0089518P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101477P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101738P.
PR	18-JUN-1998;	98US-0089808P.	PR	24-SEP-1998;	98US-0101739P.
PR	18-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090252P.	PR	25-SEP-1998;	98US-0101786P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090429P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090461P.	PR	30-SEP-1998;	98US-0102487P.
PR	24-JUN-1998;	98US-0090535P.	PR	30-SEP-1998;	98US-0102570P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090676P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090678P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090688P.			
PR	25-JUN-1998;	98US-0090690P.			
PR	25-JUN-1998;	98US-0090694P.			
PR	25-JUN-1998;	98US-0090695P.			
PR	25-JUN-1998;	98US-0090696P.			
PR	25-JUN-1998;	98US-00105413.			
PR	26-JUN-1998;	98US-0090862P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-0091359P.			
PR	01-JUL-1998;	98US-0091544P.			
PR	02-JUL-1998;	98US-0091478P.			
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091626P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091632P.			

Query Match

Best Local Similarity

Mismatches

Conservative

Score

DB

Length

2846;

71.3%;

Pred. No. 0.00023;

0;

Mismatches

35;

Indels

0;

Gaps

0;

QY	2121	CCTTTCCTTTTACCACCTCTTTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG	2180
Db	2653	CCTTTCCTTTCCCATCTCTGTACACATTTAATAAATAGGTTGGTCTTCTGACTA	2712
QY	2181	NCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Db	2713	CAAA	2772
QY	2241	AA	2242

Db 2773 AA 2774

RESULT 584

ACF34171

ID ACF34171 standard; cDNA; 2846 BP.

XX

AC ACF34171;

DT 25-SEP-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnary; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

FN US2003064458-A1.

XX

PD 03-APR-2003.

XX

PF 18-JUL-2002; 2002US-00199313.

XX

PR 26-AUG-1998; 98US-0097952P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-596622/56.

DR P-PSDB; ABM13766.

XX

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, or for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g., cancer.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The invention relates to human PRO secreted/transmembrane polypeptides and nucleic acids encoding them, the invention also provides recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. The present sequence appears in the exemplification of the specification. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 596 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTATTAATAAAATGTGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAGGGTTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 585

ACD46396

ID ACD46396 standard; cDNA; 2846 BP.

XX

AC ACD46396;

XX

DT 13-SEP-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX

OS Homo sapiens.

XX

PN US2003064460-A1.

XX

PD 03-APR-2003.

XX

PF 22-JUL-2002; 2002US-00201329.

XX

PR 02-SEP-1998; 98US-0098843P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-605862/57.

DR P-PSDB; ABO28504.

XX

PT Isolated secreted and transmembrane PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy for cancers, chromosome

```
PT identification, tissue typing, or as hybridization probes in chromosome
PT and gene mapping.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB |||
2773 AA 2774

RESULT 586
ACD48238
ID ACD48238 standard; cDNA; 2846 BP.
XX
AC ACD48238;
XX
DT 14-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
XX US2003064464-A1.
XX
XX 03-APR-2003.
XX
XX 26-JUL-2002; 2002US-00206924.
PF
XX
XX 05-JUN-2000; 2000US-0209832P.
PR

PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605864/57.
DR P-PSDB; ABO30334.
XX
XX New secreted and transmembrane PRO polypeptides, useful in gene therapy,
PT stimulating the release of tumor necrosis factor-alpha, stimulating
PT proliferation or differentiation of chondrocyte cells and detecting the
PT presence of a tumor.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB |||
2773 AA 2774

RESULT 587
ACF27619
ID ACF27619 standard; cDNA; 2846 BP.
XX
XX ACF27619;
XX
XX 20-SEP-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX
XX Human; PRO; secreted protein; transmembrane protein;
KW
```


XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003068729-A1.

XX 10-APR-2003.

XX 18-JUL-2002; 2002US-00199460.

XX 11-MAR-1998; 98US-0077632P.

XX 08-MAR-1999; 99WO-US005028.

XX 25-AUG-1999; 99US-00380138.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-625470/59.

XX P-PSDB; ABO41671.

XX New isolated nucleic acid encoding a secreted and transmembrane PRO

XX polypeptide, e.g. PRO1079 or PRO827, useful in molecular biology, and in

XX chromosome and gene mapping, in generating antisense RNA and DNA, and in

XX gene therapy for cancers.

XX Claim 2; Fig 169; 699pp; English.

XX The invention discloses human nucleic acids encoding secreted and

XX transmembrane (PRO) polypeptides, with or without their associated signal

XX peptide. Also disclosed is an antibody that specifically binds to the PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor alpha (TNF-alpha) from human blood by contacting the blood with a

XX PRO polypeptide, a method for stimulating the proliferation or

XX differentiation of chondrocyte cells by contacting the cells with a PRO

XX polypeptide, a method for detecting the presence of a tumour in a mammal

XX and an oligonucleotide probe derived from any of the PRO nucleotide

XX sequences. The nucleotide sequences are useful as probes, in chromosome

XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO

XX polypeptides by recombinant techniques and in gene therapy (e.g. for

XX replacement of defective gene). The PRO polypeptides are useful as

XX molecular weight markers for protein electrophoresis purposes, for

XX chromosome identification, as chromosome markers, as therapeutic agents,

XX for stimulating the release of TNF-alpha from human blood, for

XX stimulating the proliferation or differentiation of chondrocytes and

XX detecting the presence, prevention and/or treatment of a tumour, such as

XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

XX The PRO polypeptides and nucleic acids may also be used diagnostically

XX for tissue typing. The sequence presented is a cDNA encoding one of the

XX PRO polypeptides of the invention. Note: The sequence data for this

XX patent can also be obtained in electronic format directly from USPTO at

XX seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;

XX Best Local Similarity 71.3%; Pred. No. 0.00023;

XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGTTTACCACTCTTCTCTTTATCTATTATTAATAAATGTGCTCCACCACTG 2180

Db 2653 CCTTTTCCTCCCACTCTCTTGTACACATTTTATAAATAAGGGTTTGGCTTCTGAAC 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 591

ACD83704

XX ACD83704 standard; cDNA; 2846 BP.

XX AC ACD83704;

XX 22-SEP-2003 (first entry)

XX Human PRO polynucleotide #85.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

XX cytosolic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;

XX chondrocyte cell; cancer.

XX Homo sapiens.

XX US2003068738-A1.

XX 10-APR-2003.

XX 23-JUL-2002; 2002US-00201535.

XX 08-OCT-1998; 98US-0103633P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-625472/59.

XX P-PSDB; ABO35266.

XX New isolated nucleic acid encoding a secreted and transmembrane PRO

XX polypeptide e.g. PRO1079 or PRO827, useful in molecular biology,

XX chromosome and gene mapping, in generating antisense RNA and DNA, and in

XX gene therapy for cancers.

XX Claim 2; SEQ ID NO 169; 207pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal. The polynucleotides are

XX useful in molecular biology, including uses as hybridisation probes, in

XX chromosome and gene mapping, in generating antisense RNA and DNA, and in

XX gene therapy. The polynucleotides may also be used in preparing PRO

XX polypeptides by recombinant techniques and in generating either

XX transgenic animals or knock-out animals which are useful in the

XX development and screening of therapeutically useful reagents. The PRO

XX polypeptides or antibodies are used in preparing a medicament for

XX treating a condition responsive to the polypeptides or antibodies, such

XX as tumours, and in various diagnostic assays. Sequences ACD83620-ACD83924

XX represent human PRO polynucleotides of the invention. Note: The sequence

XX data for this patent is available in electronic format from USPTO at

XX seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;

XX Best Local Similarity 71.3%; Pred. No. 0.00023;

XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTGGCTTTACCACTCTTTCTTTATCTATTAATAAAATGGTGCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTTCTCTCCCACTCTTGACACATTTTAATAAAATAGGTTGGCTTCTGAACATA 2712
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Db |||
QY 2773 AA 2774
Db |||

RESULT 592
ACF49141
ID ACF49141 standard; cDNA; 2846 BP.
XX AC ACF49141;
XX DT 04-OCT-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003104540-A1.
XX PD 05-JUN-2003.
XX PF 24-JUN-2002; 2002US-00179518.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 28-OCT-1997; 97US-0063540P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066120P.
XX PR 24-NOV-1997; 97US-0066466P.
XX PR 24-NOV-1997; 97US-0066772P.
XX PR 11-DEC-1997; 97US-0069335P.
XX PR 12-DEC-1997; 97US-0069425P.
XX PR 17-DEC-1997; 97US-0069870P.
XX PR 18-DEC-1997; 97US-0068017P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077649P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 20-MAR-1998; 98US-0078939P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 31-MAR-1998; 98US-0080107P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
98US-0081195P.
98US-0081838P.
98US-0082568P.
98US-0082569P.
98US-0082704P.
98US-0082797P.
98US-0083322P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083559P.
98US-0084366P.
98US-0084414P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085579P.
98US-0085580P.
98US-008582P.
98US-0085700P.
98US-0086023P.
98US-0086392P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088029P.
98US-0088033P.
98US-0088326P.
98US-0088367P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.
98US-0088740P.
98US-0088811P.
98US-0088824P.
98US-0088825P.
98US-0088826P.
98US-0088861P.
98US-0088863P.
98US-0088876P.
98US-0089090P.
98US-0089105P.
98US-0089512P.
98US-008952P.
98US-008952P.
98US-0090246P.
98US-0090252P.
98US-0090254P.
98US-0090429P.
98US-0090435P.
98US-0090444P.
98US-0090461P.
98US-0090535P.
98US-0090540P.
98US-0090676P.
98US-0090678P.
98US-0090688P.
98US-0090690P.
98US-0090694P.
98US-0090695P.
98US-0090696P.
```


PR	26-JUN-1998;	98US-00105413.	QY	2121	CCTTTGCTTTACCACTCTTTCTTTATCTTATTAATAAATGTTGGTCTCCACCACTG	2180
PR	26-JUN-1998;	98US-0090862P.	DB	2653		2712
PR	26-JUN-1998;	98US-0090863P.	QY	2181	NCTCCAAAAA	2240
PR	01-JUL-1998;	98US-0091010P.	DB	2713	CAAAAAA	2772
PR	01-JUL-1998;	98US-0091359P.	QY	2241	AA	2242
PR	01-JUL-1998;	98US-0091544P.	DB	2773	AA	2774
PR	02-JUL-1998;	98US-0091478P.				
PR	02-JUL-1998;	98US-0091486P.				
PR	02-JUL-1998;	98US-0091626P.				
PR	02-JUL-1998;	98US-0091628P.				
PR	02-JUL-1998;	98US-0091632P.				
PR	04-JUL-1998;	98US-0094006P.				
PR	10-AUG-1998;	98US-0095282P.				
PR	10-AUG-1998;	98US-0095998P.				
PR	17-AUG-1998;	98US-0096012P.				
PR	17-AUG-1998;	98US-0096757P.				
PR	17-AUG-1998;	98US-0096766P.				
PR	17-AUG-1998;	98US-0096867P.				
PR	17-AUG-1998;	98US-0096891P.				
PR	17-AUG-1998;	98US-0096897P.				
PR	18-AUG-1998;	98US-0096949P.				
PR	18-AUG-1998;	98US-0096959P.				
PR	18-AUG-1998;	98US-0097022P.				
PR	26-AUG-1998;	98US-0097952P.				
PR	26-AUG-1998;	98US-0097954P.				
PR	26-AUG-1998;	98US-0097955P.				
PR	26-AUG-1998;	98US-0097971P.				
PR	26-AUG-1998;	98US-0097974P.				
PR	26-AUG-1998;	98US-0098014P.				
PR	01-SEP-1998;	98US-0098716P.				
PR	01-SEP-1998;	98US-0098723P.				
PR	02-SEP-1998;	98US-0098803P.				
PR	02-SEP-1998;	98US-0098821P.				
PR	02-SEP-1998;	98US-0098843P.				
PR	09-SEP-1998;	98US-0099602P.				
PR	10-SEP-1998;	98US-0099741P.				
PR	10-SEP-1998;	98US-0099754P.				
PR	10-SEP-1998;	98US-0099763P.				
PR	10-SEP-1998;	98US-0099812P.				
PR	15-SEP-1998;	98US-0100388P.				
PR	16-SEP-1998;	98US-0100662P.				
PR	16-SEP-1998;	98US-0100664P.				
PR	16-SEP-1998;	98US-0101751P.				
PR	16-SEP-1998;	98US-01019330.				
PR	17-SEP-1998;	98US-0100683P.				
PR	17-SEP-1998;	98US-0100684P.				
PR	17-SEP-1998;	98US-0100919P.				
PR	17-SEP-1998;	98US-0100930P.				
PR	18-SEP-1998;	98US-0100849P.				
PR	18-SEP-1998;	98US-0101014P.				
PR	18-SEP-1998;	98US-0101068P.				
PR	23-SEP-1998;	98US-0101471P.				
PR	23-SEP-1998;	98US-0101472P.				
PR	23-SEP-1998;	98US-0101475P.				
PR	23-SEP-1998;	98US-0101477P.				
PR	24-SEP-1998;	98US-0101738P.				
PR	24-SEP-1998;	98US-0101739P.				
PR	24-SEP-1998;	98US-0101743P.				
PR	24-SEP-1998;	98US-0101922P.				
PR	25-SEP-1998;	98US-0101786P.				
PR	29-SEP-1998;	98US-0102207P.				
PR	29-SEP-1998;	98US-0102240P.				
PR	29-SEP-1998;	98US-0102330P.				
PR	29-SEP-1998;	98US-0102331P.				
PR	30-SEP-1998;	98US-0102487P.				
PR	30-SEP-1998;	98US-0102570P.				
PR	30-SEP-1998;	98US-0102571P.				
PR	01-OCT-1998;	98US-0102684P.				
PR	01-OCT-1998;	98US-0102687P.				
Query Match 3.0%; Score 66.6; DB 9; Length 2846;						
Best Local Similarity 71.3%; Pred. No. 0.00023;						
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;						
RESULT 593						
ACH07226						
ID	ACH07226 standard; cDNA; 2846 BP.					
XX	ACH07226;					
AC	ACH07226;					
DT	09-OCT-2003 (first entry)					
XX	Human secreted/transmembrane protein (PRO) cDNA #85.					
DE	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;					
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;					
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;					
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.					
XX	Homo sapiens.					
OS	US2003049742-A1.					
XX	13-MAR-2003.					
PD	09-JUL-2002; 2002US-00192015.					
XX	05-JUN-2000; 2000US-0209832P.					
PR	28-FEB-2001; 2001WO-US006520.					
PR	15-JAN-2002; 2002US-00052586.					
XX	(GETH) GENENTECH INC.					
PA	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;					
XX	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;					
PI	WPI; 2003-669835/63.					
XX	P-PSDB; ABO47507.					
DR	Three hundred and five nucleic acids encoding PRO polypeptides, useful in					
XX	gene therapy, chromosome identification, tissue typing, or as					
PT	hybridization probes in chromosome and gene mapping.					
XX	Claim 2; Fig 169; 699pp; English.					
PS	The invention discloses human nucleic acids encoding secreted and					
XX	transmembrane (PRO) polypeptides, with or without their associated signal					
CC	peptide. Also disclosed is an antibody that specifically binds to the PRO					
CC	polypeptide, a method for stimulating the release of tumour necrosis					
CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a					
CC	PRO polypeptide, a method for stimulating the proliferation or					
CC	differentiation of chondrocyte cells by contacting the cells with a PRO					
CC	polypeptide, a method for detecting the presence of a tumour in a mammal					
CC	and an oligonucleotide probe derived from any of the PRO nucleotide					
CC	sequences. The nucleotide sequences are useful as probes, in chromosome					
CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO					
CC	polypeptides by recombinant techniques and in gene therapy (e.g. for					
CC	replacement of defective gene). The PRO polypeptides are useful as					
CC	molecular weight markers for protein electrophoresis purposes, for					
CC	chromosome identification, as chromosome markers, as therapeutic agents,					
CC	for stimulating the release of TNF-alpha from human blood, for					
CC	stimulating the proliferation or differentiation of chondrocytes and					
CC	detecting the presence, prevention and/or treatment of a tumour, such as					

CC	differentiation of chondrocyte cells by contacting the cells with a PRO
CC	polypeptide, a method for detecting the presence of a tumour in a mammal
CC	and an oligonucleotide probe derived from any of the PRO nucleotide
CC	sequences. The nucleotide sequences are useful as probes, in chromosome
CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC	polypeptides by recombinant techniques and in gene therapy (e.g. for
CC	replacement of defective gene). The PRO polypeptides are useful as
CC	molecular weight markers for protein electrophoresis purposes, for
CC	chromosome identification, as chromosome markers, as therapeutic agents,
CC	for stimulating the release of TNF-alpha from human blood, for
CC	stimulating the proliferation or differentiation of chondrocytes and
CC	detecting the presence, prevention and/or treatment of a tumour, such as
CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC	The PRO polypeptides and nucleic acids may also be used diagnostically
CC	for tissue typing. The sequence presented is a cDNA encoding one of the
CC	PRO polypeptides of the invention. Note: The sequence data for this
CC	patent can also be obtained in electronic format directly from USPTO at
CC	seqdata.uspto.gov/sequence.html
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
	Query Match 3.0%; Score 66.6; DB 9; Length 2846;
	Best Local Similarity 71.3%; Pred. No. 0.00023;
	Matches 8; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY	2121 CCTTGGCTTTACCACATCTTCCTCTTAATATAAATAAGTGTTGCTCACCACACTG 2180
DB	2653 CCITTTCTCTCCCATCTCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAAC TA 2712
QY	2181 NCTCCCAAA 2240
DB	2713 CAA 2772
QY	2241 AA 2242
DB	2773 AA 2774
RESULT 595	
ACH08147	
ID	ACH08147 standard; CDNA; 2846 BP.
XX	
AC	ACH08147;
XX	
DT	10-OCT-2003 (first entry)
XX	
DE	Human secreted/transmembrane protein (PRO) CDNA #85.
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
OS	Homo sapiens.
XX	
PN	US2003049750-A1.
XX	
PD	13-MAR-2003.
XX	
PF	17-JUL-2002; 2002US-00197699.
XX	
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1999; 99WO-U012252.
PR	25-AUG-1999; 99US-00380137.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XR	WPI; 2003-669838/63.

DR P-PSDB; ABO48422.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in

PT gene therapy, in chromosome and gene mapping, as chromosome markers, in

PT tissue typing, and in identifying chromosome.

XX Claim 2; Fig 169; 700pp; English.

PS The invention discloses human nucleic acids encoding secreted and

XX transmembrane (PRO) polypeptides, with or without their associated signal

CC peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO

CC polypeptide, a method for detecting the presence of a tumour in a mammal

CC and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome

CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as

CC molecular weight markers for protein electrophoresis purposes, for

CC chromosome identification, as chromosome markers, as therapeutic agents,

CC for stimulating the release of TNF-alpha from human blood, for

CC stimulating the proliferation or differentiation of chondrocytes and

CC detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC The PRO polypeptides and nucleic acids may also be used diagnostically

CC for tissue typing. The sequence presented is a cDNA encoding one of the

CC PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at

CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATAAATAATGTTGCTCCCACTG 2180

Db 2653 CTTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 596

ACH11338

ID ACH11338 standard; cDNA; 2846 BP.

XX ACH11338;

AC ACH11338;

DT 13-OCT-2003 (first entry)

XX cDNA encoding human PRO polypeptide #85.

DE Human; PRO polypeptide; secreted protein; transmembrane protein;

XX molecular biology; hybridisation probe; chromosome mapping; gene mapping;

KW cytostatic; gene; ss.

XX Homo sapiens.

OS US2003049766-A1.

XX PN 13-MAR-2003.

XX PD 19-JUL-2002; 2002US-00199669.

XX PF

XX 05-JUN-1998; 98US-0088212P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-669843/63.

DR P-PSDB; ABO51472.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in

PT gene therapy, chromosome identification, tissue typing, or as

PT hybridization probes in chromosome and gene mapping.

XX Claim 2; Fig 169; 700pp; English.

CC The present invention relates to the isolation of novel human PRO

CC polypeptides, and the polynucleotide sequences encoding them. The PRO

CC polypeptides are secreted and transmembrane proteins. The PRO

CC polynucleotide sequences are useful in molecular biology as hybridisation

CC probes, in chromosome and gene mapping, in generating antisense RNA and

CC DNA, and in gene therapy. The PRO polypeptides are useful as molecular

CC weight markers for protein electrophoresis purposes. The anti-PRO

CC antibodies may be used in diagnostic assays for PRO, or for the affinity

CC purification of PRO from recombinant cell culture or natural sources.

CC ACH11254-ACH11558 represent cDNA sequences encoding the human PRO

CC polypeptides of the invention. Note: The sequence data for this patent

CC was obtained in electronic format directly from the USPTO web site at

CC seqdata.uspto.gov/psipsIDEntry.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATAAATAATGTTGCTCCCACTG 2180

Db 2653 CTTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 597

ACH11645

ID ACH11645 standard; cDNA; 2846 BP.

XX ACH11645;

AC ACH11645;

DT 13-OCT-2003 (first entry)

XX cDNA encoding human PRO polypeptide #85.

DE Human; PRO polypeptide; secreted protein; transmembrane protein;

XX molecular biology; hybridisation probe; chromosome mapping; gene mapping;

KW cytostatic; gene; ss.

XX Homo sapiens.

OS US2003049767-A1.

XX PN 13-MAR-2003.

XX PD

XX	22-JUL-2002; 2002US-00201534.	PD	13-MAR-2003.
PF		XX	
XX		XX	24-JUL-2002; 2002US-00205509.
XX		XX	
PR	03-MAR-2000; 2000US-0187202P.	PR	20-MAR-1998; 98US-0078939P.
PR	28-FEB-2001; 2001WO-US006520.	PR	08-MAR-1999; 99WO-US005028.
PR	15-JAN-2002; 2002US-00052586.	PR	25-AUG-1999; 98US-00380138.
XX		PR	18-FEB-2000; 2000WO-US004341.
PA	(GETH) GENENTECH INC.	PR	28-FEB-2001; 2001WO-US006520.
XX		PR	15-JAN-2002; 2002US-00052586.
XX		XX	(GETH) GENENTECH INC.
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;	XX	
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
DR	P-PSDB; ABO51777.	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
DR		XX	
XX		XX	WPI; 2003-669844/63.
XX		DR	P-PSDB; ABO50557.
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful in	XX	
PT	gene therapy, chromosome identification, tissue typing, or as	PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT	hybridization probes in chromosome and gene mapping.	PT	for the manufacture of a medicament for diagnosing or treating tumor or
XX		PT	for tissue typing.
PS	Claim 2; Fig 169; 700pp; English.	XX	
XX		XX	Claim 2; Fig 169; 700pp; English.
CC	The present invention relates to the isolation of novel human PRO	XX	
CC	polypeptides, and the polynucleotide sequences encoding them. The PRO	CC	The invention discloses human nucleic acids encoding secreted and
CC	polypeptides are secreted and transmembrane proteins. The PRO	CC	transmembrane (PRO) polypeptides, with or without their associated signal
CC	polynucleotide sequences are useful in molecular biology as hybridisation	CC	peptide. Also disclosed is an antibody that specifically binds to the PRO
CC	probes, in chromosome and gene mapping, in generating antisense RNA and	CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	DNA, and in gene therapy. The PRO polypeptides are useful as molecular	CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC	weight markers for protein electrophoresis purposes. The anti-PRO	CC	PRO polypeptide, a method for stimulating the proliferation or
CC	antibodies may be used in diagnostic assays for PRO, or for the affinity	CC	differentiation of chondrocyte cells by contacting the cells with a PRO
CC	purification of PRO from recombinant cell culture or natural sources.	CC	polypeptide, a method for detecting the presence of a tumour in a mammal
CC	ACH1561-ACH11865 represent cDNA sequences encoding the human PRO	CC	and an oligonucleotide probe derived from any of the PRO nucleotide
CC	polypeptides of the invention. Note: The sequence data for this patent	CC	sequences. The nucleotide sequences are useful as probes, in chromosome
CC	was obtained in electronic format directly from the USPTO web site at	CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC	seqdata.uspto.gov/psipsDIDentry.html	CC	polypeptides by recombinant techniques and in gene therapy (e.g. for
XX		CC	replacement of defective gene). The PRO polypeptides are useful as
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	CC	molecular weight markers for protein electrophoresis purposes, for
		CC	chromosome identification, as chromosome markers, as therapeutic agents,
		CC	for stimulating the release of TNF-alpha from human blood, for
		CC	stimulating the proliferation or differentiation of chondrocytes and
		CC	detecting the presence, prevention and/or treatment of a tumour, such as
		CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
		CC	The PRO polypeptides and nucleic acids may also be used diagnostically
		CC	for tissue typing. The sequence presented is a cDNA encoding one of the
		CC	PRO polypeptides of the invention. Note: The sequence data for this
		CC	patent can also be obtained in electronic format directly from USPTO at
		CC	seqdata.uspto.gov/sequence.html
		XX	
		SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
			Query Match 3.0%; Score 66.6; DB 9; Length 2846;
			Best Local Similarity 71.3%; Pred. No. 0.00023;
			Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY	2121 CCTTTGCTTTTACCACCTCTTTTCCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180	QY	2121 CCTTTGCTTTTACCACCTCTTTTCCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180
DB	2653 CCTTTTCTTTCCCACTCTCTGTACACATTTTAATAAAATAGGTTGGTCTCTGAACATA 2712	DB	2653 CCTTTTCTTTCCCACTCTCTGTACACATTTTAATAAAATAGGTTGGTCTCTGAACATA 2712
QY	2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240	QY	2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
DB	2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772	DB	2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772
QY	2241 AA 2242	QY	2241 AA 2242
DB	2773 AA 2774	DB	2773 AA 2774
			RESULT 598
			ACH10296
ID	ACH10296 standard; cDNA; 2846 BP.	ID	ACH10296 standard; cDNA; 2846 BP.
XX		XX	
AC	ACH10296;	AC	ACH10296;
XX		XX	
XX		XX	
DT	10-OCT-2003 (first entry)	DT	10-OCT-2003 (first entry)
DE	Human secreted/transmembrane protein (PRO) cDNA #85.	DE	Human secreted/transmembrane protein (PRO) cDNA #85.
XX		XX	
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX		XX	
OS	Homo sapiens.	OS	Homo sapiens.
XX		XX	
XX		XX	
XX	US2003049779-A1.	XX	US2003049779-A1.

AC ACF01299;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003040059-A1.
PN
XX
PD 27-FEB-2003.
XX
XX 24-JUN-2002; 2002US-00179519.
XX
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.

```
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096881P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 24-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAAGGTTTGGCTTCTGACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 600
ACF40874
ID ACF40874 standard; cDNA; 2846 BP.
```

```
XX ACF40874;
AC 06-NOV-2003 (first entry)
XX DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX DE Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003040078-A1.
XX PD 27-FEB-2003.
XX PF 16-JUL-2002; 2002US-00196762.
XX PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 01-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 10-MAY-2001; 2001US-00854280.
```


PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090689P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 28-JUN-1998; 98US-00105413.
PR 28-JUN-1998; 98US-0090862P.
PR 28-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-010240P.
PR 25-SEP-1998; 98US-0102330P.
PR 25-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;


```
OY 2121 CCTTGGCTTTACCACTCTTCTCTTTTCTTATTAATAAAGTTGGTCTCCACCACTG 2180
D 2653 CTTTCTCTTCCCATCTCTTGTACACATTTTAATAAATAAGGCTTGGCTTCTCACTA 2712
OY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
D 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
OY 2241 AA 2242
D 2773 AA 2774

RESULT 602
ACD31315
ID ACD31315 standard; cDNA; 2846 BP.
XX
AC ACD31315;
XX
DT 30-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003032132-Al.
XX
PD 13-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184646.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080134P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
```

PR	26-JUN-1998;	98US-0090863P.	Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
PR	26-JUN-1998;	98US-0091010P.										
PR	01-JUL-1998;	98US-0091359P.	QY	2121	CCTTTGCTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG	2180						
PR	01-JUL-1998;	98US-0091544P.	DB	2653	CCTTTTCTTCCCTCCCATCTCTTGACACATTTTAAATAAATAGGGTGTGCTTCTTGAACTA	2712						
PR	02-JUL-1998;	98US-0091478P.										
PR	02-JUL-1998;	98US-0091486P.	QY	2181	NCTCCCAA	2240						
PR	02-JUL-1998;	98US-0091626P.	DB	2713	CAA	2772						
PR	02-JUL-1998;	98US-0091628P.										
PR	02-JUL-1998;	98US-0091632P.	QY	2241	AA	2242						
PR	04-JUL-1998;	98US-0094006P.	DB	2773	AA	2774						
PR	10-AUG-1998;	98US-0095282P.										
PR	10-AUG-1998;	98US-0095998P.										
PR	10-AUG-1998;	98US-0096012P.										
PR	17-AUG-1998;	98US-0096757P.										
PR	17-AUG-1998;	98US-0096766P.										
PR	17-AUG-1998;	98US-0096867P.										
PR	17-AUG-1998;	98US-0096891P.	RESULT 603									
PR	17-AUG-1998;	98US-0096897P.	ACFI7816									
PR	18-AUG-1998;	98US-0096949P.	ID	ACFI7816	standard; cDNA; 2846 BP.							
PR	18-AUG-1998;	98US-0096959P.	XX	AC	ACFI7816;							
PR	18-AUG-1998;	98US-0096959P.	XX	AC	ACFI7816;							
PR	18-AUG-1998;	98US-0097022P.	XX	DT	17-SEP-2003 (first entry)							
PR	26-AUG-1998;	98US-0097952P.	XX	DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.							
PR	26-AUG-1998;	98US-0097955P.	XX	DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.							
PR	26-AUG-1998;	98US-0097971P.	XX	XX	Human; PRO; secreted protein; transmembrane protein;							
PR	26-AUG-1998;	98US-0097974P.	XX	XX	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;							
PR	26-AUG-1998;	98US-0098014P.	KW	KW	chondrocyte; proliferation; differentiation; cartilage disorder;							
PR	01-SEP-1998;	98US-0098716P.	KW	KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;							
PR	01-SEP-1998;	98US-0098723P.	KW	KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;							
PR	02-SEP-1998;	98US-0098803P.	KW	KW	liver; drug screening; transgenic animal; genetic analysis;							
PR	02-SEP-1998;	98US-0098821P.	KW	KW	antiarthritic; vulnery; gene therapy; gene; ss.							
PR	02-SEP-1998;	98US-0098843P.	XX	XX								
PR	09-SEP-1998;	98US-0099602P.	OS	OS	Homo sapiens.							
PR	10-SEP-1998;	98US-0099741P.	XX	XX	US2003054462-A1.							
PR	10-SEP-1998;	98US-0099754P.	PN	PN	20-MAR-2003.							
PR	10-SEP-1998;	98US-0099763P.	XX	XX	17-JUL-2002; 2002US-00197694.							
PR	15-SEP-1998;	98US-0099812P.	PD	PD	16-SEP-1998; 98WO-US019330.							
PR	16-SEP-1998;	98US-0100662P.	XX	XX	25-AUG-1999; 99US-00380139.							
PR	16-SEP-1998;	98US-0101751P.	PR	PR	28-FEB-2001; 2001WO-US006520.							
PR	16-SEP-1998;	98US-01019330.	PR	PR	15-JAN-2002; 2002US-00052586.							
PR	17-SEP-1998;	98US-0100683P.	XX	XX	(GETH) GENENTECH INC.							
PR	17-SEP-1998;	98US-0100819P.	XX	XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;							
PR	17-SEP-1998;	98US-0100930P.	PA	PA	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;							
PR	18-SEP-1998;	98US-0101751P.	XX	XX	WPI; 2003-540608/51.							
PR	18-SEP-1998;	98US-0101751P.	DR	DR	P-PSDB; ABR96886.							
PR	18-SEP-1998;	98US-0101751P.	XX	XX	New isolated, secreted and transmembrane PRO polypeptides and nucleic							
PR	18-SEP-1998;	98US-0101751P.	PT	PT	acids, useful for diagnosing, preventing and/or treating tumors, such as							
PR	23-SEP-1998;	98US-0101471P.	PT	PT	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.							
PR	23-SEP-1998;	98US-0101472P.	XX	XX	Claim 2; Fig 169; 700pp; English.							
PR	23-SEP-1998;	98US-0101475P.	DR	DR	The invention relates to human PRO secreted/transmembrane polypeptides							
PR	23-SEP-1998;	98US-0101477P.	XX	XX	(ABR96802-ABR97106) and nucleic acids encoding them (ACFI7732-ACFI8036).							
PR	24-SEP-1998;	98US-0101738P.	CC	CC	The invention also relates to sequences at least 80% identical to the PRO							
PR	24-SEP-1998;	98US-0101739P.	CC	CC	nucleic acid and polypeptide sequences of the invention, recombinant							
PR	24-SEP-1998;	98US-0101743P.	CC	CC	vectors and host cells comprising a PRO nucleic acid, a method for the							
PR	24-SEP-1998;	98US-0101922P.	CC	CC	recombinant production of a PRO polypeptide, antibodies against a PRO							
PR	25-SEP-1998;	98US-0101786P.	CC	CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic							
PR	25-SEP-1998;	98US-0102207P.	CC	CC	acids encoding PRO polypeptides of the invention were initially							
PR	25-SEP-1998;	98US-0102240P.	CC	CC	identified via homology screening using consensus sequences based on the							
PR	25-SEP-1998;	98US-0102330P.	CC	CC	extracellular domain sequences from known secreted proteins. Human cDNA							
PR	25-SEP-1998;	98US-0102331P.	CC	CC	libraries containing sequences of interest were identified using							
PR	30-SEP-1998;	98US-0102487P.	CC	CC	oligonucleotides based on the consensus sequences, and cDNA clones were							
PR	30-SEP-1998;	98US-0102570P.	CC	CC	isolated and characterised. The PRO polypeptides are useful for							
PR	30-SEP-1998;	98US-0102571P.										
PR	01-OCT-1998;	98US-0102684P.										
PR	01-OCT-1998;	98US-0102687P.										
PR	02-OCT-1998;	98US-0102965P.										
PR	06-OCT-1998;	98US-0103258P.										
PR	06-OCT-1998;	98US-0103449P.										

```

RESULT 604
ADA38671
ID ADA38671 standard; cDNA; 2846 BP.
XX
XX AC ADA38671;
XX
XX DT 20-NOV-2003 (first entry)
XX
XX Human cDNA encoding secreted/transmembrane protein PRO1344.
XX
XX PRO; secreted protein; transmembrane protein; gene therapy; tumour;
XX cancer; human; ss; gene; colon cancer; lung cancer; breast cancer.
XX
XX Homo sapiens.
XX
XX US2003059780-A1.
XX
XX 27-MAR-2003.
XX
XX 14-NOV-2001; 2001US-00991854.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX

```

PR 02-JUL-1998;	98US-0091626P.	PR 01-DEC-1999;	99WO-US028301.
PR 02-JUL-1998;	98US-0091628P.	PR 01-DEC-1999;	99WO-US028634.
PR 02-JUL-1998;	98US-0091633P.	PR 16-DEC-1999;	99WO-US030095.
PR 02-JUL-1998;	98US-0091646P.	PR 20-DEC-1999;	99WO-US030911.
PR 02-JUL-1998;	98US-0091673P.	PR 05-JAN-2000;	2000WO-US000219.
PR 07-JUL-1998;	98US-0091978P.	PR 06-JAN-2000;	2000WO-US000376.
PR 07-JUL-1998;	98US-0091982P.	PR 11-FEB-2000;	2000WO-US003565.
PR 09-JUL-1998;	98US-0092182P.	PR 18-FEB-2000;	2000WO-US004341.
PR 10-JUL-1998;	98US-0092472P.	PR 22-FEB-2000;	2000WO-US004414.
PR 20-JUL-1998;	98US-0093339P.	PR 24-FEB-2000;	2000WO-US004914.
PR 30-JUL-1998;	98US-0094651P.	PR 24-FEB-2000;	2000WO-US005004.
PR 04-AUG-1998;	98US-0095282P.	PR 02-MAR-2000;	2000WO-US005841.
PR 04-AUG-1998;	98US-0095285P.	PR 10-MAR-2000;	2000WO-US006319.
PR 04-AUG-1998;	98US-0095301P.	PR 15-MAR-2000;	2000WO-US006884.
PR 04-AUG-1998;	98US-0095302P.	PR 20-MAR-2000;	2000WO-US007377.
PR 04-AUG-1998;	98US-0095318P.	PR 30-MAR-2000;	2000WO-US008439.
PR 04-AUG-1998;	98US-0095321P.	PR 15-MAY-2000;	2000WO-US013358.
PR 04-AUG-1998;	98US-0095325P.	PR 17-MAY-2000;	2000WO-US013705.
PR 10-AUG-1998;	98US-0095916P.	PR 22-MAY-2000;	2000WO-US014042.
PR 10-AUG-1998;	98US-0095929P.	PR 30-MAY-2000;	2000WO-US014941.
PR 10-AUG-1998;	98US-0096012P.	PR 02-JUN-2000;	2000WO-US015264.
PR 11-AUG-1998;	98US-0096143P.	PR 23-JUN-2000;	2000US-0213637P.
PR 11-AUG-1998;	98US-0096146P.	PR 28-JUL-2000;	2000WO-US020710.
PR 12-AUG-1998;	98US-0096329P.	PR 11-AUG-2000;	2000WO-US022031.
PR 17-AUG-1998;	98US-0096757P.	PR 23-AUG-2000;	2000WO-US023522.
PR 17-AUG-1998;	98US-0096766P.	PR 24-AUG-2000;	2000WO-US023328.
PR 17-AUG-1998;	98US-0096768P.	PR 07-SEP-2000;	2000US-0230978P.
PR 17-AUG-1998;	98US-0096773P.	PR 08-NOV-2000;	2000WO-US030952.
PR 17-AUG-1998;	98US-0096791P.	Query Match 3.0%; Score 66.6; DB 9; Length 2846;	
PR 17-AUG-1998;	98US-0096867P.	Best Local Similarity 71.3%; Pred. No. 0.00023;	
PR 17-AUG-1998;	98US-0096891P.	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
PR 17-AUG-1998;	98US-0096894P.		
PR 17-AUG-1998;	98US-0096895P.	QY 2121	CGTTTCCTTACCACTCTTCCTTTATCTTATTATAAAATGTTGGTCTCCACCACCTG 2180
PR 17-AUG-1998;	98US-0096897P.	DB 2653	CGTTTTCCTTCCCACTCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
PR 18-AUG-1998;	98US-0096949P.	QY 2181	NCTCCCAA 2240
PR 18-AUG-1998;	98US-0096950P.	DB 2713	CAAA 2772
PR 18-AUG-1998;	98US-0096959P.	QY 2241	AA 2242
PR 18-AUG-1998;	98US-0096960P.	DB 2773	AA 2774
PR 18-AUG-1998;	98US-0097022P.		
PR 18-AUG-1998;	98US-0097141P.		
PR 20-AUG-1998;	98US-0097218P.		
PR 24-AUG-1998;	98US-0097661P.		
PR 26-AUG-1998;	98US-0097952P.		
PR 26-AUG-1998;	98US-0097954P.		
PR 26-AUG-1998;	98US-0097955P.		
PR 26-AUG-1998;	98US-0097971P.		
PR 26-AUG-1998;	98US-0097974P.		
PR 26-AUG-1998;	98US-0097978P.		
PR 26-AUG-1998;	98US-0097979P.		
PR 26-AUG-1998;	98US-0098014P.		
PR 31-AUG-1998;	98US-0098525P.		
PR 16-SEP-1998;	98WO-US019330.		
PR 17-SEP-1998;	98US-0100858P.		
PR 17-SEP-1998;	98WO-US019437.		
PR 07-OCT-1998;	98WO-US021141.		
PR 01-DEC-1998;	98WO-US025108.		
PR 22-DEC-1998;	98US-0113296P.		
PR 05-JAN-1999;	99WO-US000106.		
PR 08-MAR-1999;	99WO-US005028.		
PR 12-MAR-1999;	99US-0123957P.		
PR 02-JUN-1999;	99WO-US012252.		
PR 23-JUN-1999;	99US-0141037P.		
PR 07-JUL-1999;	99US-0143048P.		
PR 20-JUL-1999;	99US-0144758P.		
PR 26-JUL-1999;	99US-0145698P.		
PR 28-JUL-1999;	99US-0146222P.		
PR 17-AUG-1999;	99US-0149396P.		
PR 15-SEP-1999;	99WO-US021090.		
PR 15-SEP-1999;	99WO-US021547.		
PR 08-OCT-1999;	99US-0158663P.		
PR 30-NOV-1999;	99WO-US028313.		
RESULT 605			
ACF32599			
ID	ACF32599 standard; cDNA; 2846 BP.		
XX	AC	ACF32599;	
XX	AC	ACF32599;	
DT	24-SEP-2003	(first entry)	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
XX	Human; PRO; secreted protein; transmembrane protein;		
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulnery; gene therapy; gene; ss.		
XX	Homo sapiens.		
OS	US2003064445-A1.		
XX	03-APR-2003.		
PN	12-JUL-2002; 2002US-00194363.		
XX	05-JUN-2000; 2000US-0209832P.		


```
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090433P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094005P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098718P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 09-SEP-1998; 98US-0098843P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.

PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGCTCCACACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACATTTTATAATAAATAGGCTTGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 608
ACF38169
ID ACF38169 standard; cDNA; 2846 BP.
XX ACF38169;
AC ACF38169;
DT 08-OCT-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO.169.
XX Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
OS Homo sapiens.
XX US2003068696-A1.
PN 10-APR-2003.
XX 09-JUL-2002; 2002US-00192014.
XX 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615873/58.
XX P-PSDB; AWM14681.
XX New secreted and transmembrane PRO nucleic acids, useful for the
PT manufacture of a medicament for diagnosing or treating tumors or for
XX tissue typing.
XX Claim 2; Fig 169; 700pp; English.
PS
```

XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM14597-ABM14901) and nucleic acids encoding them (ACF38085-ACF38389).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human CDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF38085-ACF38389 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTATTATTAATAAAATGTTGGTCTCCACCACGTG 2180
 DB 2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA 2712
 QY 2181 NTCCCAA 2240
 DB 2713 CAAAAAATAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 609
 ACF25105
 ID ACF25105 standard; cDNA; 2846 BP.
 XX
 AC ACF25105;
 DT
 DT 01-OCT-2003 (first entry)
 XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 XX antiarthritic; vulnertary; gene therapy; gene; ss.
 OS Homo sapiens.
 PN US2003068712-A1.
 XX 10-APR-2003.
 PD
 XX 17-JUL-2002; 2002US-00197693.
 PF
 XX 24-NOV-1997; 97US-0066466P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 25-AUG-1999; 99US-00380139.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Fan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-615882/58.
 DR P-PSDB; ABM04562.
 XX
 PT New secreted and transmembrane PRO nucleic acids, useful for the
 PT manufacture of a medicament for diagnosing or treating tumors or for
 PT tissue typing.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM04478-ABM04782) and nucleic acids encoding them (ACF25021-ACF25325).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF25021-ACF25325 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACP26921-ACF27225 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX	(GETH) GENENTECH INC.		RESULT 611
XX			ACF29461
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;		ID ACF29461 standard; cDNA; 2846 BP.
XX	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;		XX
XX			AC ACF29461;
XX			XX
DR	WPI; 2003-615889/58.		DT 20-SEP-2003 (first entry)
DR	P-PSDB; ABM06751.		XX
XX			DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or		XX
PT	PRO827, useful in molecular biology, chromosome and gene mapping, in		XX
PT	generating antisense RNA and DNA, and in gene therapy.		KW Human; PRO; secreted protein; transmembrane protein;
XX			extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX			chondrocyte; proliferation; differentiation; cartilage disorder;
XX			bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX			adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX			KW liver; drug screening; transgenic animal; genetic analysis;
PS	Claim 2; Fig 169; 699pp; English.		KW antiarthritic; vulnery; gene therapy; gene; ss.
XX			XX
XX	The invention relates to human PRO secreted/transmembrane polypeptides		OS Homo sapiens.
CC	(ABM06667-ABM06971) and nucleic acids encoding them (ACF26921-ACF27225).		XX
CC	The invention also relates to sequences at least 80% identical to the PRO		XX
CC	nucleic acid and polypeptide sequences of the invention, recombinant		XX
CC	vectors and host cells comprising a PRO nucleic acid, a method for the		XX
CC	recombinant production of a PRO polypeptide, antibodies against a PRO		PN US2003073174-A1.
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic		XX
CC	acids encoding PRO polypeptides of the invention were initially		XX
CC	identified via homology screening using consensus sequences based on the		PD 17-APR-2003.
CC	extracellular domain sequences from known secreted proteins. Human cDNA		XX
CC			27-JUN-2002: 2002US-00184541.

XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066456P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088336P.
PR 05-JUN-1998; 98US-0088147P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 11-JUN-1998; 98US-0088909P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 03-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.

```

PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCCCTTTATCTATTATTAATAAATGTTGGTCTCCCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGTCTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAA 2772

QY 2241 AA 2242
Db |||
2773 AA 2774

RESULT 612
ACD87695
ID ACD87695 standard; cDNA; 2846 BP.
XX
AC ACD87695;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
XX US2003068775-A1.
XX
PD 10-APR-2003.
XX
PF 29-JUL-2002; 2002US-00208029.
XX
XX 23-MAR-1999; 99US-0125775P.

```

```

PR 02-MAR-2000; 2000WO-US005841.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625481/59.
DR P-PSDB; ABO39231.
XX
PT Novel isolated PRO polypeptides e.g. PRO1079, PRO827 and PRO791, useful
PT for stimulating the release of TNF alpha from human blood and for
PT stimulating the proliferation or differentiation of chondrocyte cells.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCCCTTTATCTATTATTAATAAATGTTGGTCTCCCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAAGGTTGGTCTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAA 2772

QY 2241 AA 2242
Db |||
2773 AA 2774

RESULT 613
ACF76156
ID ACF76156 standard; cDNA; 2846 BP.
XX
XX ACF76156;
XX
AC ACF76156;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;

```

KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnery; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003104545-A1.
XX	
PD	05-JUN-2003.
XX	
PF	12-JUL-2002; 2002US-00194359.
XX	
PR	05-JUN-2000; 2000US-0209832P.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-658683/62.
DR	P-PSDB; ABM75496.
XX	
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT	molecular biology, chromosome and gene mapping, in generating antisense
PT	RNA and DNA, and in gene therapy.
XX	
PS	Claim 2; Fig 169; 700pp; English.
XX	
CC	The invention relates to human PRO secreted/transmembrane polypeptides
CC	(ABM75412-ABM75716) and nucleic acids encoding them (ACF76072-ACF76376)..
CC	The invention also relates to sequences at least 80% identical to the PRO
CC	nucleic acid and polypeptide sequences of the invention, recombinant
CC	vectors and host cells comprising a PRO nucleic acid, a method for the
CC	recombinant production of a PRO polypeptide, antibodies against a PRO
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC	acids encoding PRO polypeptides of the invention were initially
CC	identified via homology screening using consensus sequences based on the
CC	extracellular domain sequences from known secreted proteins. Human cDNA
CC	libraries containing sequences of interest were identified using
CC	oligonucleotides based on the consensus sequences, and cDNA clones were
CC	isolated and characterised. The PRO polypeptides are useful for
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC	human blood and may thus be used in the treatment of conditions in which
CC	enhanced TNF-alpha release would be beneficial. They are also useful for
CC	stimulating the proliferation or differentiation of chondrocytes and as
CC	such may be used in the treatment of various bone and/or cartilage
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may
CC	be used in a method for detecting the presence of a tumour (e.g., an
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC	method involves comparing the level of expression of the PRO polypeptide
CC	in test and control samples, where a higher level of expression of PRO
CC	polypeptide in the test sample as compared to the control sample is
CC	indicative of the presence of a tumour. The PRO polypeptides are
CC	additionally useful for in drug screening to identify agonists and
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC	gene mapping, in the generation of antisense RNA and DNA and in gene
CC	therapy. The nucleic acids can also be used for mapping genes encoding
CC	PRO polypeptides, for genetic analysis of individuals with genetic
CC	disorders, and for generating either transgenic animals or knock-out
CC	animals which are useful in the development and screening of
CC	therapeutically useful compounds. Sequences ACF75412-ACF75716 represent
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC	invention. Note: the sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX	
SO	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other

Query Match	3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity	71.3%; Pred. No. 0.00023;
Matches	87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CGTTTGCTTTTACCACACTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CGTTTTCCTTCCCACTCTTGACACATTTTAATAAATAGGGTTGGCTTCGAACTA	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	

RESULT 614

ACF49448

ACF49448 standard; cDNA; 2846 BP.

ACF49448;

04-OCT-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

Human sapiens.

US2003104541-A1.

05-JUN-2003.

26-JUN-2002; 2002US-00183018.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

17-OCT-1997; 97US-0062250P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

28-OCT-1997; 97US-0063540P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063734P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

13-NOV-1997; 97US-0065311P.

21-NOV-1997; 97US-0066120P.

24-NOV-1997; 97US-0066466P.

24-NOV-1997; 97US-0066772P.

11-DEC-1997; 97US-0069335P.

12-DEC-1997; 97US-0069425P.

17-DEC-1997; 97US-0069870P.

18-DEC-1997; 97US-0068017P.

10-MAR-1998; 98US-0077450P.

11-MAR-1998; 98US-0077632P.

11-MAR-1998; 98US-0077649P.

20-MAR-1998; 98US-0078986P.

20-MAR-1998; 98US-0078939P.

27-MAR-1998; 98US-0079664P.

31-MAR-1998; 98US-0079786P.

31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081193P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097957P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101058P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.

```
PR 01-OCT-1998; 98US-0102687P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGTTTACCACCTCTTCCCTTTATCTATATATAAAAGTTGGTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 615
ACF43905
ID ACF43905 standard; cDNA; 2846 BP.
XX AC
AC ACF43905;
XX AC
DT 03-OCT-2003 (first entry)
XX AC
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX AC
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX OS
XX Homo sapiens.
XX AC
XX US2003104554-A1.
XX AC
XX 05-JUN-2003.
XX AC
XX 24-JUL-2002; 2002US-00205508.
XX AC
XX 10-JUN-1998; 98US-0088826P.
XX AC
XX 02-JUN-1999; 99WO-US012252.
XX AC
XX 25-AUG-1999; 99US-00380137.
XX AC
XX 30-MAR-2000; 2000WO-US008439.
XX AC
XX 28-FEB-2001; 2001WO-US006520.
XX AC
XX 15-JAN-2002; 2002US-00052586.
XX AC
XX (GETH ) GENENTECH INC.
XX AC
XX Baker KP, Chen J, Deanoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WL, Zhang Z;
XX AC
XX WPI; 2003-670250/63.
XX AC
XX P-PSDB; ABM19930.
XX AC
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
XX colon, breast, prostate, rectal, cervical or liver tumors.
XX AC
XX Claim 2; Fig 169; 700pp; English.
XX AC
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM19846-ABM20150) and nucleic acids encoding them (ACF43821-ACF44125).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX AC
```

```
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g. an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF43821-ACF44125 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX AC
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGTTTACCACCTCTTCCCTTTATCTATATATAAAAGTTGGTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 616
ACH06250
ID ACH06250 standard; cDNA; 2846 BP.
XX AC
AC ACH06250;
XX AC
DT 08-OCT-2003 (first entry)
XX AC
XX cDNA encoding human PRO polypeptide #85.
XX AC
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; tumour necrosis factor-alpha;
XX TNF-alpha; proliferation; differentiation; chondrocyte cell; cytostatic;
XX gene therapy; gene; ss.
XX AC
XX Homo sapiens.
XX AC
XX US2003049762-A1.
XX AC
XX 13-MAR-2003.
XX AC
XX 19-JUL-2002; 2002US-00199314.
XX AC
```

```
XX 23-SEP-1998; 98US-0101472P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-669841/63.
DR P-PSDB; ABO46836.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, or for preparing a medicament for treating a condition that
PT is responsive to the PRO polypeptide or anti-PRO antibody.
XX Claim 2; Fig 169; 700pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polynucleotide sequences are useful in molecular biology as hybridisation
CC probes, in chromosome and gene mapping, in generating antisense RNA and
CC DNA, and in gene therapy. The PRO polypeptides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors for the detection
CC of tumours. They are also useful for stimulating the release of tumour
CC necrosis factor (TNF)-alpha from human blood, or for stimulating the
CC proliferation or differentiation of chondrocyte cells. The anti-PRO
CC antibodies may be used in diagnostic assays for PRO polypeptides, or for
CC the affinity purification of PRO polypeptides from recombinant cell
CC culture or natural sources. ACH06166-ACH06470 represent cDNA sequences
CC encoding the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsdIDentry.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTCTTCTTATCTATTAATAAATGTTGCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 617
ACH06557
ID ACH06557 standard; cDNA; 2846 BP.
XX ACH06557;
XX 08-OCT-2003 (first entry)
XX cDNA encoding human PRO polypeptide #85.
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; molecular weight marker;
XX protein electrophoresis; affinity purification; tumour; adrenal; lung;
XX colon; breast; prostate; rectal; cervical; liver; cancer; cytostatic;
XX gene therapy; gene; ss.
XX
```

```
OS Homo sapiens.
XX US2003049765-A1.
XX 13-MAR-2003.
XX 18-JUL-2002; 2002US-00199666.
XX 05-JUN-1998; 98US-0088217P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-669842/63.
DR P-PSDB; ABO47141.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 169; 700pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polynucleotide sequences are useful in molecular biology as hybridisation
CC probes, in chromosome and gene mapping, in generating antisense RNA and
CC DNA, and in gene therapy. The PRO polypeptides are useful for the
CC diagnosis, prevention and/or treatment of tumours. They are also useful
CC as molecular weight markers for protein electrophoresis purposes. The
CC anti-PRO antibodies may be used in diagnostic assays for PRO
CC polypeptides, or for the affinity purification of PRO polypeptides from
CC recombinant cell culture or natural sources. ACH06473-ACH06777 represent
CC cDNA sequences encoding the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic format
CC directly from the USPTO web site at seqdata.uspto.gov/psipsdIDentry.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGGCTTTACCACTCTCTTCTTATCTATTAATAAATGTTGCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 618
ADA83238
ID ADA83238 standard; cDNA; 2846 BP.
XX ADA83238;
XX AC ADA83238;
XX 20-NOV-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX
```

KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.

XX Homo sapiens.

OS US2003049752-A1.

XX 13-MAR-2003.

XX 17-JUL-2002; 2002US-00197705.

XX 20-MAR-1998; 98US-0078886P.

PR 08-MAR-1999; 99WO-US005028.

PR 25-AUG-1999; 99US-00380138.

PR 28-FEB-2001; 2001WO-US0008520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786862/74.

DR P-PSDB; ADA83239.

XX New secreted and transmembrane mammalian PRO polypeptides, useful in the

PT diagnosis and treatment of cancer, and in the screening of drugs which

PT can affect a PRO polypeptide-associated disease or disorder.

XX Claim 2; Fig 169; 700pp; English.

XX The invention discloses human nucleic acids encoding secreted and

CC transmembrane (PRO) polypeptides, with or without their associated signal

CC peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO

CC polypeptide, a method for detecting the presence of a tumour in a mammal

CC and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome

CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as

CC molecular weight markers for protein electrophoresis purposes, for

CC chromosome identification, as chromosome markers, as therapeutic agents,

CC for stimulating the release of TNF-alpha from human blood, for

CC stimulating the proliferation or differentiation of chondrocytes and

CC detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC The PRO polypeptides and nucleic acids may also be used diagnostically

CC for tissue typing. The sequence presented is a cDNA encoding one the PRO

CC polypeptides of the invention. Note: The sequence data for this patent
 CC can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html.

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;

XX Best Local Similarity 71.3%; Pred. No. 0.00023;

XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

XX 2121 CCTTGGTTTACCACTCTTCCCTTTTATCTATTATAAAATGTTGGTCTCCACACTG 2180

XX 2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAATGAGGTTTGGTCTTGAAC 2712

XX 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240

XX 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2772

XX 2241 AA 2242

Db 2773 AA 2774

RESULT 619

ACC92613

ID ACC92613 standard; cDNA; 2846 BP.

XX ACC92613;

XX 22-AUG-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

XX chondrocyte; proliferation; differentiation; cartilage disorder;

XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

XX adrenal tumour; lung; colon; breast; prostate; kidney; cervix;

XX liver; drug screening; transgenic animal; genetic analysis;

XX antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

XX US2003032133-A1.

XX 13-FEB-2003.

XX 28-JUN-2002; 2002US-00184647.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 17-OCT-1997; 97US-0062250P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063120P.

XX 28-OCT-1997; 97US-0063121P.

XX 28-OCT-1997; 97US-0063540P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063734P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066120P.

XX 24-NOV-1997; 97US-0066466P.

XX 11-DEC-1997; 97US-0066772P.

XX 12-DEC-1997; 97US-0069425P.

XX 17-DEC-1997; 97US-0069870P.

XX 18-DEC-1997; 97US-0068017P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077649P.

XX 20-MAR-1998; 98US-0078886P.

XX 20-MAR-1998; 98US-0078939P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079786P.

XX 31-MAR-1998; 98US-0080107P.

XX 31-MAR-1998; 98US-0080194P.

XX 01-APR-1998; 98US-0080327P.

XX 01-APR-1998; 98US-0080333P.

XX 08-APR-1998; 98US-0081049P.

XX 08-APR-1998; 98US-0081070P.

XX 09-APR-1998; 98US-0081195P.

XX 15-APR-1998; 98US-0081838P.

XX 21-APR-1998; 98US-0082568P.

XX 21-APR-1998; 98US-0082569P.

XX 22-APR-1998; 98US-0082704P.

XX 22-APR-1998; 98US-0082797P.

XX 28-APR-1998; 98US-0083322P.

XX 29-APR-1998; 98US-0083495P.

XX 29-APR-1998; 98US-0083496P.

XX 29-APR-1998; 98US-0083499P.

PR	02-JUL-1998,	98US-00916321P,
PR	24-JUL-1998,	98US-0094006P,
PR	04-AUG-1998,	98US-0095282P,
PR	10-AUG-1998,	98US-0095998P,
PR	10-AUG-1998,	98US-0096012P,
PR	17-AUG-1998,	98US-0096757P,
PR	17-AUG-1998,	98US-0096766P,
PR	17-AUG-1998,	98US-0096867P,
PR	17-AUG-1998,	98US-0096891P,
PR	17-AUG-1998,	98US-0096897P,
PR	18-AUG-1998,	98US-0096934P,
PR	18-AUG-1998,	98US-0096959P,
PR	18-AUG-1998,	98US-0097022P,
PR	26-AUG-1998,	98US-0097952P,
PR	26-AUG-1998,	98US-0097954P,
PR	26-AUG-1998,	98US-0097955P,
PR	26-AUG-1998,	98US-0097971P,
PR	26-AUG-1998,	98US-0097974P,
PR	26-AUG-1998,	98US-0098014P,
PR	01-SEP-1998,	98US-0098716P,
PR	01-SEP-1998,	98US-0098723P,
PR	02-SEP-1998,	98US-0098803P,
PR	02-SEP-1998,	98US-0098821P,
PR	02-SEP-1998,	98US-0098843P,
PR	09-SEP-1998,	98US-0099602P,
PR	10-SEP-1998,	98US-0099741P,
PR	10-SEP-1998,	98US-0099754P,
PR	10-SEP-1998,	98US-0099763P,
PR	10-SEP-1998,	98US-0099812P,
PR	15-SEP-1998,	98US-0100388P,
PR	16-SEP-1998,	98US-0100662P,
PR	16-SEP-1998,	98US-0100664P,
PR	16-SEP-1998,	98US-0101751P,
PR	17-SEP-1998,	98WO-US019330,
PR	17-SEP-1998,	98US-0100683P,
PR	17-SEP-1998,	98US-0100684P,
PR	17-SEP-1998,	98US-0100919P,
PR	17-SEP-1998,	98US-0100930P,
PR	18-SEP-1998,	98US-0100849P,
PR	18-SEP-1998,	98US-0101014P,
PR	18-SEP-1998,	98US-0101068P,
PR	23-SEP-1998,	98US-0101471P,
PR	23-SEP-1998,	98US-0101472P,
PR	23-SEP-1998,	98US-0101475P,
PR	23-SEP-1998,	98US-0101477P,
PR	24-SEP-1998,	98US-0101738P,
PR	24-SEP-1998,	98US-0101739P,
PR	24-SEP-1998,	98US-0101743P,
PR	24-SEP-1998,	98US-0101922P,
PR	25-SEP-1998,	98US-0101786P,
PR	25-SEP-1998,	98US-0103207P,
PR	25-SEP-1998,	98US-0103240P,
PR	25-SEP-1998,	98US-0103330P,
PR	25-SEP-1998,	98US-0103331P,
PR	30-SEP-1998,	98US-0104877P,
PR	30-SEP-1998,	98US-0102570P,
PR	30-SEP-1998,	98US-0102571P,
PR	01-OCT-1998,	98US-0102684P,
PR	01-OCT-1998,	98US-0102687P,

	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Db	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTTATTAATAAAATATGTTGGTCTCTCGACCACTG																														
Qy	CGTTTGGCTTACGACGCTCTTCCCTTTTATCTT																														

DB 2773 AA 2774

RESULT 620
ACC93227
ID ACC93227 standard; cDNA; 2846 BP.
XX
AC ACC93227;
XX
DT 22-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032136-A1.
XX
PD 13-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00187596.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083497P.
PR 29-APR-1998; 98US-0083498P.
PR 29-APR-1998; 98US-0083499P.
PR 05-MAY-1998; 98US-0083599P.
PR 06-MAY-1998; 98US-0083666P.
PR 07-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087599P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089553P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 28-JUN-1998; 98US-00105413.
PR 28-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.

```
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

```
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCITTTGTTTACCACCTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCCACCACTG 2180
Db 2653 CCITTTCTCCCATCTCTGTACATTTTATAAAATAGGTTGGCTTCGACTA 2712

Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
```

```
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 621
ACF19272
ID ACF19272 standard; cDNA; 2846 BP.
XX
AC ACF19272;
XX
DT 17-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
US2003036129-A1.
XX
PD 20-FEB-2003.
XX
XX 28-JUN-2002; 2002US-00184617.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081070P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
```


OY 2241 AA 2242
Db 2773 AA 2774

RESULT 622
ACD12963
ID ACD12963 standard; cDNA; 2846 BP.
XX
XX ACD12963;
XX
XX 17-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX
XX US2003040053-A1.
XX
XX 27-FEB-2003.
XX
XX 17-JUN-2002; 2002US-00173708.
XX
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 29-OCT-1997; 97US-0063564P.
PR 31-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069445P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.

```
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-U019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match
Best Local Similarity 3.0%; Score 66.6; DB 9; Length 2846;
Matches 87; Conservative 71.3%; Pred. No. 0.00023;
Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGTTTACCACTCTTTCCTTTTATCTATTATATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCCTTCCCACTCTTGACACATTTTATAAAATAGGTTGGCTTCGAACTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
|||||
|||||
```

```
Db 2713 CAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 623
ACF06421
ID ACF06421 standard; cDNA; 2846 BP.
AC ACF06421;
XX
XX 13-SEP-2003 (first entry)
DT
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003040057-A1.
XX
PD 27-FEB-2003.
XX
PF 24-JUN-2002; 2002US-00179507.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
```

PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088039P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088865P.
PR 12-JUN-1998; 98US-0089030P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTTCCCTTTATCTATTATAAATGCTGCTCCCACTG 2180
Db 2653 CCTTTCTTTCCCATCTCTTGACACATTTTATAAATAAGGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240

```

Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY      2241 AA 2242
Db      2773 AA 2774

RESULT 624
ACC94455
ID ACC94455 standard; cDNA; 2846 BP.
XX
AC ACC94455;
XX
DT 29-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003054467-A1.
XX
PD 20-MAR-2003.
XX
PF 18-JUL-2002; 2002US-00199458.
XX
PR 25-JUN-1998; 98US-0090694P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-479873/45.
DR P-PSDB; ABR73402.
XX
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR73318-ABR73622) and nucleic acids encoding them (ACC94371-ACC94675).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may

```

```

CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide.
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC94371-ACC94675 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTACACACTCTTCTTTCTTTATCTTATTAATAAAATGTTGTCCTCCACCACTG 2180
Db 2653 CCTTTTCCTTCCCATCTCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 625
ACC97883
ID ACC97883 standard; cDNA; 2846 BP.
XX
AC ACC97883;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003044932-A1.
XX
PD 06-MAR-2003.
XX
DE 09-JUL-2002; 2002US-00192010.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063340P.
PR 28-OCT-1997; 97US-0063541P.

```


PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069435P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088032P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089589P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.

```

PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102884P.
PR 01-OCT-1998; 98US-0102887P.
PR 01-OCT-1998; 98US-0102887P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGGTTTACACACTTCTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CTTTTCCTCCCATCTCTGTACACATTTTAAATAAATAGGTTGGCTTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 626
ACC94148
ID ACC94148 standard; cDNA; 2846 BP.
XX
AC ACC94148;
XX
DT 22-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003027270-A1.
XX
PD 06-FEB-2003.
XX
PF 19-JUN-2002; 2002US-00175746.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 20-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 05-MAY-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 03-JUN-1998; 98US-0088217P.
PR 03-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.

```

PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100919P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089030P.	PR	18-SEP-1998;	98US-0100849P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101068P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101477P.
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101738P.
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090435P.	PR	25-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090444P.	PR	25-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090535P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102487P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090694P.			
PR	25-JUN-1998;	98US-0090695P.			
PR	25-JUN-1998;	98US-0090696P.			
PR	26-JUN-1998;	98US-00105413.			
PR	26-JUN-1998;	98US-0090862P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-0091359P.			
PR	01-JUL-1998;	98US-0091544P.			
PR	02-JUL-1998;	98US-0091478P.			
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091626P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091632P.			
PR	24-JUL-1998;	98US-0094006P.			
PR	04-AUG-1998;	98US-0095282P.			
PR	10-AUG-1998;	98US-0095988P.			
PR	10-AUG-1998;	98US-0096012P.			
PR	17-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
PR	17-AUG-1998;	98US-0096867P.			
PR	17-AUG-1998;	98US-0096891P.			
PR	17-AUG-1998;	98US-0096897P.			
PR	18-AUG-1998;	98US-0096949P.			
PR	18-AUG-1998;	98US-0096959P.			
PR	18-AUG-1998;	98US-0097022P.			
PR	26-AUG-1998;	98US-0097952P.			
PR	26-AUG-1998;	98US-0097954P.			
PR	26-AUG-1998;	98US-0097955P.			
PR	26-AUG-1998;	98US-0097971P.			
PR	26-AUG-1998;	98US-0097974P.			
PR	26-AUG-1998;	98US-0098014P.			
PR	01-SEP-1998;	98US-0098716P.			
PR	01-SEP-1998;	98US-0098723P.			
PR	02-SEP-1998;	98US-0098803P.			
PR	02-SEP-1998;	98US-0098821P.			
PR	02-SEP-1998;	98US-0098843P.			
PR	09-SEP-1998;	98US-0099602P.			
PR	10-SEP-1998;	98US-0099741P.			
PR	10-SEP-1998;	98US-0099754P.			
PR	10-SEP-1998;	98US-0099763P.			
PR	10-SEP-1998;	98US-0099812P.			</

```
PA (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-503630/47.
DR P-PSDB; ABM18163.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGGTTTACACTCTTTCCTTTTATCTATTATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTAATAAAATGAGGGTTGGCTTCTGACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 628
ACD31008
ID ACD31008 standard; cDNA; 2846 BP.
```

```
XX ACD31008;
AC 30-AUG-2003 (first entry)
DT Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS US2003032126-A1.
XX 13-FEB-2003.
XX 26-JUN-2002; 2002US-00183010.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 18-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 06-MAY-1998; 98US-0084366P.
PR 07-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
```

PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.	Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.					
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.					
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.					
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.					
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.					
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.					
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.					
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.					
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.					
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.					
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.					
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.					
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.					
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.					
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.					
PR	05-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.					
PR	10-JUN-1998;	98US-0088722P.	PR	10-SEP-1998;	98US-0099812P.					
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0100388P.					
PR	10-JUN-1998;	98US-0088740P.	PR	15-SEP-1998;	98US-0100388P.					
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100662P.					
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0100664P.					
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.					
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-01019330.					
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100683P.					
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.					
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.					
PR	12-JUN-1998;	98US-0089090P.	PR	17-SEP-1998;	98US-0100930P.					
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100849P.					
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101014P.					
PR	16-JUN-1998;	98US-0089514P.	PR	18-SEP-1998;	98US-0101068P.					
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101471P.					
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101472P.					
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101475P.					
PR	18-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101477P.					
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101738P.					
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101739P.					
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101743P.					
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101922P.					

Db 2653 CCTTTTCTCCCTCTCTGTACACATTTTAAATAAAGGCTTGGCTTGAACCTA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAA 2772

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 631
 ACF14874

ID ACF14874 standard; cDNA; 2846 BP.

AC ACF14874;

DT 02-OCT-2003 (first entry)

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

DE Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

XX US2003059879-A1.

XX 27-MAR-2003.

XX 12-JUL-2002; 2002US-00194456.

XX 15-SEP-2000; 2000US-0232887P.

XX 28-SEP-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-540681/51.

XX P-ESDB; ABR94079.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for diagnosing, preventing and/or treating tumors, such as
 PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABR93995-ABR94299) and nucleic acids encoding them (ACF14790-ACF15094).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF14790-ACF15094 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGTTGCTCCACCTG 2180

Db 2653 CCTTTTCTTTCCCATCTCTGTACACATTTTAATAAAATAGGCTTCTGTAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 632

ADA92792

ID ADA92792 standard; cDNA; 2846 BP.

AC ADA92792;

XX 20-NOV-2003 (first entry)

XX Human cDNA encoding secreted/transmembrane protein PRO1344.

XX PRO; secreted protein; transmembrane protein;

XX hypertrophy of neonatal heart; angiogenesis;

XX vascular endothelial growth factor; VEGF-stimulated proliferation;

XX endothelial cell; T-lymphocyte proliferation; retinal neuron;

XX c-fos induction; adipocyte cell; chondrocyte differentiation;

XX pancreatic beta-cell precursor differentiation; gene therapy; tumour;

XX cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;

XX rod photoreceptor cell.

XX Homo sapiens.

XX US2003060407-A1.

XX 27-MAR-2003.

XX 14-NOV-2001; 2001US-00990440.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.


```
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015254.
PR 23-JUN-2000; 2000US-0213637P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTAGCACTCTTCTTTATCTATTAATAAATGTGTGCTCCCACTG 2180
Db 2653 CTTTTCCTCCCATCTCTTGTACACATTTTATAAATAAGGTTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 633
ACF01606
ID ACF01606 standard; cDNA; 2846 BP.
XX
AC ACF01606;
XX
DT 05-SEP-2003. (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003049738-A1.
XX
XX 13-MAR-2003.
XX
XX 27-JUN-2002; 2002US-00184619.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0022250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 29-OCT-1997; 97US-0063564P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0065120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
```

PR 10-JUN-1998;	98US-0088826P.
PR 11-JUN-1998;	98US-0088861P.
PR 11-JUN-1998;	98US-0088863P.
PR 11-JUN-1998;	98US-0088876P.
PR 12-JUN-1998;	98US-0089090P.
PR 12-JUN-1998;	98US-0089105P.
PR 16-JUN-1998;	98US-0089512P.
PR 16-JUN-1998;	98US-0089514P.
PR 16-JUN-1998;	98US-0089538P.
PR 17-JUN-1998;	98US-0089598P.
PR 17-JUN-1998;	98US-0089653P.
PR 18-JUN-1998;	98US-0089908P.
PR 19-JUN-1998;	98US-0089952P.
PR 22-JUN-1998;	98US-0090246P.
PR 22-JUN-1998;	98US-0090352P.
PR 22-JUN-1998;	98US-0090354P.
PR 24-JUN-1998;	98US-0090435P.
PR 24-JUN-1998;	98US-0090444P.
PR 24-JUN-1998;	98US-0090461P.
PR 24-JUN-1998;	98US-0090535P.
PR 24-JUN-1998;	98US-0090540P.
PR 25-JUN-1998;	98US-0090676P.
PR 25-JUN-1998;	98US-0090678P.
PR 25-JUN-1998;	98US-0090688P.
PR 25-JUN-1998;	98US-0090690P.
PR 25-JUN-1998;	98US-0090694P.
PR 25-JUN-1998;	98US-0090695P.
PR 25-JUN-1998;	98US-0090696P.
PR 26-JUN-1998;	98US-00105413
PR 26-JUN-1998;	98US-0090862P.
PR 26-JUN-1998;	98US-0090863P.
PR 26-JUN-1998;	98US-0091010P.
PR 01-JUL-1998;	98US-0091359P.
PR 01-JUL-1998;	98US-0091544P.
PR 02-JUL-1998;	98US-0091478P.
PR 02-JUL-1998;	98US-0091486P.
PR 02-JUL-1998;	98US-0091626P.
PR 02-JUL-1998;	98US-0091628P.
PR 02-JUL-1998;	98US-0091632P.
PR 24-JUL-1998;	98US-0094006P.
PR 04-AUG-1998;	98US-0095282P.
PR 10-AUG-1998;	98US-0095998P.
PR 10-AUG-1998;	98US-0096012P.
PR 17-AUG-1998;	98US-0096757P.
PR 17-AUG-1998;	98US-0096756P.
PR 17-AUG-1998;	98US-0096891P.
PR 17-AUG-1998;	98US-0096897P.
PR 18-AUG-1998;	98US-0096949P.
PR 18-AUG-1998;	98US-0096959P.
PR 18-AUG-1998;	98US-0097022P.
PR 26-AUG-1998;	98US-0097952P.
PR 26-AUG-1998;	98US-0097954P.
PR 26-AUG-1998;	98US-0097955P.
PR 26-AUG-1998;	98US-0097971P.
PR 26-AUG-1998;	98US-0097974P.
PR 01-SEP-1998;	98US-0098014P.
PR 01-SEP-1998;	98US-00980716P.
PR 01-SEP-1998;	98US-0098723P.
PR 02-SEP-1998;	98US-0098803P.
PR 02-SEP-1998;	98US-0098821P.
PR 02-SEP-1998;	98US-0098843P.
PR 09-SEP-1998;	98US-0099602P.
PR 10-SEP-1998;	98US-0099741P.
PR 10-SEP-1998;	98US-0099754P.
PR 10-SEP-1998;	98US-0099763P.
PR 15-SEP-1998;	98US-0099812P.
PR 16-SEP-1998;	98US-0100388P.
PR 16-SEP-1998;	98US-0100662P.
PR 16-SEP-1998;	98US-0100664P.
PR 16-SEP-1998;	98US-0101751P.
PR 16-SEP-1998;	98WO-US019330.
PR 17-SEP-1998;	98US-0100683P.
PR 17-SEP-1998;	98US-0100684P.
PR 17-SEP-1998;	98US-0100913P.
PR 17-SEP-1998;	98US-0100930P.
PR 18-SEP-1998;	98US-0100849P.
PR 18-SEP-1998;	98US-0101014P.
PR 18-SEP-1998;	98US-0101068P.
PR 23-SEP-1998;	98US-0101471P.
PR 23-SEP-1998;	98US-0101472P.
PR 23-SEP-1998;	98US-0101475P.
PR 23-SEP-1998;	98US-0101477P.
PR 24-SEP-1998;	98US-0101738P.
PR 24-SEP-1998;	98US-0101739P.
PR 24-SEP-1998;	98US-0101743P.
PR 24-SEP-1998;	98US-0101922P.
PR 25-SEP-1998;	98US-0101786P.
PR 29-SEP-1998;	98US-0102207P.
PR 29-SEP-1998;	98US-0102240P.
PR 29-SEP-1998;	98US-0102330P.
PR 29-SEP-1998;	98US-0102331P.
PR 30-SEP-1998;	98US-0102487P.
PR 30-SEP-1998;	98US-0102570P.
PR 30-SEP-1998;	98US-0102571P.
PR 01-OCT-1998;	98US-0102684P.
PR 01-OCT-1998;	98US-0102687P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;	
Best Local Similarity 71.3%; Pred. No. 0.00023;	
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
QY 2121 CCTTTGCTTTTACCACTCTTCTCTTTTATCTATTATATAAAATGTTGGTCTCCACACTG 2180	
DB 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712	
QY 2181 NCTCCCAAA 2240	
DB 2713 CAAAAAATAAA 2772	
QY 2241 AA 2242	
DB 2773 AA 2774	
RESULT 634	
ACF31678	
ID ACF31678 standard; cDNA; 2846 BP.	
XX AC ACF31678;	
XX 24-SEP-2003 (first entry)	
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX Human; PRO; secreted protein; transmembrane protein;	
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
KW chondrocyte; proliferation; differentiation; cartilage disorder;	
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
KW liver; drug screening; transgenic animal; genetic analysis;	
XX antiarthritic; vulnery; gene therapy; gene; ss.	
OS Homo sapiens.	
XX US2003064469-A1.	
PN 03-APR-2003.	
PD 29-JUL-2002; 2002US-00208027.	
XX 11-APR-2000; 2000US-0196000P.	
PR 28-FEB-2001; 2001WO-US006520.	
PR 15-JAN-2002; 2002US-00052586.	
XX	

PA (GETH) GENENTECH INC.
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-567185/53.
 DR P-PSDB; ABM11326.
 XX
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM11242-ABM11546) and nucleic acids encoding them (ACF31594-ACF31898).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF31594-ACF31898 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTATTATTAATAAATGTGCTCCACCACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAAATAAATGAAGGTTGGCTTCTGAAC 2712
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2181 NCTCCCAAA 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAA 2772
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2241 AA 2242
 ||
 Db 2773 AA 2774

ACD67355
 ID ACD67355 standard; cDNA; 2846 BP.
 XX
 AC ACD67355;
 XX
 DT 17-SEP-2003 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #85.
 XX
 KW Human; PRO polypeptide; secreted protein; transmembrane protein; tumour;
 KW chondrocyte proliferation chondrocyte differentiation;
 KW tumour necrosis factor-alpha; chromosome mapping; gene mapping;
 KW molecular weight marker; protein electrophoresis; cytostatic;
 KW affinity purification; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FN US2003064453-A1.
 XX
 PD 03-APR-2003.
 XX
 PF 17-JUL-2002; 2002US-00197710.
 XX
 PR 07-MAY-1998; 98US-0084640P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-605859/57.
 DR P-PSDB; ABO32933.
 XX
 PT New secreted and transmembrane PRO polypeptides, useful in gene therapy,
 PT detecting a tumor, stimulating the release of tumor necrosis factor-alpha
 PT and stimulating the proliferation or differentiation of chondrocyte
 PT cells.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO polypeptide
 CC and polynucleotide sequences are useful for detecting the presence of
 CC tumours in a mammal, stimulating proliferation or differentiation of
 CC chondrocyte cells, and stimulating the release of tumour necrosis factor-
 CC alpha from human blood. The PRO polynucleotide sequences are useful in
 CC molecular biology as hybridisation probes, in chromosome and gene
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
 CC PRO polypeptides are useful as molecular weight markers for protein
 CC electrophoresis purposes. Anti-PRO antibodies may be used in diagnostic
 CC assays for PRO polypeptides, or for the affinity purification of PRO
 CC polypeptides from recombinant cell culture or natural sources. ACD67271-
 CC ACD67375 represent cDNA sequences encoding the human PRO polypeptides of
 CC the invention. Note: The sequence data for this patent was obtained in
 CC electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipsIDentry.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 Qy 2121 CCTTGGCTTTACCACTCTTCTTCTTTATCTATTATTAATAAATGTGCTCCACCACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAAATAAATGAAGGTTGGCTTCTGAAC 2712
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2181 NCTCCCAAA 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAA 2772
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2241 AA 2242
 ||
 Db 2773 AA 2774

DB 2713 CAAAAA
QY 2241 AA 2242
DB 2773 AA 2774

|||||
2713 CAAAAA
2241 AA 2242
2773 AA 2774

|||||
2713 CAAAAA
2241 AA 2242
2773 AA 2774

RESULT 636
ACD48545
ID ACD48545 standard; cDNA; 2846 BP.

ACD48545;
05-OCT-2003 (first entry)
Human secreted/transmembrane protein (PRO) cDNA #85.

Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
prostate tumour; rectal tumour; cervical tumour; liver tumour.

Homo sapiens.
US2003064466-A1.
03-APR-2003.
29-JUL-2002; 2002US-00207914.
30-OCT-1998; 98US-0106464P.
01-SEP-1999; 99WO-US020111.
18-OCT-1999; 99US-00403297.
18-FEB-2000; 2000WO-US004342.
24-AUG-2000; 2000WO-US023328.
01-DEC-2000; 2000WO-US032878.
28-FEB-2001; 2001WO-US006520.
15-JAN-2002; 2002US-00052586.
(GETH) GENENTECH INC.
Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-605865/57.
P-PSDB; ABO30639.
New secreted and transmembrane PRO polypeptides and nucleic acids
encoding the polypeptides, useful in gene therapy, chromosome
identification, tissue typing, or as hybridization probes in chromosome
and gene mapping.
Claim 2; Fig 169; 700pp; English.
The invention discloses human nucleic acids encoding secreted and
transmembrane (PRO) polypeptides, with or without their associated signal
peptide. Also disclosed is an antibody that specifically binds to the PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor alpha (TNF-alpha) from human blood by contacting the blood with a
PRO polypeptide, a method for stimulating the proliferation of
differentiation of chondrocyte cells by contacting the cells with a PRO
polypeptide, a method for detecting the presence of a tumour in a mammal
and an oligonucleotide probe derived from any of the PRO nucleotide
sequences. The nucleotide sequences are useful as probes, in chromosome
and gene mapping, in generating antisense RNA and DNA, in preparing PRO
polypeptides by recombinant techniques and in gene therapy (e.g. for
replacement of defective gene). The PRO polypeptides are useful as
molecular weight markers for protein electrophoresis purposes, for
chromosome identification, as chromosome markers, as therapeutic agents,
for stimulating the release of TNF-alpha from human blood, for
stimulating the proliferation or differentiation of chondrocytes and
detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTACCACCTCTTCTTTTATCTTATTAATAAATGTTGTCTCCACCTG 2180
DB 2653 CCTTTTCTTCTCCCATCTCTCTGTACACATTTTAATAAATAGGTTGCTTCTGAAC 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAAAA
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 637
ACD48852
ID ACD48852 standard; cDNA; 2846 BP.
XX ACD48852;
XX 05-OCT-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX US2003064468-A1.
XX 03-APR-2003.
XX 29-JUL-2002; 2002US-00207922.
XX 11-APR-2000; 2000US-0195975P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-605866/57.
XX P-PSDB; ABO30944.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX PRO polypeptide, a method for stimulating the proliferation of
XX differentiation of chondrocyte cells by contacting the cells with a PRO
XX polypeptide, a method for detecting the presence of a tumour in a mammal
XX and an oligonucleotide probe derived from any of the PRO nucleotide
XX sequences. The nucleotide sequences are useful as probes, in chromosome
XX and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX polypeptides by recombinant techniques and in gene therapy (e.g. for
XX replacement of defective gene). The PRO polypeptides are useful as
XX molecular weight markers for protein electrophoresis purposes, for
XX chromosome identification, as chromosome markers, as therapeutic agents,
XX for stimulating the release of TNF-alpha from human blood, for
XX stimulating the proliferation or differentiation of chondrocytes and
XX detecting the presence, prevention and/or treatment of a tumour, such as

CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF25693-ACF25997 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTAATAAATGTTGCTCCACACTG 2180
Db 2653 CTTTTCTTCCCATCTCTTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2240
Db 2713 CAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 641
ACF39090
ID ACF39090 standard; cDNA; 2846 BP.

XX ACF39090;

AC ACF39090;

DT 08-OCT-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.

XX Homo sapiens.

XX US2003068698-A1.
XX 10-APR-2003.
XX 12-JUL-2002; 2002US-00194362.
XX 05-JUN-2000; 2000US-0209832P.
XX 28-SEP-2001; 2001WO-US0006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615874/58.
XX P-PSDB; ABM15596.
XX New secreted and transmembrane PRO nucleic acid, useful for the
XX manufacture of a medicament for diagnosing or treating tumor or for
XX tissue typing.

Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM15512-ABM15816) and nucleic acids encoding them (ACF39006-ACF39310).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA and in gene
XX therapy. The nucleic acids can also be used for mapping genes encoding
XX PRO polypeptides, for genetic analysis of individuals with genetic
XX disorders, and for generating either transgenic animals or knock-out
XX animals which are useful in the development and screening of
XX therapeutically useful compounds. Sequences ACF39006-ACF39310 represent
XX cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGGCTTTACCACTCTTCTCTTTATCTATTAATAAATAAATGTTGCTCCACACTG 2180
Db 2653 CTTTTCTTCCCATCTCTTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAAC 2712

CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF28763-ACF29067 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CTTTGGCTTTACCACTCTTCTTTTATTTATTAATAAATGTTGGTCTCCACCACTG 2180
DB 2653 CTTTTTCTTCCCTCCCATCTCTTGACACATTTTAAATAAATAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 643
ACF28847
ID ACF28847 standard; cDNA; 2846 BP.
XX
XX ACF28847;
XX
XX 20-SEP-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003068759-A1.
XX
XX 10-APR-2003.
XX
XX 26-JUL-2002; 2002US-00206920.
XX
XX 15-SEP-2000; 2000US-0232887P.
XX
XX 28-FEB-2001; 2001WO-US006520.
XX
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-615902/58.
XX
XX P-PSDB; ABM08581.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
XX PRO827, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM08497-ABM08801) and nucleic acids encoding them (ACF28763-ACF29067).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PT PR0827, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX
PS Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGCTTTACCACTCTCTTCTTTATCTTTATTAATAAAATGTTGCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAA 2240
Db 2713 CAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 644
ACD86467
ID ACD86467 standard; cDNA; 2846 BP.
XX
AC ACD86467;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #85.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX
XX US2003068765-A1.
XX
XX 10-APR-2003.
XX
XX 29-JUL-2002; 2002US-00207916.
XX
XX

XX 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625477/59.
DR P-PSDB; ABO38011.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful in gene therapy for cancers, chromosome identification,
PT tissue typing, or as hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGCTTTACCACTCTCTTCTTTATCTTTATTAATAAAATGTTGCTCCACCCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAA 2240
Db 2713 CAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 645
ACH05329
ID ACH05329 standard; cDNA; 2846 BP.
XX
AC ACH05329;
XX
XX 07-OCT-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #85.
XX
XX

KW	Human; PRO polypeptide; secreted protein; transmembrane protein;
KW	chromosome mapping; gene mapping; molecular weight marker;
KW	protein electrophoresis; affinity purification; tumour; adrenal; lung;
KW	colon; breast; prostate; rectal; cervical; liver; cancer; cytostatic;
KW	gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003049754-A1.
PD	13-MAR-2003.
PP	18-JUL-2002; 2002US-00198764.
XX	
PR	08-APR-1998; 98US-0081049P.
PR	08-MAR-1999; 99WO-US005028.
PR	25-AUG-1999; 99US-00380138.
PR	22-MAY-2000; 2000WO-US014042.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WI; 2003-657406/62.
XX	P-PSDB; ABO45921.
XX	
PT	New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT	acids, useful for diagnosing, preventing and/or treating tumors, such as
PT	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX	
PS	Claim 2; Fig 169; 700pp; English.
CC	The present invention relates to the isolation of novel human PRO
CC	polypeptides, and the polynucleotide sequences encoding them. The PRO
CC	polypeptides are secreted and transmembrane proteins. The PRO
CC	polynucleotide sequences are useful in molecular biology as hybridisation
CC	probes, in chromosome and gene mapping, in generating antisense RNA and
CC	DNA, and in gene therapy. The PRO polypeptides are useful for the
CC	diagnosis, prevention and/or treatment of tumours such as those found in
CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver
CC	cancers. The PRO polypeptides are also useful as molecular weight markers
CC	for protein electrophoresis purposes. ACH05245-ACH05549 represent cDNA
CC	sequences encoding the human PRO polypeptides of the invention. Note: The
CC	sequence data for this patent was obtained in electronic format directly
CC	from the USPTO web site at seqdata.uspto.gov/psipdsIDEntry.html
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;	
Best Local Similarity 71.3%; Pred. No. 0.00023;	
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
Qy	2121 CCTTGGTTTACCACTCTTCCTTTATCTTAATAAAAGTGTCCTCACCACTG 2180
Db	
	2653 CCCTTTCTCCTCCCATCTCTGTGACACATTTTAATAAATGAAGGTTCGACTA 2712
Qy	2181 NCTCCAA 2240
Db	
	2713 CAIAAA 2772
Qy	2241 AA 2242
Db	
	2773 AA 2774
RESULT 646	
ID	ACF65125 standard; cDNA; 2846 BP.
XX	
AC	ACF65125;

XX	14-OCT-2003 (first entry)
DT	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX	
XX	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnery; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
XX	US2003068688-A1.
XX	
PD	10-APR-2003.
XX	
PF	02-JUL-2002; 2002US-00188766.
XX	
PR	26-JUN-1998; 98US-00105413.
PR	16-SEP-1998; 98WO-US019330.
PR	07-OCT-1998; 98US-00168978.
PR	07-OCT-1998; 98WO-US021141.
PR	06-NOV-1998; 98US-00187368.
PR	01-DEC-1998; 98WO-US025108.
PR	07-DEC-1998; 98US-00202054.
PR	03-MAR-1999; 99US-00254311.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	02-JUN-1999; 99WO-US012252.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.
PR	25-AUG-1999; 99US-00380139.
PR	25-AUG-1999; 99US-00380142.
PR	01-SEP-1999; 99WO-US020111.
PR	15-SEP-1999; 99WO-US021090.
PR	18-OCT-1999; 99US-00403297.
PR	12-NOV-1999; 99US-00423844.
PR	01-DEC-1999; 99WO-US028301.
PR	02-DEC-1999; 99WO-US028551.
PR	30-DEC-1999; 99WO-US031274.
PR	05-JAN-2000; 2000WO-US000219.
PR	18-FEB-2000; 2000WO-US004341.
PR	22-FEB-2000; 2000WO-US004414.
PR	24-FEB-2000; 2000WO-US005004.
PR	01-MAR-2000; 2000WO-US005601.
PR	02-MAR-2000; 2000WO-US005841.
PR	15-MAR-2000; 2000WO-US006894.
PR	30-MAR-2000; 2000WO-US008439.
PR	17-MAY-2000; 2000WO-US013705.
PR	22-MAY-2000; 2000WO-US014042.
PR	30-MAY-2000; 2000WO-US014941.
PR	02-JUN-2000; 2000WO-US015264.
PR	28-JUL-2000; 2000WO-US020710.
PR	22-AUG-2000; 2000US-00644848.
PR	24-AUG-2000; 2000WO-US023328.
PR	18-SEP-2000; 2000US-00664610.
PR	18-SEP-2000; 2000US-00665350.
PR	08-NOV-2000; 2000US-00709238.
PR	08-NOV-2000; 2000WO-US030952.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-00747259.
PR	20-DEC-2000; 2000WO-US034956.
PR	28-FEB-2001; 2001WO-US006

PR 05-JUN-2001; 2001US-00874503.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 30-JUL-2001; 2001US-00918585.
 PR 06-AUG-2001; 2001US-00924419.
 PR 13-AUG-2001; 2001US-00929404.
 PR 16-AUG-2001; 2001US-00931836.
 PR 28-AUG-2001; 2001US-00941932.
 PR 29-AUG-2001; 2001WO-US027039.
 PR 04-SEP-2001; 2001US-00946374.
 PR 15-JAN-2002; 2002US-00052586.
 XX XX
 PA (GETH) GENENTECH INC.
 XX XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX XX
 DR WPI; 2003-657572/62.
 DR P-PSDB; ABM66724.
 XX XX
 PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
 PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
 PT useful for diagnosing or treating tumors.
 XX XX
 PS Claim 2; Fig 169; 703pp; English.
 XX XX
 CC The invention relates to human PRO secreted/transmembrane polypeptides
 CC and nucleic acids encoding them, the invention also provides recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. The present sequence appears in the
 CC exemplification of the specification. Note: The sequence data for this
 CC patent is also available in electronic format from USPTO at
 CC seqdata.uspto.gov/sequence.html
 XX XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 2121 CCTTTGCTTTACCACTCTTCTTTATCTTTATTAATAAAATGCTGCTCCACCTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 2653 CCTTTTCTCCCATCTCTTTGTACATTTTAAATAAATAAGGGTTGGCTTCTGAACCTA 2712
 Qy 2181 NCTCCCAA 2240
 Db 2713 CAAA 2772
 Qy 2241 AA 2242
 ||
 Db 2773 AA 2774
 ||
 RESULT 647
 ADB20281
 ID ADB20281 standard; cDNA; 2846 BP.
 XX XX
 AC ADB20281;
 XX XX
 DT 20-NOV-2003 (first entry)
 XX XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX XX
 KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
 XX XX
 OS Homo sapiens.
 XX XX
 FN US2003082767-A1.
 XX XX
 PD 01-MAY-2003.
 XX XX
 PF 17-JUN-2002; 2002US-00173696.
 XX XX
 PR 18-SEP-1997; 97US-0059283P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 28-OCT-1997; 97US-0063540P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 11-DEC-1997; 97US-0069335P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 17-DEC-1997; 97US-0069870P.
 PR 18-DEC-1997; 97US-0068017P.
 PR 10-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077632P.
 PR 11-MAR-1998; 98US-0077649P.
 PR 20-MAR-1998; 98US-0078886P.
 PR 20-MAR-1998; 98US-0078939P.
 PR 27-MAR-1998; 98US-0079664P.
 PR 27-MAR-1998; 98US-0079786P.
 PR 31-MAR-1998; 98US-0080107P.
 PR 31-MAR-1998; 98US-0080194P.
 PR 01-APR-1998; 98US-0080327P.
 PR 01-APR-1998; 98US-0080333P.
 PR 08-APR-1998; 98US-0081049P.
 PR 08-APR-1998; 98US-0081070P.
 PR 09-APR-1998; 98US-0081195P.
 PR 15-APR-1998; 98US-0081838P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082569P.
 PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998;	98US-0082797P.	PR 01-JUL-1998;	98US-0091544P.
PR 28-APR-1998;	98US-0083322P.	PR 02-JUL-1998;	98US-0091478P.
PR 29-APR-1998;	98US-0083495P.	PR 02-JUL-1998;	98US-0091486P.
PR 29-APR-1998;	98US-0083496P.	PR 02-JUL-1998;	98US-0091626P.
PR 29-APR-1998;	98US-0083499P.	PR 02-JUL-1998;	98US-0091628P.
PR 29-APR-1998;	98US-0083559P.	PR 02-JUL-1998;	98US-0091632P.
PR 05-MAY-1998;	98US-0084366P.	PR 24-JUL-1998;	98US-0094006P.
PR 06-MAY-1998;	98US-0084414P.	PR 04-AUG-1998;	98US-0095282P.
PR 07-MAY-1998;	98US-0084639P.	PR 10-AUG-1998;	98US-0095998P.
PR 07-MAY-1998;	98US-0084643P.	PR 10-AUG-1998;	98US-0096012P.
PR 15-MAY-1998;	98US-0085579P.	PR 17-AUG-1998;	98US-0096757P.
PR 15-MAY-1998;	98US-0085580P.	PR 17-AUG-1998;	98US-0096867P.
PR 15-MAY-1998;	98US-0085582P.	PR 17-AUG-1998;	98US-0096891P.
PR 15-MAY-1998;	98US-0085700P.	PR 17-AUG-1998;	98US-0096897P.
PR 15-MAY-1998;	98US-0086023P.	PR 18-AUG-1998;	98US-0096949P.
PR 22-MAY-1998;	98US-0086392P.	PR 18-AUG-1998;	98US-0096959P.
PR 22-MAY-1998;	98US-0086486P.	PR 18-AUG-1998;	98US-0097022P.
PR 28-MAY-1998;	98US-0087098P.	PR 26-AUG-1998;	98US-0097952P.
PR 28-MAY-1998;	98US-0087208P.	PR 26-AUG-1998;	98US-0097954P.
PR 02-JUN-1998;	98US-0087759P.	PR 26-AUG-1998;	98US-0097955P.
PR 03-JUN-1998;	98US-0087827P.	PR 26-AUG-1998;	98US-0097971P.
PR 04-JUN-1998;	98US-0088025P.	PR 26-AUG-1998;	98US-0097974P.
PR 04-JUN-1998;	98US-0088028P.	PR 26-AUG-1998;	98US-0097974P.
PR 04-JUN-1998;	98US-0088029P.	PR 01-SEP-1998;	98US-0098014P.
PR 04-JUN-1998;	98US-0088033P.	PR 01-SEP-1998;	98US-0098716P.
PR 04-JUN-1998;	98US-0088326P.	PR 02-SEP-1998;	98US-0098723P.
PR 05-JUN-1998;	98US-0088167P.	PR 02-SEP-1998;	98US-0098803P.
PR 05-JUN-1998;	98US-0088302P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088312P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088821P.	PR 10-SEP-1998;	98US-0098843P.
PR 05-JUN-1998;	98US-0088821P.	PR 10-SEP-1998;	98US-0098741P.
PR 09-JUN-1998;	98US-0088855P.	PR 10-SEP-1998;	98US-0099754P.
PR 10-JUN-1998;	98US-0088722P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088738P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088740P.	PR 15-SEP-1998;	98US-0099812P.
PR 10-JUN-1998;	98US-0088811P.	PR 16-SEP-1998;	98US-0100388P.
PR 10-JUN-1998;	98US-0088824P.	PR 16-SEP-1998;	98US-0100662P.
PR 10-JUN-1998;	98US-0088825P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088826P.	PR 16-SEP-1998;	98US-0101751P.
PR 11-JUN-1998;	98US-0088861P.	PR 16-SEP-1998;	98US-0101751P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-SEP-1998;	98US-0100684P.
PR 12-JUN-1998;	98US-0089090P.	PR 17-SEP-1998;	98US-0100919P.
PR 12-JUN-1998;	98US-0089105P.	PR 17-SEP-1998;	98US-0100930P.
PR 16-JUN-1998;	98US-0089512P.	PR 18-SEP-1998;	98US-0100849P.
PR 16-JUN-1998;	98US-0089514P.	PR 18-SEP-1998;	98US-0101014P.
PR 17-JUN-1998;	98US-0089538P.	PR 18-SEP-1998;	98US-0101014P.
PR 17-JUN-1998;	98US-0089598P.	PR 23-SEP-1998;	98US-0101068P.
PR 17-JUN-1998;	98US-0089633P.	PR 23-SEP-1998;	98US-0101471P.
PR 18-JUN-1998;	98US-0089908P.	PR 23-SEP-1998;	98US-0101472P.
PR 19-JUN-1998;	98US-0089952P.	PR 23-SEP-1998;	98US-0101475P.
PR 22-JUN-1998;	98US-0090246P.	PR 23-SEP-1998;	98US-0101477P.
PR 22-JUN-1998;	98US-0090252P.	PR 24-SEP-1998;	98US-0101738P.
PR 22-JUN-1998;	98US-0090254P.	PR 24-SEP-1998;	98US-0101739P.
PR 24-JUN-1998;	98US-0090429P.	PR 24-SEP-1998;	98US-0101743P.
PR 24-JUN-1998;	98US-0090435P.	PR 24-SEP-1998;	98US-0101922P.
PR 24-JUN-1998;	98US-0090444P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090461P.	PR 25-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090535P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090540P.	PR 29-SEP-1998;	98US-0102240P.
PR 25-JUN-1998;	98US-0090676P.	PR 29-SEP-1998;	98US-0102330P.
PR 25-JUN-1998;	98US-0090678P.	PR 29-SEP-1998;	98US-0102331P.
PR 25-JUN-1998;	98US-0090688P.	PR 30-SEP-1998;	98US-0102487P.
PR 25-JUN-1998;	98US-0090690P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090694P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090695P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090696P.	PR 01-OCT-1998;	98US-0102687P.
PR 26-JUN-1998;	98US-00105413.	PR 02-OCT-1998;	98US-0102965P.
PR 26-JUN-1998;	98US-0090862P.	PR 02-OCT-1998;	98US-0102965P.
PR 26-JUN-1998;	98US-0090863P.	PR 06-OCT-1998;	98US-0103258P.
PR 26-JUN-1998;	98US-0091010P.	PR 06-OCT-1998;	98US-0103258P.
PR 01-JUL-1998;	98US-0091359P.	PR 06-OCT-1998;	98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Db 2653 CCTTTCTCCCTCTCTGTACACATTTTAAATAAAGGCTTGGCTTGAACCTA 2712
 Qy 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAA 2772
 Qy 2241 AA 2242
 Db 2773 AA 2774

RESULT 648

ACF43598

ID ACF43598 standard; cDNA; 2846 BP.

XX ACF43598;

XX 03-OCT-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

XX US2003104552-A1.

XX 05-JUN-2003.

XX 24-JUL-2002; 2002US-00202940.

XX 29-APR-1998; 98US-0083496P.

XX 08-MAR-1999; 99WO-US005028.

XX 25-AUG-1999; 99US-00380138.

XX 18-FEB-2000; 2000WO-US004341.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX (GENTH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-670249/63.

XX P-PSDB; ABM19625.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
 PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
 PT colon, breast, prostate, rectal, cervical or liver tumors.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM19541-ABM19845) and nucleic acids encoding them (ACF43514-ACF43818).
 CC The invention also relates to sequences at least 80% identical to the PRO
 CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid; a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF43514-ACF43818 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTGTCTCCACCTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATAAATAGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAA 2240

Db 2713 CAAAAAATAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 649

ACH09068

ID ACH09068 standard; cDNA; 2846 BP.

XX ACH09068;

XX 10-OCT-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003049774-A1.

XX 13-MAR-2003.

XX 24-JUL-2002; 2002US-00202934.

XX 06-MAY-1998; 98US-0084414P.

XX 08-MAR-1999; 99WO-US005028.

XX 25-AUG-1999; 99US-00380138.

XX 18-FEB-2000; 2000WO-US004341.

XX 28-FEB-2001; 2001WO-US006520.

XX 15-JAN-2002; 2002US-00052586.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-669848/63.

XX DR P-PSDB; ABO49337.

XX PT Three hundred and five nucleic acids encoding PRO polypeptides, useful

XX PT for the manufacture of a medicament for diagnosing or treating tumor or

XX PT for tissue typing.

XX PS Claim 2; Fig 169; 699pp; English.

XX CC The invention discloses human nucleic acids encoding secreted and

XX CC transmembrane (PRO) polypeptides, with or without their associated signal

XX CC peptide. Also disclosed is an antibody that specifically binds to the PRO

XX CC polypeptide, a method for stimulating the release of tumour necrosis

XX CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

XX CC PRO polypeptide, a method for stimulating the proliferation or

XX CC differentiation of chondrocyte cells by contacting the cells with a PRO

XX CC polypeptide, a method for detecting the presence of a tumour in a mammal

XX CC and an oligonucleotide probe derived from any of the PRO nucleotide

XX CC sequences. The nucleotide sequences are useful as probes, in chromosome

XX CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

XX CC polypeptides by recombinant techniques and in gene therapy (e.g. for

XX CC replacement of defective gene). The PRO polypeptides are useful as

XX CC molecular weight markers for protein electrophoresis purposes, for

XX CC chromosome identification, as chromosome markers, as therapeutic agents,

XX CC for stimulating the release of TNF-alpha from human blood, for

XX CC stimulating the proliferation or differentiation of chondrocytes and

XX CC detecting the presence, prevention and/or treatment of a tumour, such as

XX CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

XX CC The PRO polypeptides and nucleic acids may also be used diagnostically

XX CC for tissue typing. The sequence presented is a cDNA encoding one of the

XX CC PRO polypeptides of the invention. Note: The sequence data for this

XX CC patent can also be obtained in electronic format directly from USPTO at

XX CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGTTGGTCTCCACCACTG 2180

DB 2653 CCTTTTCTTTCCCATCTCTGTACACATTTTAATAAATAAGGGTGTCTTCTGAACCTA 2712

QY 2181 NCTCCCAAA 2240

DB 2713 CAAAAAATAAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 650

ACH09375

ID ACH09375 standard; cDNA; 2846 BP.

XX AC ACH09375;

XX DT 10-OCT-2003 (first entry)

XX DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX OS Homo sapiens.

XX PN US2003049775-A1.

XX PD 13-MAR-2003.

XX PF 24-JUL-2002; 2002US-00202935.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 28-JUL-1999; 99US-0146222P.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 18-FEB-2001; 2001WO-US006520.

XX PR 15-JAN-2002; 2002US-00052586.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-669849/63.

XX DR P-PSDB; ABO49642.

XX PT Three hundred and five nucleic acids encoding PRO polypeptides, useful

XX PT for the manufacture of a medicament for diagnosing or treating tumor or

XX PT for tissue typing.

XX PS Claim 2; Fig 169; 699pp; English.

XX CC The invention discloses human nucleic acids encoding secreted and

XX CC transmembrane (PRO) polypeptides, with or without their associated signal

XX CC peptide. Also disclosed is an antibody that specifically binds to the PRO

XX CC polypeptide, a method for stimulating the release of tumour necrosis

XX CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

XX CC PRO polypeptide, a method for stimulating the proliferation or

XX CC differentiation of chondrocyte cells by contacting the cells with a PRO

XX CC polypeptide, a method for detecting the presence of a tumour in a mammal

XX CC and an oligonucleotide probe derived from any of the PRO nucleotide

XX CC sequences. The nucleotide sequences are useful as probes, in chromosome

XX CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

XX CC polypeptides by recombinant techniques and in gene therapy (e.g. for

XX CC replacement of defective gene). The PRO polypeptides are useful as

XX CC molecular weight markers for protein electrophoresis purposes, for

XX CC chromosome identification, as chromosome markers, as therapeutic agents,

XX CC for stimulating the release of TNF-alpha from human blood, for

XX CC stimulating the proliferation or differentiation of chondrocytes and

XX CC detecting the presence, prevention and/or treatment of a tumour, such as

XX CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

XX CC The PRO polypeptides and nucleic acids may also be used diagnostically

XX CC for tissue typing. The sequence presented is a cDNA encoding one of the

XX CC PRO polypeptides of the invention. Note: The sequence data for this

XX CC patent can also be obtained in electronic format directly from USPTO at

XX CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTATTATTAATAAAATGTTGGTCTCCACCACTG 2180

DB 2653 CCTTTTCTTTCCCATCTCTGTACACATTTTAATAAATAAGGGTGTCTTCTGAACCTA 2712

QY 2181 NCTCCCAAA 2240

DB 2713 CAAAAAATAAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 650

ACH09375

ID ACH09375 standard; cDNA; 2846 BP.

XX AC ACH09375;

XX DT 10-OCT-2003 (first entry)

XX DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

```
RESULT 651
ADA78533
ID ADA78533 standard; cDNA; 2846 BP.
XX AC
XX AC ADA78533;
XX DT
XX DT 20-NOV-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
XX KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX OS
XX OS Homo sapiens.
XX PN
XX PN US2003073181-A1.
XX PD
XX PD 17-APR-2003.
XX PF
XX PF 24-JUL-2002; 2002US-00205510.
XX PR
XX PR 02-JUL-1998; 98US-0091486P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX PA
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-743812/70.
XX DR P-PSDB; ADA78534.
XX XX
XX PT New secreted and transmembrane PRO nucleic acids, useful for the
XX PT manufacture of a medicament for diagnosing or treating tumor or for
XX PT measuring or detecting expression of an associated gene.
XX PS
XX PS Claim 2; Fig 169; 700pp; English.
XX CC
XX CC The invention discloses human nucleic acids encoding secreted and
XX CC transmembrane (PRO) polypeptides, with or without their associated signal
XX CC peptide. Also disclosed is an antibody that specifically binds to the PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
XX CC PRO polypeptide, a method for stimulating the proliferation or
XX CC differentiation of chondrocyte cells by contacting the cells with a PRO
XX CC polypeptide, a method for detecting the presence of a tumour in a mammal
XX CC and an oligonucleotide probe derived from any of the PRO nucleotide
XX CC sequences. The nucleotide sequences are useful as probes, in chromosome
XX CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
XX CC polypeptides by recombinant techniques and in gene therapy (e.g. for
XX CC replacement of defective gene). The PRO polypeptides are useful as
XX CC molecular weight markers for protein electrophoresis purposes, for
XX CC chromosome identification, as chromosome markers, as therapeutic agents,
XX CC for stimulating the release of TNF-alpha from human blood, for
XX CC stimulating the proliferation or differentiation of chondrocytes and
XX CC detecting the presence, prevention and/or treatment of a tumour, such as
XX CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
XX CC The PRO polypeptides and nucleic acids may also be used diagnostically
XX CC for tissue typing. The sequence presented is a cDNA encoding one the PRO
XX CC polypeptides of the invention. Note: The sequence data for this patent
XX CC can also be obtained in electronic format directly from USPTO at
XX CC seqdata.uspto.gov/sequence.html.
XX SQ
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAAATGTTGCTCCACACTG 2180
Db 2653 CCTTTCTCTTCCCATCTCTGTACACATTTTAATAAAATAGGCTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 652
ACF09798
ID ACF09798 standard; cDNA; 2846 BP.
XX AC
XX AC ACF09798;
XX DT
XX DT 06-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS
XX OS Homo sapiens.
XX PN
XX PN US2003068720-A1.
XX PD
XX PD 10-APR-2003.
XX PF
XX PF 18-JUL-2002; 2002US-00198763.
XX PR
XX PR 07-MAY-1998; 98US-0084639P.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 25-AUG-1999; 99US-00380138.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX PA
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-576427/54.
XX DR P-PSDB; ABR88199.
XX XX
XX PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX PT for the manufacture of a medicament for diagnosing or treating tumor or
XX PT for tissue typing.
XX PS
XX PS Claim 2; Fig 169; 699pp; English.
XX CC
XX CC The invention relates to human PRO secreted/transmembrane polypeptides
XX CC (ABR88113-ABR88419) and nucleic acids encoding them (ACF09714-ACF10018).
XX CC The invention also relates to sequences at least 80% identical to the PRO
XX CC nucleic acid and polypeptide sequences of the invention, recombinant
XX CC vectors and host cells comprising a PRO nucleic acid, a method for the
XX CC recombinant production of a PRO polypeptide, antibodies against a PRO
XX CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX CC acids encoding PRO polypeptides of the invention were initially
XX CC identified via homology screening using consensus sequences based on the
XX CC extracellular domain sequences from known secreted proteins. Human cDNA
```


Db 2713 CAAAAA 2772
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 654
 ACF23877
 ID ACF23877 standard; cDNA; 2846 BP.
 XX ACF23877;
 AC ACF23877;
 DT 26-SEP-2003 (first entry)
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnary; gene therapy; gene; ss.
 XX Homo sapiens.
 OS
 XX US2003068763-A1.
 PN 10-APR-2003.
 PD 25-JUL-2002; 2002US-00206926.
 XX 20-JUL-1999; 99US-0145070P.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI WPI; 2003-615905/58.
 DR P-PSDB; ABM03342.
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
 PT PRO827, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy for cancers.
 XX Claim 2; Fig 169; 700pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM03258-ABM03562) and nucleic acids encoding them (ACF23793-ACF24097). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF23793-ACF24097 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGCTCCACACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CTTTTCTCTCCCATCTCTTTGTACACATTTTATAAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAA 2242
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAAAA 2774

RESULT 655
 ACD88309
 ID ACD88309 standard; cDNA; 2846 BP.
 XX ACD88309;
 AC ACD88309;
 DT 06-OCT-2003 (first entry)
 XX Human secreted/transmembrane protein (PRO) cDNA #85.
 DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX Homo sapiens.
 OS
 XX US2003068689-A1.
 PN 10-APR-2003.
 PD 02-JUL-2002; 2002US-00188771.
 XX 05-JUN-2000; 2000US-0209832P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI WPI; 2003-625461/59.
 DR P-PSDB; ABO39841.
 XX New PRO nucleic acid, useful for the manufacture of a medicament for

```
PT diagnosing or treating tumor or for tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTTACCACCTCTTTCTCTTTATCTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CTTTTCTCTCCCACTCTCTGTACACATTTTAATAAAATAGGTTGGTCTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 656
ACH09682
XX ACH09682 standard; cDNA; 2846 BP.
XX ACH09682;
AC AC
XX (first entry)
DT 10-OCT-2003
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS
XX US2003049776-A1.
XX 13-MAR-2003.
PD
XX 24-JUL-2002; 2002US-00202936.
XX 22-MAY-2000; 2000WO-US014042.
XX 28-FEB-2001; 2001WO-US006520.
PR
```

```
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-669850/63.
DR P-PSDB; ABO49947.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTTACCACCTCTTTCTCTTTATCTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CTTTTCTCTCCCACTCTCTGTACACATTTTAATAAAATAGGTTGGTCTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
DB 2773 AA 2774

RESULT 657
ACH10603
XX ACH10603 standard; cDNA; 2846 BP.
XX ACH10603;
AC AC
XX (first entry)
DT 10-OCT-2003
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW
```

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003049780-A1.

XX 13-MAR-2003.

XX 25-JUL-2002; 2002US-00205895.

XX 23-MAR-1999; 98US-0125778P.

PR 01-MAR-2000; 2000WO-US005601.

PR 22-MAY-2000; 2000WO-US014042.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-669853/63.

DR P-PSDB; ABO50862.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful for the manufacture of a medicament for diagnosing or treating tumor or for tissue typing.

XX Claim 2; Fig 169; 700pp; English.

CC The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTTACCCTCTCTTCTTTATTTATTAATAAATGTTGGTCTCCACCACTG 2180

DB 2653 CCTTTCTCTCCCATCTCTTGACACATTTTATAAATAGGGTTGGCTCTGACTA 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 658
ACD11410
ID ACD11410 standard; cDNA; 2846 BP.
XX
AC ACD11410;
XX
DT 13-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036126-A1.
XX
PD 20-FEB-2003.
XX
PF 26-JUN-2002; 2002US-00183013.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063546P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 97US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.

PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100652P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCCTTGGTTTACCACTCTTCCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180
Dy 2653 CCCTTCTTCCCACTCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAA 2240
Dy 2713 CAAAAAATAA 2772
Qy 2241 AA 2242
||

Db 2773 AA 2774
RESULT 660
ACC98490
ID ACC98490 standard; cDNA; 2846 BP.
XX
AC ACC98490;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003044927-A1.
XX
PD 06-MAR-2003.
XX
PF 27-JUN-2002; 2002US-00184615.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.

Db 2773 AA 2774
RESULT 661
ACF41795
ID ACF41795 standard; cDNA; 2846 BP.
XX ACF41795;
XX AC
XX DT
XX 06-NOV-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003040072-A1.
XX
XX 27-FEB-2003.
XX
XX 27-JUN-2002; 2002US-00184654.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078896P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 09-JUN-1998; 98US-0088217P.
PR 10-JUN-1998; 98US-0088222P.
PR 10-JUN-1998; 98US-0088255P.
PR 10-JUN-1998; 98US-0088266P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090896P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR


```
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
Qy 2121 CCTTGTCTTACCACTCTTCTTATCTTATTAATAAATGTGTCTCCACCACTG 2180
Db 2653 CTTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
```

```
Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 662
ACFI6716
ID ACFI6716 standard; cDNA; 2846 BP.
XX AC ACFI6716;
XX DT 13-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; KW liver; drug screening; transgenic animal; genetic analysis; KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003040073-A1.
XX PD 27-FEB-2003.
XX PF 28-JUN-2002; 2002US-00184655.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 28-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 17-DEC-1997; 97US-0069425P.
PR 12-DEC-1997; 97US-0069335P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080377P.
PR 08-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 15-APR-1998; 98US-0081195P.
PR 21-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
```

```
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088867P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 26-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-009816P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098943P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100319P.
PR 17-SEP-1998; 98US-0100330P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTTACCACCTTTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
DB 2653 CCTTTTCTTTCCCACTCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
DB 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
```

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 663
 ACD32236
 ID ACD32236 standard; cDNA; 2846 BP.
 XX
 AC ACD32236;
 XX
 DT 31-AUG-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX
 KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX
 OS Homo sapiens.
 XX
 PN US2003054475-A1.
 XX
 PD 20-MAR-2003.
 XX
 PF 23-JUL-2002; 2002US-00202408.
 XX
 PR 18-SEP-1998; 98US-0100849P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-521851/49.
 DR P-PSDB; ABO21842.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention discloses human nucleic acids encoding secreted and
 CC transmembrane (PRO) polypeptides, with or without their associated signal
 CC peptide. Also disclosed is an antibody that specifically binds to the PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
 CC PRO polypeptide, a method for stimulating the proliferation or
 CC differentiation of chondrocyte cells by contacting the cells with a PRO
 CC polypeptide, a method for detecting the presence of a tumour in a mammal
 CC and an oligonucleotide probe derived from any of the PRO nucleotide
 CC sequences. The nucleotide sequences are useful as probes, in chromosome
 CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 CC polypeptides by recombinant techniques and in gene therapy (e.g. for
 CC replacement of defective gene). The PRO polypeptides are useful as
 CC molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence, prevention and/or treatment of a tumour, such as
 CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
 CC The PRO polypeptides and nucleic acids may also be used diagnostically
 CC for tissue typing. The sequence presented is a cDNA encoding one of the
 CC PRO polypeptides of the invention. Note: The sequence data for this
 CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTTACCACTCTTTCCTTTTATCTATTATTAATAAAATGTTGGTCTCCACACTG 2180
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2653 CCTTTCCTCTCCCATCTCTTTGTACACATTTTATAAAATAGGTTGGCTTCTGAACATA 2712
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 QY 2181 NCTCCCAAA 2240
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2713 CAAAAAIAAA 2772
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 664
 ACD30394
 ID ACD30394 standard; cDNA; 2846 BP.
 XX
 AC ACD30394;
 XX
 DT 30-AUG-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX
 KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX
 OS Homo sapiens.
 XX
 PN US2003032124-A1.
 XX
 PD 13-FEB-2003.
 XX
 PF 25-JUN-2002; 2002US-00180559.
 XX
 PR 18-SEP-1997; 97US-0059263P.
 PR 18-SEP-1997; 97US-0059266P.
 PR 17-OCT-1997; 97US-0052250P.
 PR 21-OCT-1997; 97US-0063486P.
 PR 24-OCT-1997; 97US-0063120P.
 PR 24-OCT-1997; 97US-0063121P.
 PR 28-OCT-1997; 97US-0063540P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 21-NOV-1997; 97US-0066120P.
 PR 24-NOV-1997; 97US-0066466P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 11-DEC-1997; 97US-0069335P.
 PR 12-DEC-1997; 97US-0069425P.
 PR 17-DEC-1997; 97US-0069870P.
 PR 18-DEC-1997; 97US-0068017P.
 PR 10-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077632P.
 PR 11-MAR-1998; 98US-0077649P.
 PR 20-MAR-1998; 98US-0078886P.
 PR 20-MAR-1998; 98US-0078939P.
 PR 27-MAR-1998; 98US-0079664P.
 PR 27-MAR-1998; 98US-0079786P.
 PR 31-MAR-1998; 98US-0080107P.
 PR 31-MAR-1998; 98US-0080194P.

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

PR	01-APR-1998;	98US-0080327P.	PR	25-JUN-1998;	98US-0090690P.
PR	01-APR-1998;	98US-0080333P.	PR	25-JUN-1998;	98US-0090694P.
PR	08-APR-1998;	98US-0081049P.	PR	25-JUN-1998;	98US-0090695P.
PR	08-APR-1998;	98US-0081070P.	PR	25-JUN-1998;	98US-0090696P.
PR	09-APR-1998;	98US-0081195P.	PR	26-JUN-1998;	98US-00105413.
PR	15-APR-1998;	98US-0081838P.	PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998;	98US-0082568P.	PR	26-JUN-1998;	98US-0090863P.
PR	21-APR-1998;	98US-0082569P.	PR	26-JUN-1998;	98US-0091010P.
PR	22-APR-1998;	98US-0082704P.	PR	01-JUL-1998;	98US-0091359P.
PR	22-APR-1998;	98US-0082797P.	PR	01-JUL-1998;	98US-0091544P.
PR	22-APR-1998;	98US-0083322P.	PR	02-JUL-1998;	98US-0091478P.
PR	23-APR-1998;	98US-0083495P.	PR	02-JUL-1998;	98US-0091486P.
PR	23-APR-1998;	98US-0083496P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091632P.
PR	29-APR-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0094006P.
PR	05-MAY-1998;	98US-0084366P.	PR	04-AUG-1998;	98US-0095282P.
PR	06-MAY-1998;	98US-0084414P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084639P.	PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998;	98US-0084640P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0084643P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085582P.	PR	18-AUG-1998;	98US-0096897P.
PR	15-MAY-1998;	98US-0085700P.	PR	18-AUG-1998;	98US-0096949P.
PR	15-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086332P.	PR	18-AUG-1998;	98US-0097022P.
PR	22-MAY-1998;	98US-0086486P.	PR	26-AUG-1998;	98US-0097952P.
PR	22-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097954P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097955P.
PR	28-MAY-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097971P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097974P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088025P.	PR	01-SEP-1998;	98US-009816P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	03-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	03-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088722P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088740P.	PR	15-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-0101751P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.
PR	12-JUN-1998;	98US-0089030P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100930P.
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101068P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101477P.
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101738P.
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101922P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090535P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090535P.	PR	30-SEP-1998;	98US-0102487P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090678P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102687P.

CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html

XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCTTACCACTCCTTCCTTTTTATCTTAATAAATAAGTGTTGGTCTCCACCACACTG 2180
| | | | | | | | | | | | | | | | | | |
Db 2653 CCCTTTCTTCCTCCCCTCTCTGTACATTAAATAAATAGGGTTGGCTTCTGA ACTA 2712
| | | | | | | | | | | | | | | | | | |

QY 2181 NCTCCAAA 2240
| | | | | | | | | | | | | | | | | | |
Db 2713 CAIAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 666
ACF07649 ID AC F07649 standard; cDNA; 2846 BP.

XX ACF07649;
XX
XX DE 06-SEP-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX US2003049759-A1.
PN
XX 13-MAR-2003.
PD
XX 19-JUL-2002; 2002US-00199306.
PF
XX 30-SEP-1998; 98US-0102487P.
PR
XX 01-SEP-1999; 99WO-US020111.
PP
XX 18-OCT-1999; 99US-00403297.
PR
XX 28-FEB-2001; 2001WO-US006520.
PR
XX 15-JAN-2002; 2002US-00052586.
PR
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-555157/52.
DR
XX P-PADB; ABR6064.
XX

polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. The present sequence appears in the exemplification of the specification. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 G; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCGTTGGCTTTACCACTCTTCCCTTTATCTTATTAATAAAAGTTGGCTCCACCACCTG 2180
DB 2653 CCGTTTTCCTTCCCACTCTTTGTACACATTTTAAATAAAATGCGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAA 2240
DB 2713 CAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 669
ACF11026
ID ACF11026 standard; cDNA; 2846 BP.
XX ACF11026;
XX
XX 09-SEP-2003 (first entry)
XX
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003073170-A1.
XX

XX
PD 17-APR-2003.
XX
PF 18-JUN-2002; 2002US-00174578.
XX
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059486P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077886P.
PR 20-MAR-1998; 98US-0078939P.
PR 20-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083559P.
PR 29-APR-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088032P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095398P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.

Db 2713 CAAAAA... 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 671

ACF26084

ID ACF26084 standard; cDNA; 2846 BP.

XX AC ACF26084;

XX 22-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003068717-A1.

XX 10-APR-2003.

XX 19-JUL-2002; 2002US-00198757.

XX 01-SEP-1998; 98US-0098716P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-615884/58.

DR P-PSDB; ABM05836.

XX New secreted and transmembrane PRO nucleic acid, useful for the

PT manufacture of a medicament for diagnosing or treating tumors or for

PT tissue typing.

XX Claim 2; Fig 169; 703pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC (ABM05752-ABM06056) and nucleic acids encoding them (ACF26000-ACF26304).

CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. Sequences ACF26000-ACF26304 represent

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CTTTGTCTTTACCACTCTTTCTTTCTTTATTAATAAATAATGTTGGTCTCCACCACTG 2180

Db 2653 CTTTTCCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAA... 2240

Db 2713 CAAAAA... 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 672

ACD83397

ID ACD83397 standard; cDNA; 2846 BP.

XX AC ACD83397;

XX 22-SEP-2003 (first entry)

XX Human PRO polynucleotide #85.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW cytostatic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;

KW chondrocyte cell; cancer.

XX Homo sapiens.

XX US2003068728-A1.

XX 10-APR-2003.

XX 19-JUL-2002; 2002US-00199459.

XX 16-SEP-1998; 98US-0100664P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-615888/58.

DR P-PSDB; ABO34961.

Db 2773 AA 2774

RESULT 674
ACF42984
ID ACF42984 standard; cDNA; 2846 BP.
XX ACF42984;
AC ACF42984;
DT 03-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.
XX

OS Homo sapiens.
XX US2003104550-A1.
XX 05-JUN-2003.
XX 23-JUL-2002; 2002US-00202413.
XX 30-SEP-1998; 98US-0102571P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 28-FEB-2001; 2001WO-US0006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-670247/63.
XX P-PSDB; ABM19015.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
XX colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM18931-ABM19235) and nucleic acids encoding them (ACF42900-ACF43204).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterized. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF42900-ACF43204 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTCCTTTTACCACCTCTTTTCTTTTATCTTTTATTAATAAAATGTTGGTCTCCACACTG 2180
DB 2653 CCTTTTCTTCCCATCTCTGTGACACATTTTAAATAAAATAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAAAAATAA 2772
QY 2241 AA 2242
DB 2773 AA 2774

RESULT 675
ACF43291
ID ACF43291 standard; cDNA; 2846 BP.
XX ACF43291;
XX 03-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnary; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003104551-A1.
XX 05-JUN-2003.
XX 24-JUL-2002; 2002US-00202938.
XX 31-OCT-1997; 97US-0064103P.
XX 16-SEP-1998; 98WO-US019330.
XX 25-AUG-1999; 99US-00380139.
XX 22-FEB-2000; 2000WO-US004414.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX

PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0083366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086021P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088325P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088211P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101086P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101718P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Wed Feb 16 11:37:55 2005

us-10-036-342-56.rng

```
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTATTAATAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCACTCTCTGTGACACATTTTAATAAATAAGGTTGGCTTCTGAACTA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 679
ACF10719
ID ACF10719 standard; cDNA; 2846 BP.
XX AC
XX AC
XX AC
DT 06-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX OS
XX PN US2003036119-A1.
XX
XX 20-FEB-2003.
XX PF
XX PF 20-JUN-2002; 2002US-00176990.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0042250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 13-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066468P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085800P.
PR 15-MAY-1998; 98US-008582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 03-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
```


PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091355P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100663P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match

3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCITTTGTTTACCACTCTTTCCTTTATCTATTATAAATAATGTTGTCCTCCACCTG 2180
Db 2653 CCITTTGTTTACCACTCTTTCCTTTATCTATTATAAATAATGTTGTCCTCCACCTG 2712
Qy 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 680
ACC93534
ID ACC93534 standard; cDNA; 2846 BP.
XX AC ACC93534;
XX AC ACC93534;
DT 22-AUG-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS US2003036120-A1.
XX 20-FEB-2003.
PD 25-JUN-2002; 2002US-00180541.
PF 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089558P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACTCTTCTTATCTTATTAATAAATGTTGCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCACTCTCTTGACACATTTTAATAAATAAGGCTTGCTTCTGAAC 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 681
ACC96153
ID ACC96153 standard; cDNA; 2846 BP.
AC ACC96153;
XX
XX 03-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX
XX OS
XX US2003036161-A1.
XX
XX 20-FEB-2003.
XX
XX 12-JUL-2002; 2002US-00194361.
XX
XX 26-JUN-1998; 98US-00105413.
XX 16-SEP-1998; 98WO-US019330.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98WO-US021141.
XX 06-NOV-1998; 98US-00187368.
XX 01-DEC-1998; 98WO-US025108.
XX 07-DEC-1998; 98US-00202054.
XX 03-MAR-1999; 99US-00254311.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 25-AUG-1999; 99US-00380142.
XX 01-SEP-1999; 99WO-US020111.
XX 15-SEP-1999; 99WO-US021090.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 01-DEC-1999; 99WO-US028301.
XX 02-DEC-1999; 99WO-US028551.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005841.

```

```

PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.

```

(GETH) GENENTECH INC.

Baker KP, Chen J, Deanoyers L, Goddard A, Godowski RJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-479642/45.
P-PSDB; ABR74317.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, chromosome identification, tissue typing, for detecting
the presence of tumor in a mammal, or as hybridization probes in gene
mapping.

Claim 2; Fig 169; 708pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides
(ABR74233-ABR74537) and nucleic acids encoding them (ACC96069-ACC96373).
The invention also relates to sequences at least 80% identical to the PRO
nucleic acid and polypeptide sequences of the invention, recombinant
vectors and host cells comprising a PRO nucleic acid, a method for the
recombinant production of a PRO polypeptide, antibodies against a PRO
polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
acids encoding PRO polypeptides of the invention were initially
identified via homology screening using consensus sequences based on the
extracellular domain sequences from known secreted proteins. Human cDNA
libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterized. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

RESULT 682	
ACD24828	
ID	ACD24828 standard; cDNA; 2846 BP.
XX	
XX	
AC	ACD24828;
XX	
DT	29-AUG-2003 (first entry)
XX	
XX	Human secreted/transmembrane protein (PRO) cDNA #85.
XX	
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX	
OS	Homo sapiens.
XX	
PN	US2003044921-A1.
XX	
PD	06-MAR-2003.
XX	
PF	24-JUN-2002; 2002US-00179513.
XX	
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.
PR	28-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063734P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	13-NOV-1997; 97US-0065311P.
PR	

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACCTCTTCTTATCTTATTAATAAATGTGTCTCCACCCTG 2180
 Db 2653 CTTTTCCTCCCACTCTTGTACACATTTTAAATAAAGGCTTGGCTTCTGA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 685
 ACF22649
 ID ACF22649 standard; cDNA; 2846 BP.
 XX
 AC ACF22649;
 XX
 DT 19-SEP-2003 (first entry)
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2003059884-A1.
 XX
 XX 27-MAR-2003.
 XX
 XX 18-JUL-2002; 2002US-00200617.
 XX
 XX 01-APR-1998; 98US-0080333P.
 XX 08-MAR-1999; 99WO-US005028.
 XX 25-AUG-1999; 99US-00380138.
 XX 18-FEB-2000; 2000WO-US004341.
 XX 28-FEB-2001; 2001WO-US006520.
 XX 15-JAN-2002; 2002US-00052586.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-555483/52.
 XX P-PSDB; ABM02122.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 XX in gene therapy, or for preparing a medicament for treating a condition
 XX that is responsive to the PRO polypeptide or anti-PRO antibody.
 XX
 XX Claim 2; Fig 169; 700pp; English.
 XX
 XX The invention relates to human PRO secreted/transmembrane polypeptides
 CC (ABM02038-ABM02342) and nucleic acids encoding them (ACF22565-ACF22869).
 CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant
 CC vectors and host cells comprising a PRO nucleic acid, a method for the
 CC recombinant production of a PRO polypeptide, antibodies against a PRO
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
 CC acids encoding PRO polypeptides of the invention were initially
 CC identified via homology screening using consensus sequences based on the
 CC extracellular domain sequences from known secreted proteins. Human cDNA
 CC libraries containing sequences of interest were identified using
 CC oligonucleotides based on the consensus sequences, and cDNA clones were
 CC isolated and characterised. The PRO polypeptides are useful for
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
 CC human blood and may thus be used in the treatment of conditions in which
 CC enhanced TNF-alpha release would be beneficial. They are also useful for
 CC stimulating the proliferation or differentiation of chondrocytes and as
 CC such may be used in the treatment of various bone and/or cartilage
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may
 CC be used in a method for detecting the presence of a tumour (e.g., an
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
 CC method involves comparing the level of expression of the PRO polypeptide
 CC in test and control samples, where a higher level of expression of PRO
 CC polypeptide in the test sample as compared to the control sample is
 CC indicative of the presence of a tumour. The PRO polypeptides are
 CC additionally useful for in drug screening to identify agonists and
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA and in gene
 CC therapy. The nucleic acids can also be used for mapping genes encoding
 CC PRO polypeptides, for genetic analysis of individuals with genetic
 CC disorders, and for generating either transgenic animals or knock-out
 CC animals which are useful in the development and screening of
 CC therapeutically useful compounds. Sequences ACF22565-ACF22869 represent
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
 XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACCTCTTCTTATCTTATTAATAAATGTGTCTCCACCCTG 2180
 Db 2653 CTTTTCCTCCCACTCTTGTACACATTTTAAATAAAGGCTTGGCTTCTGA 2712
 QY 2181 NCTCCCAA 2240
 Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
 Db 2773 AA 2774

RESULT 686
 ACF08877
 ID ACF08877 standard; cDNA; 2846 BP.
 XX
 AC ACF08877;
 XX
 XX 06-SEP-2003 (first entry)
 XX
 XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 XX Human; PRO; secreted protein; transmembrane protein;
 XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 XX chondrocyte; proliferation; differentiation; cartilage disorder;
 XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 XX liver; drug screening; transgenic animal; genetic analysis;
 XX antiarthritic; vulnery; gene therapy; gene; ss.
 XX

OS XX Homo sapiens. 2653 CCTTTTCTCCCATCTCTTGTACACATTTTAAATAAAGGTTGGCTTCTGAACCTA 2712

PN XX US2003068687-A1. 2181 NCTCCCAA 2240

XX XX 10-APR-2003. 2713 CAAA 2772

XX XX 01-JUL-2002; 2002US-00187748. 2241 AA 2242

XX XX 03-MAR-2000; 2000US-0187202P. 2773 AA 2774

PR 28-FEB-2001; 2001WO-US006520. 2773 AA 2774

PR 15-JAN-2002; 2002US-00052586. 2773 AA 2774

XX XX (GETH) GENENTECH INC.

XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-576424/54. 23-SEP-2003 (first entry)

DR P-PSDB; ABR87284. Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX XX Three hundred and five nucleic acids encoding PRO polypeptides, useful for the manufacture of a medicament for diagnosing or treating tumor or for tissue typing.

XX PS Claim 2; Fig 169; 700pp; English.

XX CC The invention relates to human PRO secreted/transmembrane polypeptides (ABR87200-ABR87504) and nucleic acids encoding them (ACF08793-ACF09097).

CC CC The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences of known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adenoma, rectal tumour, colon tumour, breast tumour, prostate tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF08793-ACF09097 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

XX SQ Query Match 3.0%; Score 66.6; DB 9; Length 2846;

XX SQ Best Local Similarity 71.3%; Pred. No. 0.00023;

XX SQ Matches 87; Conservative 35; Mismatches 0; Gaps 0;

XX SQ 2121 CTTTGGCTTACACCTCTTCTTTTAAATAAAGGTTGGCTTCTGAACCTG 2180

XX ACF48527;
XX 07-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003064444-A1.
XX 03-APR-2003.
XX 02-JUL-2002; 2002US-00187883.
XX 01-OCT-1998; 98US-0102687P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 18-FEB-2000; 2000WO-US004342.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-605857/57.
XX P-PSDB; ABM24505.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, such as
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM24421-ABM24725) and nucleic acids encoding them (ACF48443-ACF48747).
XX The invention also relates to sequences at least 80% identical to the PRO
XX nucleic acid and polypeptide sequences of the invention, recombinant
XX vectors and host cells comprising a PRO nucleic acid, a method for the
XX recombinant production of a PRO polypeptide, antibodies against a PRO
XX polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX acids encoding PRO polypeptides of the invention were initially
XX identified via homology screening using consensus sequences based on the
XX extracellular domain sequences from known secreted proteins. Human cDNA
XX libraries containing sequences of interest were identified using
XX oligonucleotides based on the consensus sequences, and cDNA clones were
XX isolated and characterised. The PRO polypeptides are useful for
XX stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX human blood and may thus be used in the treatment of conditions in which
XX enhanced TNF-alpha release would be beneficial. They are also useful for
XX stimulating the proliferation or differentiation of chondrocytes and as
XX such may be used in the treatment of various bone and/or cartilage
XX disorders such as arthritis and sports injuries. The PRO polypeptides may
XX be used in a method for detecting the presence of a tumour (e.g., an
XX adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX method involves comparing the level of expression of the PRO polypeptide
XX in test and control samples, where a higher level of expression of PRO
XX polypeptide in the test sample as compared to the control sample is
XX indicative of the presence of a tumour. The PRO polypeptides are
XX additionally useful for in drug screening to identify agonists and
XX antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF48443-ACF48747 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CTTTGTCTTACCACTCTTCTCTTTATCTTATTAATAAATGTTGCTCTCCACCTG 2180
DB 2653 CTTTTCCTCTCCCATCTCTTGTACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
DB 2713 CAAA 2772
QY 2241 AA 2242
DB 2773 AA 2774
RESULT 690
ID ACD47317 standard; cDNA; 2846 BP.
XX ACD47317;
XX AC ACD47317;
XX DT 13-SEP-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX US2003068697-A1.
XX 10-APR-2003.
XX 09-JUL-2002; 2002US-00192016.
XX 05-JUN-2000; 2000US-0209832P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-605913/57.
XX P-PSDB; ABO29419.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, e.g.
XX adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention discloses human nucleic acids encoding secreted and
XX transmembrane (PRO) polypeptides, with or without their associated signal
XX peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
 CC PRO polypeptide, a method for stimulating the proliferation or
 CC differentiation of chondrocyte cells by contacting the cells with a PRO
 CC polypeptide, a method for detecting the presence of a tumour in a mammal
 CC and an oligonucleotide probe derived from any of the PRO nucleotide
 CC sequences. The nucleotide sequences are useful as probes, in chromosome
 CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 CC polypeptides by recombinant techniques and in gene therapy (e.g. for
 CC replacement of defective gene). The PRO polypeptides are useful as
 CC molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence, prevention and/or treatment of a tumour, such as
 CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
 CC The PRO polypeptides and nucleic acids may also be used diagnostically
 CC for tissue typing. The sequence presented is a cDNA encoding one of the
 CC PRO polypeptides of the invention. Note: The sequence data for this
 CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTATTAATAAATGTTGGTCTCCACCACTG 2180
 DB 2653 CTTTTCTCTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
 QY 2181 NCTCCCAA 2240
 DB 2713 CAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774

RESULT 691
 ACD49159
 ID ACD49159 standard; cDNA; 2846 BP.
 AC ACD49159;
 XX
 DT 05-OCT-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein (PRO) cDNA #85.
 XX
 KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
 KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
 KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
 KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
 XX
 OS Homo sapiens.
 XX
 XX US2003068710-A1.
 XX
 PD 10-APR-2003.
 XX
 PF 16-JUL-2002; 2002US-00196761.
 XX
 PR 18-APR-2000; 2000US-0198585P.
 PR 28-FEB-2001; 2001WO-US0006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 XX

DR WPI; 2003-605916/57.
 DR P-PSDB; ABO31249.
 XX
 PT New PRO nucleic acid, useful for the manufacture of a medicament for
 PT diagnosing or treating tumors or for tissue typing.
 XX
 PS Claim 2; Fig 169; 700pp; English.
 XX
 CC The invention discloses human nucleic acids encoding secreted and
 CC transmembrane (PRO) polypeptides, with or without their associated signal
 CC peptide. Also disclosed is an antibody that specifically binds to the PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
 CC PRO polypeptide, a method for stimulating the proliferation or
 CC differentiation of chondrocyte cells by contacting the cells with a PRO
 CC polypeptide, a method for detecting the presence of a tumour in a mammal
 CC and an oligonucleotide probe derived from any of the PRO nucleotide
 CC sequences. The nucleotide sequences are useful as probes, in chromosome
 CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
 CC polypeptides by recombinant techniques and in gene therapy (e.g. for
 CC replacement of defective gene). The PRO polypeptides are useful as
 CC molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence, prevention and/or treatment of a tumour, such as
 CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
 CC The PRO polypeptides and nucleic acids may also be used diagnostically
 CC for tissue typing. The sequence presented is a cDNA encoding one of the
 CC PRO polypeptides of the invention. Note: The sequence data for this
 CC patent can also be obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html
 XX
 SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
 Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
 QY 2121 CCTTGGCTTACCACTCTTCTTTATCTATTATTAATAAATGTTGGTCTCCACCACTG 2180
 DB 2653 CTTTTCTCTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC 2712
 QY 2181 NCTCCCAA 2240
 DB 2713 CAA 2772
 QY 2241 AA 2242
 DB 2773 AA 2774
 RESULT 692
 ACF37862
 ID ACF37862 standard; cDNA; 2846 BP.
 XX
 AC ACF37862;
 XX
 DT 07-OCT-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnery; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2003068686-A1.

us-10-036-342-56.rng

Wed Feb 16 11:37:55 2005

XX PN 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PD 17-OCT-1997; 97US-0062250P.
XX PF 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 11-DEC-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 17-DEC-1997; 97US-0069435P.
XX 18-DEC-1997; 97US-0069870P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082588P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 05-MAY-1998; 98US-0083559P.
XX 06-MAY-1998; 98US-0084366P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087208P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 25-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.

DT 10-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
XX Human; gene, ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX
XX US2003036158-A1.
XX
XX 20-FEB-2003.
XX
XX 02-JUL-2002; 2002US-00188770.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 28-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 11-DEC-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 17-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 11-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 01-APR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 08-APR-1998; 98US-0081049P.
XX 09-APR-1998; 98US-0081070P.
XX 15-APR-1998; 98US-0081195P.
XX 21-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.